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Chapter 1 
C h a p t e r 1 
P h a r m a c o t h e r a p e u t i c t r e a t m e n t o f c a r d i o v a s c u l a r d i s e a s e s ; 
d r u g e f fec t s o n f u n c t i o n s o f the h e a r t a n d the c i r c u l a t o r y s y s t e m 
1 Introduction 
To understand causes of cardiovascular diseases and the effects of drugs, certain 
pathophysiological functions of the heart and the circulatory system have to be 
c o n s i d e r e d 1 . A number of factors play an important role in the regulation of the 
circulatory system. These factors consist of the pump function of the heart, the 
vascular system, the blood, and the function of the kidney and the renal vascular 
system. 
In this chapter only aspects of the function of the heart and the vascular system will 
be described. The properties of the blood determining the blood flow, such as 
aggregation, coagulation, and the deformability of the blood cells , will not be 
considered. Besides, the function of the renal vascular system will not be discussed. 
In the first part, the function of the heart and the blood pressure regulation will be 
discussed. The following part deals with several drugs available for the treatment of 
card iovascular d iseases . A dis t inct ion will be made upon an t ia r rhy thmics , 
antianginals, positive inotropic agents, and antihypertensives. Finally a summary will 
be presented about the prospects to achieve drugs with improved therapeutic value 
for the treatment of cardiovascular diseases. 
2 The heart 
An optimal functioning of the heart is of vital interest for all mammals. The function of 
the heart is to pump blood throughout the body to supply all living cells with oxygen 
and nutrients. 
In a simplified view, the heart consists of two sections each acting as a pump. 
In the pulmonary circulation, blood deprived of oxygen and rich of carbon dioxide is 
pumped from the right part of the heart to the lungs. In the lungs carbon dioxide in 
the blood is removed and oxygen is taken up. The oxygenated blood is transported 
from the lungs to the left part of the heart. In the systemic circulation, the oxygenated 
blood is transported from the left part of the heart through the body to supply, for 
instance, muscles and organs with oxygen. 
The pump function of the heart is regulated in ^n extremely sophisticated manner. 
This includes automatism, rhythmicity and contractility. 
2.1 Automatism and rhythmicity 
Automat ism and rhythmicity are two important functions to control an optimal 
performance of the heart. 
Cardiac muscle cells (myocytes) are electrically excitable like most other muscle cells 
but differ by having sino-atrial (SA) and atrio-ventricular (AV) nodes which generate 
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spontaneous rhythm. This is called the intrinsic rhythm of the heart showing a 
frequency of about 70 beats per minute. As a result of an electrical or chemical 
stimulus, the transmembrane action potential of a cardiac muscle cell changes. This 
cardiac t ransmembrane action potential , manifested as a propagat ing wave of 
transient depolarisation, can be divided into several phases (fig. 1). 
At resting potential, cardiac ventricular cells maintain a t ransmembrane potential 
varying from -80 to -95 mV. The resting potential is maintained by the concentration 
of intra- and extracellular potassium and is determined by K + -permeabil i ty of the cell 
membrane and a N a + / K + - A T P a s e which exchanges three sodium ions for two 
potassium ions. 
At phase 0, a rapid depolarisation occurs by opening of Na + -channels leading to a 
fast inward Na + -current. 
At phase 1, a partial repolarisation takes place, known as the transient outward 
current caused almost exclusively by K + -eff lux 2 ' 3 . 
At phase 2, a plateau region exists as a result of reduced K + -efflux and a slow influx 
of N a + and C a 2 + leading to a net slow inward current. 
At phase 3 , a rapid repolarisation takes place because of the closure of N a + - and C a 2 + -
channels and activation of one or more fast outward K + -channels . 
This eventually leads to phase 4 in which the resting potential is reached. The K + -
concentration is restored via the N a + / K + - p u m p and by K + -permeabi l i ty of the cell 
membrane. 
b 
+30 to +40 mV 
•80 to -95 mV 
0 100 200 300 400 ms 
a) phase 0;fast inward Na+-current 
b) phase 1; partial repolarisation by K+-efflux 
c) phase 2; reduced K+-efflux and slow Na+- and Ca2* -influx 
d) phase 3; closure ofNa+- and Ca*+-channels, fast outward K+-current 
e) phase 4; resting potential, K+-concentration is restored via the Na+IK+-pump and by 
the K+-permeability of the cell membrane 
Figure 1: Action potential curve 
This intrinsic rhythm, however, is not the only factor influencing heart rate. Also the 
sympathet ic nervous sys tem, which accelerates heart beat ing and the para­
sympathetic nervous system, which slows heart beating, play a role. 
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2.2 Role of calcium 
Calcium is involved in all processes of excitation resulting in biological effects. These 
excitation processes can be initiated by either an electrical or chemical stimulus. A 
calcium concentration gradient across the cell membrane contributes to generation 
and maintenance of a potential gradient. 
Calcium homeostasis in the cell is regulated by several mechanisms. Calcium influx 
takes place via calcium channels. Calcium efflux proceeds via a N a + / C a 2 + - e x c h a n g e 
process driven by the N a + electrochemical potential and a C a 2 + - A T P a s e which relies 
on the utilization of ATP. Calmodulin-calcium-sensitive Ca 2 + -ATPases with different 
properties are present in the plasma membrane and in the endoplasmic reticulum of 
smooth muscles. 
Activation of calcium channels, leading to Ca 2 + - in f lux , can occur by membrane 
depolarization or by receptor stimulation. Calcium channels which are primarily 
regulated by electrical signals are called voltage-operated channels (VOC), potential-
dependent channels (PDC), or voltage-dependent calcium channels (VDCC). Calcium 
channels which respond to chemical signals are called receptor-operated channels 
(ROC) or ligand-gated channels. 
The cellular system is provided with mitochondria and sarcoplasmic reticulum, which 
prevent intracellular calcium overload. The mitochondria and sarcoplasmic reticulum 
are intracellular pools responsible for the calcium sequestration and calcium liberation 
after stimulation. Influx of C a 2 + through VOCs or ROCs triggers the release of a 
relatively large amount of calcium from intracellular stores to reach an intracellular 
calcium concentration which is above a threshold resulting in a contractile response. 
In the heart, the intracellular Ca 2 + - re lease occurs via a calcium release channel which 
is thought to be part of a large protein called the ryanodine receptor and is located in 
the membrane of the sarcoplasmic ret iculum 4 . The alkaloid ryanodine exhibits two 
opposing effects on the calcium release channels in the sarcoplasmic reticulum, which 
are concentrat ion dependent . At high concentrat ions (> 30 | iM) the channel is 
deactivated (closed), and at lower concentrations the channel is activated (opened). 
Gerzon et al. reported synthetically modified ryanodine analogues which are able to 
open the channels and lack the ability to close them 5 . 
In the skeletal muscle, the Ca 2 + - re lease from the sarcoplasmic reticulum is initiated by 
"voltage sensors", located in specialized regions of the sarcoplasmic membrane, 
instead of activation of the sarcoplasmic Ca 2 + - re lease channels by calcium, as in heart 
cells 6 . 
In addition also in smooth muscles evidence exists Tor calcium being released from the 
sarcoplasmic reticulum either through Ca 2 + - induced Ca 2 + - re lease mechan i sms 7 ' 8 or 
through a mechanism linked to phosphatidylinositol metabol i sm 9 ' 1 0 . 
The reaction pathway leading to contraction in heart and skeletal muscle differs from 
that in smooth muscle. Therefore, in the next section, these contractile processes will 
be discussed in more detail. 
3 
Chapter 1 
Calcium homeostasis in the cell is influenced by modification of cellular calcium-
binding proteins that regulate calcium metabolism. 
There are two types of calcium-binding prote ins 1 1 : 
- calcium-transport ing proteins integrated in the cell wall or integrated in 
membranes of intracellular organelles. 
- calcium-modulated proteins which are freely dissolved in the cell or are part of 
a nonmembranous intracellular structure like troponin or calmodulin. 
Drugs affecting cardiac calcium-binding proteins can therefore act on calcium-
transporting proteins or calcium-modulating proteins by direct binding to the protein 
or by modification of the binding through drug-receptor interaction. 
As mentioned before, calcium homeostasis is regulated by Ca 2 + - in f lux and efflux 
processes. Indirectly, the intracellular calcium concentration is also influenced by the 
N a + / K + - e x c h a n g e process. Interferences of N a + / K + - p u m p disturbs the steady state 
concentration of sodium and hence via the N a + / C a 2 + - p u m p also the intracellular 
calcium concentration. 
2.3 Contractility 
The heart exerts its work by rhythmic contraction (systole) and relaxation (diastole). 
Contraction of the cardiac muscle at constant ventricular volume causes a rise in 
ventricular pressure . When this ventricular pressure exceeds the actual aortic 
pressure, the ventricular valve will be opened and the blood flows into the aorta. The 
stroke volume is about 70 ml and a rest volume of about 70 ml remains in the 
ventricle. With the decrease in ventricular pressure, the aortic valve is closed and the 
atr io-ventricular valve is opened when the aortic pressure is higher then the 
ventricular pressure. The influx of blood into the atrium and ventricle takes place via 
a passive mechanism. 
The contractile process of the cardiac myocytes is regulated by biochemical factors 
such as A T P and intracellular calcium and hence depends on Ca 2 + - en t ry across the 
cell membrane. The slow inward Ca 2 + -current promotes the release of a much larger 
amount of C a 2 + from the sarcoplasmic reticulum. The increased intracellular C a 2 + -
concentration unblocks the effects of troponin and tropomyosin, which then in turn 
allows actin and myosin to interact with the muscle fiber filaments to contract. 
The contractile activity in smooth muscle is also regulated by the free intracellular 
Ca 2 + -concentrat ion and Ca 2 + -sensit ivi ty of the contractile proteins. Upon stimulation, 
the intracellular Ca 2 + -concent ra t ion is increased from about 10~7 M to 10~5 M, by 
influx of extracellular C a 2 + and from release M C a 2 + from intracellular stores. In the 
cytosol, the increased Ca 2 + -concent ra t ion allows calcium to interact with specific 
binding sites on calmodulin. Calmodulin is an intracellular protein involved in several 
activation processes of target enzymes. This protein is the mediator of the excitation-
contraction coupling in smooth muscle. The calcium-calmodulin complex interacts 
with another protein, the myosin light chain kinase. This newly formed complex then 
phosphorylates a smooth muscle myosin light chain which, in its phosphorylated 
form, interacts with actin leading to shortening (contraction) of the myofilaments. 
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The excitation-contraction process is reversible and therefore dephosphorylation of 
myosin light chain causes the muscle to relax. In these processes, calmodulin plays a 
complex regulatory role. However, the consideration of the several distinct classes of 
so-called calmodulin antagonists and their putative applications in therapy, is beyond 
this scope, they are reviewed e l s e w h e r e 1 2 , 1 3 . 
2.4 Cardiac performance 
Cardiac performance and the mean arterial pressure are increased when the stroke 
volume of the heart is increased at constant peripheral resistance. The stroke volume 
depends on the central venous pressure (pre-load) which influences the cardiac filling 
pressure and hence the end-diastolic volume. By increasing the pre-load, the cardiac 
work is increased and the oxygen consumption of the heart is enhanced. 
When the peripheral resistance is increased without changes in the central venous 
pressure, the after-load is increased. To achieve the same cardiac output, the cardiac 
work and hence the oxygen consumption are increased. 
At exercise, cardiac output is influenced by changes in stroke volume and heart 
frequency. Sympathetic activation gives an increased positive inotropic effect so that 
more of the rest volume can be used and hence more stroke volume is available or it 
can overcome a higher peripheral resistance. 
Increasing of the heart frequency gives a shortening of the diastole and thus a shorter 
t ime for ventricle filling and less coronary perfusion of the ventricle if it is not 
accompanied with coronary dilation. A fast increase in frequency is thereby 
economically unfavourable. 
2.5 Myocardial oxygen supply, angina, and myocardial infarction 
The heart consumes energy for all the processes executed. This energy is mainly 
supplied by glucose and by oxygen delivered by the blood in the cardiac chamber 
and, especially, from blood in the coronary artery system. The heart is particularly 
sensitive to disturbances in blood supply. If the heart is deprived of blood (becomes 
ischemic), the pump function of the heart is reduced within seconds. Atherosclerosis 
is often the underlying mechanism which leads to ischemic heart disease. Partial 
occlusion of coronary arteries by formation of atherosclerotic plaques leads to angina, 
because of oxygen depletion of the heart. Angina is felt as a severe pain in the chest 
and occurs upon exercise or excitement. Total occlusion of a coronary artery, also 
called myocardial infarction, can lead to necrosis of certain parts of the heart. 
Antianginal drugs reduce the oxygen demand of the heart and increase myocardial 
oxygen supply by improving myocardial perfusion. 
Decreased cardiac p-adrenoceptor density and tissue reactivity, as a result of 
prolonged treatment with P-adrenergics, are reported in heart failure in both clinical 
and animal s t u d i e s 1 4 , 1 5 . Also, evidence for reduction of both ATP-sensi t ive K + -
channel and dihydropyridine-sensi t ive Ca 2 + - channe l densities are shown in left 
ventricular tissue homogenates from rats with heart fai lure 1 6 . 
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In the majority of patients with heart failure an enlargement of the left ventricle is the 
initial process leading to progressive cardiac dysfunction. Congestive heart failure 
(CHF) results when the left ventricle is unable to adequately perfuse the peripheral 
t issue and thereby cannot provide the cardiac output demanded by exercise. 
Insufficient cardiac output initiates a cascade of responses which gives a reduction of 
peripheral circulation eventually leading to a worsening of the effect. 
Congestive heart failure (CHF) can be therapeutically attended by: 
-improving the action of the left ventricle with positive inotropic agents also called 
cardiotonics 
-lowering of the peripheral resistance with antihypertensive agents as vasodilators 
2.6 Blood pressure 
Hyper tension is a health problem of wide dimensions and is correlated with 
cardiovascular disease and results from an increase in peripheral vascular resis tance 1 7 . 
Initially, hypertension is caused by vasoconstriction; prolonged hypertension leads to 
structural changes of the vessel walls by hypertrophy of the arteries and increase of 
left ventricular m a s s 1 8 . Increased peripheral vascular resistance remains a major risk 
for cardiovascular disease, especially for stroke, myocardial infarction, congestive 
heart failure, and renal failure. 
The electrochemical, mechanical, and metabolic activities of the heart are mediated by 
transmembrane movements of ions and the intracellular calcium concentration. The 
mechanical output of the heart is not only determined by the force of contraction but 
also dependent on the state of the circulation system, such as the peripheral 
resistance of the blood vessels and the viscosity of the blood. The peripheral 
resistance of the blood vessels affects the performance of the heart by influencing the 
systole-diastole mechanism. 
Vasodilators increase blood flow by lowering the peripheral resistance. Depending on 
the class to which vasodilators belong, they are used as antianginal drugs or for the 
treatment of congestive heart failure or in peripheral vasoconstrictive conditions. 
3 Cardiovascular drugs 
Cardiovascular drugs are used for the treatment or prevention of cardiovascular 
diseases and can be divided in: 
- antiarrhythmics 
- antianginal drugs 
- cardiotonics, also called positive inotropic agents 
- antihypertensives 
3.1 Antiarrhythmics 
Cardiac arrhythmias result from disorders in impulse generation and/or conduction 
[for details see ref. 19]. 
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Antiarrhythmic drugs modify or restore an abnormal cardiac rhythm. Therefore, drugs 
used for the treatment of arrhythmia can be directed towards several phases of the 
cardiac action potential. 
There are at least four different groups of antiarrhythmic drugs originally defined by 
Vaughan Wil l iams 2 0 : 
- Class I 
The class I antiarrhythmic agents exists of three subtypes I a , I b and I c 2 1 (e.g., I a 
agents: quinidine 1, procainamide 2, disopyramide 3; I b agents: tocainide 4, 
mexiletine 5; I c agents flecainide 6, and encainide 7; fig. 2a). This subclassifica-
tion is based on their effect on action potential duration. All class I agents are 
sodium channel blockers and inhibit the propagation of the action potential by 
reducing the rate of depolarisation during phase 0 (reduction of the fast 
inward Na + -current) . 
3 Disopyramide 4 Tocainide 5 Mexiletine 
Figure 2a: Class I antiarrhythmics; sodium channel blockers 
7 
Chapter 1 
- Class n 
Arrhythmias occurring after myocardial infarction are partly a result of 
increased sympathetic activity. Adrenaline can cause ventricular extrasystoles 
by affecting the rest ing potential of the action potential curve. The AV 
conduction is disturbed and the refractory period is shortened by an increased 
sympa the t i c ac t iv i ty . p r a d r e n e r g i c an tagonis t s [ l ike p roprano lo l 8 
(nonselective), metoprolol 9 and atenolol 10; fig. 2b] increase the refractory 
period of the AV node, interfere with AV conduction, and slow down the 
ventricular rate. The most important adverse effect of p r b l o c k e r s is the 
negative inotropic activity and reduced cardiac output. 
Figure 2b: Class II antiarrhythmics; p r adrenerg ic blockers 
- Class IH 
The primary antiarrhythmic activity of agents belonging to this class rely on 
the fact that they prolong the cardiac action potential and so increase the 
refractory period of the cardiac muscle. These electrophysiological changes are 
caused by cardiac potassium channel blockade. Amiodarone 11 (fig. 2c) was 
one of the first drugs showing K + -channel blockade. Since then major interest 
was shown in this field of drugs. Nowadays sotalol 12, originally developed as 
a p-adrenergic receptor antagonist, is the typical class III antiarrhythmic drug. 
The majority of potent class III anti-arrhythmic drugs recently developed (E-
4031 13, UK-68,798 14, L-691,121 1 5 2 2 ; fig. 2c) all possess the methanesulfon-
amide group as present in sotalol.
 N 
- Class IV 
Calcium channel blockers reduce the slow calcium influx and shorten the 
plateau phase of the cardiac action potential and restore the intrinsic rhythm. 
The disadvantageous effect is the reduction in myocardial contractility. 
Calcium channel blockers are discussed in more detail as antihypertensives. 
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Until now, no selective class III antiarrhythmic drug has reached the market and, 
therefore, the effectiveness of these type of agents in therapy is still unproved 2 3 . 
In clinical use, the choice of the best antiarrhythmic drug is often a matter of trial and 
error. A special problem is that some antiarrhythmic drugs used to suppress 
arrhythmias actually turned out to act pro-arrhythmogenic 2 4 . In practice the dihydro-
pyridine calcium channel blockers carry a serious risk for proischemia, a term defined 
by Wa te r s 2 5 . The most likely possibility to cause proischemia is that dihydropyridine-
induced peripheral vasodilation simultaneously reduces coronary perfusion pressure 
and, as a reflex, increases heart rate. 
i 
11 Amiodarone 12 Sotalol 
14 UK-68,798 C H 3 
Figure 2c: Class III antiarrhythmics; potassium channel blockers 
The most promising drugs for the treatment of arrhythmias seem to be the sodium 
channel blockers. However, much is still unclear about the exact mechanisms of these 
drugs. 
All antiarrhythmic drugs exert negative inotropic effects which may induce or worsen 
congestive heart failure in up to 5% of all treated pat ients 2 6 . Treatment of arrhythmia 
with single drugs is often ineffective. Therefore, combinations of antiarrhythmic drugs 
are used. In general, drugs belonging to the same electrophysiological class are not 
applied in combina t ion therapy. However , a lso drugs with pharmacokine t ic 
interactions, such as quinidine and amiodarone, should be avoided 2 7 . 
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3.2 Antianginal drugs 
As already discussed, angina is caused by a disturbance in balance between oxygen 
supply by the coronary blood flow and the oxygen demand of the heart. Relief of 
anginal pain can be achieved by drugs increasing the oxygen supply or by drugs 
which decrease the oxygen demand of the heart by reducing contractility (inotropy) 
and frequency (chronotropy). Drugs used for the treatment of angina are vasodilators 
as the organic nitrate esters and the calcium channel blockers, which both reduce the 
oxygen demand and simultaneously improve myocardial perfusion, p-adrenoceptor 
antagonists only affect the oxygen demand of the heart. The antianginal drugs can 
be divided into three classes: 
- nitrate and nitrites 
- calcium channel blockers 
- P r a d r e n o c e p t o r antagonists 
3.2.1 Nitrates and nitrites 
Nitrates and nitrites exert their effects on the systemic circulation by relaxation of 
small bloodvessels, arterioles, capillaries and the venous capacitance vesse ls 2 8 . The 
secondary effect is the reduction of the pre-load. Reduction of the arterial pressure 
and cardiac output leads to a lowering of the cardiac oxygen consumpt ion . 
Continuous treatment with nitrates, however, results in a diminishing relaxant effect. 
This tolerance especially occurs with long-acting organic nitrates, like isosorbide 
dinitrate 16 and to a lesser extent with nitroglycerin 17. Organic nitrates and nitrites 
most likely produce their vasodilation by releasing nitric oxide. Organic nitrites (like 
amylnitrite 18) release nitric oxide via a simple one-electron reduction. The organic 
nitrates require a three-electron reduction to release nitric oxide, proceeding via an 
enzyme system attached to the cellular surface of vascular smooth muscle membranes. 
The nitric oxide releasing activity mimics the effect of the endothelium-derived 
relaxing factor (EDRF), originating from endothelial cells present in bloodvessels, 
which also turned out to be nitric ox ide 2 9 . 
ON02 
ON02 
16 I s o s o r b i d e dinitrate 17 Nitroglycerin 18 Amyl nitrite 
The nitrate esters are extensively reviewed in chapter 3. 
3.2.2 Calcium channel blockers 
Reduction of myocardial oxygen consumption is thought to result from both an 
increase in coronary blood flow and a reduction of total heart work. From these 
effects and from the afterload reduction due to their hypotensive action, dihydro-
Chapter 1 
pyridines are expected to be beneficial for the treatment of angina. The calcium 
channel blockers are discussed in a following section (Antihypertensives). 
3.2.3 ^-Adrenoceptor antagonists 
Pi-antagonists are used to reduce the frequency of anginal attacks. They reduce the 
cardiac work by inhibition of the sympathetic nervous system and inhibit the action 
of circulating catecholamines on the heart. The catecholamines exert a positive 
inotropic and chronotropic action on the heart. By blockade of the p r ad renocep to r s 
the frequency of the heart is reduced during exercise and at rest. 
p r ad renocep to r antagonists have already been discussed in the section of class II 
antiarrhythmics. 
3.3 Cardiotonics (inotropic agents) 
Cardiotonic drugs increase the contractile force (inotropy) of the heart and exert 
important actions on cardiac excitability, automaticity, conduction velocity and 
refractory periods and are mainly indicated for congestive heart failure. 
A number of agents have effects on cardiac function and can be classified as follows: 
- cardiac glycosides 
- p r adrenoceptor agonists and histamine H 2 -agonists 
- phosphodiesterase (III) inhibitors 
- calcium channel activators 
Figure 3 shows the sites of action of the different positive inotropic agents in which 
they interfere in the intracellular calcium concentration. Positive inotropic agents act 
by increasing the intracellular Ca 2 + -concentrat ion which then becomes available for 
the contractile proteins (troponin, myosin, actin). 
Stimulation of G-protein coupled receptors (p 2 -adrenoceptors , h i s tamine H 2 -
receptors) activates the adenylate cyclase system, converting ATP into c A M P . In 
cardiac tissue a special form of adenylate cyclase has been found recently, which is 
inhibited by C a 2 + . It is proposed that the physiological significance of this type of 
adenylate cyclase provides a negative feedback control on elevation of c A M P and 
hence on cardiac contractility and rhythmici ty 3 0 . cAMP is capable to phosphorylate 
certain protein kinases . These kinases , in turn, phosphoryla te proteins in the 
sarcolemma and proteins in the sarcoplasmic ret iculum 3 1 . Although the primary signal 
to which voltage-operated calcium channels respond is constituted by the membrane 
potential, also a variety of ligand-receptor initiated modulations of these channels 
occur. This happens by phosphorylation of certain proteins in the sarcolemma, which 
are part of voltage dependent L-type Ca 2 + - channe l s . When phosphorylated, these 
proteins allow the ion channel configuration to switch in the open, also called 
activated, state. This leads to a slow inward Ca 2 + - cu r ren t 3 2 . 
p r Adrenocep to r stimulation increases the slow inward Ca 2 + -current through cardiac 
L-type Ca 2 + - channe l s . Guanidine nucleotide binding proteins (G-proteins) provide 
the link between p r adrenoceptors and K + - or Ca 2 + -channels . This link can be either 
11 
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indirect (also called cytoplasmic pathway) or direct (also called the membrane-
delimited pathway). Indirectly activation takes place via activation of cytoplasmic 
kinases which phosphoryla te the ion c h a n n e l s 3 3 ' 3 4 . The stimulating protein G s 
directly activates K + - and C a 2 + - c h a n n e l s 3 5 . Although a direct effect of G-proteins on 
neuronal Ca 2 + -channels have been established, it is still debated if such a mechanism 
also regulates cardiac C a 2 + - c h a n n e l s 3 6 , 3 7 ' 3 8 . 
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Figure 3 : Mode of action of cardiotonics 
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Like the p-adrenoceptor system, calcium channels seem to be subject to up and down 
regulat ion. Both homologous and heterologous desensit ization can occur, and 
various factors that may alter the number and function of voltage-operated channels 
have been described by Ferrante et a l . 3 9 . Despite the existing evidence that voltage-
operated channels are subject to drug- or disease-induced regulatory influences, 
several controversial results demonstrate that much of the underlying mechanism is 
still unclear. 
3.3.1 Cardiac glycosides 
Cardiac glycosides (like digitoxin 19 and digoxin 20; fig. 4a) inhibit the N a + / K + -
exchange process by N a + / K + - A T P a s e 4 0 . This inhibition then causes a decrease in the 
intracellular sodium concentration which in turn lowers the extrusion of intracellular 
C a 2 + , by the Na + /Ca 2 + -pump , across the sarcolemma. 
The increase of intracellular C a 2 + indirectly activates the myocardial contraction. 
Obviously also drugs that increase intracellular N a + , such as Na + -channe l openers, 
trigger the Ca 2 + -med ia ted contractile process. One of the major disadvantages of 
cardiac glycosides is their rather small therapeutic range in which they can be used. 
Figure 4a: Cardiotonics; cardiac glycosides 
3.3.2 p}-Adrenoceptor agonists 
p r A d r e n o c e p t o r agonists (like dobutamine 2 1 , isoprenaline 22 ( nonse l ec t i ve ) , 
ibopamine 23 , denopamine 24 and xamoterol 25; fig. 4b) and histamine H 2 -agonis ts 
( i m p r o m i d i n e 4 1 26 and a rp romid ine 4 2 27; fig. 4c) stimulate the adenylate cyclase 
system and increase the intracellular cAMP concentration and subsequently the 
intracellular Ca 2 + -concen t ra t ion . Prolonged p r a d r e n o c e p t o r stimulation leads to 
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recep tor down- regu la t ion and finally the receptor becomes insens i t ive to 
catecholamine stimulation. 
Figure 4b: Cardiotonics; p r ad renocep to r agonists 
Histamine H 2 -agonists also stimulate the gastric acid secretion. Therefore new drugs 
of this kind need to be cardioselective. Good prospects are expected for the thiazole 
derivative 28 of arpromidine like compounds 4 3 . However, probably also the histamine 
H 2 -receptors are subject to receptor down-regulation. 
26 Impromidine 
27 Arpromidine 
28 VUF 9012 
Figure 4c: Cardiotonics; histamine H 2-agonists 
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3.3.3 Phosphodiesterase III inhibitors 
The phosphodies te rase const i tutes a family of enzymes which regula te the 
intracellular degradation of cAMP to 5'-AMP. PDE inhibitors selective for the cAMP 
PDE isoenzyme found in brain tissue are of interest for treatment of central nervous 
system disorders. Three different cardiac phosphodiesterases (PDE I, II and III) have 
been distinguished. Only PDE III is highly specific for cAMP, while PDE I and II also 
affects cGMP. The prototype PDE(III)-inhibitors amrinone 29 and milrinone 30 (fig. 
4d) inhibit the turnover of c A M P and thus increases the intracel lular C a 2 + 
-concentration. This results in increased cardiac output and decreased left ventricular 
filling pressure. Besides a positive inotropic effect, PDE(III)-inhibitors also possess a 
vasodilator activity. In long term therapy PDE(III)-inhibitors increase heart rate which 
rises oxygen demand of the heart and also due to their proarrhythmogenic activity 
often lead to arrhythmias 4 4 . 
29 amrinone 30 milrinone 
Figure 4d: Cardiotonics; phosphodiesterase (III) inhibitors 
3.3.4 Calcium channel activators 
Calcium channel activators, such as the dihydropyridines Bay K 8644 3 1 , CGP 
28392 3 2 and 202-791 3 3 (fig. 4e), stabilize the open state of the slow inward 
calcium channels and thus increase intracellular C a 2 + . However calcium channel 
activators also promote Ca 2 + - in f lux in vascular smooth muscle cells leading to a 
vasoconstriction of the peripheral and coronary vessels which is unfavourable in the 
treatment of congestive heart failure. 
31 BAY K 8644 32 CGP 28392 33 202-791 
Figure 4e: Cardiotonics; calcium channel activators 
In cases of severe cardiac insufficiency, often stimulators of the adenylate cyclase ( p r 
adrenoceptor agonists) are combined with PDE(III)-inhibitors to simultaneously 
increase the c A M P production and decrease the c A M P degradation. However, in 
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patients suffering from severe heart failure, drugs acting by c A M P elevation fail to 
increase contracti l i ty because of desensit ization of adenylate cyclase coupled 
receptors . Therefore, ß x -adrenoceptor agonists are thought to have no future in 
treating patients suffering from chronic heart fa i lure 4 5 . Calcium channel activators 
hold promise for future development of cardiotonics. However, until now no calcium 
channel act ivator is repor ted possess ing a posi t ive inotropic effect without 
simultaneously increasing vascular resistance and enhanced blood pressure. 
3.4 Antihypertensives 
For the treatment of hypertension one can choose from a wide variety of drugs, such 
as: 
- diuretics 
- direct acting vasodilators 
- modulators of the renin-angiotensin system 
- ß r a d r e n o c e p t o r antagonists 
- ocj-adrenoceptor antagonists 
- oc 2-adrenoceptor agonists 
- K + -channel activators 
- calcium channel blockers 
The mode of action of antihypertensive agents is depicted in figure 5. 
3.4.1 Diuretics 
Diuretics, especially the thiazides (chlorothiazide 34; fig. 6), are the most common 
drugs for the treatment of hypertension. They increase the salt excretion via the urine 
and thus reduce the blood volume and the extracellular volume which is essential for 
treating hypertension. The blood pressure lowering effect of diuretics is based on the 
lowering of the plasma and extracellular volume. 
34 Chlorothiazide 
Figure 6: Diuretic N 
3.4.2 Direct acting vasodilators 
The direct acting vasodilators hydralazine 35 and minoxidil 36 are of limited 
therapeutic significance. They induce baroreflexes, thereby leading to stimulation of 
the sympathetic nervous system causing reflex tachycardia, and stimulation of the 
renin-angiotensin, causing fluid retention. 
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Figure 5: Sites of action of antihypertensive agents on blood pressure regulation 
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Figure 7: Direct acting vasodilators 
3.4.3 Modulators of the renin-angiotensin system 
The renin-angiotensin system is one of the hormonal mechanisms involved in cardiac 
regulation and control of blood pressure 4 6 . In the coronary circulation the endocrine 
and paracr ine renin-angiotensin system modulates the vasoconstr ictor tone. In 
myocytes it increases contractility partly because of the facilitation of noradrenaline 
r e l e a s e 4 7 . An historical overview of the development of renin-angiotensin system 
modulators is given by Mena rd 4 8 . 
Angiotensin is enzymatically formed from 
ang io tens inogen , an a 2 - g l o b u l i n . T h e 
enzyme renin cleaves angiotensinogen to 
afford the decapep t ide angio tens in I. 
Another c l eavage of two amino acid 
res idues by the angiotensin-conver t ing 
e n z y m e ( A C E ) gives the oc tapept ide 
angio tens in II . By several pept idases 
angiotensin II is degraded to angiotensin 
HI and fur ther to i nac t i ve pep t i de 
fragments. 
AO 
AI 
All 
AMI 
angiotensinogen 
^ renin 
angiotensin-l 
J A C E 
angiotensin-l I 
^ aminopeptidase 
angiotensin-lll 
I pept idase 
inactivé fragments 
Figure 8. The renin-angiotensin system 
Angiotensin II is a potent vasoconstrictor, it stimulates aldosteron secretion, increases 
sympathetic nervous system activity, and has a positive inotropic activity. Production 
of angiotensin II results in an increase in systemic blood pressure. Angiotensin-
converting enzyme inhibitors (ACE-inhibitors: Captopril 37, enalapril 38, lisinopril 39; 
fig. 9a) show side effects which are thought to be due to inhibited breakdown of the 
inflammatory peptide b radyk in in 4 9 . Bradykinin accumulation near the endothelial 
cells stimulates the nitric oxide synthase and induces vasodilation causing an increase 
in coronary f low 5 0 . 
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The development of renin inhibitors is complicated because of the poor oral 
bioavailability of these drugs which all possess a peptic character. Improvements are 
made by modifying their physical properties and reducing their peptic character 5 1 . 
37 Captopril 38 Enalapril 
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Angiotensin II antagonists get more and more attention as drugs for the treatment of 
arterial hypertension, heart failure and coronary artery disease. They regulate the 
renin-angiotensin system via blockade of the effector hormone rather than inhibition 
of its production and are potentially more selective than angiotensin-converting 
enzyme inhibi tors 5 2 . 
The discovery of the non pept ide angiotensin II antagonist S-(83 08) 4 0 5 3 , a 
benzylimidazole derivative led to the development of many b iphenyl imidazoles 5 4 ' 5 5 
based upon DuP 753 4 1 5 6 . Radioligand binding studies with DuP 753 in rat brain 
have demonstrated that there are two subtypes of Angiotensin II receptors, called the 
A T j and A T 2 - r e c e p t o r s 5 7 . In rat brain the A T r r e c e p t o r is located in the peri­
ventricular areas and the AT 2 -receptor in midbrain, cerebellum and brainstem 5 8 . In rat 
heart the AT X and AT 2 -receptors are equally distributed over the myocard ium 5 9 . The 
prototype A T r r e c e p t o r antagonist is DuP 753 , while the prototype AT 2 - r ecep to r 
antagonist is PD-123,319 4 2 6 0 . Only AT!-receptor antagonists are able to block the 
vasoconstr ictor effects of angiotensin II. The functional role of A T 2 - r e c e p t o r 
antagonists is still unclear. 
3.4.4 ßrAdrenoceptor antagonists 
ß^Blocker s are used as antihypertensives, antianginal and antiarrhythmic drugs. 
Blockade of the cardiac ß r r e c e p t o r s results in the reduction of heart rate, myocardial 
contractility, cardiac output and blood pressure. This class of drugs was already 
discussed in the section of antiarrhythmics. 
3.4.5 a-Adrenoceptor modulators 
Noradrenaline and adrenaline are the endogenous agonists for the a-adrenoceptors 
present in synapses of the sympathetic nervous system. Both central and peripheral 
a r and a 2 -adrenoceptors are present at postsynaptic sites. At the presynaptic site 
only a 2 - a d r e n o c e p t o r s occur and their st imulation leads to auto-inhibit ion of 
noradrenaline release. Stimulation, by an appropriate agonist, of both postsynaptic 
a r and oc 2-adrenoceptors in vascular smooth muscle can trigger extracellular C a 2 + -
influx through receptor-operated calcium channels. Calcium channel blockers do not 
interfere with the formation of the ligand-receptor complex, and only prevent C a 2 + -
influx through calcium channels . oe r adrenoceptor stimulation involves both I P 3 
induced intracellular re lease of calcium from the sarcoplasmic re t iculum and 
extracellular Ca 2 + - in f lux 6 1 .
 N 
The alkaloid reserpine depletes catecholamines from central and peripheral neurones 
by preventing the uptake of catecholamines from the cytoplasmic pool into the 
s torage ves ic les of sympathet ic neurones , leading to deple t ion of neuronal 
catecholamine stores. Reserpine, once used in antihypertensive therapy, has become 
obsolete. 
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^ -ADRENOCEPTOR ANTAGONISTS 
^ - A d r e n o c e p t o r antagonists are vasodilators and give a decrease in blood pressure 
because of the blockade of vascular a r a d r e n o c e p t o r s . Prazosin 43 and doxazosin 44 
(fig. 9b) are selective a r a d r e n o c e p t o r antagonists and have become valuable drugs 
for the treatment of hypertension and congestive heart fa i lure 6 2 . In contrast to non­
selective a 1 / a 2 - a d r e n o c e p t o r blockers, these drugs are virtually devoid of reflex 
tachycardia triggered by the baroreflex system and the autonomic nervous system. 
Figure 9b: Antihypertensives; oc r adrenoceptor antagonists 
(^-ADRENOCEPTOR AGONISTS active in the central nervous system 
Agonists of the a 2 -adrenoceptors in the central nervous system mediate hypertension 
and bradycardia. Centrally acting <x2-agonists ( a -methy l -DOPA 45 , Clonidine 46, 
guanfacine 4 7 , and azepexole (B-HT 933) 48; fig. 9c) lower blood pressure by 
decreasing the activity of the sympathetic nervous system. The bradycardiac effects 
of o^-agonists results from centrally induced stimulation of cardiac pre-synaptic oc2-
adrenoceptors . The lipophilic nature of a 2 - a g o n i s t s determines the central or 
peripheral a 2 -agonis t i c action upon systemic administration. Therefore, centrally 
acting (^-adrenoceptor agonists must be lipophilic to be able to cross the blood brain 
barrier. A side effect of oc 2-agonists is sedation, which is possibly mediated by pre­
synaptic o^-adrenoceptors. 
CI 
CI 
45 a-methyl-DOPA 46 Clonidine 
o CI 
47 Guanfacine 48 Azepexole (B-HT 933) 
Figure 9c: Antihypertensives; oc 2-adrenoceptor agonist 
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0C2-ADRENOCEPTOR ANTAGONISTS active at peripheral arterial (^-adrenoceptors 
The selective a 2 -adrenoceptor antagonists SK&F 86466 49 and SK&F 104078 50 
(fig. 9d) have been shown to reduce blood pressure in some animal models, by 
blocking the post-synaptic a 2 - a d r e n o c e p t o r 6 3 . However, in humans S K & F 86466 
caused tachycardia and had little effect on blood pressure. Post-synaptic a 2 -
adrenoceptor b lockers are impor tan t tools in identifying the vascular oc 2-
adrenoceptor. However , in contrast to vascular a r a d r e n e r g i c antagonists , post­
synaptic vascular a 2 - ad renocep to r antagonists have not yet been established in 
antihypertensive treatment. 
R 
49 SK&F 86466 R = H 
50 SK&F 104078 R = O C H 2 C H = C ( C H 3 ) 2 
Figure 9d: Antihypertensives; o^-adrenoceptor antagonist 
3.4.6 Potassium channel activators 
K + - c h a n n e l activators affect K + -channe ls in cardiac muscles , neurones, and in 
secretory cells but exhibit their greatest effect in the smooth muscle sys tem 6 4 . Since 
cromakalim 5 1 (fig. 9e) was discovered to enhance the transport of potassium ions 
across smooth muscle membranes, it increased the interest in the function of ATP-
sensi t ive K + - c h a n n e l s 6 5 ' 6 6 . K+-channel activators are under deve lopment for 
treatment of hypertension, angina and asthma. K + -channel activators relax vascular 
smooth muscle and protect the heart during acute i schemia 6 7 . Different tissues, like 
smooth muscle, pancreatic and cardiac cells have different subtypes of ATP-sensitive 
K + - c h a n n e l s 6 8 . Various activators of the ATP-sensitive K + -channels in cardiac cells 
(like nicorandil 52 , pinacidil 53; fig. 9e) protect the myocardium without depressing 
myocardial function. Nicorandi l has additional properties such as vasodilation 
because of the present nitrate ester (see antianginal drugs). 
Recently, aprikalim 54 (fig. 9e) was selected for further investigations to establish the 
antihypertensive and antianginal ac t ions 6 9 . Attempts have been made by Brown et 
a l . 7 0 to remove one of the chiral centers of aprikalim to give synthetically easily 
accessible compounds, but this has led to less active compounds. 
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51 Cromakalim 52 Nicorandil 
5 3 Pinacidil 54 Aprikalim 
Figure 9e: Antihypertensives; K + -channel activators 
3.4.7 Calcium channel blockers 
Calcium channel blockers (CCBs) are now of primary importance in the treatment of 
cardiovascular diseases, particularly for angina pectoris and hypertension, because 
they influence the free cytosolic Ca 2 + -concentrat ion. The Ca 2 + -concentrat ion plays a 
key role in the smooth muscle contraction-relaxation process. As mentioned in a 
previous section, calcium homeostasis in the cell is regulated by several influx and 
efflux mechanisms. 
The calcium influx occurs via voltage-operated (VOC) or potential-operated channels 
(POC). 
Nowadays, 4 different types of VOCs have been identified. Each subtype may be 
distinguished by electrophysiological, pharmacological , and distribution criteria. 
These criteria are based upon differences in their activation and inactivation kinetics,, 
and their drug and toxin sensit ivity 7 1 . 
1) L-type channels are the primary type in h e a t , skeletal, and smooth muscle cells. 
High voltage activated L-type channel openings produce a slowly inactivat­
ing long lasting Ca 2 + -current . Therefore, these channels are also referred to as 
slow inward calcium channels. 
2) T-type, or low voltage activated, channels are responsible for a rapidly 
inactivating transient Ca 2 + -current . These channels are located in myocardial 
cells, particularly in sinoatrial nodes, atrioventricular nodes, and in smooth 
muscle cells and neurones. 
23 
Chapter 1 
3) N- type channels are found in neurones and may regulate neurotransmitter 
release. Like P-type channels, they have an intermediate single-channel con­
ductance compared to L- or T-type channels . N-type channels are highly 
sensitive to co-conotoxins. 
4) P-type channels, like L- and N-type channels, are high voltage activated C a 2 + -
channels. P-type channels are located in cerebellar Purkinje cells and may be 
responsible for neurotransmitter release in many brain regions. 
In vascular smooth muscle cells, calcium influx mainly takes place via specific L-type 
Ca 2 + -channels and to a lesser extent via the Na + /Ca 2 + - exchange process. 
Several exogenous ligands exist which can selectively block Ca 2 + - en t ry through L-
type calcium channels. These ligands can be classified according to several criteria, 
based upon: chemistry, specificity on calcium current inhibition and tissue selectivity / 
clinical u s a g e 7 2 . 
In this chapter the chemical criterion is used to define the classes of CCBs (fig. 9f): 
- phenylalkylamines, like verapamil 55 
- benzodiazepines, like diltiazem 56 
- dihydropyridines (DHPs), like nifedipine 57 
57 Nifedipine 58 Nicardipine 
Figure 9f: Antihypertensives; calcium channel blockers 
24 
Chapter 1 
The CCBs are a heterogeneous group of agents that differ in their affinity for 
vascular smooth muscle and myocardial cells, which both are more dependent on 
extracellular Ca 2 + - inf lux than skeletal muscle. Despite their structural heterogeneity, 
they all block Ca 2 + - inf lux through L-type calcium channels. 
CCBs have favourable effects on ischemia which could be contributed to their direct 
cardioprotective effects, prevention of Ca 2 + -accumula t ion in the mitochondria in 
ischemic cells, decrease in oxygen consumption or coronary artery vasoconstriction 
and/or prevention of ischemia induced arrhythmias 7 3 . 
CCBs prevent ventricular arrhythmias via reduction of the free intracellular C a 2 + -
concentration and their negative inotropic, chronotropic, and dromotropic effects and 
by vasodilation. Myocardial oxygen consumption is decreased by negative inotropic 
and chronotropic effects, as well as, peripheral vasodilation. Dilation of the coronary 
artery system enhances oxygen supply to the myocardium. The ratio of the negative 
inotropic effects versus vasodilation determines the use of CCBs in clinical practice. 
Verapamil and diltiazem analogues reduce the heart rate and elongate atrioventricular 
conductance and, therefore, makes them particularly useful for the treatment of 
supraventricular arrhythmias and prevention of heart fai lure 7 4 . 
DHPs have a higher degree of selectivity for vascular smooth muscle cells and exhibit 
greater vasodilating properties, but show less depressant effects on myocardial 
contractility than verapamil or diltiazem and their analogues, and therefore makes 
them less suitable for cardiac a r rhy thmias 7 5 . The first generation of DHPs, like 
nifedipine, have the disadvantage of a short duration of action, especially in chronic 
treatment of essential hypertension. Therefore, new DHPs (like nicardipine 58; fig. 9f) 
have been developed, which have a longer duration of action or selectivity for 
specific vascular beds which include the resistance vessels for hypertension, the 
coronary system for angina pectoris , and the renal vascular system for renal 
d i seases 7 6 . 
4 Prospects for drug therapy of cardiovascular disorders 
4.1 Single drug therapy 
For quite a long time it was believed that CCBs should not be used for treatment of 
congestive heart failure, because of their hazardous negative inotropic e f fec ts 7 7 . 
However , the newer generation of DHPs have emerged CCBs which are now 
thought to be suitable for therapeutic t reatment 7 8 . 
Progress in antianginal therapy can be achieved by developing nitrate esters which 
dissolve the problems of nitrate-tolerance, hypotension and reflex tachycardia. 
Although the use of long-acting orally available drugs is recommended, their benefit 
has not been proven yet. The use of (3 r antagonists in chronic treatment of angina 
has to be carried out with care. Especially, because sudden interruption of antianginal 
treatment with p x -antagonists worsen the symptoms of angina pectoris and even 
myocardial infarcts can occur. 
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Today, qui te a number of distinct agents can be applied for the treatment of 
hypertension. Traditionally p-adrenergic blockers and diuretics were the drugs of 
choice. Nowadays the use of calcium channel blockers and angiotensin-converting 
enzyme inhibitors gain more interest for the treatment of hypertension. The position 
of the p-adrenergic antagonists and diuretics seem to remain constant 7 9 . 
The major d isadvantage of thiazide diuretics is their induct ion of metabolic 
disturbances affecting circulating lipids, blood glucose, and serum electrolytes. These 
d isadvantageous effects are also observed upon treatment with P - ad rene rg i c 
blockers, but are absent with ACE-inhibitors and CCBs. Furthermore, side effects 
exhibited by p-blockers are the reduction of left ventricular functioning and 
appearance of chronic obstructive pulmonary d isease 8 0 . 
ACE-inhibitors and CCBs reduce cardiac hypertrophy, and are thought to prevent 
remodell ing of the vascular system and renal damage, often accompanied with 
hypertension. It is suggested that drugs which prevent left ventricular hypertrophy 
may reduce mortality in patients suffering from heart failure, whereas antiarrhythmic 
drugs failed to do s o 8 1 . The a r a n t a g o n i s t prasozin and the p-antagonists are devoid 
of these actions. Despite the suggestion that ACE-inhibitors can have beneficial 
effects in the treatment of coronary artery disease, clinical findings are inconsistent 
and controvers ia l 8 2 . 
Selective angiotensin II subtype antagonists (ATX and A T 2 ) will present a valuable 
tool for further unravelling of the possible beneficial contribution to treatment of 
atherosclerosis and certain cardiovascular diseases. Extensive research is going on in 
the development of new selective angiotensin II antagonists. This is clearly noticed in 
literature; presently almost each new issue of the Journal of Medicinal Chemistry 
contains articles concerning both peptidic and nonpeptidic ACE-inhibitors and ACE-
antagonists. 
As mentioned before, CCBs are devoid of adverse effects on circulating lipids or on 
insulin insensitivity. One of the advantages of CCBs over ACE-inhibitors is that 
CCBs are metabolized in the liver and that their dosages do not have to be reduced 
in patients suffering from hypertension and malfunctioning of the k i d n e y 7 4 . The 
DHP-type calcium channel blockers have been shown to be more vascular selective 
than the phenylalkylamine- or benzothiazepine-type calcium channel blockers. Still 
these DHP-type calcium channel blockers may be improved by prolongation of their 
duration of action and by increasing their vascular selectivity, and by incorporation 
of additional biological activit ies 8 3 . 
The most intriguing new aspect of DHP-type CCBs which still has to be fully 
explored, is their antiatherogenic effect. Such effects would add most desirable 
properties to calcium entry blockade, since clinical trials with hypertensive patients 
have demonstrated that vasodilation and blood pressure reduction are not sufficient 
enough to protect against coronary diseases. 
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4.2 Combination of cardiovascular drugs 
Although it is still preferred to start antihypertensive treatment with one single drug, 
most of the antihypertensive effects of the described agents can be increased by 
combination with agents belonging to one of the other antihypertensive c l a s ses 8 4 . 
However, not every combination results in beneficial effects. The beneficial effect of 
ß-blockers with DHP-type CCBs is their prevention of initial reflex tachycardia 
occurring upon D H P treatment. Especially useful combinations are the DHP-type 
CCBs with ß-blockers or with ACE-inhibitors. The verapamil- and diltiazem-type 
CCBs should be avoided in combination with ß-blockers because of the increased 
negative inotropic and dromotropic effects, which will lead to bradycardia and 
atrioventricular block. 
Not only combinations within one certain pharmacological class can give beneficial 
effects, also combinations of antiarrhythmics, cardiotonics, antianginals and anti­
hypertensives are possible, ßi-Adrenoceptor antagonists are used as antiarrhythmic, 
antianginal, and antihypertensive drugs. Because one single class of compounds ( ß r 
adrenoceptor antagonists) is used in the t reatment of three dist inct types of 
cardiovascular disorders, it might be expected that, in principal, combinations of drugs 
belonging to the antihypertensive, antianginal and antihypertensive classes can 
contribute additional beneficial properties. 
Inodilation, the combination of enhanced contractility and vasodilat ion therapy 
should hypothetically be ideal for the treatment of heart fa i lure 8 5 . Inodilators should 
reduce systolic and diastolic wall stress by improving cardiac pump function. As 
mentioned before, in severe heart failure, the positive inotropic action in inodilation 
should not be achieved by increasing cAMP levels. More benefit could be obtained 
by increasing the calcium sensitivity of the contractile proteins. Such an effect then 
could open a field for new therapeutic drugs. 
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C h a p t e r 2 
H y b r i d m o l e c u l e s : 
c o m b i n a t i o n of m o r e t h a n o n e p h a r m a c o l o g i c a l p r o p e r t y in o n e 
s i n g l e m o l e c u l e 
1 Introduction 
A problem often faced in the treatment of certain diseases is the complex and 
he terogeneous pa thogenes is . A variety of media tors can be involved in the 
pathophysiological process leading to a disease. In many instances, treatment with a 
single drug cannot adequately control the illness. Sometimes, the use of a therapeutic 
agent alone in the treatment of a disease may be limited by side effects caused by its 
own action. Then combinations of drugs with different pharmaco-therapeutic effects 
are feasible. 
Combination drug therapy can be applied either to overcome the side effects of the 
single drug or to add beneficial effects. The principle of combination drug therapy 
can be achieved by either using concomitant administration of two or more single 
active drugs or by drugs in which the single active agents are combined in one 
molecule, so-called hybrid molecules . These hybrid molecules often consist of 
different pharmacophoric groups which are linked to each other via spacers. 
Although it is tempting to designate every molecule which produces more than one 
biological effect as a hybrid molecule, there are certain restrictions: 
- first of all, hybrid molecules must contain two or more pharmacophoric groups 
which exert biological actions via different receptors. 
- secondly, to be of clinical value, the biological properties must be present in the 
same concentration range. 
- thirdly, hybrid molecules must be resistant to metabolic processes which, after 
administration, would result in regeneration of the original drugs. 
In this r ev iew, the examples of hybrid molecules are main ly confined to 
cardiovascular drugs, besides some examples of anti-inflammatory and antiallergic 
agents discussed. If not indicated, the chiral compounds were pharmacologically 
evaluated as racemic mixtures. 
2 Classification of hybrid molecules 
The classification of hybrid molecules will be discussed only briefly, because this 
theme has extensively been reviewed by Ariens 1 . 
In scheme 1 a classification of compounds having more than one biological action or 
compounds containing two or more pharmacophores is given. 
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1 p r o d r u g s 
2 t w i n drugs a) identical twins 
b ) non- ident ica l twins 
c) symmet r ica l d rugs ("s iamese twins" ) 
3 p seudo-hybr id s 
4 hyb r id d rugs 
Scheme 1: Classification of hybrid molecules 
2.1 Prodrugs 
Prodrugs are used to increase the bioavailability and/or the local concentration of 
drugs. These prodrugs contain a chemical moiety which, after administration, is 
cleaved from the parent drug. This implies that the metabol i te of the applied 
compound contains the pharmacological activity, while the prodrug itself is often 
inactive. Depending on the target area of action and the physicological properties of 
the drug, lipophilic or hydrophilic structural moieties are used. L-DOPA is an example 
of a naturally occurring (endogenous) prodrug which is metabolized by the enzyme 
DOPA-decarboxylase into dopamine. Prednisolone succinate (fig. 1) is an example of 
a synthet ic prodrug. The succinate moiety adds hydrophil ici ty to the steroid 
derivative and is split after administration. 
Figure 1: The prodrugs 1-DOPA and prednisolone 
2.2 Twin drugs 
Compounds classified as twin drugs are not hybrid molecules in the definition of our 
classification. Although the non-identical twin drugs exist of two structural different 
moie t ies , these compounds are considered as chemical hybr ids and not as 
pharmacological hybrids. 
All twin drugs are in vivo metabolized into their parent drugs. Actually, also twin 
drugs can be considered as prodrugs from which the original drug molecules are 
released. A schematic representation of twin drugs and their metabolites is given in 
figure 2. 
O 
O 
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identical twin drug (A-A) - 2A 
non-identical twin drug (A-A 1) ^ A + A' 
(A-B) - A + B 
symmetrical drug (A-A) 2A 
Figure 2: Twin drugs and their metabolites 
2.2.a Identical twins (fig. 3) 
Compounds belonging to this class consist of two identical structural moieties, 
having the same pharmacological profile. After administrat ion, twin drugs are 
metabolized into their identical agents. In figure 3 the dotted lines indicate the place 
were the identical twin drugs are cleaved during metabolization. 
Figure 3: Identical twin drugs 
2.2.b Non-identical twins (fig. 4) 
This class consis ts of drugs which have different structural moie t ies . Upon 
administration, the non-identical twin drugs are metabolized into two structural 
moieties which can have an identical or non-identical pharmacological profile. For 
example, etofibrate is cleaved into a clofibric acid derivative and nicotinic acid, both 
having lipolytic activity. The analgesic compound benorilate is constructed of the 
analgesics acetylsalicylic acid and paracetamol. Metabolization of non-identical twins 
into structural moieties which have different pharmacological profiles can be 
considered as an unwanted side effect on hybrid molecules. 
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clofibric acid nicotinic acid 
Figure 4: Non-identical twin drugs 
2.2.C Symmetrical twin drugs 
Symmetrical twin drugs, also called "Siamese twins", contain two identical structural 
moieties (fig. 5). After administration these compounds, however, remain intact. In 
bifunctional symmetrical drugs, the two identical pha rmacophore groups can be 
directly linked to each other or via a spacer. The examples shown in figure 5 are the 
anticoagulant dicoumarol , the analgesic forbisen and the a -adrenocep tor blocker 
dibozane. 
H,C. 
H 3 C - N N 
Figure 5: Symmetrical drugs ("Siamese twins") 
Many symmetrical ligands have been used to identify the interbinding site distances 
at pharmacological receptors. In these drugs the affinity for the receptors might be 
enhanced by dimeric agents which are capable of successfully bridging two adjacent 
receptors. 
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Dimeric 1,4-dihydropyridine (DHP) calcium channel blockers have been synthesized 
and pharmacologically evaluated in a radioligand binding assay 2 . The alkylene spacer 
linking the two identical DHP derivatives was varied from an ethyl to a dodecyl chain 
(fig. 6). However, the affinities of the dimeric compounds were similar to that of the 
corresponding monomelic DHPs. Inactivation, by proper structural changes, of one of 
the DHP structural moieties revealed that this series of ligands did not bridge adjacent 
1,4-DHP receptors of the calcium channel. 
H H 
Figure 6: Dimeric 1,4-dihydropyridines; n varies from 2,4,6,8,10 to 12 
2.3 Pseudo-hybrids 
Pseudo-hybrids are drugs which combine two or more pharmacological actions in a 
racemic mixture of a chiral molecule. Many chiral adrenoceptor l igands, tested as 
racemates exhibit more than one pharmacological action. However, separation of the 
stereoisomers often revealed that the pharmacophoric groups are localized in the 
different stereoisomers 3 . 
Labetalol (AH-5158) is the best known example of a pseudohybrid molecule . 
Labetalol contains two chiral centers and therefore consists of four stereoisomers 
(fig.7). Racemic labetalol exhibits o c r , p r and p2-adrenergic blocking activities. In 
table 1 the adrenoceptor blocking activities of racemic labetalol and its enantiomers 
are given. 
Figure 7: Racemic labetalol (* indicates chiral center) 
Table 1 shows that, although the racemic labetalol is a potent antagonist for all three 
receptors, the oci-adrenergic blocking activity mainly resides in the (S,R) isomer, while 
(3-adrenergic blocking activity is found in the (R,R) isomer called dilevalol. Therefore, 
labetalol is considered to be a pseudo-hybrid molecule. 
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Table 1: Adrenoceptor blocking activities of labetalol and its stereoisomers 
compound p A 2 (ßi) p A 2 (ß 2 ) p A 2 (a i ) 
(±)-labetalol a 8.31 8.10 7.44 
(R,R) b 8.26 8.52 5.87 
(S,S) b 6.43 < 6 . 0 5.98 
(R,S) b 6.97 6.33 5.5 
(S,R) b 6.37 < 6 . 0 7.18 
a) Data determined by Brittain et al. 4 (1976) b) Brittain et al. 5 (1982) 
Many other compounds possessing both a - and p-adrenergic blocking activity such 
as celiprolol, bevantolol, arotinolol, amosulalol and carvedilol (reviewed by Sponer et 
a l . 6 ) must be considered as pseudo-hybrid molecules, as long as their individual 
stereoisomers are not evaluated for their adrenergic activity and selectivity. 
Trimetoquinol 7 (TMQ; fig. 8), marketed for its bronchodilating effects, is a competitive 
inhibitor of prostaglandin (PGH2)/thromboxane A 2 mediated responses in rat aorta 
and human platelets. Besides T M Q is a nonspecific p-adrenergic agonist. However, 
T M Q has to be considered as a pseudo-hybrid, because the PGH2/TXA2 inhibitory 
actions mainly resided in the (R)-(+) enantiomer, while the most potent nonspecific p-
adrenergic agonistic activity was found in the (S)-(-) enantiomer of T M Q 8 . 
Figure 8: Trimetoquinol 
N 
2.4 Hybrid molecules 
Hybrid molecules are constituted of different pharmacophoric groups which are 
directly linked to each other or via spacers. 
The advantage of hybrid molecules over fixed-ratio drug combinations in one dosage 
form would be that hybrid drugs are absorbed, distributed, metabolized and excreted 
at one rate, implying that the concentration of the drug during the entire course 
remains in balance. While concomitant applied drugs compete with each other for 
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plasma-protein binding sites and thus influencing each others bioavailability, the total 
plasma-protein bound fraction and the free drug concentration remain the same for 
hybrid drugs. 
A disadvantage of hybrid molecules could be the fixed concentration ratio of the 
p h a r m a c o p h o r e groups. Although in theory each pharmacophoric group should 
retain its own pharmacological profile, this could imply that at a certain concentration 
of the hybrid molecule, only one of the pharmacophoric groups is able to exert its 
biological effect. Therefore, it is important that the pharmacophoric groups must exert 
their biological action in a narrow concentration range. 
The quest ion arises whether every compound which exhibits besides its main 
(desired) action, more or less unwanted side effects are due to the fact that the 
molecule contains more than one pharmacophoric group. Both main action and side 
effect obeys the receptor-ligand theory. However, if the side effect is based on a 
common mechanism (same ligands and receptors) one cannot speak of hybrid 
molecules. 
In nature and among current drugs, a number of molecules exist which exhibit more 
than one biological activity. In contrast to designed hybrid molecules, it is often very 
difficult to distinguish the pharmacophoric groups. The chemical moieties responsible 
for the different biological effects may coincide or overlap to a considerable degree. 
At this point , s tructure-act ivi ty relat ionship studies together with the three 
dimensional structure of the molecule could contribute to the insight how to modify 
the molecular structure in such a way that the biological action responsible for the 
side effect is eliminated. A nice example of "destruction" of a hybrid molecule to 
unravel the distinct pharmacophor ic groups is given by Chenard et a l . 9 who 
examined the minimal structural requirements of ifenprodil (fig. 9) to be active as a N-
methyl-D-aspartate (NMDA) antagonist. 
Figure 9: Ifenprodil and the minimal structure in this class exhibiting N M D A 
antagonistic activity 
Racemic ifenprodil possesses both potent a r a d r e n o c e p t o r and N M D A antagonistic 
activity. Separation of the stereoisomers revealed that a ! -adrenerg ic and N M D A 
potencies can be distinguished between the erythro and threo diastereoisomers of 
ifenprodil. Within the (+)- and (-)-enantiomers of threo ifenprodil these activities run 
together (table 2). By individual removal of most of the structural fragments from 
HO 
minimal structure with 
NMDA antagonistic activity 
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ifenprodil, a minimal structure has been identified with nearly equivalent in vitro 
activity as ifenprodil This minimal structure has little selectivity for the NMDA and 
oq-adrenergic actions. By appropriate substitution this minimal structure could afford 
potent antagonists selective for NMDA or a r a d r e n o c e p t o r s . 
Table 2: N M D A antagonistic activity and a r a d r e n e r g i c affinity of ifenprodil isomers 
ifenprodil N M D A 1 (Xi 2 (Xi/NMDA 
erythro (+/-) 2 6 3 100 0.38 
erythro (+) - - -
erythro (-) 110 135 1.23 
threo (+/-) 5 5 8 4 3 15.3 
threo (+) 4 8 2306 4 8 
threo (-) 13.3 629 47.3 
minimal structure 290 347 1.19 
1 Measured on rat hippocampal cell cultures 
2 Displacement of [3H]prazosin from rat brain membranes 
3 The selectivity ratio of ifenprodil for NMDA receptor and ai-adrenoceptors 
Although in many cases drug design aims at the elimination of side effects of 
particular drugs, it is also possible to modify the chemical structure in such a way that 
the side effect is converted into the main therapeutic effect. Such a shift from 
therapeutic effect to side effect and vice versa is described for the anti-infectious 
agent sulfanilamide 1 (fig. 10). Structural modifications carried out on sulfanilamide 
analogues with a main anti-infectious action and hypoglycemic side effects, afforded 
the oral antidiabetic tolbutamide (fig. 10), which was devoid of anti-infectious 
activity. 
sulfanilamide tolbutamide 
Figure 10: The anti-infectious agent sulfanilamide and the antidiabetic tolbutamide 
Another example of shifting from action A via a hybrid molecule (action A+B) to 
action B is demonstrated by the platelet activating factor (PAF) antagonists UK-
74,505 (fig. I I ) 1 0 . The 1,4-dihydropyridine-type calcium channel blocker amlodipine 
(fig. 11) is a potent and long-lasting antihypertensive agen t 1 1 . The search for other 
potent vasodilators resulted in the amlodipine derivative compound 6 a 1 2 . Besides, 
being a potent vasodilator, compounds 6a also possessed potent P A F antagonistic 
activity. A synthesis program undertaken to eliminate the calcium channel blocking 
activities of compound 6a resulted in UK-74,505. UK-74,505 is highly selective as a 
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P A F antagonist, showing only weak affinity for the dihydropyridine binding site 
(table 3). 
UK-74,505 
Figure 11: Structures of the calcium channel blocker (CCB) amlodipine, a hybrid 
CCB/PAF antagonist, and the PAF antagonist UK-74,505 
Table 3 : Pharmacological data of amlodipine 1 1 , compound 6a 1 2 , and UK-74,505 
K ; ; n M a I C 5 0 ; n M b KJ; nM c I C 5 0 ; nM à 
amlodipine N P 7 . 9 N A N A 
compound 6a N P 5 . 0 1 2 2 5 
U K - 7 4 , 5 0 5 6 6 0 0 N T N P 4 . 3 
NP Not presented, NT Not tested, NA Not active 
a Inhibition of [3H]nitrendipine binding to rat cortex membranes 
b Inhibition of K+-depolarization induced contraction in rat aorta 
c Inhibition of [ 3H]PAF binding to rabbit washed platelets 
d Inhibition of PAF-induced aggregation of rabbit washed platelets 
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Sunkel et a l . 1 3 have descr ibed the synthesis of several other select ive P A F 
antagonists which are devoid of calcium channel blocking activity. PCA 4248 
(fig. 12) is, just like UK-74,505, derived from D H P calcium channel blockers, which 
were structurally modified in such a way that the therapeutic profile was completely 
switched from calcium channel blockers via hybrid molecules to P A F antagonists 1 4 . 
H 
Figure 12: The selective P A F antagonist PCA 4248 
PCA 4248 has been shown to be a potent P A F antagonist in v i t r o 1 5 and in v i v o 1 6 
and was devoid of calcium channel blocking activity. 
While most of the fortuitously discovered hybrid molecules have coinciding or 
overlapping pha rmacophore groups, in most of the designed hybrid molecules the 
pharmacophore groups are linked to each other via spacers. 
Combinat ion of different p h a r m a c o p h o r e groups does not automatically lead to 
successful hybrid drugs. Rather, it often appears that the individual structure-activity 
relationships may be mutually exclusive. Structural modifications of moderately 
active hybrid molecules to increase the biological activities is also often restricted to 
the narrow structure-activity relationships. The following examples illustrate the 
failure of combination of two pharmacophore groups. 
Baldwin et a l . 1 7 have synthesized hybrid molecules (fig. 13) combining a 1,4-
dihydropyridine (1,4-DHP) calcium channel blocker with a pj-adrenergic blocker 
(aryloxypropanolamine). Both substitution on the ortho- and para-position on the 4-
phenyl ring of the 1,4-DHP structure afforded hybrid molecules which were devoid of 
potent pj-adrenergic activity. 
OH 
H 
Figure 13: A hybrid molecule containing DHP and p r adrene rg ic blocking structural 
moiety 
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Corsano et a l . 1 8 have synthesized a series of hybrid molecules based on the calcium 
channel blocker cinnarizine and the p r a n t a g o n i s t propranolol (fig. 14). Whereas 
some of the hybrid molecules showed low affinity for atrial p a d r e n o c e p t o r s , none of 
the designed hybrid molecules exhibited in vitro calcium channel blocking activity. 
Figure 14: A hybrid molecule related to cinnarizine and propranolol 
Laguerre et a l . 1 9 have synthesized several hybrid molecules in which the calcium 
channel blocker verapamil was combined with a - and p -adrenergic b locking 
structural moieties and with cinnarizine type calcium channel blockers (fig. 15). Some 
hybrid molecules with a p-adrenergic blocking moiety were nearly as potent as 
verapamil in calcium channel blocking activity. The in vitro calcium channel blocking 
activities (PIC50 values) determined on K + -depolarizat ion-induced contractions on 
rabbit aorta ranged from 6.11-6.63. However, in vivo no increase in blood pressure 
reduction was observed in spontaneously hypertensive rats. Besides, no adrenergic 
blocking activities or affinities are presented. Therefore, it is impossible to confirm 
whether these compounds can be considered as pharmacological relevant hybrid 
molecules. 
Willard et a l . 2 0 have synthesized hybrid molecules based on a benzodioxane P-
adrenergic blocker and the diuretic quincarbate (fig. 16). However , the designed 
tricyclic amino alcohols appeared to be inactive as a diuretic or as a p-adrenergic 
blocker. 
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HoCO 
modified part 
calcium 
channel 
blocker 
OCHo 
OCHo 
r w verapamil 
C H a
 p l C 5 0 = 6.80 
ß-blocker moiety 
p l C 5 0 = 5.76 
structural moiety 
present in cinnarizine 
p l C 5 0 = 4.72 
a-blocker moieties 
r~\ 
H 3CO 
— N N 
p l C 5 0 = 4.88 
Figure 15: Structural modifications on verapamil and the corresponding calcium 
channel blocking activities (PIC50) . 
Cl O 
COOC 2H 5 
COOC 2H 5 
X = H or CI 
Figure 16: Hybrid molecules combining diuretic and (3-antagonist structural moieties 
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Görlitzer et a l . 2 1 synthesized dihydropyridines (1,4-DHPs) with combined etacrynic 
acid structural moieties (fig. 17). Etacrynic acid is a diuretic, while 1,4-DHPs are 
vasodilators. This combination could be useful as antihypertensive drugs. However, 
the 1,4-DHPs were easily oxidized to the corresponding pyridines, which are inactive 
as calcium channel blockers. 
Cl O 
Figure 17: Hybrid molecules combining vasodilating and diuretic activities 
These few examples demonstrate that even if designed hybrid molecules can be 
synthesized, the resulting compounds often are inactive at one or both systems. 
3 Replacement of combination drug therapy by hybrid drugs 
Combination drug therapy is applied in the treatment of many disorders. In many 
cases combination drug therapy could be successfully be replaced by hybrid drug 
therapy. Among the hybrid drugs developed for the treatment of certain disorders 
belong, inter alia, antibiotics, central nervous system therapeutics, anti-inflammatory 
and antiallergic agents, and cardiovasculair agents. With the aid of two different 
principles, the inflammatory / allergic disorders and cardiovascular disorders, the 
rational idea behind hybrid molecules will be explained. In section 4 antagonists and 
inhibitors of inflammatory/allergic disorders are discussed and some examples of 
synergistically acting hybrid molecules will be presented. In section 5, cardiovascular 
drugs used for the treatment of arrhythmias, angina pectoris, congestive heart failure, 
and hypertension are discussed. Furthermore, several hybrid drugs will be discussed 
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with regard to their potenciáis for the treatment of a combination of cardiovascular 
disorders. 
4 Inflammatory and allergic disorders 
The pa thogenes i s of inf lammatory and allergic disorders is a complex and 
he te rogeneous p rocess . Leuko t r i enes , p ros tag land ins , and t h romboxane are 
arachidonic acid metabolites synthesized and released from their stores in response to 
a variety of inflammatory and immunological stimuli. Furthermore, several other 
mediators, such as histamine, are released. 
Arachidonic acid is stored in cell membranes as a phospholipid. Phospholipase A 2 
hydrolyzes the cellular phosphol ipid and releases arachidonic acid (fig. 18). 
Arachidonic acid can be oxygenated by the enzyme cyclooxygenase resulting in the 
formation of the prostaglandins P G G 2 and P G H 2 . Subsequently, these prostaglandins 
are converted into the prostaglandins (PGD 2 , PGE^, and P G F 2 a ) , p ros t acyc l in (PGI 2 ) 
and thromboxane A 2 (TxA 2 ) . 
cell membrane 
arachidonic acid-phospholipid ester 
phospholipase A 2 — 
arachidonic acid 
T prostacycline 
LTÈ4 ^ PGI2 
Figure 18: Biosynthesis of leukotrienes, prostaglandins, prostacycline and 
thromboxane 
Pros tag land ins are involved in inf lammat ion (e.g. , capi l lary permeabi l i ty ) . 
P ros tacyc l ine ( P G I 2 ) is a vasodilator and an inhibitor of platelet aggregation. 
Thromboxane A 2 produces vasoconstriction, platelet aggregation, and contributes to 
airway hyperresponsiveness, induced by the platelet activating factor (PAF). The 
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enzyme cyclooxygenase is inhibited by non-steroidal anti- inflammatory drugs 
(NSAIDs), such as indometacin and flurbiprofen (fig. 23). 
The other oxygenat ion routes of arachidonic acid proceed via l ipoxygenases 
resulting in the formation of several hydroperoxyeicosatetraenoic acid derivatives 
(HPETE) which are precursors of the leukotrienes. By several peroxidases HPETE is 
converted into leukotriene L T A 4 which than can be further metabolized to L T B 4 , 
LTC4, L T D 4 , and L T E 4 . LTB4 is involved in inflammatory processes, while LTC4, 
L T D 4 , and L T E 4 play a role in asthma (bronchoconstriction). 
During allergic reactions histamine and PAF are released from a variety of cells and 
are able to induce bronchoconstriction and capillary permeability. 
Summarized, inflammation and allergic disorders can be treated with the following 
drugs: 
- cyclooxygenase inhibitors or prostaglandin antagonists 
- thromboxane A 2 synthetase inhibitors (TxSI) or thromboxane A 2 receptor 
antagonists (TxRA) 
- platelet activating factor (PAF) antagonists 
- nonsteroidal anti-inflammatory drugs (NSAIDs) 
- histamine H r an t agon i s t s 
- lipoxygenase inhibitors or leukotriene antagonists 
- steroids 
- immuno suppressant agents 
4.1 Hybrid molecules combining synergistic effects 
The complementary action of histamine and PAF in asthma offers the opportunity to 
inhibit their actions by hybrid molecules. 
Sch 37370 (fig. 19) has been reported to antagonize both histamine- and PAF-
induced allergic responses 2 2 . Although Sch 37370 is structurally related to histamine 
Hi-antagonis ts , such as loratadine, the latter ones are unable to antagonize PAF-
induced platelet aggregation. Furthermore, while many of the tricyclic histamine H r 
antagonists also possess ax-adrenoceptor blocking activities and antiserotonin (5-
H T 2 ) activity, Sch 37370 seems to be devoid of such actions. 
Figure 19: Sch 37370 a dual P A F and histamine ^ - a n t a g o n i s t (structurally related 
N 
Sch37370 R = C H 3 
Loratadine R = OC 2H; 
to loratadine) 
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Structural modifications carried out at the C-3 position of Sch 37370 revealed that 
analogues with electron withdrawing groups were less active dual antagonists than 
those with electron donating groups 2 3 * 2 4 . Thus structurally modifying Sch 37370 can 
afford compounds which are more selective for histamine Hj-receptors or for the 
TxA2-receptor. 
Although in vivo Sch 37370 exhibits equipotent P A F and histamine H r a n t a g o n i z i n g 
activities, the P A F activity is rapidly lost. This loss in P A F activity has been explained 
by metabolization into compounds which are devoid of P A F activity but which 
retained histamine H r an t agon i s t i c activity. The peculiar question arises whether Sch 
37370 can really be considered as a hybrid molecule, because the histamine H r 
antagonistic activity resides in the metabolite and is not caused by the original 
supposed hybrid molecule. 
Other examples of antiallergic agents possessing thromboxane A 2 and histamine H r 
dual antagonizing activity are KW-4099 and K F 1 5 7 6 6 2 5 (fig. 20). Both compounds 
are based on the observation that KW-4994 (fig. 20) has histamine H r a n t a g o n i s t i c 
and antiallergic act ivi t ies 2 6 . KW-4994, however, is devoid of potent thromboxane A 2 
receptor antagonistic ( T x R A 2 ) activity. Although racemic KW-4099 seems to be one 
of the most promising dual TxRA 2 / h i s t amine 1AX-antagonists, separation of the 
enantiomers reveals that KW-4099 is actually a pseudo-hybrid. The highest activity 
for both T x R A 2 - and histamine H r r e c e p t o r s does not reside in one enantiomer, the 
two modes of actions are devided among the optical isomers (table 4). Structural 
modifications of KW-4099 resulted in KF15766 (fig. 20), in which the E-isomer 
con ta ins both act iv i t ies , demons t ra t ing that it is poss ib le to obtain dual 
TxRA 2 /h is tamine H r a n t a g o n i s t s possessing a dibenzoxepin ring system. 
Figure 20: Hybrid molecules with dual TxRA 2 /histamine H r an tagon i s t i c activity 
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Table 4: T x A 2 / P G H 2 binding (guinea pig washed platelets) and Hj receptor binding 
(guinea pig cerebellum) of the several dual H ^ - T x A ^ G H k antagonists. 
compound T x A 2 y P G H 2 binding; Kj [nM] Hi receptor binding; K; [nM] 
KW-4994 1 8 % at 1 u.M 9.0 + 1.6 
(±)-KW-4099 140 + 3 18 + 3.8 
(+)-KW-4099 14000 ± 1 1 0 0 9.9 ± 0.29 
0 -KW-4O99 42 + 3.8 740 + 69 
(E)-KF15766 740 ± 44 20 + 0.8 
(Z)-KF15766 2600 15 + 1.6 
Examples of fortuitous hybrid molecules are terfenadine (fig. 21) and AHR-5333 (fig. 
22) . Terfenadine has been originally developed in a program searching for 
tranquill izers 2 7 . Later on, the antihistaminergic activity was discovered 2 8 . Terfenadine 
is the first non-sedating histamine H r a n t a g o n i s t and one of the most frequently 
prescribed antiallergic agents. Furthermore, terfenadine is structurally related to the 
diphenylalkylamine-type calcium channel blockers, and has affinity for the calcium 
channels. The calcium channel blocking activity of terfenadine might contribute to its 
antiallergic action. Recently it has been described that calcium channel blockers are 
capable to relax bronchial smooth m u s c l e 2 9 and to inhibit histamine release from 
human mast ce l l s 3 0 . Zhang et a l . 3 1 have synthesized the optical isomers of terfenadine 
and determined their ant ihistamine ( H r a n t a g o n i s m ) act ivi t ies 3 2 and calcium channel 
affinities 3 3 (table 5). 
(+)-R-terfenadine — c — 
(-)-S-terfenadine — c — 
VUF4591 - C H 2 — 
Figure 2 1 : Structure of terfenadine enantiomers and the terfenadine analogue V U F 
4591 
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Table 5: Ant ih i s tamine act ivi ty and ca lc ium channel affinity of terfenadine 
enantiomers and V U F 4591 
Hj-antagonism H^affinity calcium channel affinity 
p A 2 a p K d b p K d c 
terfenadine (R/S) 7.65 ±0.11 6.88 ±0.10 6.36 ± 0.03 
R-(+) 7.72 ± 0.09 7.06 ± 0.08 6.39 ± 0.08 
s-(-) 7.61 ±0.11 6.81 ± 0.08 6.40 ± 0.08 
V U F 4591 7.73 ±0.16 6.49 ±0.18 7.18 ±0.12 
a Inhibition of histamine-induced contraction in guinea pig ileum 
b Displacement of [3H]mepyramine from guinea pig cerebellum membranes 
c Displacement of [3H]nitrendipine from rat cortex membranes 
Terfenadine is an example of chiral hybrid drugs in which stereochemistry does not 
seem to play a role in several pharmacological tests, as the individual enantiomers are 
equally active as histamine Hi-antagonists and have similar affinities for calcium 
channels. Elucidation of the metabolic process of terfenadine has to reveal whether 
one of the enant iomers is favoured, confirming the necessi ty to use a single 
enant iomer 3 4 . 
Originally AHR-5333 (fig. 22) was developed for a central nervous system (CNS) 
project, but in vitro screening tests revealed that AHR-5333 has antiallergic 
properties. Profound in vitro investigations demonstrated that AHR-5333 inhibited 5-
lipoxygenase activity and inhibited leukotriene induced contractions in guinea pig 
ileum. Furthermore, AHR-5333 inhibited histamine release from rat mast ce l ls 3 5 . 
Figure 22: Antiallergic and antihistaminic hybrid molecules structurally related to 
terfenadine 
The AHR-5333 analogue AHR-13268D (fig. 22) was developed because drug 
metabolism studies revealed that AHR-5333 was extensively metabolized and that 
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the compound had poor oral availability in rats and dogs. Table 6 shows that AHR-
13268D has a lower affinity for the histamine H r r e c e p t o r than AHR-5333, but is a 
more potent antiallergic agent. 
Table 6: Histamine H r r e c e p t o r affinity and antiallergic activity of AHR-13268D and 
AHR-5333 
compound I C 5 0 ; nMa PFAb 
AHR-13268D 600 +++ 
AHR-5333 8 ++ 
astemizole 10 NT 
terfenadine 2 9 5 -
a Inhibition of [ 3H]mepyramine histamine Hj-receptor binding to guinea pig cortex 
membranes 
b Relative oral antiallergic activity in the passive foot anaphylaxis (PFA) model in rats 
(+++ very active; ++ active; - inactive; NT not tested) 
AHR-5333 and AHR-13268D show no affinity for the 5 -HT 2 receptor. Determination 
of the drug metabol ism process and of the bioavailability have to confirm the 
therapeutic efficacy of AHR-13268D as an antiallergic agent. 
The acidic non-steroidal anti-inflammatory drugs (NSAIDs) are widely used against 
inflammatory diseases, but they also cause gastroduodenal injury. NSAIDs inhibit the 
synthesis of prostaglandins by blocking the enzyme cyclooxygenase. However , 
prostaglandins are also believed to regulate gastric acid secretion and gastric mucosal 
blood flow. The major observed side effect of NSAIDs is therefore due to their main 
action. At the same time, inhibition of prostaglandin synthesis implies an increase of 
leukotriene synthesis, which in turn activates several biological effects. 
Histamine H 2 -antagonists have anti-ulcerogenic activity. Therefore, hybrid molecules 
constructed of an NSAID and a histamine H 2 -antagonist have been developed with 
the goal to counteract the side effects of NSAIDs. 
The designed hybrid molecule CP-331 (fig. 23) is based on the NSAID indometacin 
and the histamine H 2 -antagonist roxat idine 3 6 , while the hybrid molecule FP-PPA (fig. 
23) contains the structural moieties of roxatidine and of the NSAID flurbiprofen 3 7 . 
The anti-inflammatory, analgesic, and antipyretic effects of FP-PPA and CP-331 are 
exerted at about equimolar concentrations as indometacin while they are devoid of 
gastric mucosal damaging effects and induce less damage to the intestinal mucosa 3 8 . 
However, insufficient evidence is presented to exclude the possibility of hydrolysis of 
these hybrid molecules. 
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H 
a roxatidine analogue (histamine H 2 -antagonist) 
FP-PPA 
N 
Figure 2 3 : The hybrid molecules CP-331 and FP-PPA, constructed of a NSAID 
moiety and a histamine H 2 -antagonist 
5 Designed hybrid molecules as potential cardiovascular drugs 
Cardiovascular diseases involve several distinct disorders such as arrhythmia, angina 
pectoris, congestive heart failure or hypertension. The pharmacotherapeutic treatment 
of cardiovascular disorders has been discussed in chapter 1. In this chapter only some 
antiarrhythmic, antianginal, inotropic/cardiotonic, and antihypertensive agents are 
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presented to explain why hybrid molecules could be successful in treating these 
disorders. 
From table 7 it follows that several of the designed hybrid molecules are based on 
calcium channel blockers and on ß x -adrenoceptor antagonists. Probably because 
these type of cardiovascular agents , as ' s ing le ' drug, can be applied as anti­
arrhythmics, antianginals, and as antihypertensive drugs. Furthermore, combination 
drug therapy in a single dosage form has been proven to be successful in certain 
cardiovascular disorders. 
Table 7: Cardiovascular drugs used for the treatment or prevention of 
cardiovascular disorders 
antiarrhythmics: antianginals: 
class I; Na + -channel blockers nitrates and nitrites 
classll; -adrenoceptor antagonists Ca 2 + -channel blockers 
class III; K + -channel blockers ß x -adrenoceptor antagonists 
class IV; Ca 2 + -channel blockers 
antihypertensives 
inotropics / cardiotonics diuretics 
cardiac glycosides direct vasodilators 
-adrenoceptor agonists ßi-adrenoceptor antagonists 
histamine H 2 -agonists oc r adrenoceptor antagonists 
phosphodiesterase (III) inhibitors ot 2-adrenoceptor agonists 
Ca 2 + -channe l activators angiotensin II converting enzyme (ACE)-
inhibitors 
K + -channel activators 
Ca 2 + -channel blockers 
ANTIHYPERTENSIVE DRUGS 
In hypertensive patients the total peripheral vascular resistance is abnormally high, 
while the cardiac output and heart rate could still be unaffected. In the long-term 
treatment of hypertension, the use of vasodilators alone does not adequately control 
blood pressure, because of arising side effects which are a consequence of their 
action: the induced reduction in blood pressure activates the baroreceptor complex 
leading to increased sympathetic stimulation a n d l h u s activation of ß-adrenoceptors, 
result ing in tachycardia, increase in heart rate, and vasoconstrict ion and fluid 
retention via the renin-angiotensin sys tem 3 9 (fig. 24). 
In the long-term treatment of hypertension, there is no single antihypertensive drug 
which is able to normalize the elevated blood pressure in all hypertensive patients. 
R a h n 4 0 has described the principles in the combination of antihypertensive drugs and 
indicated that many antihypertensive drugs have synergistic effects upon combined 
application (table 8). 
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a 1 - a d r e n o c e p t o r 
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reduction in blood pressure 
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renin/angiotensin 
system 
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contractility and in plasma 
noradrenaline concentration 
retention of sodium 
and water 
Figure 24: The mode of action of several antihypertensive agents. 
Table 8: Percentage of patients with mild to moderate hypertension (diastolic blood 
pressure in the range of 90-114 mmHg) responding to antihypertensive 
agents (to a target diastolic blood pressure below 90 mmHg) . 
single drug % combination of drugs % 
propranolol (p) 52 propranolol + H C T 81 
atenolol (p) 57 N atenolol + nifedipine 100 
nifedipine (CCB) 64 HCT + nifedipine ++ 
HCT(D) 56 HCT + diltiazem (CCB) n.a.e. 
enalapril (ACE) 60 ACE + CCB ++ 
P P-adrenergic blocker CCB calcium channel blocker 
HCT hydrochlorothiazide D diuretic 
ACE angiotensin (II) converting enzyme inhibitor 
n.a.e. no additional effect ++ better than either one of them alone 
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When two antihypertensive drugs together are insufficiently effective, even triple 
drug combinations can be used such as the combination of: 
(3-adrenergic blocker + diuretic + nifedipine 
p-adrenergic blocker + diuretic + angiotensin (II) converting enzyme inhibitor 
diuretic + angiotensin (II) converting enzyme inhibitor + calcium channel blocker 
On theoretical grounds, combination of p-blockers and calcium channel blockers 
should be avoided, because they both exhibit myocardial depressant effects. This is 
especially valid for verapamil- and diltiazem-like calcium channel blockers because 
they have potent negative chronotropic and inotropic activities. Dihydropyridine 
calcium channel blockers have less cardiodepressant effects and have been proved to 
have beneficial antihypertensive effects when combined with p-blockers. 
5.1 Antiarrhythmic hybrid drugs 
Reentrant ventricular arrhythmias are one of the major contributors to sudden cardiac 
death. Because no single agent is effective against all types of arrhythmia, hybrid 
drugs have been developed combining class II and III antiarrhythmic activity. 
Class III antiarrhythmic agents (K + -channe l blockers) prolong action potential 
duration and are effective against reentrant arrhythmias. Class II antiarrhythmic 
agents (p r ad renocep to r blockers) reduce sympathetic activity, which is thought to 
be involved in the generation of reentrant arrhythmias. The standard class II/III agent 
sotalol, originally developed as a px-adrenoceptor blocker, also appeared to possess 
K + -channel blocking activity. 
Lis et a l . 4 1 have prepared several hybrid molecules combining the structure of the K + -
channel blocker sematilide with the structures of several p r a d r e n o c e p t o r blockers, 
such as propranolol, metoprolol, and epanolol (fig. 25). 
Figure 25: Class II/III antiarrhythmic agent 
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A new class of 4-imidazolylphenyl selective class III agen t s 4 2 (compound 2; fig. 26) 
expanded the possibilities to synthesize more class II/III agents. Combination of 
compound 2 with the p r se l ec t ive compound 3b resulted in compound l 4 3 (fig. 26). 
compound 2 compound 3 b 
compound 1 
Figure 26: Compound 2, 3b, and 1 
Furthermore, Phillips et a l . 4 4 combined sematilide with 1-arylpiperazine derivatives, a 
se ldom used class II pharmacophore to afford compound 7a (fig. 27) . The 
pharmacological data are shown in table 9. 
O 
Figure 27: Compound 7a, combination of sematilide and a 1-arylpiperazine 
derivative 
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Table 9: p-Receptor affinity and class III activity of a number of classII/III agen t s 4 4 
i c 5 0 ; M M p 1 / p 2 a relative class III activity b ref. 
propranolol 0.018/0.017 not active 41 
sematilide 7000 (p! / p 2 not specified) ++ 41 
sotalol 8.9/5.2 + 41 
compound 5 0.15 (p! / p 2 not specified) ++ 41 
compound 1 (R/S) 2.4/46.5 +++ 42 
compound 1-(S) 1 . 6 / c a . 100 +++ 42 
compound 1-(R) 37.5 />100 +++ 42 
compound 2 - ++ 43 
compound 7 a 0.16/3.4 +++ 44 
a Concentration of compounds which inhibited the binding of [3H]dihydroalprenolol (4.5 
nM) by 50% in partially purified membrane fractions, pi-adrenoceptor affinities were 
determined in canine ventricular muscle in the presence of 1 |iM zinterol (p2-blocker). p 2 -
adrenoceptor affinities were determined in canine lung tissue in the presence of 1 }i,M 
metoprolol (pi-blocker). 
b Electrophysiological activity was assessed in isolated canine cardiac Purkinje fibers using 
standard microelectrode techniques 
Table 9 shows no correlation between p-adrenergic affinity and class III activity as is 
demonstrated by propranolol and compound 2. Compound 1 is presently undergoing 
clinical investigations, while compound 5 was not further investigated, because of the 
relatively low class III activity. 
These examples of hybrid class II/III molecules developed by the same research group 
demonstrated the potential benefits of antiarrhythmic hybrid molecules. 
5.2 Antianginal hybrid drugs 
In theory every combination of a nitrate ester with a p a d r e n o c e p t o r antagonist or a 
calcium channel blocker could act synergistically as antianginal agents. 
Presently calcium channel blockers are the most widest used drugs for the treatment 
of myocardial ischemia. The reduction in oxygen demand of the heart by P J -
adrenoceptor antagonists could add beneficial effects to calcium channel blockers for 
treating patients with severe angina. s 
1,4-Dihydropyridine (DHP) type calcium channel blockers are used in particular for 
the treatment of ischemic heart disease and cerebrovascular disorders . Organic 
nitrates have already been used medicinally for more than 100 years. DHP calcium 
channel blockers with nitrate ester moieties might be used as antihypertensive agents 
or antianginals . Sterk et a l . 4 5 have synthesized a number of 1,4-DHPs with a 
nitratoalkyloxy moiety at the 4-phenyl ring of the 1,4-DHP structure (fig. 28). 
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Figure 28: 1,4-Dihydropyridines with nitrate ester moieties 
Increasing the alkyl chain length from ethyl to tetradecyl showed an opt imum in 
relaxation of KCl-induced contractions in rat aorta for the hexyl and octyl derivatives 
(PIC50 = 8.0), while the highest DHP-receptor affinity was found for the tetradecyl 
derivative (pKj = 9.7; displacement of [ 3H]nitrendipine from rat cortex membranes). It 
is not possible to determine the individual contribution to vasodilation of nitrate 
esters and calcium channel blockers, because of their synergistically mechanism of 
actions. 
Numerous 1,4-DHPs with one or two nitrate ester groups on the C3 and/or C5 
position on the 1,4-DHP ring have been synthes ized 4 6 and evaluated in structure-
activity relat ionship s t ud i e s 4 7 resulting in C D - 3 4 9 4 8 (fig. 29). CD-349 is a potent 
vasodilator. Besides its actions as an antihypertensive agent, CD-349 appeared to be 
a potent cerebrovasodilator in d o g s 4 9 and ca t s 5 0 , and, therefore, could be useful in the 
treatment of cerebrovascular disorders in human. 
Figure 29: CD-349 
The synthesis of the stereoisomers of CD-349 is currently under invest igation 5 1 and 
might reveal whether the cardiovascular and cerebrovascular actions reside in the 
same stereoisomer. 
Nicorandil (fig. 30), originally developed as a nitrovasodilator, can be considered as a 
hybrid molecule combining a nitrate ester function with a potass ium channel 
activating moiety. The profound antianginal effects of nicorandil are ascribed to the 
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dual vasodilating mechanisms 5 2 . The dual vasodilating mechanism was demonstrated 
by the nicorandil analogue KRN2391 and its denitrated derivative K i 3 3 1 5 5 3 (fig. 30). 
Figure 30: Vasodilator / K + -channel activator hybrid molecules 
While KRN2391 has similar vasodilating effects as nicorandil, Ki3315 was less active 
as a vasodilator. The vasodilating properties of Ki3315 could solely be ascribed to 
K + - channe l activation because of the lack of a nitrate ester function. Structure-
activity relationship studies revealed that the nitroxy moiety was not only important 
for its action as a nitrate ester, but also for its action as a K + -channel activator. 
Nipradilol (K-351 ; fig. 31) is a nonselective (3-adrenoceptor blocking agent with 
vasodilating properties without intrinsic sympathomimetic ac t ion 5 4 . The nitrate ester 
is important for vasodilation as was shown by the compound desnitro K-351 
(hydroxyl group instead of a nitrate ester function) which had no relaxant effects on 
K + -depolarization induced contractions in isolated canine blood vessels. Furthermore, 
nipradilol has also a r and a 2 - adrenergic blocking activit ies 5 5 . 
Figure 31 : Nipradilol 
However, the pharmacological activities of nipradilol were evaluated for the racemic 
mixture. It therefore, cannot be excluded that pharmacological actions reside in the 
different stereoisomers. As a consequence, nipradilol might have to be considered as a 
pseudo-hybrid. 
5.3 Cardiotonic hybrid molecules 
In search for products which could replace digital is-l ike compounds , several 
cardiotonic (inotropic) drugs have been designed and clinically evaluated for their 
use in the treatment of congestive heart fai lure 5 6 . 
z 
KRN2391 Z = NCN;R = N 0 2 
Ki3315 Z = NCN; R = H 
nicorandil Z = O; R = N 0 2 
CH 3 
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His tamine H 2 - agon i s t s have posi t ive inotropic and chronotropic act ions. An 
important side effect of histamine H 2 -agonis ts is the stimulation of gastric acid 
secretion. In order to develop histamine H 2 -agonis ts with more selective positive 
inotropic activity over chronotropic activity and to abolish gastric acid secretion, 
c o m p o u n d s have been synthes ized in which both h i s t amine H p and H 2 -
pharmacophores are present. Based on the histamine H 2 -agonist impromidine and the 
general diarylalkylamino structure of histamine Hj-antagonis ts , several hybrid 
molecules, such as arpromidine (fig. 32), have been synthesized (reviewed by Van der 
Goot et a l . 5 7 ) . 
impromidine 
arpromidine 
figure 32: Histamine H 2 -agonists impromidine and arpromidine 
Arpromidine may represent a promising therapeutic improvement for the treatment of 
patients suffering from congestive heart fai lure 5 8 . 
Phosphodiesterase (PDE) is a family of enzymes which increase the total intracellular 
cAMP concentration, resulting in an increase of the contractile force of muscles. The 
card io tonic ac t ions of phosphodies te rase inhibi tors migh t be enhanced by 
combinat ion with other inotropic agents which elevate the intracellular c A M P 
concentration, such as p 2-adrenoceptor agonists or histamine H 2 -agonis ts . 
GlaB et a l . 5 9 have synthesized a series hybrid molecules based on the phospho­
dies terase III (PDE III) inhibi tor enoximone and the h is tamine H 2 - a g o n i s t 
impromidine. DG20 and its ethyl derivative (fig. 33) demonstrated potent inotropic 
activities in a screening assay, despite the weak PDE III inhibitory action of DG20 
(table 1 0 ) 6 0 . 
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Figure 33 : Hybrid molecule DG20 (R = C H 3 ) , constructed of enoximone and 
impromidine 
Table 10: Inhibition of PDE III from guinea pig heart and positive inotropic activities 
of DG20 and its ethyl analogue 
I C 5 0 [\m E C 5 0 [\m i.a. 
DG20 51.6 16 1.0 
ethyl derivative 50.1 3 1.0 
enoximone 2.6 30 0.4 
IC50 PDE HI inhibition 
EC50 Positive inotropic activity determined on guinea pig papillary muscle 
i.a. Intrinsic activity relative to isoprenaline 
The affinity for the histamine H 2 - receptor is lower than that of impromidine (pKj = 
5.15 and 7.5 , respectively), whereas the DG20-induced stimulation of adenylate 
cyclase is about 8 times lower than that produced by histamine (0.1 mM) , indicating 
weak histamine H2-agonistic activity. Nevertheless, DG20 and its ethyl derivative 
have shown to be potent cardiotonic agents, which combine, in vitro, both PDE III 
inhibitory and histamine H 2 -agonistic activity. 
Recently Shaffer et a l . 6 1 have suggested to use a combination of phosphodiesterase 
inhibitors and p-adrenergic blockers in a hybrid molecule. However, at first instance, 
this combination seems rather peculiar because p-adrenergic blockers have opposite 
actions to PDE inhibitors. Overall, p-adrenergic blockers have potential benefits in 
treating congestive heart failure, e.g., by a decrease of sympathetic induced renin-
release, by antiarrhythmic actions and by improving coronary blood flow and 
increasing diastolic period. The accompanied negative inotropic actions of p-
blockers could be antagonized by the positive inotropic actions of PDE III inhibitors. 
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The hybrid molecule GI104313 (fig. 34) combines both p-blocking and PDE III 
inhibiting properties in one single agent. 
C! O OH CN 
Figure 34: GI104313 
In vitro G i l 0 4 3 1 3 appeared to be a potent and selective PDE III inhibitor (pKj = 0.1 
| iM) , whereas it is a nonselective p-antagonist ( p A 2 = 8.8). In vivo GI104313 
exhibited both p-blocking and PDE III inhibitory activity. The combined actions of 
GI104313 as an inotropic and p-blocker are congruent . Fur ther studies are 
undertaken to examine whether the actions occur in the settings of ventricular 
failure. 
Today, most of the newly developed cardiotonic agents incorporate pronounced 
vasodilating properties. Examples of such combined inotropic/vasodilator agents are 
the histamine H 2 -agonis t hybrid molecules type A 6 2 , B 6 3 and C 6 2 (fig. 35). These 
hybrid molecules can be considered as vasodilators to which a positive inotropic 
act ion is added to o v e r c o m e the nega t ive inot ropic ac t ions exer ted by 
dihydropyridines. 
H 
type A : = 2-O-Q; R 2 = C 2 H 5 ; R 3 = C H 3 
type B: R 1 = 3 -N0 2 ; R 2 = Q; R 3 = C H 3 
type C: = 3 - N 0 2 ; R 2 = C 2 H 5 ; R 3 = CH 2 -S-Q 
Figure 35 : Hybrid molecules with combined histamine H 2-agonistic/calcium channel 
blocking activity 
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Figure 36: Prizidalol derived from hydralazine 
The hydrazino group of prizidilol was found to be responsible for the toxicological 
effects and therefore, the hydrazinopyridazine moiety was replaced by 4,5-dihydro-
3(2//)-pyridazinone moieties resulting in SK&F95018 (fig. 3 7 ) 6 5 . SK&F95018 is a 
moderately active ß i -adrenoceptor antagonist with a prolonged antihypertensive 
ac t ion 6 6 (table 11). 
Figure 37: SK&F95018, derived from a direct vasodilator (shown at the left) and 
betaxolol 
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5.4 Antihypertensive hybrid molecules 
5.4.a Hybrid molecules combining direct vasodilators and ß^adrenoceptor 
blockers 
The side effects of vasodilators, the increase of intrinsic sympathetic activity, can be 
inhibited by $i-adrenoceptor antagonis ts . Therefore , hybrid molecu les with 
vasodilating and $i-adrenoceptor blocking properties have been developed. 
Prizidilol (fig. 36) is a combination of the vasodilator hydralazine and a ß p a d r e n o -
ceptor antagonist . The therapeutic profile of prizidalol looked very promising. 
Prizidilol appeared to be a potent antihypertensive agent without affecting the action 
of the h e a r t 6 4 . However , the occurrence of toxicological effects upon long-term 
treatment abolished further investigations. 
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Table 11: Reduction in rat blood pressure and p r adrenocep to r antagonistic 
activities of SK&F95018 and prizidalol 
compound lowering of rat blood ß r a d r e n o c e p t o r antag; 
pressure E D 4 0 (imol/kg I D 5 0 pmol/kg 
SK&F 95018 1.6 1.0 
hydralazine 1 -
prizidilol 14 0.06 
propranolol - 0.08 
SK&F95018 appeared to be a potent antihypertensive agent with ß r a d r e n o c e p t o r 
selective blocking properties without baroreflex induced sympathetic activity. 
Baldwin et a l . 6 7 have combined other type direct vasodilators with ßj-adrenoceptor 
antagonists (fig. 38). However, the peripheral vasodilating properties of the hybrid 
molecule had to be ascribed mainly to ß 2 -adrenoceptor agonistic activity. 
direct vasodilator ß-blocker CL 
N JL 
Figure 38: ß r A d r e n o c e p t o r blocker with acute antihypertensive activity (due to ß 2 -
adrenoceptor agonistic activity) 
Replacement in this compound of the t r i f luoroimidazolylphenyl moiety by a 
cyanopyridinyl moiety (fig. 39) diminished the intrinsic ß 2 -adrenoceptor agonistic 
activity, while antihypertensive activity was re ta ined 6 8 . 
CN OH 
Figure 39: A vasodilator / ß r a d r e n o c e p t o r antagonist 
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However, due to the teratogenic effects of this hybrid molecule, further clinical 
investigations were terminated. 
5.4.b Hybrid molecules combining diuretics and ßradrenoceptor blockers 
Diuretics are the most often used antihypertensive drugs which are combined with 
other classes of antihypertensive drugs. 
Clinical investigations have shown that propranolol, a ß r a d r e n o c e p t o r antagonist, 
improves certain side effects of diuretics, such as reduction of diuretic-induced renin 
release. 
Cecchetti et a l . 6 9 have designed hybrid molecules combining P r a d r e n o c e p t o r 
blockers with the diuretic hydrochlorothiazide, resulting in hybrid molecule A 
(fig.40). Hybrid A was found to inhibit isoprenaline induced tachycardia in the same 
concentra t ion range as propranolol , and had 3-fold lower affinity for p r 
adrenoceptors than propranolol (table 12). 
hybrid m o l e c u l e A 
Figure 40: Hybrid molecule A, based on hydrochlorothiazide 
Hybrid molecules B and C were synthesized to investigate the influence of the chain 
connecting the two pha rmacophore g roups 7 0 . The modifications carried out on the 
connecting bridge did not affect the Px-adrenergic activity, while the diuretic activity 
was improved 2-fold (table 12). 
•CI 
hybrid m o l e c u l e B; X = S 
hybrid m o l e c u l e C; X = CH 2 
Figure 4 1 : Hybrid molecule B and C 
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Table 12: ß r Adrenoceptor activity of hybrid molecules A, B and C 
compound ß r aff ini ty ; K{ [nM] E D 5 0 [pM]; i .V., mg/kg E D 5 0 [pM]; oral; mg/kg 
hybrid A 7.4 0.67 ± 0.031 36.24 ± 3.465 
hybrid B 5.2 0.45 ± 0 . 0 1 6 34.70 ± 2.093 
hybrid C 1.4 1.80 ±0 .041 53.78 ± 3 . 1 8 5 
propranolol 2.3 0.18 ± 0 . 0 2 3 22.33 ± 1.306 
ED50 Concentration required to inhibit 50% of isoprenaline induced tachycardia in rats 
Until now it is not clear whether dual behaviour of the hybrid molecule is responsible 
for its antihypertensive action, because no animal model of hypertension is available 
which satisfactory responds to both ßj -adrenoceptor blockers and diuretic agents. 
Kau et a l . 7 1 have synthesized ICI 147,798 (fig. 42) with both diuretic and ß r 
adrenoceptor blocking activity. ICI 147,798 is based on propranolol and a slightly 
modified diuretic amiloride derivative. The natriuretic activity of ICI 147,798 is about 
6 5 % of the value of hydrochlorothiazide, whi le the ß r a d r e n e r g i c activity is 
equipotent to propranolol in several animal studies. 
NH O 
Figure 42: Structure of ICI 147,798, derived from amiloride 
N 
The observation that propranolol has some diuretic activity in rat led to a screening 
program involving several (3\-adrenoceptor antagonists . Based on the obtained 
results of the screening program, Bouley et a l . 7 2 have synthesized a hybrid molecule 
with a thienylamido moiety (fig. 43). 
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OH 
Figure 4 3 : Hybrid molecule possessing p r adrenerg ic blocking and diuretic 
properties 
The p-adrenergic pharmacophore group of the presented hybrid molecule can clearly 
be distinguished, while the diuretic activity is thought to reside in the thienylamido 
moiety. This hybrid molecule has a cardioselective action equipotent to propranolol. 
Although the hybrid molecule exhibits diuretic activity in vivo, the data are not 
related to known diuretics, making a comparison of the activity impossible. 
5.4.c A hybrid molecule combining angiotensin converting enzyme inhibitor and 
fi^adrenergic activities 
A hybrid molecule combining angiotensin I I converting enzyme (ACE) inhibitor and 
p! -adrenoceptor blocking propert ies is BW A 5 7 5 C (fig. 44) . BW A575C is 
consti tuted of the p j -adrenoceptor blocker p indolo l and the ACE- inh ib i to r 
enalapri l 7 3 . 
H 
Figure 44: BW A575C; based on pindolol and enalapril 
The p r adrenocep tor blocking activities were only assessed in vitro, and revealed that 
BW A575C is 50 times less active than pindolol. The ACE-inhibitory activities of BW 
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A575C were in vitro and in vivo equipotent to that of the well-known ACE-inhibitor 
enalapril. Overall, B W A575C has shown to be 2-10 times more effective as an ACE-
inhibitor than as a ß r ad renocep to r blocker in several animals. 
5A.d Hybrid molecules combining thromboxane A2 (TXA2) inhibitory effects and 
calcium channel blocking activities 
Antihypertensive agents significantly reduce the incidence of stroke, congestive 
heart failure and renal damage , but have little influence on reduction of angina 
pectoris and sudden cardiac death. The formation of atherosclerotic plaques has been 
implicated in the onset of coronary artery disease. Thromboxane A 2 antagonists 
inhibit platelet aggregation and TxA 2 - induced vasoconstriction. Combination of an 
antihypertensive agent with a platelet aggregation inhibitor might have beneficial 
effects in the majority of patients suffering from coronary artery disease. 
Imidazole is a thromboxane A 2 synthetase inhibitior (TxSI). Several research groups 
have incorporated the imidazole moiety in the well-known dihydropyridine anti­
hypertensive agents (calcium channel blockers) resulting in W y 27569 and FCE 
24265 (fig. 45). 
r=\ 
W y 27569 F C E 24265 
Figure 45 : Structure of the hybrid molecules W y 27569 and FCE 24265 
Wy 27569 is a vascular selective calcium channel blocker and has been shown to be 
similar in potency to nitrendipine as an antihypertensive agent 7 4 . The in vitro calcium 
channel blocking activity (IC50) of Wy 27569 and nitrendipine, determined on K + -
depolarization induced contractions on rat aorta was 7.3 and 0.28 nM, respectively. 
In the same concentration dose levels Wy 27569 inhibited T x A 2 synthetase and the 
collagen-stimulated production of thromboxane B 2 , the stable T x A 2 metabolite, in 
v i v o 7 5 . FCE 24265 is a less potent calcium channel blocker than nifedipine both in 
vitro and in vivo, it lowers blood pressure without inducing reflex tachycardia in 
vivo, which is often observed with calcium channel blockers. In vitro FCE 24265 
displayed thromboxane synthetase inhibiting properties similar to dazoxiben, a 
selective thromboxane A 2 synthetase inhibitor 7 6 . 
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5.4.e Hybrid molecules combining calcium channel blocking and adrenergic (a 
and ß) blocking properties 
Calcium channel blockers, 04- and ß r a d r e n e r g i c antagonists are well documented 
antihypertensive agents. Most of the research on hybrid molecules has been focused 
on combinations of dihydropyridine (DHP)-type calcium channel blockers and 04- or 
ßj-adrenergic antagonists. In the following sections, some of the many reported 
hybrid molecules of this type are presented. 
N i g u l d i p i n e 7 7 is an antihypertensive agent with slow onset kinetics and a long 
duration of action. Niguldipine incorporates the well-known DHP-type calcium 
channel blocking moiety and a diphenylpiperidinyl moiety often observed in a j -
adrenergic antagonists (fig. 46). Niguldipine also significantly inhibits thromboxane 
A 2 - induced coronary vasoconstrict ion 7 8 . 
Figure 46: Niguldipine 
All three biological activities were the most potent for the (S)-(+) enantiomer of 
niguldipine. (S)-(+)-niguldipine binds with nearly equal affinity to skeletal muscle, 
brain, and heart (table 13). 
Table 13: DHP-receptor affinities determined on rat brain and skeletal muscle (SM) 
and a ^ - a d r e n e r g i c affinity determined on rat liver membranes of 
niguldipine 
p I C 5 0 [ n M ] ; brain (DHP) pIC 5 öfnM];SM(DHP) p I C 5 0 [nM]; (XiA 
niguldipine (±) 9.00 9.66 8.82 
( S H + ) 9.44 9.74 9.14 
(R)-(-) 7 .93 8.09 7.80 
prazosin - - 10.04 
At first instance, (S) and (R)-niguldipine were reported to bind with equal affinity to 
a 1-adrenoceptors in rat liver cell membranes (oc 1 A -adrenoceptors ) and to 04-
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adrenoceptors in guinea pig rat cortex membranes ( a 1 B - a d r e n o c e p t o r s ) 7 9 . More 
recently, it has been shown that (S)-(+)-niguldipine has a 40-fold higher affinity for 
oci A-adrenoceptors than for a ig -adrenocep to r s 8 0 . 
The stereoselective ratios for 1,4-DHP receptor binding, inhibition of TxA 2 - induced 
coronary vasocons t r ic t ion , and ant ihyper tens ive activity for (S)-(+) / (R)-(- ) -
niguldipine are 4 5 , 2 8 and 35, respectively. 
Manidip ine 8 1 (CV-4093; fig. 47) is a DHP derivative with a diphenylmethylpiperazine 
moiety, also known from a r a d r e n o c e p t o r antagonists. 
Figure 47: (S)-(+)-Manidipine 
Manidipine, like niguldipine, has slow onset kinetics and a long lasting duration of 
antihypertensive action. The (S)-(+)-enantiomer of manidipine is about 30 and 80-
fold more potent as an antihypertensive agent and as an inhibitor of 1,4-DHP receptor 
binding, respectively, than the (R)-(-)-enantiomer. The IC50 values for the inhibition 
of [ 3H]nitrendipine binding to rat aorta of (S)-(+), (±)- and (R)-(-)-manidipine are 0.05, 
0.3 and 4.0 nM, respectively 8 2 . 
Marciniak et a l . 8 3 have synthesized hybrid molecules combining DHPs with a 
benzodioxan moiety, which also appears in oci-adrenergic blockers. The most potent 
hybrid molecule, shown in figure 48, consists of four stereoisomers. 
Figure 48 : D H P calcium channel blocker with a benzodioxan structural moiety 
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The two pairs of enantiomers have been synthesized. The most potent calcium 
channel blocking activity resides in the R-configuration of the DHP moiety, whereas, 
the highest 0C2-adrenergic blocking activity is observed in the compounds with an S-
configuration of the benzodioxan ring (table 14). No stereoselectivity is found for 04-
adrenoceptors. 
Table 14: Biological data of the stereoisomers of the hybrid molecules 
compound p i c 5 0 ; a 2 a pIC 5 0 ; a, b p I C 5 0 ; D H P c pIC 5 0 ;DHPd 
hybrid (±) 6.32 6.30 10.00 8.35 
(R,R) 5.40 5.62 10.74 8.82 
(S,S) 6.85 5.64 8.55 8.00 
(S.R) 4.72 5.70 9.00 8.60 
(R,S) 6.68 5.72 e e 
yohimbine 8.04 6.00 - -
prazosin 6.85 9.22 5.52 -
nicardipine 5.85 5.44 10.59 9.52 
a Inhibition of [3H]yohimbine binding to 0C2-adrenoceptors 
b Inhibition of [3H]prazosin binding to ai-adrenoceptors 
c Inhibition of [3H]nitrendipine binding to DHP receptors 
d Inhibition of K+-depolarization induced contractions in pig coronary artery 
e Not dose dependent 
The ai' and ot2-adrenoceptor affinities are higher than the in vitro determined 
adrenergic activities, likely caused by a masking effect of the calcium channel 
blocking activity. 
B M Y 20064 and B M Y 20014 are two examples of hybrid molecules bearing a 
methoxyphenylp iperaz ine (04-adrenergic) moiety at the ester position of a DHP 
(fig.49). 
Figure 49: B M Y 20064 (X = O) and BMY 20014 (X = NH) 
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BM Y 20064 is equipotent to nifedipine as an inhibitor of depolarization induced 
contractions in smooth muscle, but has less pronounced negative inotropic effects 8 4 . 
Furthermore, B M Y 20064 is a selective oc r adrene rg ic antagonist in radioligand 
binding assays and in functional studies, both in vitro and in vivo. BMY 20064 has 
po ten t an t ihype r t ens ive effects in both no rmo tens ive and spon taneous ly 
hypertensive rats and is effective against myocardial ischemia, being more potent 
than a combination of nifedipine and prazosin, or either of them alone. Remarkably, 
BMY 20064 was pharmacologically evaluated as a racemic mixture. 
The stereoisomers of B M Y 20014, an amido analogue of B M Y 20064, have been 
prepared and in vitro biologically evaluated for its calcium channel blocking and a r 
adrenergic blocking act ivi t ies 8 5 (table 15). 
Table 15: Dual activities of B MY 20014 
pKi (DHP) a pKiCocOb p I C 5 0 ( D H P ) c p l C s o C a ^ d 
BMY20014 (±) 7.46 7.89 8.20 -
(R) 7.80 8.33 8.60 8.08 
(S) 6.47 7.44 6.97 7.30 
nifedipine 9.28 < 6 9.30 < 6 
prazosin < 6 9.52 < 6 8.80 
a Inhibition of [ 3H]PN-200-l 10 binding to rat brain synaptosomes 
b Inhibition of [3H]prazosin binding to rat brain synaptosomes 
c Inhibition of K+-depolarization induced contractions on rat aorta 
d Inhibition of phenylephrine-induced contractions on rabbit aorta 
The more potent calcium channel and 04-adrenergic blocking activities resided in the 
(R) -O-enant iomer of B M Y 20014. (R)-(-)-BMY 20014 is presently under clinical 
investigation. 
5.4 ƒ A hybrid molecule combining aj-adrenoceptor blocking and 5-HTIA-receptor 
antagonistic properties 
The antihypertensive agent urapidil (fig. 50) is a selective a r a d r e n o c e p t o r antagonist 
with additional central ac t iv i ty 8 6 . Although^ initially an ot2-agonistic action was 
thought to be involved, more recently, it was shown that this additional action was 
due to the intervent ion of the serotonergic 5 - H T 1 A - r e c e p t o r s 8 7 . Despi te the 
unresolved mechanistic actions (are central oq-adrenoceptors involved ? 8 8 ) , urapidil is 
widely used for the control of perioperative arterial hypertensive episodes. 
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I H 
CH 3 
Figure 50: Urapidil, an 04-adrenoceptor blocker/5-HT 1 A -agonist 
6 Concluding remarks 
In summary, this review of hybrid molecules describes only the tip of an iceberg of 
the many designed hybrid molecules. Most of the hybrid molecules are described in 
patents, showing no precise pharmacological data. Thus it might be expected that a 
considerable amount of claimed hybrid molecules are devoid of substantial desired 
pharmacological actions. 
As has been shown in the first part of this review, combination of pha rmacophore 
groups into one single entity often fails to produce active hybrid molecules, because 
the hybrid molecule does not obey the established structure-activity relationships 
observed for the single structural moieties. 
Both, hybrid molecules with coincidal pharmacophoric groups and hybrid molecules 
with pharmacophoric groups linked via a bridge, could afford drugs with improved 
pharmacological actions. However, especially the chiral hybrid drugs with multiple 
adrenergic actions have to be regarded with suspicion. Separation of the enantiomers 
might reveal that the pharmacophoric groups reside in the distinct enantiomers, as 
first observed for labetalol. These compounds are no real hybrid drugs and are called 
pseudo-hybrids. Because pseudo-hybrids are a fixed-ratio combination of different 
pharmacological agents, they lack the advantages of real hybrid drugs (equal 
absorption, distribution, metabolization and excretion). 
To be of clinical value, the pharmacophoric groups have to retain affinity for their 
receptors and exhibi t their act ions in a balanced rat io. Thus , the combined 
pharmacophoric groups have to exert their activity in the same concentration range. 
Determination of the separate activities is not always possible because of synergistic 
mechanisms of action of the pharmacophoric groups, e.g., the 1,4-dihydropyridine-
type calcium channel blockers bearing a nitrate ester function (fig. 28 and 29) which 
have both vasodilat ing propert ies . An o t h e r s p r o b l e m for determinat ion of the 
individual pharmacophoric actions occurs when the mechanism of actions interfere 
with each other. This is observed in, e.g., hybrid molecules with combined histamine 
H 2 -agonis t ic and 1,4-dihydropyridine-type vasodilating properties (chapter 7; this 
thesis), where the mechanisms of action interfere with each other in an antagonistic 
fashion. In clinical investigations, some of the presented hybrid molecules, such as 
sotalol, nicorandil (fig. 30) and urapidil (fig. 50), have been shown to be very efficient 
for the treatment of certain disorders. Surely, such encouraging results will increase 
the interest in the development of hybrid drugs. 
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0 2NO ON02 
1 2 3 
Figure 1: Amyl nitrite, glyceryl trinitrate (GTN) and pentaerythreitol tetranitrate 
(PETN) 
Nitrovasodilators comprise chemically distinct types of vasodilators: 
- Organic nitrites are mono- or polyesters of nitrous acid, thus containing an 
R - 0 - N = 0 structure moiety (amyl nitrite 1). 
- Organic nitrates are mono- or polyesters of nitric acid, containing an R-O-NO2 
structure moiety (GTN 2, and PETN 3 (fig. 1), ISDN 4 and its stereoisomers isoidide 
dinitrate ( 5 ; I IDN) and isomannide dinitrate (6; IMDN) , and isosorbide-5-
mononitrate (7; IS-5-MN; fig. 2), CEDO 8811 8, CEDO 8816 9, CEDO 8956 10, 
and V U F 9059 11 (fig. 3). V U F 9059 11 is an intermediate prepared in a program to 
synthesize hybrid molecules combining histamine ITragonistic properties with a 
nitrovasodilating action (see section 5 of this chapter). 
- Sodium nitroprusside (12; fig. 4) is a nitrovasodilator not belonging to either one of 
these two groups. 
4 ISDN 5 IIDN 6 IMDN 7 IS-5-MN 
Figure 2: Stereoisomers of isosorbide dinitrate and a mononitrate derivative 
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O r g a n i c n i t r a t e e s t e r s a s s y n t h o n s for t h e s y n t h e s i s o f h y b r i d 
m o l e c u l e s c o m b i n i n g h i s t a m i n e H2 -agonis t i c p r o p e r t i e s a n d 
n i t r o v a s o d i l a t i o n 
1 Introduction 
Among modern cardiovascular therapeutic agents the so-called nitrovasodilators, 
introduced more then a century ago, are still of major importance 1 . Nitrites, such as 
amyl nitrite ( 1 , f ig . l ) described by Brunton 2 , were the first drugs to be used as 
therapeutic agents for the treatment of angina pectoris. In 1879, Murrel l 3 investigated 
the biological actions of glyceryl trinitrate (GTN; 2, fig. 1) and discovered that GTN 
could also be used to treat angina pectoris. A new organic nitrate, isosorbide dinitrate 
(ISDN; 4 , fig. 2) discovered by Krantz et a l . 4 in 1940 increased the interest in these 
type of antianginal drugs. 
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Figure 3 : Recently developed organic nitrate esters 5 (pharmacological data in table 1) 
CN 
12 
Figure 4: Sodium nitroprusside (Na2[Fe(CN)sN0] 
2 Ni t rovasodi la tors : m o d e of act ion 
Nowadays, nitrovasodilators are clinically used as therapeutics for the treatment of 
several forms of angina, silent myocardial ischemia (ischemia without anginal pain), 
myocardial infarction, and congestive heart fai lure 6 ' 7 . In fact, nitrovasodilators were 
the first vasodilators used to produce hemodynamic improvement in patients with 
ventricular failure. The basic and clinical nitrate ester pharmacology has been 
reviewed by Ahlner et a l . 8 recently. 
Nitrate esters cause vasodilat ion, and in vitro studies revealed that the nitro 
compounds are more effective as relaxant agents for venous tissue than for arterial 
tissue. Venodilation reduces the pre-load of the heart, resulting in a decreased oxygen 
demand, thus improving the imbalance between myocardial oxygen demand and 
supply engendered by myocardial ischemia. 
Endothelium cells of intact vessel wall release a substance called endothelium-derived 
relaxing factor (EDRF) upon stimulation by specific mediators, such as histamine, 
serotonin, acetylcholine and bradykinin, result ing in vasodilat ion. This E D R F 
substance has been identified as nitric oxide ( N O ) 9 ' 1 0 , and circulates in the blood as 
an S-nitroso adduct of serum a lbumin 1 1 . NO is formed from arginine on demand by 
the action of NO-synthase (NOS). There appear to be at least three isoforms of NO 
synthase, the so-called inducible NOS (iNOS), neuronal NOS (nNOS) and endothelial 
NOS (eNOS). The action of NOS has recently been reviewed by Dinerman et a l . 1 2 . 
Endogenous N O can stimulate the enzyme guanylate cyclase to produce cytosolic 
cyclic guanos ine-S '^ ' -monophosphate (cGMP). The rise of c G M P increases the 
NO 
NC— CN 
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phosphoryla t ion of contract i le proteins by cGMP-dependen t protein k inases , 
resulting in vasodilat ion 1 3 . 
Nitrovasodilators are able to cause vasodilation even when the endothelial cell layer 
of vessels have been damaged. They generate nitric oxide and/or S-nitrosothiols, 
which subsequently activate the guanylate cyclase. This activation process is 
sulfhydryl-dependent and proceeds via an enzymatic process, involving glutathione 
S-transferase and probably cytochrome P 4 5 0 1 4 or via a non-enzymatic process which 
appears to require glutathione or a closely related thiol, such as cysteine, eventually 
resulting in vasodilat ion 1 5 . 
Despi te their common biochemica l and physiological mechan i sm of act ion, 
nitrovasodilators have substantially different pharmacological and pharmacokinetic 
profiles. An often observed phenomenon of nitrovasodilators is the apparent lack of 
correlation between the in vitro relaxant effects and their relative in vivo potency. 
This apparent lack of correlation might be ascribed to different pharmacokinetic 
behaviour of the n i t rovasod i la to r s 1 6 . Tzeng et a l . 1 7 suggested that compet i t ive 
metabol ism of nitrovasodilators in the systemic circulation versus that in the 
vasculature partially accounts for the narrow range of in vivo potency. Both the 
chemica l s t ruc ture of the n i t rovasodi la tor and its fo rmula t ion de te rmine 
pharmacokinetic processes and therefore, the onset and duration of action and nitrate 
tolerance. 
Tolerance to drugs exist when, after repeated administration, increasing doses of the 
drugs are required to maintain the same pharmacological effect. The mechanism of 
action responsible for the observed nitrate ester tolerance is unknown yet. Nitrate 
tolerance probably accounts to critical sulfhydryl co-factors, both of enzymatic and 
non-enzymatic origin. Thus, the mechanism of action to release nitric oxide might be 
responsible for nitrate tolerance, as organic nitrate esters showed a greater tendency 
towards tolerance development than nitrite esters, such as amyl nitrite, and sodium 
nitroprusside 1 8 . Both nitrite esters and sodium nitroprusside directly release NO, thus , 
not requiring (non)enzymatic biotransformation. 
3 Hybrid molecules containing a nitrate ester moiety 
A special type of nitrovasodilators comprises nicorandil 13, nipradilol 14 (racemic 
mixture) , CD-349 15 (racemic mixture) and the compounds CEDO 20-068 16 and 
CEDO 20-074 17, which all are hybrid molecules containing a nitrate ester function 
(fig. 5). 
The nitrovasodilators nicorandil , nipradilol, ancf CD-349 have been described in 
chapter 2; they possess additional activities such as K + - channe l act ivat ing, (3-
adrenergic blocking and calcium channel blocking activities, respectively. For a 
review on the therapeutic efficacy of nicorandil in angina pectoris , we refer to 
Frampton et a l . 1 9 . 
CEDO 20-068 and CEDO 20-074 contain a 1,4-dihydropyridine s t ructure 2 0 , like CD-
349, a structure moiety well known from the antihypertensive calcium channel 
blockers. 
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ONOo 
HXOOC 
16 CEDO 20-068 17 CEDO 20-074 
Figure 5: Hybrid molecules containing a nitrate ester function 
The nitrate ester with a thiazolidine backbone CEDO 20-006 2 1 18 (racemic mixture; 
fig. 6) is not a hybrid molecule, but a prodrug. In vivo, the thiazolidine structure is 
either enzymatically or non-enzymatically hydrolyzed, affording thiol derivatives (fig. 
6). The thiol derivatives might be beneficial in avoiding nitrate ester tolerance, which 
is thought to be a result of thiol depletion (see section 2 of this chapter). 
COOH 
ONOP 
18 CEDO 20-006 
X 
COOH 
COOH o 
HS NH 2 
HoO 
Figure 6: CEDO 20-006, a prodrug existing of a thiazolidine moiety (hydrolysis 
depicted on the right) and nitrate ester function 
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In table 1, the in vitro and in vivo activities of some nitrate esters are shown. All 
vasodilating activities of the nitrate esters are in vitro determined on phenylephrine-
induced contractions in rat aorta. The decrease in diastolic arterial blood pressure, 
measured in v ivo , indicates the potency of vasodi la t ing ac t ion . The 1,4-
dihydropyridines bearing a nitrate ester function, CEDO 20-068, CEDO 20-074 and 
CD-349 were evaluated on KCl-induced contractions. The synergistic mechanisms of 
action of 1,4-dihydropyridines and nitrate esters make it impossible to evaluate their 
individual vasodilating activities. Therefore, the presented in vitro activity of these 
compounds results from both pharmacophoric groups. 
Table 1 : In vivo and in vitro activities of some nitrate esters 
compound in vitro in vivo reference 
pECso decrease DAP d 
CEDO 8811 8 8.6 a ++ 5 
CEDO 8816 9 7.7 a +++ 5 
CEDO 8956 10 8.8 a +++ 5 
VUF 9059 11 6.5 a not tested 
CEDO 20-068 16 8.0 b ++++ 2 0 
CEDO 20-074 17 8.2 b ++++ 2 0 
CEDO 20-006 18 8.1 a +++ 21 
ISDN 3 6.3 a +++ 5 
GTN 2 8.1 a +++ 5 
nicorandil 1 3 6.9 a +++ 5 
nifedipine e 8.7 b +++ 20 
CD-349 15 9 . 0 ° - 2 2 
a Inhibition of phenylephrine (10~7 M) induced contractions on rat aorta 
b Inhibition ofKCl (50 mM) induced contractions on rat aorta 
c Inhibition ofKCl (62.5 mM) induced contractions on canine basilar artery 
d Relative decrease of diastolic arterial blood pressure (DAP) in anesthetized 
rabbit 
e Nifedipine is a 1,4-dihydropyridine calcium channel blocker 
As ment ioned before the l ipophil ici ty of nitrate esters is impor tant for their 
bioactivation because the isoenzyme guanylate cyclase is located in the cytoplasm. 
An example of a designed lipophilic compound is K F 14124 (fig. 7), an isoidide 
dinitrate derivative in which a lipophilic substituted piperazine ring was introduced 
to increase the solubility of the compound 2 3 . Isoidide dinitrate (IIDN) was chosen 
because it appeared to be the most active stereoisomer among the dianhydrohexitol 
dinitrates, such as ISDN, and isomannide dinitrate (IMDN). 
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Figure 7: K F 14124 
K F 14124 is a clear example of a prodrug. The phenylthiopropyl moiety of the 
molecule can be considered as a structure moiety contributing to the lipophilicity. 
The vasodilating activity is caused by the metabolization of the nitrate ester to nitric 
oxide, like in all nitrate esters. Although KF 14124 has proven to be an orally-active, 
nitrate-type vasodilator and showed a more potent antiarrhythmic activity than 
nicorandil, it causes several side effects, such as central nervous system depression 2 3 . 
4 Hybrid molecules combining histamine H2-agonistic and nitrovasodilating 
properties 
4.1 Introduction 
His tamine H2-agonists possess posit ive inotropic and chronotropic activit ies. 
Histamine 20 (fig. 8), the natural ligand, is a non selective histamine H2-agonist as it is 
also the ligand for histamine Hi - and H3-receptors. I m p r o m i d i n e 2 4 21 (fig. 8) is a 
potent histamine H2-agonist ( p D 2 = 7.8; on guinea pig spontaneously beating right 
atrium) and is also a histamine H3-antagonist (pIQ = 7.2; rat cortex). 
Prel iminary investigations of the effects of impromidine in patients with severe 
congestive heart failure have revealed the possible clinical value of histamine H2-
a g o n i s t s 2 5 . Despite the beneficial vasodilating and positive inotropic properties of 
impromidine, it will not be introduced as a drug for the treatment of congestive heart 
failure, because of its stimulation of gastric acid secretion. 
Initiated by the positive hemodynamic and cardiac stimulant effects exhibited by 
impromidine 2 6 , newer histamine H2-agonists have been synthesized (reviewed by Van 
der Goot et a l . 2 7 ) . Among them belong the moderately active phenoxy der ivat ive 2 8 of 
impromidine 22 (fig. 8), V U F 8 4 0 1 2 9 23 (fig. 8) and the potent histamine H 2 -agonist 
a r p r o m i d i n e 3 0 24 (racemic mixture; fig. 8). Both in vitro and in vivo studies with 
arpromidine showed that it has more potent vasodilator and inotropic properties, 
while exerting less chronotropic and arrhythmogenic actions than impromidine. The 
improved hemodynamic profile of arpromidine, compared to impromidine, makes this 
compound more suitable as a potential drug for the treatment of congestive heart 
fai lure 3 1 . 
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Figure 8: Ligands for the histamine ^ - r e c e p t o r s 
Table 2: His tamine H2-agonistic (pD2) and Hi-antagonis t ic (pA2) activities of a 
number of impromodine analogues (see fig. 8) 
compound p D 2 a i . a . b P A 2 C reference 
impromidine 21 7.8 1.0 5.5 24 
2 2 6.0 1.0 6.2 28 
V U F 8401 23 6.0 1.0 6^5 29 
arpromidine 24 8.0 1.0 7.7 30 
histamine 20 6.1 1.0 agonist 
a Measured at guinea pig right atrium 
b Intrinsic activity relative to histamine 
c Measured at guinea pig ileum 
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The imidazo ly lp ropy lguan id ine moie ty of impromid ine 2 1 is believed to be 
responsible for the histamine H2-receptor stimulating activity, while the methyl-
imidazole moiety contributes to affinity. Replacement of the methylimidazole moiety 
of impromidine by structural moieties containing a nitrate ester affords therefore 
hybr id m o l e c u l e s wi th po ten t i a l h i s t amine H2-agonist ic p r o p e r t i e s and 
nitrovasodilating effects. 
4.2 Synthesis of the proposed hybrid molecules 
The general structure of the proposed hybrid molecules is shown in figure 9. 
NH 
Figure 9: General hybrid structure 
The hybrid molecules are constructed of two building blocks which are both amines 
(synthon A and B), linked to each other via a guanidine structure (G) (fig. 10). 
(CH 2)m-NH 2 
,ON02 
s y n t h o n A 
NH 
X NHo N = / 
© s y n t h o n B 
s y n t h o n A s y n t h o n B 
s y n t h o n A 
- 0 - 1 s y n t h o n B 
Figure 10: Schematic diagram to obtain the hybrid molecule 
(synthon A-G-synthon B) 
The route proceeding via the (synthon A + G) complex (fig. 10) has been chosen, 
because coupling of an amine to the (G + synthon B) complex proceeds in very low 
yields. 
Synthon A contains an amine function and a nitrate ester; its synthetic pathway is 
given in scheme 1. 
88 
Chapter 3 
Nitrate esters can be obtained in many different synthetic ways, such as: 
- reaction of alcohols with nitric acid in acetic anhydride 3 2 . 
- reaction of alcohols with nitronium salts, such as nitronium tetrafluoroborate 3 3 - 3 4 or 
via transfer nitration of alcohols with N-nitrocollidinium tetrafluoroborate 3 5 . 
- alkylhalides can be converted into the corresponding nitrate esters by mercury-
assisted substitution reaction using mercury(I) nitrate [Hg(N03>] or mercury(II) 
n i t r a t e [ H g ( N 0 3 ) 2 ] 3 6 ' 3 7 
- reaction of alcohols with thionyl chloride nitrate [SOCl(N03)] or thionyl nitrate 
[ S O ( N 0 3 ) 2 ] 3 8 . 
W e have nitrated the alcohols with a mixture of nitric acid and acetic anhydride, 
because in this way the nitrate esters are easily obtained with high yields. 
Scheme 1: Synthesis route of nitrate ester E (synthon A; VUF 9059; m = 3) 
The co-substituted-alkoxybenzene derivatives C are obtained by reaction of 2-(2-
hydroxyethoxy)phenol A with N-(co-bromoalkyl)phthalimides B . The phthalimido 
group is removed with hydrazine hydrate affording the co -aminoa lkoxybenzene 
derivatives D. The hydroxy group is converted into a nitrate ester E , using a mixture 
of acetic anhydride and nitric acid. The other possibility is to introduce the nitrate 
ester in an earlier stage of the synthesis route shown in scheme 1. The derivative C 
can be nitrated affording compound F. However, removal of the phthalimido group 
with hydrazine hydrate will result in the loss of the nitrate ester, leading to compound 
D. Hydrazines are described as effectively agents to remove nitrate ester g roups 3 9 . 
Therefore, route C-D-E is chosen to obtain nitrate ester E. 
The next step in the synthesis of the proposed hybrid molecules is the coupling of the 
guanidyl group to synthon A. 
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To introduce the guanidino function, several routes can be applied as is indicated in 
scheme 2. 
Scheme 2: Synthesis route to afford the hybrid molecules , in t roduct ion of a 
guanidino function 
In route 1 (scheme 2), the introduction of the guanidine function is accomplished by 
reaction of dimethyl N-cyanodithiocarbonimidate or diphenyl N-cyanocarbonimidate 
G (the Z groups in scheme 2 represent leaving groups) with a primary amine E from 
scheme 1 affording H. The next step involves the addition of aminopropylimidazole I, 
under the same reaction conditions as for addition of the first amine E, resulting in the 
cyanoguanidine derivative J . The cyano group can be removed by acid hydrolysis. 
However, it appeared that this route cannot be applied to afford the guanidine K, 
because of the instability of the ethers under the acidic conditions. 
In route 2a (scheme 2), the amine E is reacted with benzoyl isothiocyanate L to give 
the thiourea derivatives M . However, the removal of the benzoyl group, to afford the 
isothiourea derivatives N , is performed under basic conditions (route 2a; scheme 2) 
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resulting in the loss of the nitrate ester function. To avoid basic hydrolysis, ammonium 
isothiocyanate P was used, in stead of benzoyl isothiocyanate L , to afford the 
thiourea derivatives N (route 2b; scheme 2). However, this reaction gave a mixture of 
large amounts of unidentified compounds. 
In the proposed total synthesis scheme (scheme 1), it is impossible to introduce nitrate 
esters in the final stage of the synthesis route (synthon A-G-synthon B). Despite the 
many ways to obtain nitrate esters, none of the mentioned nitrating agents can afford 
the proposed hybrid molecules, as they lead to nitration of the imidazole moiety 
and/or the guanidino moiety 4 0 * 4 1 . 
5 Conclus ion 
This chapter reveals that the proposed hybrid molecules cannot be synthesized 
accord ing to the presented react ion schemes . Rep lacemen t of the eo- [ (2-
nitroxyethoxy)substi tuted-phenoxy]alkylammonium nitrates (synthon A; fig. 9) by 
structure moieties which are stabile under acidic conditions and do not require 
alkaline condi t ions , may provide a route to hybrid molecules with combined 
histamine H2-agonistie and nitrovasodilating properties, proving the potential benefit 
in treatment of certain cardiovascular disorders. 
Experimental method to obtain V U F 9059 
N-{3-[2-(2-hydroxyethoxy)phenoxy]propyl}phthalimide 
0.2 mol 2-(2-hydroxyethoxy)phenol and 1 equivalent sodium are disolved in 500 ml 
ethanol and stirred at room temperature. After 1 hr, 1 equivalent N-(3-bromopropyl) 
phthalimide was added and the reaction mixture was refluxed 2 days under nitrogen 
atmosphere. The crude reaction mixture was filtered and the solvent concentrated. 
The product was crystallized from ethanol. 
Yield: 8 1 % ; m.p. 114.1-115.6°C 
! H-NMR (CDC1 3): 2.04-2.28 ppm (m, 2H, C-C// 2 -C), 3.95-4.09 ppm (m, 8H, 0 - C / / 2 - C -
C-N, 0 - C - C - C / / 2 - N , and 0 - C / / 2 - C / / 2 - 0 ) , 6.90 ppm (s, 4H, 4x phthalimide-/ /) , 7.70-
7.83 (m, 4H, 4x phenyl-//). 
3-[2-(2-hydroxyethoxy)phenoxy]propylamine 
0.1 mol N-{ 3-[2-(2-hydroxyethoxy)phenoxy]propyl}phthalimide was refluxed 15 
minutes with 4 equivalents hydrazine hydrate in methanol . The crude reaction 
mixture was filtered. The solvent was evaporated ^nd the residue was disolved in hot 
ethyl ace ta te and fil tered. T h e solvent was evapora ted , ob ta in ing 3-[2-(2-
hydroxyethoxy)phenoxy]propylamine as an oil. 
Yield: 86%; m.p. oil 
^ - N M R (DMSO-d 6 ) : 1.94-2.13 ppm (m, 2H, C-C/ / 2 -C) , 2.55-2.70 ppm (m, 2H, O-C-
C-C/ / 2 -N) , 3.75-4,05 ppm (m, 6H, 0 -C/ / 2 -C-C-N and 0 - C / / 2 - C / / 2 - 0 ) , 6.80-7.05 ppm 
(m, 2H, 2x phenyl-//) , 7.45-7.79 ppm (m, 2H, 2x phenyl-//). 
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3-[2-(2-nitroxyethoxy)phenoxy]propylammonium nitrate VUF 9059 
At 0°C, 2 equivalents of a 1/1 molar mixture of nitric acid and acetic anhydride are 
added d ropwise to a solution of 20 mmol 3- [2- (2-hydroxyethoxy)phenoxy]-
propylamine in 80 ml ethyl acetate/acetic acid (1/7 v/v) and stirred 1 hr at 0°C. The 
crude react ion mixture was poured into ether and filtered. The res idue was 
crystallized from methanol/ether. 
Yield: 89%; m.p.93.3-93.9°C 
*H-NMR (DMSO-d 6 ) : 1.96-2.15 ppm (m, 2H, C-C/ / 2 -C) , 2.90-3.10 ppm (m, 2H, O-C-
C-C/ / 2 -N) , 4.08-4.32 ppm (m, 4H, 2x 0 - C / / 2 - ) , 4.85-5.03 ppm (m, 2H, - C / / 2 - O N 0 2 ) , 
6.89-7.08 ppm (m, 2H, 2x phenyl - / / ) , 7.65-7.85 ppm (m, 3.8H, 2x phenyl - / / and 
N / / 3 + ) . 
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C h a p t e r 4 
L - t y p e v o l t a g e - o p e r a t e d C a 2 + - c h a n n e l s : 
m o l e c u l a r b i o l o g y , l i g a n d s , m o l e c u l a r s t r u c t u r e , a n d m o l e c u l a r 
p h a r m a c o l o g y 
1 Introduction 
Ion channels are proteins embedded in the cell membrane that form pores through 
which passive ion movement takes place selectively. There are two categories of ion 
channels: 
1) channels that are regulated by electrical signals. They are called voltage-operated 
channels (VOCs). 
2) channels that are regulated by ligand-receptor interactions. They are called 
receptor-operated channels (ROCs). 
Ion channels of several distinct types exist and therefore these two classes can be 
further subclassified. Ion channels may be considered as receptors. However, to be 
considered as pharmacologica l receptors , ion channels have to fulfil certain 
requirements, including the existence of endogenous ligands for the receptor. In the 
last decade much evidence has been obtained to prove that these channels may be 
considered as receptors indeed. 
2 Classification of the voltage-operated calcium channels 
There are several different types of calcium channels. Based upon electrochemical, 
pharmacological, and physiological properties these types are called L, T, N, and P-
type calcium channels 1 . 
T-type channels 
T-type channels are low voltage activated channels and have a transient (T from 
Transient) duration of opening due to rapid inactivation. They are found in several 
tissues including SA and AV nodes and in neurones from a variety of brain areas. 
L-type channels 
L-type channels are found in the heart, smooth muscle and neurones of the central 
nervous system, but they predominate in the cardiovascular system, where they are 
important for the regulation of the excitation-contraction coupling. High voltage 
activation of the channel produces a long lasting opening (L for Long lasting). These 
type of channels are highly sensitive to calcium channel blockers, like the DHPs. The 
peptide co-agatoxin IIIA (co-aga-IIIA) is a neurotoxin isolated from venom of a spider 
which blocks L- and N-type channels in neurones (see next section) and L-type 
channels in myocardial cells, with high affinity, making it useful in studies to 
determine and differentiate distinct types of C a 2 + - c u r r e n t in myocardia l cells 
containing both L- and T-type channels 2 . 
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To date, the L-type channel is the most extensively characterized Ca 2 + -channel . This 
characterization revealed that there are functional differences among Ca 2 + -channe l s 
in different tissue, reflecting differences in the structure of the receptor protein. 
N-type channels 
N-type channels are high voltage activated and the time constant for activation is in 
between the values of L- and T-type channels (N of Neuronal). They are only found 
in peripheral neurones (nerve cells) and may play a role in neurotransmitter release. 
Despite the diversity of neuronal calcium channels, it is difficult to distinguish N-type 
channels from L-type channels both present in neurones, because the DHPs are not 
only highly sensitive to L-type channels but also affect N-type channels 3 . Both L-
and N-type current can be blocked with co-conotoxin (co-CgTx), isolated from the 
venom of a snail. 
P-type channels 
P-type channels are also high voltage activated and are located in Purkinje cells of 
the cerebel lum (P for Purkinje). These channels are sensitive to a fraction of a 
neurotoxin, called FTX, isolated from the venom of a spider 4 . Unfortunately, the 
complete structure of FTX has not yet been elucidated. 
3 Molecular structure of calcium channels 
3.1 Molecular structure of the L-type voltage-dependent calcium channels 
Tanabe et a l . 5 were the first reporting to have deduced the complete structure of the 
L- type vo l t age -dependen t C a 2 + - c h a n n e l from rabbit skeletal muscle using a 
combination of protein chemistry and complementary DNA cloning experiments. This 
channel is a hetero-oligomeric structure consisting of four subunits a h a2, p, and y. 
In recent years, a fifth subunit, designated as the 8 subunit was discovered (fig. 1). 
Ca 2+ 
Figure 1 : L-type calcium channel subunit structure 
In Table 1 the relative molecular masses of the subunits are depicted as described in 
literature. 
The hydrophobic nature of the oci subunit allows it to span the membrane. The rabbit 
skeletal oci subuni t prote in structure possesses four repea t ing hydrophobic 
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homologous domains surrounding a central pore . Each domain contains six 
t ransmembrane spanning segments. The oci subunit forms the pore of the calcium 
channel 6 . Modifications of the pore proteins resulted in altered permeation properties. 
In this way, it was possible to elucidate that the discriminatory properties are 
determined by ion binding affinity and by ion-ion electrostatic interactions 7 . 
So far the primary structures of the a i subunits of the L-type Ca 2 + - channe l s have 
been elucidated for skeletal and cardiac muscle, aorta, lung, and brain 8 . They exhibit 
small differences in amino acid sequence between the different muscle types (e.g., 
there is ± 95 % homology between cardiac and aortic a i subunits, while the cardiac, 
aortic and brain cci subunits are 65-75 % homologous to skeletal muscle a i subunits). 
Differences in a i subunit structures are also shown in Table 1, where the cci subunit 
of rabbit heart is larger than that of skeletal muscle (195 versus 165 kD) which may 
arise from different encoded genes or from alternative splicing 9 . 
The a i subunit is the largest calcium channel protein subunit which carries the 
binding sites of the three major classes of calcium channel blockers. Therefore, the 
subtle differences in amino acid composition could contribute to the tissue specificity 
of the calcium channel blockers. 
The a2 subunit, like the 8 and y subunits, is heavily glycosylated and is slightly smaller 
than the ax subunit. Their precise function is unknown yet. 
The p subunit is hydrophilic and is located at the intracellular surface. As for the ax 
subunit, also subtle differences in amino acid sequence of the p subunit demonstrate 
the existence of multiple isoforms in heart, skeletal, smooth muscle and brain. It is 
thought that the P subunit is able to regulate the sensitivity to DHP modulation and 
gating propert ies of the channel , by acceleration of the gating activation and 
inactivation kinetics. 
The P and ax subunits can be phosphorylated. $ { - ad renocep to r s t imulat ion in 
cardiac and skeletal muscle cel ls activates cAMP-dependen t k inases , which 
phosphorylate the a j and P subunits, resulting in an increase the Ca 2 + - inf lux through 
VOCs . However , it is unknown whether the al or p subunit regulates the open 
probabil i ty of the ion channel upon phosphorylat ion. Phosphorylat ion of the 
subunits by protein kinases rises the question if this is restricted to p-adrenoceptors 
or that also other cAMP elevating ligand-receptor interactions are capable to do so. 
Until now only speculations and no clear evidence has appeared whether histamine 
H 2 -receptor stimulation can modulate the L-type VOCs. 
The y subunit is a glycosylated transmembrane unit. The specific role of the y subunit 
is unknown. However, the fact that there is no evidence for the presence of y-like 
mRNA in other than skeletal muscle, may suggest that the y subunit is a skeletal 
muscle specific component which may contribute to the large amount of L-type 
voltage-dependent calcium channels in skeletal musc le 1 0 . 
The 8 subunit is covalently linked to the oc2 subunit via disulfide bridges. The precise 
function is unknown yet. 
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Transmembrane folding models of the subunits and coexpression of the ax subunit 
from L-type calcium channels with several other subunits have been briefly reviewed 
by Ca t t e r a l l 1 1 . Experiments with mouse cells deficient of oc2, p, y a n d 8 subunits 
demonst ra ted that the ax subunit itself is able to produce calcium currents . 
Coexpression of the ax subunit with the P subunit generated an almost normalized 
calcium current. It is thought that the p subunit is able to increase the number of 
binding sites of the calcium channel blockers (CCBs). Coexpression of combined o^, 
a 2 , and p subunits further improved the ability of the cell lines to express C a 2 + -
currents. Not surprisingly, coexpression of the a t subunit with the other subunits 
clearly demonstrated that the combination of all subunits is crucial for modulation of 
the gating properties of the channel and for the binding of C C B s 1 2 ' 1 3 . 
Table 1: Relative molecular mass of the subunits of rabbit skeletal muscle L-type 
Ca 2 + -channe l s . 
subunit M r ref.5 Href.77 M.ref.108 M.ref.18 M r ref.9 
170 145-175 155-175 212 * heart 195 heart 
2 1 2 # 175 skeletal 165 skeletal 
a 2 140 135-150 143 140 140 
P 55 55 55 54 55 
Y 33 33 30 30 32 
8 - 24-29 27 27 32 
Mr Molecular mass in kD 
& The rabbit skeletal muscle a\ subunit contains 1.873 amino acids with a calculated 
relative molecular mass (Mr) of 212 kD. This differs from the experimental deduced Mr of 
170 kD which is ascribed to proteolytic modification in vivo or during the protein 
purification or even could be inherent to the inaccuracy of the analytical method. 
* The a¡ subunit of skeletal muscle is very similar to that of the a¡ subunit of the heart, 
except it lacks 320 amino acids located at the C-terminal end 
3.2 Structural homology between the N- and L-type calcium channels 
Witcher et a l . 1 4 purified the N-type channel from rat CNS and elucidated the several 
subunits and revealed that this channel contains four subunits with a relative 
molecular mass of 230 kD (ocj), 160 kD (oc28; in reduced form 140 kD for oc2), 57 kD 
(p) and a 95 kD glycoprotein subunit not further specified. The subunit composition 
of the N-type channel is comparable to but distinct from the L-type channel. Whereas 
the <xx and P subunits from the distinct channels and tissues differ, the a 2 8 subunit 
seems to be similar in brain N-type channel and smooth muscle L-type channel. 
Mori et a l . 1 5 deduced the primary structure of a high-voltage activated, DHP- and co-
CgTx-insensitive voltage-dependent calcium channel in rabbit brain, designated as BI 
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channel, which is suggested to be the P-type channel. Although, there are many 
similarities between the BI channel and P-type channel, there also exist substantial 
differences which do not allow to identify them as identical channe ls 1 6 . 
3.3 Structural homology between different ion channels 
N a + - , K + - , C a 2 + - c h a n n e l s are all voltage-operated ion channels belonging to a 
structurally homologous family 1 7 . The similarities of the membrane spanning segments 
among the three types of ion channels may explain the affinity of some drugs to more 
than one ion channel. For example, the a{ subunit of L-type vol tage-dependent 
calcium channel is highly homologous (55 %) to the corresponding a subunit of the 
sodium channel. 
The displayed homology of the three ion channels indicate that the voltage-
dependent ion channels originate from a common ancestor which is believed to be 
the K + - c h a n n e l 1 8 . 
4 Ligands for the L-type voltage-operated calcium channel 
The ligands for the L-type voltage-operated calcium channels exist of both channel 
blockers and activators. Only a few endogenous ligands have been reported; most of 
the active compounds are of exogenous nature. 
4.1 Calcium channel blockers 
There exist a great variety of compounds which are able to modulate the function of 
L-type voltage-operated calcium channels. In this tangle of heterogeneous chemical 
structures, five classes can be distinguished which each interacts with individual 
binding sites (Table 2). Three major classes of calcium channel blockers currently in 
cl inical use are: phenyla lky lamines (PAAs) , benzoth iazepines (BTAs) , and 
dihydropyr id ines (DHPs) . They exhibit differences in negat ive inotropic and 
chronotropic activity. These differences are related to a certain cardiovascular 
selectivity. The cardiac actions (antiarrhythmic) of these agents increase from DHPs, 
via BTAs to PAAs. The differences in relative potencies exerted on vascular smooth 
muscle and the heart determine their use in treatment of specific cardiovascular 
disorders. 
Often a fourth class of compounds is added to this classification namely the 
diphenylbutylpiperidines (DPBPs); these derivatives are also L-type calcium channel 
blockers and they possess affinity for a fourth "binding site of calcium channels. A 
fifth class contains all other compounds which are not chemically related to each 
other but are able to modulate the calcium influx through the calcium channels. 
Compounds belonging to this class interact with not specified binding sites at the 
calcium channel, which are distinct from the PAA, BTA, DHP or DPBP binding sites. 
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Table 2: Classification of L-type voltage-operated calcium channel blockers 
1 phenylalkylamines (PAAs) 
2 benzothiazepines (BTAs) 
3 dihydropyridines (DHPs) 
4 diphenylbutylpiperidines (DPBPs) 
5 miscellaneous selective and non selective compounds 
4.1.1 Phenylalkylamines (PAAs) 
The standard example of the PAAs is verapamil 1 (fig. 2). In 1962 it was shown by 
A p p e l 1 9 that verapamil exerts a calcium channel blocking activity, which made this 
compound extremely suitable for treating certain cardiovascular diseases. Although 
verapamil was the first calcium channel blocker with therapeutic value, only a few 
examples of verapamil analogues have been reported in literature. Gallopamil (D600) 
2, devapamil 3, ludopamil 4, anipamil 5 and thiapamil 6 belong to the scanty examples 
of verapamil analogues. The (S)-(-)-isomers of verapamil and its analogues are more 
potent vasodilators and have higher negative inotropic effects than the (R)-(+)-
isomers (table 3). The (R)-(+)-isomers of verapamil, gallopamil and devapamil (D888) 
have a higher vascular over myocardial selectivity, but are less potent vasodilators 
than the (S)-(-)-isomers 2 0 . 
The affinity of (S)-emopamil 7 for the verapamil binding sites in rat cortex membranes 
is the same as for gallopamil and verapamil. The in vitro calcium channel blocking 
activity is one magnitude less than that of verapamil and gal lopamil 2 1 . 
Figure 2: Phenylalkylamines 
The calcium channel blockers belonging to the class of PAAs also exhibit anti-
serotonergic (5-HT2) properties. This antiserotonergic activity could be beneficial in 
the treatment of cerebrovascular disorders. (S)-Emopamil has a high affinity for the 
serotonin (5 -HT 2 ) receptor. Although emopamil shows no stereoselectivity in calcium 
1 R1 
2 R1 
3 R, 
4 R1 
H, R2 = CH30, R3 = CH3O verapamil (D365) CH3O, R2 = CH3O, R3 = CH3O gallopamil (D600) 
H, R2 = CH3O, R3 = H devapamil 
CH3O, R2 = Na, R3 =H ludopamil 
5 anipamil 
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channel blocking activity in in vitro studies or for the verapamil binding site, the (S)-
enantiomer of emopamil has an affinity for the serotonin receptor (5-HT2) which is 
distinctly higher than that of the (R)-enantiomer (table 3). Therefore, (S)-emopamil 
appears to be a potential drug for the treatment of cerebrovascular d isorders 2 1 . 
Table 3: Calcium channel blocking (CCB), negative inotropic and serotonergic 
CCB inotropy 5-HT 2 
compound p I C 5 0 p E C 5 0 p E C 5 0 
(±)-verapamil (D365) 6.85 a 5.96 c 2 , 5.46 e 7.38 c i 
(S) 7.62 b 
(R) 6.66 b 
(±)-gallopamil (D600) 7.36 a 6.72 «a, 5.91 e 7.37 c 1 
(S) 7.74 b 7.52 à 
(R) 6.36 b 5.52 <* 
(D888)devapamil (S) 8.70 b 
(R) 6.41 b 
emopamil (S) 6.57 c 1 4.54 c 2 8.35 0 1 
(R) 6.66 c 1 4.70 c 2 6.80 c 1 
a Van Meet et al.22 ; data from rabbit aorta 
b Nawrath et al.23 ; data from rat aorta 
c Hofmann et al21 ; data from el rat aorta; c2 guinea pig left atrium 
d Ludwig et al24 ; data from cat papillary muscle 
e Mannhold et al25 ; data from cat papillary muscle 
Mitani et a l . 2 6 have synthesized verapamil analogues with a phenoxyalkylamino 
moiety instead of a phenethylamino moiety, thus introducing oc-adrenergic blocking 
activity (fig. 3) . By variation of the carbon chains and the substituents on the 
nitrogen atom (Ri) of verapamil analogues, it was shown that the conditions of m = n 
= 3 and Ri = C H 3 are best for calcium channel blocking activity, while those of m = 
3, n = 2 and Ri = H are favourable for oc-adrenergic blocking activity (table 4 ) 2 6 . 
I 
' -H7C3 <f y 1 (CH 9 ) m N 
i-C 3H 7 
—(CH 2 ) n -0 
H 3 C O 
Figure 3 : Structure of described verapamil analogues 
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Variations of the substituent on the q u a t e r n a r y carbon atom from methyl to n-
dodecyl, branched alkyl or a benzyl moiety revealed that the opt imum in calcium 
channel blocking activity is present in the isopropyl substi tuent 2 7 . 
Table 4: Calcium channel blocking (CCB) and oc-adrenergic blocking activities of 
verapamil ana logues 2 7 
m n R i R 2 p A 2 ( C C B ) pA 2(cc) 
3 2 H 2-OCH 3 6.59 8.42 
3 2 M e 2-OCH3 7.20 7.04 
3 3 M e 2-OCHj 8.05 5.79 
3 3 M e 3-OCH3 9.00 
3 2 M e 3,5-diOCH 3 10.20 
verapamil 7.88 5.79 
CCB: pA2 values in the K+-depolarized guinea pig taenia coli 
a: pA2 values in rabbit thoracic aorta 
4.1.2 Benzothiazepines (BTAs) 
Chemically considered, the compounds referred to as benzothiazepines are more 
properly described as benzothiazepinones. Diltiazem 8 (fig. 4) is the most important 
drug of the benzothiazepinones and selectively blocks calcium entry through the L-
type calcium channe l s 2 8 . Diltiazem has two asymmetric carbon atoms, the (2S,3S)-
isomer is the most active CCB. Diltiazem is clinically used as an antihypertensive 
drug. The rather short duration of action of dilt iazem urged the development of 
agents with improved cardiovascular activity, such as TA-3090 9 (fig. 4 ) 2 9 . TA-3090 
is a more potent antihypertensive agent in animals than diltiazem and is now subject 
to clinical investigations. 
8 diltiazem 9 TA-3090 (R = 8-C1) 
10 SQ 32,910 (R = 6 - C F 3 ) 
Figure 4: Benzothiazepine analogues 
102 
Chapter 4 
Structural modifications on the benzothiazepinone ring system revealed that the 
sulfur a tom is not essential for its antihypertensive activity or antagonism of 
[ 3 H]dil t iazem binding in guinea pig skeletal muscle membrane preparations, as is 
demonstrated by compounds in which the sulfur atom is replaced by an oxygen atom 
(benzoxazepinone) , a nitrogen atom (benzodiazepinone) or a methylene group 
( b e n z a z e p i n o n e ) 3 0 . The benzazepinone SQ 32,910 10 (fig. 4) is a potent calcium 
channel blocker in vitro (table 5) and exhibits antihypertensive activity in v i v o 3 1 . 
Table 5: Calcium channel blocking activities of diltiazem and ana logues 3 0 3 
compound pICso 
diltiazem 6.68 / 6 .42 a 
TA-3090 5.11 
SQ 32,910 6.62 
a) Van Meel et al . 2 2 , 
pICso In rabbit aorta strips contracted by KC1 
4.13 Dihydropyridines (DHPs) 
The DHPs are the most extensively studied class of L-type voltage-operated calcium 
channel blockers. Ever since Vater et a l . 3 2 established that the coronary dilator 
nifedipine (fig. 5) exhibited a calcium channel blocking activity and was selective for 
smooth musc le over cardiac muscle , large numbers of analogues have been 
synthesized. An intriguing review of the first twenty years of research at the Bayer 
company by Bossert et a l . 3 3 shows the long way via more than 2000 compounds to 
the extremely successful drug nifedipine. The field of DHPs appealed many other 
research groups as can be seen in this review in which more than 50 industrial 
companies are cited which are or have been working on DHPs. 
The first structural alterations on DHPs were confined to minor modifications in the 
small alkyl substituents of the ester functions resulting in compounds with only small 
differences in their pharmacological profile (fig. 5). Little by little, more structural 
changes were realized. The increasing interest proceeded from certain limitations in 
therapeutic use of the so-called first generation DHPs. Despite the ability of the first 
generation DHPs to lower blood pressure, these drugs exhibited a negative inotropic 
effect on cardiac function and they have a short duration of action. The initial 
increase of heart rate often observed with DHPs, seems to be due to a sympathetic 
reflex caused by the decrease in blood pressure; it is of a temporary nature. Compared 
with PAAs and BTAs, DHPs have a higher selectivity for vascular tissues than for 
cardiac t issues. Generally, DHPs are more effective in hypertensive animals and 
humans than in normotensive ones, which might suggest that the nature of the 
voltage-operated Ca 2 + -channels is altered in hypertension. 
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F^OOC COOR2 
compound R i R 2 
nifedipine (Bay a 1040) M e M e 2-N0 2 
nitrendipine (Bay e 5009) M e Et 3-NO2 
nimodipine (Bay e 9736) iPr C H 2 C H 2 O C H 3 3 - N 0 2 
niludipine (Bay a 7168) C H 2 C H 2 0 - i P r C H 2 C H 2 0 - i P r 3 -N0 2 
nisoldipine (Bay k 5552) M e 
felodipine M e 
riodipine M e 
isradipine M e 
(PN 200-110) 
sec-butyl 
Et 
M e 
iPr 
2 - N 0 2 
2,3-diCl 
2-OCF3 
phenyl-Ca"^ \ 
pheny!-C2 ^ ' 
darodipine Et Et phenyl-C3 ^ \ 
phenyl-C2 ^ N ' 
oxodipine M e Et phenyl-C3* 
phenyl-C2* > 
Figure 5: 1,4-Dihydropyridines with mainly small esters and various 4-phenyl 
substituents 
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Table 6: Calcium channel blocking (pICso; determined on aorta) and negative 
inotropic activities (pECso; determined on papillary muscle) of DHPs from 
figure 5 
a 
d 
8 
j 
I 
m 
compound 
nifedipine 
nitrendipine 
nimodipine (±) 
nimodipine (-) 
nimodipine (+) 
niludipine 
nisoldipine 
felodipine 
isradipine (+) 
isradipine (+) 
isradipine (-) 
oxodipine 
nicardipine 
elgodipine 
pICso 
8.09*.f rabbit 
8.77* rat 
8.35* rabbit 
8.72 1 guinea pig 
8 .24 h rabbit 
8 .53 f rabbit 
8.52h rabbit 
9 . 6 3 e rat 
7 .80 h rabbit 
8 .86 e rat 
7 .89 f rabbit 
8.62»
 r a b b i t 
10.158 rat 
12 .1 k ra t 
9 . 2 0 m rabbit 
10.038 rat 
7.918 rat 
8.64 1 guinea pig 
p E C 5 p 
7.66 a/7.22i guinea pig 
6 . 4 3 b cat 
7.32d rabbit 
6.12b
 C a t 
6 .24 d rabbit 
5 . 8 9 b cat 
5 .96 d rabbit 
5 .70 b cat 
7 .19 a guinea pig 
7 .10 d rabbit 
5 .3 C rat 
8.12J guinea pig 
5 .76 d rabbit 
8.6QJ guinea pig 
Kazdaetal.34 
Boyd et al36 
Wibo et al38 
Tamargoet al.46 
b Rodenkirchen et al?5 
e Godfraind et al.37 
h Towart et al39 
k Hagiwara et al.4& 
c Edgar35 
ƒ Van Meel et al?2 
i Christiaans et al.56 
Inglesi et al41 data from guinea pig taenia coli 
Mellemkjaer et al42 data from rabbit coronary artery 
The break-through in increasing the duration of action and lowering of the negative 
inotropic and chronotropic activities came with nicardipine (fig. 6; table 6 and 7) 
bearing a large ester substituent and showing less cardiodepressant effects than 
nifedipine 4 3 . Introduction of larger ester substituents, instead of a lower alkyl ester, at 
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the C 3 or C 5 posit ion of the D H P ring is accompanied by a longer duration of 
antihypertensive action, which is believed to result from increased lipophilicity. 
Az idop ine 4 4 (fig. 6) proceeded from the investigation which led to nicardipine, and is 
used in photoaffinity labelling / binding studies to locate the L-type voltage-operated 
calcium channels in several tissues. 
In figure 6, a selection of the DHPs bearing a large ester substituent is presented. 
These compounds are developed to obtain drugs with even more vascular selectivity 
than cardiac selectivity. In table 7, the in vitro relative calcium channel blocking 
activities (determined on rabbit aorta strips contracted by K + ) of the compounds in 
figure 6, are presented. 
Benidipine (KW-3049; fig. 6) exhibits a potent and long-lasting antihypertensive 
effect in spontaneously hypertensive rats and shows slow onset kinetics. Benidipine 
has two asymmetric carbon atoms. It appeared that the enantiomer with the (S,S)-
configuration possesses the most potent and long lasting antihypertensive effect. 
This is in agreement with nicardipine, where the (S)-enantiomer (C4 carbon atom of 
the 1,4-DHP ring) also shows stronger antihypertensive effects than the (R)-
enant iomer 4 5 . 
Elgodipine ( IQB-875; fig. 6; table 6) has a potent arterial vasodilator action in 
anaesthetised dogs. This action results in a reduction of systemic blood pressure and 
improved left ventricular systolic performance due to a reduction of the afterload. 
Although elgodipine displays a 100-fold higher vascular than myocardial potency, it 
still has a marked negative inotropic and negative chronotropic activity. The decrease 
in contractile force is more evident than the reduction in contractile rate. Elgodipine, 
oxodipine and nifedipine are as negative inotropic agents, determined on guinea pig 
right atria, equipotent namely I C 5 0 = 5 x 1 0 9 M. However, elgodipine has a more 
potent negative chronotropic activity than oxodipine or nifedipine; I C 5 0 = 2.5 x 10~8 
M, 7 x 10 ' 7 M, 2 x 10" 6 M, respectively. The negative inotropic and chronotropic 
activities displayed by these three DHPs makes them unsuitable for the treatment of 
cardiovascular disorders, such as congestive heart fai lure 4 6 . 
TC-81 (fig. 6) is a strong antihypertensive agent with slow onset kinetics and long-
lasting ant ihyper tens ive effect, especial ly after oral admin i s t r a t i on 4 7 * 4 8 . The 
antihypertensive potency is approximately 3 times higher than that of nifedipine or 
nicardipine. The duration of the antihypertensive effect of TC-81 is twice as long as 
that of nicardipine. Both TC-81 and nicardipine demonstrate a negative chronotropic 
effect on isolated guinea pig right atria, but ^hese effects appear at about 100-fold 
higher concentra t ions as compared with the relaxing effects on K + - i n d u c e d 
contractile responses of isolated rat aorta. 
Pranidine (OPC-13340, carrying a 3-phenyl-2(E)-propenyl ester function; fig. 6) 
exerts an antihypertensive effect in both normotensive and hypertensive rats and 
d o g s 4 9 . The equipotent antihypertensive action of pranidine and TC-81 after oral 
administration is stronger than that of nifedipine or nicardipine. The duration of the 
ant ihyper tensive action is longer than that of nifedipine and nicardipine. Its 
pharmacological action and potency is equal to that of TC-81 . 
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RiOOC COORo 
compound R\ R 2 
nicardipine M e CH 2CH 2 
azidopine Et - CH 2CB 
benidipine M e 
(KW-3049) 
3 -N0 2 
2 - C F 3 
3 - N 0 2 
TC-81 
— CH 2 CH 2 
elgodipine iPr 
(IQB-875) 
M e 
— CH 
pranidine M e 
(OPC-13340) 
CV-159 M e 
- C H 
N— NH 
phenyl G 
• > phenyl C 2 
2-F-5-N02 
- (CH 2 ) ( 
3-NO2 
3-NO2 
Figure 6: 1,4-Dihydropyridines with large ester substituents 
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CV-159 (fig. 6) shows a similar increase in coronary flow, aortic flow and heart rate 
and decrease in mean blood pressure as nicardipine after intravenous administration 
in anaes thet ized open-ches t d o g s 5 0 . However , CV-159 has a slower onset of 
activation kinetics and a longer duration of antihypertensive action than nicardipine. 
CV-159 has a slight negative inotropic and chronotropic which is absent with 
nicardipine. 
Table 7: Relative calcium channel blocking potencies of DHPs from figure 6 
compound relative potency reference 
nicardipine +++ 51 
benidipine (S,S) +++ 4 5 
(R,R) ++ 4 5 
(S,R)/(R,S) + 4 5 
elgodipine ++ 46 
TC-81 +++ 47 
pranidine +++ 51 
CV-159 ++ 50 
The search for both more vascular selective and long-lasting drugs has led to other 
changes than presented so far. Originally, structure-activity relationship studies on 
DHPs suggested that lower alkyl substituents were preferred at the 2-position on the 
1,4-DHPring. 
Amlodipine (fig. 7) was the first compound demonstrating that extended substituents 
bearing a basic functionality, linked via an ether oxygen atom to the 2-methyl group 
on the D H P ring are well tolerated (fig. 7). It appeared that amlodipine has an affinity 
for the D H P binding site similar to that of nifedipine, but exhibited a slower onset and 
offset kinetics and a longer duration of action. Although the enantiomer with the 
absolute (R)-(-)-configuration was designated to be the most active enan t iomer 5 2 , 
Goldmann et a l . 5 3 repeated the separation of the racemic mixture and found out that a 
serious mistake was made in the determination of the absolute configuration. They 
established that the enantiomer with the (S)-(-)-configuration is the most active 
calcium channel blocker. 
Since the discovery of amlodipine, more examples of DHPs with substituted higher 
alkyl chains, carrying a basic function, have been introduced. To the amlodipine 
analogues belong SI 1568 and the thio-bioisosteres t i amdip ine 5 4 and V U F 4 7 3 1 5 5 
and its ana logues 5 6 (fig. 7). 
The racemic mixture of compound SI 1568 (fig. 7) was separated into its enantiomers. 
In vitro calcium channel blocking studies revealed that (-)-Sl 1568 was 300 more 
potent than (+)-S11568 (table 8). (-)-S 11568 displays affinities similar to that of 
nifedipine and racemic compound (±)-S11568 for the DHP binding site, determined 
on rat heart microsomes, whereas it is 17-fold more potent than the (+)-S11568 
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enantiomer.(-)-S11568 inhibits L-type Ca 2 + -current in whole-cell patch clamp studies 
in both guinea pig ventricular myocytes and in the so-called A 7 r 5 rat aortic smooth 
muscle cell line 30-fold more potent than (+)-Sl 1 5 6 8 5 7 . In vivo studies revealed that 
(-)-S 11568 has a higher selectivity for cardiac tissue than for vascular smooth muscle 
and, thus not having the selectivity required for an antihypertensive agen t 5 8 . 
The presence of a basic moiety in amlodipine is not an absolute requirement for either 
calcium channel blocking activity or selectivity for vascular tissue over the heart. This 
is demonstrated by a number of compounds in which the primary amino group is 
replaced by polar functionalities such as amides (BBR-2160, NB-818, UK-51,656; 
fig.7) or by a number of five- and six-membered nonbasic polar heterocycles (UK-
52,831, UK-55,444, UK-56,593; fig. 7). 
In table 8 the in vitro vascular calcium channel blocking activities and the negative 
inotropic activities on cardiac tissue of a number of amlodipine analogues are 
presented . T h e biological act ivi t ies demons t ra te the to lerance of nonbas ic 
substituents in calcium channel blocking activity and vascular selectivity. 
Table 8: Ca lc ium channel b locking activit ies ( p E C 5 0 ) and negat ive inotropic 
activities (pIC 2 5) of a number of amlodipine analogues (fig. 6) 
compound P E C 5 0 p i c 2 5 ref. 
(±)-amlodipine 8.1 a 7.2 52 
(-)-amlodipine 8.7 a nt 52 
(+)-amlodipine 5.8 a nt 52 
(-)-S 11568 8.7 b nt 59 
(+)-S11568 6.9 b nt 59 
UK-51,656 8.4 a 7.1 60 
UK-52,831 8.2 a 6.3 61 
UK-55,444 8.1 a 6.5 62 
UK-56,593 8.8 a 6.7 6 3 
VUF4731 8.4 a nt 55 
BBR 2160 9.7 a 6.4* 65 
(±)-tiamdipine 7 . 2 C nt 64 
(-)-tiamdipine 7 . 5 C N 
(+)-tiamdipine 5.4C 
pEC$o-' Negative logarithm of the concentration required to inhibit 50% of K+-depolarization 
induced contraction in rat: a) aorta, b) mesenteric artery, c) tail artery 
PIC25: Negative logarithm of the concentration required to depress contraction by 25% of 
Langendorjf (guinea pig) heart 
nt: Not tested 
*: PIC50 in stead ofplC2s 
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F^OOC. 
H,CT N 
compound Ri R 2 Z X R 3 
amlodipine C H 3 C 2 H 5 2-C1 0 CH2CH2-NH2 
S-11568 C H 3 C 2 H 5 2,3-diCl 0 CH2CH20CH2CH2-NH2 
0 
N JL 
C H J C H J ' ^ V — ^ ^ N H 2 
UK-51,656 C H 3 C 2 H 5 2-C1 0 
UK-52,831 C H 3 C 2 H 5 2,3-diCl 0 
N — N 
C H 2 C H 2 . J*. \ ^ 
N N N H 2 
H H 
UK-55,444 C H 3 C 2 H 5 2,3-diCl O 
C H 2 C H 2 . / ^ ^ w 
N N 
N H 2 
X 
UK-56,593 C H 3 C 2 H 5 2,3-diCl O 
N H 2 
1 
I A 
C H 2 C H 2 ' X ^ » ; S S : ^ ^ O H 
O 
NB-818 C H 3 i - C 3 H 7 2,3-diCl O 
tiamdipine C H 3 C 2 H 5 3 - N 0 2 
BBR-2160 C H 3 C 2 H 5 3 - N 0 2 S 
VUF4731 C2H5 C2H5 3-NO2 S 
Y 
CH2CH2-NH2 
O 
C H 2 C H 2 
H 
(CH 2 ) 6 -NH 2 
Figure 7 : D H P s with var ious subst i tuents on the 2-posi t ion of the 1,4-
dihydropyridine ring 
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The cardiovascular activities of BBR-2160 have been determined by Germini et a l 6 5 . 
In their test system, the relaxant effect of BBR-2160 (pECso = 9.72) on K M n d u c e d 
contractions on rat aorta appeared to be about 74 and 21 times more potent than 
nifedipine (pECso = 7.85) and a m l o d i p i n e (pEC5o = 8.40), respectively. The negative 
inotropic effects determined on guinea pig atria were equal for all three compounds. 
The vasoselectivity is expressed as the ratio between the E C 5 0 / I C 5 0 values on atria 
(negative inotropic activity) and aorta. In this respect, BBR 2160 is 16 and 188 times 
more selective than amlodipine and nifedipine, respectively. However, if the ratio 
between the negative chronotropic activity and the vasorelaxing effect (determined 
on rat aorta) is considered, then BBR 2160 is not more vasoselective than amlodipine 
(the negat ive inotropic activity of BBR 2160 is 23 t imes more potent than 
amlodipine). 
In a number of tiamdipine analogues and BBR-2160 analogues with a benzyl group 
next to the formamido function, thus introducing an extra chiral center, it appeared 
that the chiral center in the 1,4-DHP ring is determinant with regard to the chiral 
center in the substituent on the 2-position on the 1,4-DHP ring. Like most DHP 
calcium channel blockers, the enantiomer with the R-configuration at the C 4 -carbon 
atom of the 1,4-DHP ring, is more active than the enant iomer with the S-
conf igurat ion 6 6 . 
Lacidipine is the first commercially available DHP derivative bearing a large lipophilic 
alkyl substituent at the ortho-position on the 4-phenyl ring. 
Lacidipine exerts a long-lasting inhibition 
on K + -depolarization-induced contractions 
of vascular preparat ions in vi t ro, and a 
long-las t ing ant ihyper tens ive act ion in 
vivo. The PIC50 values determined on K + -
depo la r i za t ion induced cont rac t ion in 
i so la ted ra t aor ta for l ac id ip ine and 
n i t r e n d i p i n e a r e 10 .10 and 10 .52 , 
respect ively 6 7 . 
This l ipophi l ic compound crosses the 
b lood brain barr ier and, therefore , is 
believed to be suitable for the treatment of 
cerebrovascular d iseases 6 7 . 
H3COOC 
CH=CH-COO(CH3)3 
C O O C H 3 
'CHA 
11 lacidipine 
4.2 Calcium channel activators (CCAs) 
Among the DHPs , both potent activators and blockers of calcium channels are 
present. The CCAs are able to stimulate Ca 2 + - in f lux through the L-type voltage-
operated calcium channel. The calcium channel activators are structurally related to 
the DHP calcium channel blockers. A peculiar phenomenon is observed among some 
racemic DHPs . While one of the enantiomers exerts a calcium channel blocking 
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activity, the other enant iomer is capable to activate the calcium channel . This 
important aspect that within a single class of compounds both activators and 
inhibitors can be found, led to extended structure-activity relat ionship studies. 
Nowadays, Bay k 8644 1 2 6 8 , which produces positive inotropic and vasoconstrictor 
effects, is the most used calcium channel activator in pharmacochemical research. 
Other compounds showing comparable features are PN 202-791 13 and the lactone 
CGP 28-392 14. From both PN 202-791 ® and Bay k 864470, the enantiomer with the 
(S)-configuration of the chiral compound is the activator while the enantiomer with 
the (R)-configuration is a calcium channel blocker. 
12 (S)-(-)-Bay k 8644 13 (S)-(+)-PN-202-791 
H H 
14 C G P 28-392 15 FPL 64176 
Figure 8: Calcium channel activators 
The benzoylpyrrole derivative FPL 64176 15 is a new nondihydropyridine type of 
C C A 7 1 . It produces similar contractile responses on cardiac and vascular smooth 
muscle as (S)-(-)-Bay k 8644 and (S)-(+)-PN 202-791. However, these contractile 
responses are noncompetitively antagonized by compounds belonging to the classes 
of PA As, BTAs or DHPs. The different mechanism and site of action of FPL 64176 
demonstrate that the allosteric binding site on the a r s u b u n i t of the calcium channel 
protein is distinct from the one known for CCBs and C C A s 7 2 . Moreover, in vitro (S)-
Bay k 8644 acts as a potent inhibitor of FPL 64176-induced contractile responses in 
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rat tail a r t e ry 7 3 . Also in vivo experiments suggest that (S)-Bay k 8644 exerts a 
negative allosteric interaction on FPL 64176 binding s i tes 7 4 . 
Until now, there exists no clinical application for calcium channel activators. 
4.3 Calcium channel blockers with additional biological activities 
Besides vasodilating properties, most of the described DHPs often exhibit negative 
inotropic and chronotropic activities at the myocard. This is very often elicited by 
reflex tachycardia. One possibility to suppress the negative actions on the heart is to 
add a positive inotropic or chronotropic action. Traditionally, this was accomplished 
by drug combination therapy. The other possibility is to combine the additional 
actions in one molecule affording so-called hybrid molecules. An example of useful 
hybrid molecules are the ax and p x adrenoceptor blockers, used in combined drug 
therapy for the treatment of cardiovascular diseases and therefore the idea emerged 
to add their action to the calcium channel blockers. 
Many combinations to form hybrid molecules have been carried out. In figure 9 only 
two examples of hybrid molecules with a DHP moiety are shown, especially because 
they have been described in detail in chapter 2. 
16 manidipine (CV-4093) 17 CD -349 
Figure 9: Two examples of calcium channel blocking hybrid molecules 
Manidipine (CV-4093; fig. 9) 16 is a long-acting 1,4-DHP with a piperazine moiety at 
the ester p o s i t i o n 7 5 . This piperazine moiety is often present in o c r a d r e n o c e p t o r 
blockers and vasodilators, such as flunarizine. CD-349 (fig. 9) 17 is a 1,4-DHP with 
nitrate ester g r o u p s 7 6 . Nitrate esters (like nitroglycerin and nicorandil) are potent 
vasodilators used for the treatment of angina pectoris. Although elgodipine (fig. 6) is 
classified as a D H P calcium channel blocker, ifc has to be considered as a hybrid 
molecule, because it has a structure moiety which resembles to verapamil. 
Ev iden t ly , combina t ions of an t ihyper tens ive d rugs , ant ianginal drugs , and 
cardiotonics can afford hybrid molecules with improved therapeutic value. 
4.4 Endogenous ligands 
Although the calcium channel activators and blockers discussed so far are all 
exogenous l igands , recent ly several putat ive endogenous l igands have been 
r e p o r t e d 7 7 . However in most cases the chemical structure of the newly isolated 
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endogenous lipid and peptidic fractions have not been elucidated yet. By screening 
methods it was found that heparin and certain arachidonic acid derivatives are able to 
modify D H P binding or the L-type calcium current 7 8 . Johnson et a l . 7 9 have isolated a 
lipid-soluble brain fraction that noncompetitively inhibits DHP binding to rat cortex 
membranes and elucidated the chemical structure of the fraction. The structure, N-
arachidonic acid-2-hydroxy-ethylamide, was confirmed by compar ison of this 
substance with the synthetically obtained compound. 
The few examples of endogenous ligands indicate that we are just at the start of a 
search for new ligands. Potent endogenous ligands could help to better understand 
and further elucidate calcium channel functioning. Finally, the existence of these 
endogenous ligands fulfil to the criteria for voltage-operated calcium channels to be 
regarded as receptors. 
4.5 Diphenvlbutvlpiperidines (DPBPs) 
The diphenylbutylpiperidines, structurally related with the diphenylalkylamine-type 
calcium channel blockers, are believed to define a fourth site of action of CCBs, this 
class includes both selective and non-selective compounds 8 0 . This class will not be 
discussed here, because this subject has extensively described by Ca ld i ro la 8 1 ' 8 2 . 
4.6 Miscellaneous selective and non-selective compounds 
A number of compounds with selective or non-selective calcium channel blocking 
activity have been described in several r ev i ews 8 3 * 8 4 ' 8 5 . Although compounds is this 
group exhibit a large variety in chemical structure, in several of them moieties are 
present which could be considered as pharmacophores for calcium channel blocking 
activity (for instance, some compounds bear the (2-[3,4-dimethoxyphenyl]ethyl)-
amino substituent identified in verapamil). 
Recently some potent and selective CCBs have been discovered which could 
contribute to further define novel sites of action on calcium channels. Among them 
are HOE 1 6 6 8 6 18 and fantofarone (SR 33557) 8 7 19 (fig. 10). 
18 H O E 166 19 fantofarone (SR 33557) 
Figure 10: Novel compounds believed to define additional classes of CCBs. 
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The compound HOE 166 18 (fig. 10), both competitively and non-competit ively 
inhibits classical CCB binding to muscle membranes with high affinity ( K d = 0.25 nM) 
and blocks L-type Ca 2 + -channel in smooth muscle ce l l s 8 8 . 
The ca lc ium channel b locker fantofarone 19 (fig. 10) is an inhibitor of K + -
depolarization-induced contractions in rat aorta in vitro with an I C 5 0 value of 5.6 nM 
and inhibits [ 3 H]-(±)-nitrendipine binding with a K{ value of 0.19 nM. Fantofarone 
has a distinct binding site on the 04-subunit of the L-type calcium channel protein 
and exerts a negative allosteric interaction on DHPs, BTAs and PAAs. The indolizine 
group in fantofarone is not essential for its calcium channel blocking activity as was 
demonstrated by compounds in which the indolizine group was replaced by an 
indole group which afforded even more potent calcium channel b lockers 8 9 . 
5 S t r u c t u r e activity re la t ionships and stereoselectivity of C C B s 
In 1984 M e y e r 9 0 reviewed the structure-activity relationship (SAR) studies on 
verapamil 1 (fig. 2) and diltiazem 8 (fig. 4) analogues; since then relatively few 
progress seems to have been made. 
SAR studies on verapamil analogues have revealed that very few structural 
modifications on verapamil are allowed. Verapamil has many rotational degrees of 
freedom and all attempts to restrict the molecular flexibility with rigid analogues have 
resulted in a drastic decrease of calcium channel blocking activi ty 9 1 . 
The basic aminoalkyl substituent at the Nx substituent of the seven-membered ring 
and the C 4 -phenyl moiety are believed to constitute the two pharmacophoric groups 
of SQ 32,910 10 (fig. 4), a diltiazem analogue. The suggestion made by Banish et a l . 9 2 
that the seven-membered ring only acts as a spacer between the two pharmacophoric 
groups was confirmed by conformat ional^ rigid diltiazem analogues containing a 
bicyclic framework, showing similar calcium channel blocking activities as diltiazem. 
The dihydropyridines include both calcium channel blockers and activators and, 
therefore, it is not surprising that the structure-activity relat ionships of these 
compounds belong to the most extensively studied. 
Both qualitative and quantitative structure-activity investigations have been carried 
out by Loev et a l . 9 3 based on in vitro obtained hypotens ive data, and by 
Rodenkirchen et a l . 9 4 based on in vitro cardiac muscle experiments. For a number of 
ethyl 2 ,6-d imethyl - l ,4 -d ihydropyr id ine-3 ,5-d icarboxyla tes the basic structural 
requirements are defined: 
1) the 1,4-DHP ring is essential (oxidation to pyridines affords inactive compounds) 
2) the presence of N r H is essential (alkylation reduces activity) 
3) activity increases with substitution at C 4 -carbon atom in the sequence of H < Me < 
cycloalkyl < heterocycle < phenyl < substituted phenyl 
4) substituents in the 4-phenyl ring are preferred in the sequence ortho > meta » 
para 
5) ester groups in the C 3 and C 5 position are important 
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Although in the past 15 years a number of DHPs appeared which do not completely 
imply with the defined structural requirements, the proposed general model still 
stands today. 
An excellent description of the important role of chirality and conformation in 
calcium channel modulation is given by Goldmann and StoltefuB 9 5 . Therefore the role 
of chirality and conformation will be briefly discussed in the following section. 
Chirality is an important property for drug-receptor interactions for both calcium 
channel activators and blockers. Among them, compounds are found in which one of 
the enantiomers is more potent than the other enantiomer, or even exhibits a reverse 
action. Differences in steric and electronic propert ies between the C 3 and C 5 
substituents increase the stereoselectivity of DHP interact ions 9 6 . Replacement of the 
C 3 - ca rboxya lky l group by hydrogen results in a decrease in activity for both 
activators and b lockers 9 7 . Ho l t j e 9 8 suggested that the activator/blocker behaviour is 
controlled by substituents on the C 5 -posi t ion, whereas phenyl ring substituents 
determine the negative inotropic activity, as was shown by Rodenkirchen et a l . 9 4 
Tissue selectivity is determined by the ester substituents. The ester groups are 
thought to fit into specific l ipophilic pockets in the D H P receptor, and their 
differences in vo lume, shape and l ipophil ic character de te rmine the tissue 
select ivi ty 9 9 . 
The N r H group of the D H P ring is important for activity and is believed to be 
necessary for hydrogen bonding interactions to an acceptor group of the calcium 
channel. By replacement of the amine proton by an alkyl group or oxidation to a 
pyridine ring, the calcium channel blocking activity is reduced dramatical ly 9 9 . 
The 1,4-DHPs like nifedipine and nitrendipine possess rotational freedom between the 
4-phenyl ring and the 1,4-DHP ring, and both ester substituents. 
X-ray crystallographic methods and quantum chemical calculations on 1,4-DHPs have 
revealed a molecular structure which most properly can be described in nautical 
terms. The crystallographic studies indicated that the 1,4-DHP ring adopts a flattened 
boat conformation and the N r a t o m is defined as the stern position and the C 4 -a tom 
as the bow position in the boat conformation. A boat conformation implies that the 4-
phenyl ring can be orientated either in a pseudo axial or a pseudo equatorial position. 
The crystal lographic data demonstrate that the 4-phenyl ring is orientated in a 
pseudo axial conformation at the bow and lies close to the N r C 4 vertical bisecting 
plane of the 1,4-DHP ring (coplanar to the N r C 4 vertical plane of the 1,4-DHP ring). 
Ortho substituents on the 4-phenyl ring of nifedipine derivatives are all positioned 
towards the C 4 -hydrogen atom of the 1,4-DHP ring (synperiplanar position), as was 
determined by the nuclear Overhauser enhancement m e t h o d 1 0 0 . The synperiplanar 
position is most probably also adopted by meta-substituted 4-phenyl rings (fig. 11). 
The carboxylic esters play an important role in tissue selectivity and this selectivity is 
thought to be achieved by the orientation and the l ipophil ici ty of the ester 
substituents. 
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Figure 11: Molecular structure of alkyl 2,6-dimethyl-4-(substituted-phenyl)-l,4-
dihydropyridine-3,5-dicarboxylates 
The position of each ester group can be orientated either in a synperiplanar (sp or cis) 
or an antiperiplanar (ap or trans) conformation with regard to the adjoining carbon-
carbon double bond in the 1,4-DHP ring (fig 12). X-ray crystallographic experiments 
revealed that DHPs with an ortho-substituent on the 4-phenyl ring prefer the sp/sp 
conformation for their ester groups, while meta or para-substituted 4-phenyl-1,4-
DHPs prefer the ap/sp conformation. 
H H H 
ap / ap ap / sp sp / sp 
Figure 12: Possible orientations of the esters groups on the 1,4-DHP ring 
No ap/ap ester conformations have yet been d i scove red 1 0 1 . The ester groups form 
hydrogen bonds only to their keto oxygen atoms. An ortho substituent at the 4-
phenyl ring shields the outer or bowsprit side of the DHP molecule, thus preventing 
hydrogen bond formation to the ester group in the ap-conformation. 
In the final part of this section, exceptions on the structural requirements are 
discussed and provided with some examples. 
The first requirement, the presence of the 1,4-DHP ring is not confirmed by some 1,4-
DHP mimetics, as is demonstrated by 3-substituted-l ,2,3,4-tetrahydropyrimidines 1 0 2 . 
Among the 1,2,3,4-tetrahydropyrimidines potent calcium channel blockers, such as 
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SQ 32,321 20103 and SQ 32,547 21*04 (fi g. n ; t a b i e 9), exist with long-lasting 
antihypertensive action. At the N 3 -a tom of these 1,2,3,4-tetrahydropyrimidines a wide 
variety of substituents (alkyl, acyl, carbamate) are tolerated in vitro, while at the C 5 -
position the isopropyl ester is preferred. However, in vivo the tolerance of several N 3 -
substituents is restricted due to rapid metabolization to inactive c o m p o u n d s 1 0 5 . 
20 SQ 32,321 21 SQ 32,547 
Figure 13: 1,2,3,4-Tetrahydropyrimidines as potent 1,4-dihydropyridine mimetics 
Table 9: Calcium channel blocking activities (pICso) of the enantiomers of SQ 32,321 
and SQ 32,547 determined on rabbit aorta 
(R)-SQ32,321 (S)-SQ32,321 (R)-SQ32,547 (S)-SQ32,547 nitrendipine 
pIC 5 o 8.07 5 1 42 7JJ2 5 1 93 9.00 
It is proposed that substituents on the N 3 -a tom of the 1,2,3,4-tetrahydropyrimidines 
exert a nonspecific effect, not directly part icipating in receptor binding. The 
suggestion that only one alkylcarbonyl moiety is required in receptor binding is 
confirmed by the DHP analogues SM-6586 22 and S-312-d 23 (fig. 14). 
H 
22 SM-6586 23 S-312-d 
Figure 14: 1,4-DHPs with only one alkylcarbonyl moiety 
SM-6586 22 (fig. 14) demonstrates that the introduction of a 1,2,4-oxadiazolyl group 
at the 3-position on the 1,4-DHP ring instead of a simple alkylcarbonyl moiety can 
afford CCBs with longer duration of antihypertensive action. The (+)-enantiomer of 
118 
Chapter 4 
SM-6586 was a more potent calcium channel blocker than the (-)-enantiomer (table 
10). Like the DHPs with large alkylcarbonyl moieties, it is believed that the increased 
lipophilicity of SM-6586 contributes to the longer duration of ac t i on 1 0 6 . 
Table 10: Calcium channel blocking activities (pA2) of the enantiomers of SM-6586 
determined on rat aorta 
(±)-SM-6586 (+)-SM-6586 (-)-SM-6586 nicardipine nitrendipine 
p A 2 9.76 10.06 8A6 9L80 10.19 
The dihydrothienopyridine S-312-d 23 (fig. 14) bears a thiophene ring instead of an 
alkylcarbonyl moiety and exhibits slightly more potent vasodilating properties than 
nifedipine and nicardipine. The enantiomer with the (S)-(+)-configuration is more 
potent than the (R)-(-)-enantiomer (table l l ) 1 0 7 . The (S)-enantiomers of most of the 
known D H P calcium channel blockers are more potent than the (R)-enantiomers. 
Often exceptions to this behaviour are caused by errors in the determination of the 
exact conf igura t ion 5 3 ' 9 5 . 
Table 11: Calcium channel blocking activities (pICso) of the enantiomers of S-312-d 
determined on rabbit femoral artery 
(S)-(+)-S-312-d (R)-(-)-S-312-d 
p IC 5 o 9.28 7.96 
6 Binding sites of the L-type voltage-operated calcium channel ligands 
The binding domains of the three major classes of CCBs have recently been 
established and are all located at the ax subunit of the L-type calcium channel 
protein. The D H P and PAA binding domains on skeletal muscle L-type calcium 
channels were localized with fluorescent sensitive DHPs and PA As. After purification 
of these binding domains and antibody mapping techniques these domains were 
identified. It appeared that the PAA binding domain is located at amino acid residues 
at the intracellular side near the cytoplasmic opening of the c h a n n e l 1 0 8 . The DHP 
binding domain has been found at amino acid residues at the extracellular side close 
to the extracellular mouth of the channel p o r e 1 0 9 * 1 1 0 . 
The location of the BTA binding domain has been located with the quaternary 
analogue (SQ 32,428) of the diltiazem like benzazepine SQ 32,910 10. SQ 32,428 
blocks the L-type calcium channel in A 7 r 5 cell lines only after extracellular and not 
after intracellular application. Therefore, the conclusion has been drawn that the 
benzothiazepine binding domain is located near the extracellular side of the calcium 
channel p o r e 1 1 1 . 
The PAAs and DHPs allosterically influence each others binding, which can be 
explained by their binding domains, found on the same polypeptide transmembrane 
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spanning segment of the channel . In particularly, PAAs are linked in a negative 
allosteric manner to the DHPs, which means that they decrease the number of binding 
sites of the DHPs. The benzothiazepines are linked in a positively allosteric way, and 
therefore increase the number of binding sites for DHPs. In figure 15 an allosteric 
model of the drug binding domains of L-type channels is depicted, also showing the 
fourth proposed class of CCBs, the diphenylbutylpiperidines and the CCBs HOE 166 
and fantofarone. 
BTA = benzothiazepines 
DHP = 
1,4-dihydropyridines 
(containing both calcium 
channel blockers and 
activators) 
PAA = 
phenylalkylamines 
SR = 
fantofarone (SR 33557) 
DPBP = 
diphenylbutylpiperidines 
Figure 15: Allosteric interactions between several calcium channel blockers [(-) = 
negative; (+) = positive] 
The allosteric interactions between DHPs and BTAs are temperature-dependent. At 
low temperature (0°C), B T A s and DHPs inhibit each others binding, at higher 
temperature (37°C) BTAs and DHPs exert a positive allosteric interaction at each 
others b ind ing 8 3 . 
7 State of t he calc ium channe l 
The "modulated receptor hypothesis", originally proposed to explain blockade of 
Na + -channels , has also been applied for C a 2 + - c h a n n e l s 1 1 2 . This hypothesis propounds 
that binding of a drug to a site located within the channel is modulated by the so-
called activation state of the channel , determined by, inter alia, the membrane 
potent ia l , and impl ica tes different affinities and different s t ructure-act ivi ty 
relationships of a drug for the distinct channel states. Electrophysiological studies to 
characterize the calcium channel revealed that the calcium channel can exist in three 
distinct states called the closed, inactivated (or resting), and open state. Under normal 
physiological conditions without the presence of calcium channel modulators, the 
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inactivated (resting) state is the naturally occurring channel state. Each channel state 
has a different mode of gating behaviour, originally postulated by Hess et a l . 1 1 3 . In 
single channel current experiments three different modes were defined. 
In mode 0, no channel openings are recorded and the channels fails to open in 
response to depolarization 
In mode 1, short openings of the channel are recorded 
In mode 2, long-lasting openings and very short closings are recorded. This mode 
can only seldom be observed in the absence of drugs 
INACTIVATED 
(RESTING) 
mode 1 
OPEN 
mode 2 
Figure 16: Calcium channel states according to the "modulated receptor hypothesis" 
The opening probability (P 0 ) of the calcium channel varies from closed (P Q = 0) to 
open ( P 0 = 1). CCBs modify the opening probability of the channel by favouring 
mode 0 behaviour of gating, while the CCAs increase Ca 2 + -currents by promoting the 
long channel openings (mode 2). 
In conclusion, although intensive information on calcium channel modulators has 
become available, several questions remain to be answered. Biochemical methods 
such as site-directed mutagenesis and affinity labeling methods can contribute to 
understand the structure-activity relationships of calcium channel modulators. Based 
on the known protein structure and the affinities for the different kinds of isolated 
binding sites, it would be challenging to design better tissue selective and clinically 
efficacious drugs in the treatment of cardiovascular diseases, as well as several other 
vascular diseases. 
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Synthesis and in vitro pharmacology of a series of new 
1,4-dihydropyridines . 1 . 
Diethyl 2 - (co -aminoa lky l th io )methy l -2 ,6 -d imethy l -4 -
[ ( subs t i tu ted)pheny l ] - l , 4 -d ihydropyr id ine -3 ,5 -d icarboxy la tes 
as potent calcium channel blockers 1 
1 Introduction 
The 1,4-dihydropyridine (DHP) calcium channel blockers are important drugs in 
ant ianginal and ant ihyper tens ive therapy [1-51 because of their vasodi la tor 
properties. Nifedipine 1 [6], nitrendipine 2 [7], nimodipine 3 [8] and nicardipine 4 [9] 
represent the classical 1,4-dihydropyridines and exert their pharmacologic activity by 
interaction with specific receptors present on L-type voltage-dependent calcium 
channels. 1,4-DHPs block calcium entry through slow calcium channels resulting in 
vasodilation and hence reduce vascular resistance. Coronary dilatation increases the 
oxygen and nutrients supply to the heart. Peripheral vasodilatation lowers the 
oxygen demand of the heart through a reduction in cardiac work and also accounts 
for the antihypertensive properties of these drugs. 
Systematic modifications of the 2-position of the D H P ring have been performed to 
increase the rather disadvantageous short duration of action and to improve the 
bioavailability of the classical DHPs, resulting in amlodipine 5 [10] and its derivatives 
and their thio-bioisosters such as tiamdipine 6 [11,12]. Amlodipine, presently under 
clinical investigation for treatment of angina pectoris and hypertension, was the first 
compound demonstrating that extended 2-substituents bearing a basic functionality 
were well tolerated at the DHP-receptor. Amlodipine has an affinity for the 1,4-DHP 
binding site comparable to that of nifedipine, but has a longer duration of action and 
H H 
1 nifedipine 2 nitrendipine Ri = C H 3 , R 2 = C2H5 
3 nimodipine Ri = C H ( C H 3 ) 2 , R2 = C H 2 C H 2 O C H 3 
4 nicardipine Ri = C H 3 , R 2 = C H 2 C H 2 N ( C H 3 ) C H 2 C 6 H 5 
1 Eur. J.Med.Chem., 28, 859-867 (1993) 
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slower onset and offset kinetics. These kinetic effects of amlodipine/t iamdipine 
derivatives have to be ascribed to additional interaction with the binding site of the 
L-type calcium channel due to an ionic interaction between the protonated amino 
function and the negatively charged phosphate group of a phospholipid [13,14]. 
N0 2 
COOC2H5 
CH2-S-CH2"CH2"NH2 
5 amlodipine 6 tiamdipine 
Our objective was to determine whether DHPs with identical ester groups are as 
potent as the corresponding DHPs with non-identical ester groups. Furthermore the 
influence of variation of the co-aminoalkyl chain length in tiamdipine analogues on 
the calcium channel blocking activity was examined. 
2 C h e m i s t r y 
In general, the synthesis of 2-substituted dihydropyridines shown in table 1 can be 
accomplished by several modifications of the classical three component Hantzsch 
reaction shown in scheme 1. 
Thus, condensation of a benzaldehyde 7 with an alkyl 3-aminocrotonate 9 and a 
substituted p-keto ester 8 can afford the title compounds (method A). The substituted 
keto esters are obtained by reaction of a suitable sodium thiolate with the enolate of 
alkyl 4-chloroacetoaceta te . When alkyl 4-chloroacetoaceta te , condensed with 
cysteamine or a longer co-mercaptoalkylamines, are used in the Hantzsch conden­
sation reaction, the amine function (method A; R3 contains an amine function) has to 
be prevented from participation in the condensation reaction with a benzaldehyde. 
For that reason the amine function must be protected by first transforming it into a 
phthalimide group. 
According to Pointdexter et al. [15] tiamdipine analogues can also be obtained via a 
metalation methodology (method B). Metalation of DHPs 11 with two equivalents of 
n-butyllithium afforded dilithio species 12. The cysteamine precursor E was used as 
an electrophile to give the tiamdipine analogues 13 [16]. 
The third way to accomplish the synthesis of the tiamdipine analogues proceeds via 
the reaction of 2-halomethyl-l ,4-dihydropyridines with sodium thiolate derivatives. 
Several methods have been described to afford the 2-halomethyl - l ,4-d ihydro-
pyridines 14 (method C). Young et al. [17] reported that reaction of 1,4-dihydro-
pyridines 11 with pyridinium bromide perbromide gives unstable brominated species. 
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Alker and Swanson [18] used this method to react these 2-bromomethyl-l ,4-dihydro-
pyridines in situ with a range of nucleophiles. As expected, reaction of DHPs 11 with 
different 3- and 5-esters with pyridinium bromide perbromide followed by in situ 
reaction with nucleophiles give mixtures of the two possible isomeric 2- and 6-
bromomethyl-l ,4-dihydropyridines. For this reason Alker and Denton [19] developed 
an alternative synthetic route in which 2-hydroxymethyl-l,4-dihydropyridines 15 are 
chlorinated by reaction with thionyl chloride and imidazole in THF. Cho et al. [20] 
performed the chlorination of 2-hydroxymethyl-l ,4-dihydropyridines by refluxing in 
phosphorus oxychloride. A major disadvantage of this method is the long and 
complex reaction route to obtain the 2-hydroxymethyl-l,4-dihydropyridines. 
Cupka et al. [21] reported the synthesis of 2-chloromethyl-l ,4-dihydropyridines by 
reaction of equimolar amounts of alkyl 4-chloroacetoacetate, alkyl 3-aminocrotonate 
and a benzaldehyde in refluxing methanol . On the other hand, several authors 
describe reactions in which 2-halomethyl- l ,4-dihydropyridines 17 are refluxed in 
alcohol to afford 4-aryl-2-methyl-5-oxo-l ,4 ,5,7- tetrahydro-furo[3,4b]pyridine-3-
carboxylates 18 (scheme 2) [17,22,23]. 
H 
18 
Scheme II 
Our choice of synthesis was method A based on the easy preparat ion of 2-
chloromethyl- l ,4-dihydropyridines using ethyl 4-chloroacetoacetate according to 
Archibald et al. [24]. However, in the work-up procedures before acid treatment we 
discovered a product which structure was identified as a 2-chloromethylene-l,2,3,4-
tetrahydropyridine 16. These exoisomers of DHPs were firstly described by Frigerio et 
al. [25]. The *H-NMR and 1 3 C - N M R spectra of the exoisomers 16 clearly differed 
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from the 1,4-DHPs 17. In table I the *H-NMR and 1 3 C - N M R data of the 4-(2,3-
dichlorophenyl) and 4-(2-nitrophenyl)-1,4-DHPs are shown. 
Compounds 16a (Z = 2,3-diCl; R = Et) and 16b (Z = 2-NO2 ; R = Et) reveal a singlet 
in *H-NMR (3.45 and 3.60 ppm resp.) with an integral of one proton. This signal is 
coupled to an s p 3 carbon atom signal in 1 3 C - N M R (at 45.9 and 46.7 ppm resp.) 
indicating a proton connected to carbon C3. Both structures also have singlet signals 
in iH-NMR (5.45 and 5.58 ppm resp.) each having an integral of one proton. These 
signals are each coupled to an s p 2 carbon atom signal in 1 3 C - N M R (at 97.4 and 98.2 
ppm resp.) indicating that these signals are originated from the exocyclic carbon atom 
and the pro ton in the 2-chloromethylene group . The N M R spectra of the 
corresponding compounds 17a and 17b lack the signals from the proton and the s p 3 
carbon atom at position 3 . Both structures 17 give signals of an AB-system to be 
ascribed to the protons on an s p 3 carbon atom of the 2-chloromethyl group. The 
NMR of the lacton 18 lacks signals from one ethyl ester group, instead methylene 
signals in the *H-NMR and 1 3 C - N M R from the lacton ring appear. 
The exoisomers 16 are quite stable in pyridine or methanol solutions while they 
isomerize to the endoisomers 17 in acidic alcohol. 
All attempts to synthesize the 2-chloromethyl-4-(2-chlorophenyl)-l ,4-DHP 17 (with 
Z = 2-C1 ; R =Et) failed and only the corresponding lacton 18 could be isolated 
(scheme 2). 
The synthesis of N-[co-mercaptoalkyl]phthalimides was performed according to an 
improved method of Gabriel et al. [26]. In situ reaction of the thiolate anions of N-[co-
mercaptoa lkyl ]phtha l imides with the 2-chloromethyl -1 ,4-d ihydropyr id ines 19 
afforded the corresponding thioethers 2 0 . Subsequent hydrazinolys is of the 
phthalimides 20 gave the tiamdipine analogues 21 shown in table II (scheme 3). 
H H 
N 
H 
2 1 
Scheme HI 
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Table I: Chemical shifts of characteristic protons [lH] and carbon atoms [ 1 3 C] determined with HH-cosy and CH-cosy NMR experiments in 
DMSO-d6 of DHPs according to scheme 2 
Z = 2,3-diCl ; R = Et Z = 2-NO2; R = Et 
16a 17a 18a 16b 17b 18b 
JH-NMR pyridine-CH2-Cl - 4.76 and 4.85 (AB, - - 4.67 and 4.75 (AB, -
Jab=13.3 Hz, 2H) Jab=13.1Hz, 2H) 
CH2-lacton - - 4.83 (s,2H) - - 4.84 (s,2H) 
pyridine=CH-Cl 5.45 (s, 1H) - 5.58 (s, 1H) -
pyridine-H3 3.45 (bs, 1H) - - 3.60 (bs, 1H) / -
pyridine-KLt 4.97 (bs, 1H) 5.54 (s, 1H) 5.3 (s, 1H) 4.79 (bs,lH) 5.68 (s, 1H) 5.63 (s, 1H) 
CH3-CH2-O 1.01 and 1.15 (2x 1.21 (m,6H) 0.95 (t, J=7.1 0.93 and 1.15 (2x 1.09 (m, 6H) 0.89 (t, J=7.2 
t, J=7.6 Hz, 6H) Hz, 3H) t, J=7.1 Hz, 6H) Hz, 3H) 
CH3-CH2-O 3.89 and 4.12 (2x 4.12 (m,4H) 3.85 (q, J=7.1 3.81 and 4.13 (2x 3.96 (m, 4H) 3.86 (q, J=7.2 
q, J=7.6 Hz, 4H) Hz, 2H) q, J=7.1 Hz, 4H) Hz, 2H) 
13C-NMR 
pyridine-CH2-Cl - 39.46 - - 39.5 -
CH2-I acton - - 65.0 - - 65.0 
pyridine=CH-Cl 97.4 - - 98.2 - -
pyridine-C3/Cs 45.9 and 95.6 101.0 and 103.6 100.0 and 102.3 46.7 and 96.5 101.0 and 103.6 99.9 and 102.2 
pyridine-C4 36.4 38.40 35.2 35.5 33.6 31.6 
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3 P h a r m a c o l o g y 
3.1 In vitro calcium channel blocking activities 
Male Wistar rats (200-250g, Harlan C.P.B., Zeist, The Netherlands) were killed by 
decapitat ion. The thorax was opened and thymus, lungs and oesophagus were 
removed. Next the heart was taken at the apex and removed together with the 
thoracial aorta, by gently cutting the latter from the spine up to the diaphragm and 
placed in Krebs Ringer solution (composition [mM]: NaCl 118.5, KC14.74, MgSCU 
1.18, K H 2 P 0 4 1.18, C a C b 2.5, N a H C 0 3 25 and glucose 10) at room temperature. The 
aorta was prepared free from heart and adhering tissue. After removal of the aortic 
arch, the aorta was spirally cut by gently unwinding it from a horizontally placed 
metal bar. Thus 3 to 4 strips per animal were obtained. Strips of aortic tissue (length: 
1-1.5 cm; width: 1-2 mm) were placed (using silk thread, Perma-Hand 0.7 metric, 
Ethicon, Nordestedt , Germany) in an organ bath (20 ml; Krebs Ringer medium 
bubbled with O2/CO2 (95/5%) at 37°C. A resting tension of 0.5 g was applied and 
the aortic strips were equilibrated during 100 minutes and placed in fresh buffer 
solution every 20 minutes . Next the strips were isotonically contracted by a 
modificated buffer solution (composition [mM]: NaCl 73.2, KC1 50, MgSCU 1.18, 
KH2PO4 1.18, C a C h 1.25, NaHCC>3 25 and glucose 10). Concentration-response 
curves of t iamdip ine analogues were provoked to de termine pICso values . 
Measurements of inhibition were started 15 minutes after depolarisation. Additional 
increasing doses to generate dose-response curves were given every 45 minutes. 
3.2 Dihydropyridine receptor binding assay 
The cortices from the rats were isolated and homogenised in ice-cold Tris HC1 buffer 
(50 m M p H 7.4 at 0°C) in a ratio of 1:3 (v/v). The homogenate was centrifuged 
(48,000 g for 10 minutes) which was repeated three times with resuspension of the 
pellet in the buffer and stored in liquid nitrogen until required. 
Binding experiments were performed under sodium light because of the photolability 
of [ 3H]nitrendipine. 
All binding assays were carried out according to Boer et al. [27] by adding in each 
incubation tube 200 [il of Tris Buffer (50 mM, p H 7.4, 0°C); 100 | i l rat brain 
membrane suspension (170 |Xg protein/ml); incubated for 60 minutes at 37°C with 
100 |il of 1 n M [ 3H]-nitrendipine solution, and 100 p i of the drug concentration for a 
final volume of 0.5 ml. The final DMSO concentration never exceeded 1% (v/v) 
which did not affect the binding. The incubation was stopped with 4 ml ice-cold Tris 
HC1 buffer filtered under reduced pressure onto Whatman GF/C filters and washed 
twice with 4 ml ice-cold buffer using a Brandel filtration apparatus. The radioactivity 
was counted after addition of 5 ml scintillation liquid (Optiphase HiSafe-3) to the 
filter, by liquid scintillation spectrometry (Packard 1900 CA tri-card liquid scintillation 
counter) at an efficiency of approximately 55%. 
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Saturat ion analysis at equi l ibr ium was performed by incubat ing increasing 
concentrations of [ 3H]nitrendipine up to 2 nM with 50 pi of purified protein and Tris-
HC1 buffer (pH 7.4,37°C) for a total volume of 0.25 ml. 
Non-specific binding was determined in presence of 1 p M nifedipine. Specific 
binding was determined by subtracting the non-specific binding from the total 
binding. Equilibrium dissociation constant (Kd) 0.75 n M of the labelled compound 
and the maximal binding ( B m a x ) of 270 fmol/mg protein were determined with the 
non-linear fitting program LIGAND 4.1 [28]. 
4 R e s u l t s a n d D i s c u s s i o n 
In vitro vascular calcium antagonistic activity (expressed as pICso) was assessed as 
the concentration of the compound required to inhibit the K + -depolarisat ion induced 
(50 mmol/1) contractile responses in rat aorta strips by 50%. All compounds, tested as 
racemic mixtures, caused complete inhibition of contractile responses as verified by 
addition of 1 m M papaverine. As reported earlier, the development of antagonism of 
amlodipine and tiamdipine analogues occurred slowly and did not reach equilibrium 
after 2 hours [29]. Because additional increasing doses to generate dose-response 
curves were given every 45 minutes, no complete equilibrium was reached and this 
can lead to underestimated calcium inhibitory activities. 
The influence of substituents in the 4-phenyl ring of the compounds with an (2-
aminoethylthio)methyl side chain on the 2-position of the 1,4-dihydropyridine on the 
calcium channel blocking activity is rather small (table II). Compounds with a nitro 
substituent in the 4-phenyl ring and with m = 2 (VUF 4574 and V U F 9055) are 
almost as potent as amlodipine 4 and slightly more active than those compounds 
possessing 2,3-dichloro substituents (VUF 9158) or no substituent at all (VUF 9056). 
The D H P with a 3-nitro substituent in the 4-phenyl ring was chosen to explore the 
influence of increasing (co-aminoalkylthio)methyl side chain length. There is no 
difference in calcium channel blocking activity when the alkyl chain length is 
increased from a ethyl chain to a pentyl chain. 
The phenomenon of unaltered potency with changing alkylchain length is not shared 
for compounds V U F 9158 and V U F 4621. Increasing the alkylchain length from ethyl 
to propyl results in a decrease in calcium channel blocking activity. V U F 9109, in 
which the amine function is replaced by a phthalimide group, is less active than the 
corresponding compound V U F 9055 with a primary amine group. 
Alker and Denton [12] compared two 4-(2-chlorophenyl) - l ,4-dihydropyr idines 
bearing identical (Me/Me) or different este* substitution (Me/Et) . The calcium 
inhibitory potencies of both compounds against K + -depolarisation induced responses 
in rat aorta strips were almost equal. The DHPs with non-identical esters were tested 
as racemic mixtures. 
Kwon et al. [29] investigated the influence of substitution on the phenyl group in 2-
(2-aminoethylthio)methyl-3-carboethoxy-5-carbomethoxy-4-phenyl-l ,4-dihydro-
pyridines on their calcium inhibitory potencies against K + -depolar isa t ion induced 
responses in rat tail artery. In their series, the DHP with Z = H (table II) seemed to be 
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Table II. Calcium blocking activities and radioligand binding affinities of tiamdipine 
analogues 
compound Z m R1/R2 p I C 5 o # rat tissue pKd* 
V U F 9 0 5 6 H 2 Et/Et 7.27 1 0.08 aorta 8.57 + 0.10 
V U F 4 5 7 4 2 - N 0 2 2 Et/Et 8.02 ± 0.07 aorta 8.58 ± 0 . 1 2 
V U F 9 1 5 8 2,3-diCl 2 Et/Et 7.47 ± 0.03 aorta 8.37 1 0 . 1 0 
VUF4621 2,3-diCl 3 Et/Et 6.77 ± 0.06 aorta 8 . 0 0 1 0 . 1 2 
V U F 9055 3-NO2 2 Et/Et 7.96 ± 0.07 aorta 8.61 1 0 . 0 6 
V U F 9 1 0 8 3-NO2 3 Et/Et 7.82 ± 0.04 aorta 8.43 i 0.05 
V U F 9159 3-NO2 5 Et/Et 7 . 9 6 1 0 . 1 2 aorta 8.55 i 0.08 
V U F 9109* 3-NO2 2 Et/Et 6.64 + 0.11 aorta not tested 
2-Cl 
2-C1 2 
nifedipine 
2 Me /Me 
Et /Me 
7.8" 
7 .6 a 
8.77 1 0.08 
8 . 4 a / 8 . 9 b 
aorta 
aorta 
aorta 8 . 7 0 1 0 . 1 4 
8 .44 c 
amlodipine aorta 
2-NO2 2 Et /Me 
H 2 Et/Me 
5 3-NO2 2 Et /Me 
# AH values are means 1 s.d. for 3 independent observations 
$ All values are means 1 s.d. for 6 to 9 independent observations. All radioligand binding 
affinities (pKd) were determined on isolated rat cortex membranes 
* Amine protected as a phthalimid 
a Alkeretal. [12] b Godfraind [33] c Wibo et al. [34] 
d Kwon et al. [29] PIC50 data calculated from IC50 values. 
dl/d2/d3 data expressed as pKj d l Rat brain; d2 Rat heart; d3 Guinea pig ileum 
7 .08 d
 N tail artery 7 .25 d l /7 .74 d 2 /8 .12 c 
7 . 4 5 d tail artery 7 .44 d l / 7 . 68 d 2 / 8 . 01 c 
7.18 d tail artery 7 .70 d l /8 .03 d 2 /8 .44 ( 
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the most potent calcium channel inhibitor compared to the 2- or 3-nitrophenyl 
substituted DHP. In the case of 3-nitrophenyl substituted D H P , the individual 
enantiomers were examined. 
In table III the inhibitory potencies of three different racemic DHPs and their 
enantiomers are given. Each racemate and its enantiomeric pair were tested on the 
same tissue. Although the pairs of DHPs were tested on different tissues, all (-)-
enantiomers are 100 till 1000 fold more active than their (+)-enantiomers. 
Table I I I . In vitro inhibitory effect of racemates and their enantiomers on 
K + - induced contractions on different tissues expressed as pICso values 
compound tissue racemate (-)-enantiomer (+)-enantiomer ref. 
nimodipine rabbit aorta 8.24 8.52 7.80 [30) 
tiamdipine rat tail artery 7.19 7.51 5.35 [29] 
amlodipine rat aorta 8.10 8.70 5.80 [31] 
All data are taken from literature and were calculated from IC50 values 
In table IV the organ dependency of nifedipine for its calcium channel blocking 
activity is given. On all three different smooth muscle preparations the calcium 
inhibitory potency of nifedipine varies only within a small range (pICso = 8.1 - 8.8). 
Therefore, the calcium inhibitory potencies of the tiamdipine analogues tested on rat 
aorta strips and rat tail artery might be regarded as equipotent. In table II the 
tiamdipine analogues with identical esters appeared to be as potent as the tiamdipine 
analogues with different esters, although it has to be realized that they were tested on 
different smooth muscle preparations. 
Tab le IV. In vitro calcium inhibitory activities of nifedipine against 
K + -depolarisation induced contractions on different tissues 
tissue pICso ref. 
rabbit aorta 8.09 + 0.12 (95% C.L) [32] 
rat aorta 8.77 ± 0.08 
8.40 - 8.88 [12;33] 
rat tail artery 8.17 ± 0 . 1 7 (95% C.L.) [29] 
95% confidence limit. Number of observations are 4 to 6 
All data are taken from literature and were calculated from IC50 values 
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Radioligand binding affinities of the t iamdipine analogues (pK^), determined by 
displacement of [ 3H]nitrendipine from rat cortex membranes, exhibit similar binding 
affinities and are almost equal to that of nifedipine 1 (table II). The differences 
between the pICso values (determined on rat aorta) and p IQ values (determined on 
rat cortex membranes) might be caused by the possible underestimated calcium 
channel blocking activities or might be explained by organ specificity. Thus, Kwon et 
al. [29] determined the affinities on rat brain, rat heart and guinea-pig i leum 
membranes and found an increase in their pKi values. 
Additional interaction of the protonated aminoalkyl side chain of amlodipine and 
tiamdipine analogues with the 1,4-DHP binding site might lead to a conformation in 
which the 4-phenyl ring is displaced from the binding site, seen for nifedipine and 
related 1,4-DHPs. This conformation diminishes the contribution of 4-phenyl ring 
substituents in the mode of interaction with the 1,4-dihydropyridine binding site. This 
explains why V U F 9109, without a primary aminoalkyl group, does bind to a lesser 
extent than the DHPs with a free amine group which under physiological conditions 
can be protonated. 
5 C o n c l u s i o n s 
All tiamdipine analogues discussed are potent inhibitors of K + -depolarisation induced 
contractions in isolated rat aorta. This activity is relatively independent of the nature 
of the substituent in the 4-phenyl ring. It can be concluded that identical or non-
identical ester substitution does not play a major role for potency. Furthermore, 
concerning the 4-(3-ni trophenyl)- l ,4-dihydropyridines, calcium channel blocking 
activities are sustained with increasing alkylchain length (m = 2-5; Table II). 
The rather small numbers of compounds and especially the narrow activity range do 
not permit to quantify the structure activity relationships of the presented 1,4-
dihy dropyridines. 
E x p e r i m e n t a l p r o t o c o l s 
If indicated crude reaction products were purified by flash chromatography on 
silicagel (J.T.Baker 70242). Melting points were determined on a Mettler FP 52 with 
microscope. !H-NMR and 1 3 C-NMR-spect ra were recorded on a Bruker AC 200. The 
chemical shifts are in ppm relative to tetramethylsilane. Mass spectra were determined 
on a Mat 90 (Finnigan Mat) mass spectrometer with Fast Atom Bombardment 
ionisation (matrix: glycerol + ammonium acetate, thioglycerol or 3-nitrobenzylalcohol, 
Ion Tech saddlefield gun, 8 keV Xenon with xenon ioncurrent 0.2 mA) . All 
compounds gave the expected ( M + H ) + and to a lesser extend (M-H)" peaks 
(negative ions). Furthermore the purity of the compounds were checked by thin layer 
chromatography (Merck silica gel 60, F254 0.25 mm). 
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General synthetic procedure 
2~chloromethyl-3£-dicarboethoxy-6-methyl-4-(substitutedp 
pyridine 
0.1 mol 3-nitrobenzaldehyde, 0.1 mol ethyl 4-chloroacetoacetate, 6.6 mmol benzyl-
amine and 6.6 mmol acetic acid were stirred for 24 hours in 2-propanol at room 
temperature. Then 0.1 mol ethyl 3-aminocrotonate was added and the reaction 
mixture was stirred for another 24 hours at room temperature. Then 5 ml concentrated 
hydrochloric acid was added and stirring was continued for 2 hours. The precipitate 
was filtered off and the filtrate was evaporated. The residue was dissolved in ethyl 
acetate and diethyl ether was added until no further precipitation occurred. The solid 
material was filtered off, the filtrate was evaporated and the residue was crystallised 
from methanol. 
2-chloromethyl-3,5-dicarboethoxy-6-methyl-4-(3-nitrophenyl)-l ,4-dihydropyridine 
Yield 5 8 % , melting point 120.2-121.1°C. 
1H-NMR (DMSO-d 6 ) : 1.10 ppm (t, J = 6.6 Hz, 6H, 2x CH3-CH2-O), 2.40 ppm (s, 3H, 
pyridine-CH3), 4.12 ppm (m, 4H, 2x CH3-CH2-O), 4.90 ppm (AB, J a b = 13.2 Hz, 2H, 
pyridine-CH2-Cl), 5.14 ppm (s, 1H, pyridine-ILO, 6.68 ppm (s, 1H, pyridine-NH), 7.63 
ppm (t, J = 7.3 Hz, 1H, phenyl-Hs), 7.74 ppm (d, J = 7.3 Hz, 1H, phenyl-H 6 > ) , 8.05 ppm 
(d, / = 7.3 Hz, 1H, phenyl-aO, 8.14 ppm (s, J = 7.3 Hz, 1H, phenyl-Hb). 
13C-NMR (DMSO-d 6 ) : 13.58 and 13.76 ppm (2x £ H 3 - C H 2 - 0 ) , 17.99 ppm (pyridine-
£ H 3 ) , 38.96 ( p y r i d i n e ^ ) , 39.41 ppm (pyr idine-£H 2 -Cl) , 59.15 and 59.70 ppm (2x 
C H 3 - £ H 2 - 0 ) , 100.55 and 102.80 ppm ( p y r i d i n e ^ and £5), 121.12 and 121.75 and 
129.42 and 133.97 ppm ( p h e n y l - ^ , £4, £5 and £5), 144.35 and 146.22 and 147.26 
and 149.12 ppm (phenyl-£i and £3 and pyridine-C? and £5), 165.12 and 165.99 ppm 
(2x carbonyl-£) . 
2-chloromethyl-3,5-dicarboethoxy-6-methyl-4-(phenyl)-l,4-dihydropyridine 
Yield 4 8 % , melting point 111.7-112.3°C. 
1H-NMR (DMSO-d 6 ) : 1.14 ppm (m, 6H, 2x CH3-CH2-O), 2.31 ppm (s, 3H, pyridine-
C H 3 ) , 3.95-4.11 ppm (m, 4H, 2x CH 3 -CH2 -0) , 4.72 and 4.82 ppm (AB, J a b = 10.7 Hz, 
2H, pyridine-CHb-Cl), 4.95 ppm (s, 1H, pyridine-IJO, 7.11-7.22 ppm (m, 5H, 5x phenyl-
H), 9.25 ppm (s, 1H, pyridine-NH). 
13C-NMR (DMSO-d 6 ) : 13.68 and 13.86 ppm (2x £ H 3 - C H 2 - 0 ) , 17.91 ppm (pyridine-
£ H 3 ) , 38.67 ( p y r i d i n e ^ ) , 39.61 ppm (pyr id ine-£H 2 -Cl) , 58.91 and 59.47 ppm (2x 
C H 3 - £ H 2 - 0 ) , 101.30 and 103.84 ppm (pyridhte-Os and £5), 125.95 ppm (phenyl -£ 4 ) , 
127.15 and 127.72 ppm ( p h e n y l - ^ , £ 3 , £5 and £5), 143.25 and 145.22 and 147.07 
ppm (phenyl-£i and pyridine-Co and £5), 165.61 and 166.43 ppm (2x carbonyl-£). 
2-chloromethyl-3,5-dicarboethoxy-6-methyl-4-(2-nitrophenyl)-l ,4-dihydropyridine 
Yield 60%, melting point 99.8-100.4°C 
1H-NMR ( D M S O - d 6 ) : 1.07-1.11 ppm (m, 6H, 2x C H 3 - C H 2 - 0 ) , 2.27 ppm (s, 3H, 
pyridine-CEb), 3.80-4.15 ppm (m, 4H, 2x CH 3 -CH2 -0) , 4.67 and 4.75 ppm (AB, Jab = 
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13.1 Hz, 2H, pyridine-CHb-Cl), 5.67 ppm (s, 1H, p y r i d i n e - ^ ) , 7.32-7.83 ppm (m, 4H, 
4x Phenyl-H), 9.38 ppm (s, 1H, pyridine-NH). 
1 3 C - N M R (DMSO-d 6 ) : 13.51 and 13.67 ppm (2x £ H 3 - C H 2 - 0 ) , 18.02 ppm (pyridine-
£ H 3 ) , 33.62 ppm (pyr id ine-£ 4 ) , 39.50 ppm (pyridine-£H 2 -Cl) , 59.05 and 59.65 ppm 
(2x C H 3 - £ H 2 - 0 ) , 101.02 and 103 .58 ppm (pyr id ine-£ 3 and £ 5 ) , 123.54 and 127.38 
and 130.49 and 133.13 ppm ( p h e n y l - £ 3 , £ 4 , £ 5 and £ 6 ) , 141.29 and 143.94 ppm 
(phenyl-£i and £ 2 ) , 146.80 and 146.82 ppm (pyridine-C^ and £ 6 ) , 156.32 and 166.04 
ppm (2x carbonyl-£) . 
2-chloromethyl-3,5-dicarboethoxy-4-(2,3-dichlorophenyl)-6-methyl-l ,4-dihydro-
pyridine 
Yield 52%, melting point 135.4-136.6°C. Mass spectrum (Electron Impact (70eV); 
mass of C i 9 H 2 0 3 5 C l 2 3 7 C l N O 4 mass calculated = 433.043, mass found = 433.044 
±0.003) . 
1H-NMR (DMSO-d 6 ) : 1.21 ppm (m, 6H, 2x C H 3 - C H 2 - 0 ) , 2.33 ppm (s, 3H, pyridine-
C H 3 ) , 4.06-4.18 ppm (m, 4H, 2x CH^CIfc-O) , 4.76 and 4.85 ppm (AB, JAB = 13.3 Hz, 
2H, pyridine-CEb-Cl), 5.54 ppm (s, 1H, pyridine-EU), 6.95 ppm (br s, 1H, pyridine-NH), 
7.05-7.38 ppm (m, 3H, 3x phenyl-H). 
i 3 C - N M R (DMSO-d 6 ) : 13.74 and 13.84 ppm (2x £ H 3 - C H 2 - 0 ) , 18.58 ppm (pyridine-
£ H 3 ) , 38.40 ppm (pyr id ine-£ 4 ) , 39.46 ppm (pyridine-£H 2 -Cl) , 58.43 and 60.66 ppm 
(2x C H 3 - £ H 2 - 0 ) , 100.98 and 103.56 ppm (pyr id ine-£ 3 and £ 5 ) , 126.83 and 127.70 
and 128.66 ppm (phenyl -£ 4 , £ 5 and £ 6 ) , 131.29 and 131.60 ppm (phenyl-C^ and £ 3 ) , 
145.63 and l47 .88 and 150.35 ppm (pheny l -£ i and p y r i d i n e - ^ and £ 6 ) , 150.35 
(phenyl-£i) , 169.17 ppm (2x carbonyl es te r -Q. 
Method a. 2-(2-aminoethylthio)methyl-3£-dicarboethoxy-6-methyl-4-[(substituted) 
phenyl]-1,4-dihydropyridine fumarate 
4 ml 5M NaOH solution in water was added to 10 mmol cysteamine.HCl in ethanol. 
To this solution, 10 mmol 2-chloromethyl-3,5-dicarboethoxy-6-methyl-4-[(substi-
tuted)phenyl]-l,4-dihydropyridine in 10 ml ethanol/dimethoxyethane (5:1) was added 
dropwise at -15°C. After stirring for 15 minutes at -15°C the reaction mixture was 
slowly heated until room temperature. The solution was brought to p H = 4.5 with 
acetic acid. After evaporation of the solvent, the reaction mixture was dissolved in 
water and washed with diethyl ether (3 x 30 ml). The water layer was made basic 
with a sodium bicarbonate solution and washed 5 t imes with 50 ml ethyl 
acetate/diethyl ether (1:1). The combined organkMayers were dried with M g S 0 4 and 
the solvent evaporated. The free base was dissolved in ethyl acetate at 40°C. Then 
fumaric acid in methanol 60°C was added. The product was obtained after cooling. 
2-(2-aminoethylthio)methyl-3f5-dicarboethoxy-6-methyl-4-(3-nitrophenyl)-lF4-
dihydropyridine fumarate VUF 9055 
Yield 2 4 % , melting point 151.4-152.8°C. Mass spectrum (matrix = glycerol + 
ammoniumacetate) (FAB+) 450 [M+HJ+, ( F A B ) 448 [M-H]-. 
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1H-NMR (DMSO-d 6 ) :1 .02-1 .23 ppm (m, 6H, 2x C H 3 - C H 2 - 0 ) , 2.23 ppm (s, 3H, 
pyridine-Qfc), 2.82 ppm (br s, 2H, Q f c ) , 3.00 ppm (br s, 2H, CH2), 3.73-4.12 ppm (m, 
6H, pyridine-CH2-S and 2x C H 3 - C H 2 - 0 ) , 4.98 ppm (s, 1H, pyridine-H 4 ) , 6.47 ppm (s, 
2H, fumaric acid), 7.47-7.71 ppm (m, 2H, 2x phenyl-H), 7.93-8.07 ppm (m, 2H, 2x 
phenyl-H), 7.47-8.67 (br s, 2H, NH9J, 9.48 ppm (br s, 0.8 H, pyridine-NH). 
13C-NMR (DMSO-d 6 ) : 13.65 and 13.80 ppm (2x £ H 3 - C H 2 - 0 ) , 17.94 ppm (pyridine-
£ H 3 ) , 28.46 and 29.59 ppm ( S - £ H 2 - C H 2 - N and S-CH 2 -CH 2 -N) , 38.49 ppm (pyridine-
CH 2 -S ) , 38.96 ppm (pyr id ine-£ 4 ) , 59.08 and 59.39 ppm (2x C H 3 - £ H 2 - 0 ) , 100.77 and 
101.11 ppm (pyr id ine -£ 3 and £5), 120.98 and 121.72 and 129.37 and 133.98 ppm 
(phenyl-C2, C 4 , £5 and £5), 135.03 ppm (2x £ H fumaric acid), 146.29 and 147.21 and 
147.86 and 149.69 ppm (pheny l -£ i and £5 and p y r i d i n e - ^ and £5) , 165.80 and 
166.15 ppm (2x carbonyl ester-£) , 168.13 (2x carbonyl-£ fumaric acid). 
2-(2-aminoethylthio)methyl-3,5-dicarboethoxy-6-methyl-4-phenyl-l ,4-dihydro-
pyridine fumarate VUF 9056 
Yield 5 0 % , melt ing point 120.5-123.0°C. Mass spectrum (matrix = glycerol + 
ammoniumacetate) (FAB+) 405 [M+H] + , (FAB+) 403 [M-H]+. 
*H-NMR ( D M S O - d 6 ) : 1.15 ppm (t, J = 6.6 Hz, 6H, 2x CH3-CH9 . -O) , 2.29 (s, 3H, 
pyr id ine-CH 3 ) , 2.80 ppm (t, J = 7.3 Hz, 2H, S -CH 2 -CH 2 -N) , 3.02 ppm (t, J = 7.3 Hz, 
2H, S-CH 2-CH2-N), 3.88 ppm (s, 2H, pyridine-CIfc-S), 3.99 ppm (q, J = 6.6 Hz, 4H, 2x 
CH3-CE1-O), 4.90 ppm (s, 1H, pyridine-BO, 6.52 ppm (s, 2H, fumaric acid), 7.05-7.30 
ppm (m, 5H, 5x phenyl-H), 9.33 ppm (br s, 0.8 H, pyridine-NH). 
13C-NMR (DMSO-d 6 ) : 13.75 and 13.89 ppm (2x £ H 3 - C H 2 - 0 ) , 17.89 ppm (pyridine-
£ H 3 ) , 28.48 and 29.68 ppm ( S - £ H 2 - C H 2 - N and S -CH 2 -£H 2 -N) , 38.46 ppm (pyridine-
£ H 2 - S ) , 38.60 ppm (pyr idine-£ 4 ) , 58.84 and 59.16 ppm (2x C H 3 - £ H 2 - 0 ) , 101.54 and 
102.15 ppm (pyridine £3 and £5), 125.78 ppm (pheny l -£ 4 ) , 127.10 and 127.65 ppm 
(phenyl-£2, £3, £5 and £5), 135.00 ppm (2x £ H fumaric acid), 145.27 and 146.58 and 
147.56 p p m ( p h e n y l - £ i and pyridine-C? and C^), 166.24 and 166.56 ppm (2x 
carbonyl ester-£) , 168.03 (2x carbonyl-£ fumaric acid). 
2-(2-aminoethylthio)methyl-3£-dicarboethoxy-6-methyl-4-(^ 
dihydropyridine fumarate VUF 4574 
Yield 6 7 % , melting point 101.7-102.0°C. Mass spectrum (matrix = glycerol + 
ammoniumacetate) (FAB+) 450 [M+H]+, ( F A B ) 448 [M-H]-. 
!H-NMR (DMSO-d 6 ) : 1.02-1.33 ppm (m, 6H, 2x C H 3 - C H 2 - 0 ) , 2.29 (s, 3H, pyridine-
C H 3 ) , 2.77 and 2.98 ppm (m, 4H, S - C H 2 - C H ^ N and S-CH^CIfc-N), 3.78-4.08 ppm 
(m, 6H, pyridine-CH9-S and 2x CH^-CH9-Q), 5.65 ppm (s, 1H, pyridine-EU), 6.48 ppm 
(s, 2H, fumaric acid), 7.33-7.79 ppm (m, 4H, 4x phenyl-H), 9.50 ppm (br s, 0.7 H, 
pyridine-NH). 
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2-(2-aminoethylthio)methyl-3,5-dicarboethoxy-4-(2,3-dichlorophenyl)-6-methyl-
1,4-dihydropyridine fumarate VUF 9158 
Yield 5 7 % , melting point 147.6-150.3°C. Mass spectrum (Electron Impact (70eV); 
mass of C 2 i H 2 6 3 5 C l 2 N 2 0 4 S : mass calculated = 472.099, mass found = 472.100 
±0.003) . 
*H-NMR ( D M S O - d 6 ) : 1.01-1.24 ppm (m, 6H, 2x C H 3 - C H 2 - 0 ) , 2.26 ppm (s, 3H, 
pyridine-CH3), 2.80 ppm (t, J = 6.6 Hz, 2H, Cfib), 3.00 ppm (t, J = 6.6 Hz, 2H, Clfc), 
3.80 and 3.91 ppm (AB, JAB = 13.3 Hz, 2H, pyridine-CIfc-S), 3.90-4.15 ppm (m, 4H, 
2x CH3-CH2-O), 5.35 ppm (s, 1H, pyridine-!^) , 6.62 ppm (s, 2H, 2x CH fumaric acid), 
7.08-7.48 ppm (m, 3H, 3x phenyl-H), 9.30 ppm ( b r s, 1H, pyridine-NH). 
!3C-NMR (DMSO-d 6 ) : 13.80 and 13.89 ppm (2x CH3 -CH2 -O) , 17.86 ppm (pyridine-
C H 3 ) , 28.90 and 29.56 ppm ( S - £ H 2 - C H 2 - N and S-CH 2 -CH 2 -N) , 37.65 ppm (pyridine-
£4), 38.50 (py r id ine -£H 2 -S ) , 58.83 and 59.20 ppm (2x C H 3 - £ H 2 - 0 ) , 101.20 and 
101.86 ppm (pyridine £3 and £5), 127.80 and 128.0 and 129.15 ppm (pheny l -£ 4 , £5 
and £5), 131.17 ppm (phenyl-£2 and £3), 135.04 ppm (2x £ H fumaric acid), 145.72 
and 146.53 ppm ( p y r i d i n e ^ and £5), 148.44 (phenyl -£ i ) , 166.09 and 166.31 ppm 
(2x carbonyl ester-£) , 167.98 ppm (2x carbonyl-£ from fumaric acid). 
Method b. In situ preparation of 2-(2-aminoalkylthio)methyl-3 J5-dicarboethoxy-6-
methyl-4-[(substituted)phenyl]-l ,4-dihydropyridine fumarate 
2 ml 10M N a O H solution in water was added dropwise to a solution of 20 mmol 
NaSH and 20 mmol N-(co-bromoalkyl)phthalimide in 75 ml DMSO . After stirring for 4 
hours , 20 mmol of 2-chloromethyl-3,5-dicarboethoxy-6-methyl-4-[(subst i tuted) 
phenyl]-1,4-dihydropyridine in 50 ml D M S O was added dropwise. The reaction 
mixture was stirred 1 day at room temperature. The reaction mixture was poured into 
water and extracted with ethyl acetate. The combined organic layers were dried with 
M g S 0 4 and the solvent evaporated. The crude reaction mixture was dissolved in 150 
ml ethanol and 3 equivalents of hydrazine monohydrate was added. After refluxing 
for 3 hours, the reaction mixture was cooled, filtered and evaporated. The residue was 
dissolved in dichloromethane and extracted with 1 M NaOH. The organic layer was 
evaporated and the residue dissolved in ethanol/water (5:1) and acidified with acetic 
acid. After evaporation of the solvent the residue was dissolved in water and washed 
with diethyl ether (3 x 40 ml) . The water layer was made basic with a sodium 
bicarbonate solution and extracted with ethyl acetate. The combined organic layers 
were dried with M g S 0 4 and the solvent evaporated. The free base was dissolved in 
ethyl acetate at 40°C. Then fumaric acid in methanol 60°C was added. The product 
was obtained after cooling. According to this method the following compounds were 
prepared. 
2-(3-aminopropylthio)methyl-3,5-dicarboethoxy-6-methyl-4-(3-nitrophenyl)-l ,4-
dihydropyridine fumarate VUF 9108 
Yield 5 4 % , melting point 124.3-127.2°C. Mass spectrum (matrix = glycerol + 
ammoniumacetate) (FAB+) 464 [M+H]+, ( F A B ) 462 [M-H]-. 
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1H-NMR (DMSO-d 6 ) : 1.07-1.27 ppm (m, 6H, C H 3 - C H 2 - 0 ) , 1.77-1.96 ppm (m, 2H, C-
CH2-C), 2.32 ppm (s, 3H, pyr idine-CH 3 ) , 2.47-2.72 (m, 5.9 H, CJfc + DMSO), 2.85 
ppm (t, J = 6.6 Hz, 2H, CH2), 3.69-4.12 ppm (m, 6H, pyridine-CH2-S and 2x C H 3 - C H 2 -
O), 5.01 (s, 1H, pyridine-EU), 6.48 ppm (s, 2H, fumaric acid), 7.50-7.70 ppm (m, 2H, 2x 
phenyl-H), 7.93-8.10 ppm (m, 2H, 2x phenyl-H), 8.51-9.67 ppm ( br s, 2H, NH2), 9.47 
ppm (s, 1H, pyridine-NH). 
2-(5-aminopentylthio)methyl-3,5-dicarboethoxy-6-methyl-4-(3-nifr^ 
dihydropyridine fumarate VUF 9159 
Yield 6 9 % , melt ing point 100.6-102.5°C. Mass spectrum (matrix = glycerol + 
ammoniumacetate) (FAB+) 492 [M+HJ+, ( F A B ) 490 [M-H] \ 
*H-NMR (DMSO-d 6 ) : 1.10-1.18 ppm (m, 6H, 2x CH3-CH2-O), 1.21-1.30 ppm (m, 2H, 
C-C-CFb-C-C), 1.48 ppm (m, 4H, C-CH 2 -C-C-C and C-C-C-CJfc-C), 2.31 ppm (s, 3H, 
pyridine-CIfc), 2.45-2.52 ppm (m, 2H, CEb), 2.72 ppm (t, / = 7.35 Hz, 2H, Clfc), 3.73 
and 4.07 ppm (AB, JAB = 13.1 Hz, 2H, pyridine-CKb-S), 3.99 ppm (m, 4H, 2x C H 3 . 
CEh-O), 5.00 ppm (s, 1H, pyridine-ELO, 6.44 ppm (s, 2H, fumaric acid), 7.51-8.01 ppm 
(m, 4H, 4x phenyl-H), 9.42 ppm (br s, 1H, pyridine-NH). 
2-(3-aminopropylthio)methyl-3,5-dicarboethoxy-4-(2,3-dichloro^ 
1,4-dihydropyridine fumarate VUF 4621 
Yield 3 5 % , melting point 127.9-129.3°C. Mass spectrum (matrix = thioglycerol) 
(FAB+) 487 [M+H]+, (FAB-) 485 [M-H]-. 
1H-NMR (DMSO-d 6 ) : 1.10 ppm (t, J = 6.6 Hz, 6H, Clfe-CH^O), 1.83 ppm (m, 2H, C-
Ofc -C) , 2.27 ppm (s, 3H, pyridine-CIfe), 2.60 (m, 2 H, S-CH 2 -C-C-N), 3.20 ppm (m, 
2H, S-C-C-CH2-N), 3.74 and 3.92 ppm (AB, JAB = 12.9 Hz, 2H, pyridine-CH 2 -S), 3.98 
ppm (m, 4H, 2x CHvCTb-O) . 5.36 (s, 1H, pyridine-jHU), 6.46 ppm (s, 2H, fumaric acid), 
7.22-7.41 ppm (m, 3H, 3x phenyl-H), 9.39 ppm (s, 1H, pyridine-NH). 
13C-NMR (DMSO-d 6 ) : 13.91 ppm (2x C H 3 - C H 2 - 0 ) , 17.93 ppm (pyridine-CH 3 ) , 27.31 
and 28.07 and 29.61 ppm ( S - C H 2 - C H 2 - C H 2 - N ) , 58.80 and 59.15 ppm (2x C H 3 - C H 2 -
O), 100.97 and 102.11 ppm (pyridine-C 3 and £5), 127.41 and 128.04 and 129.22 ppm 
(phenyl-£4, £5 and Qs), 131.15 ppm (phenyl-C? and £3), 135.13 ppm (2x £ H fumaric 
acid), 145.78 and 146.65 ppm ( p y r i d i n e - ^ and £5), 148.55 (phenyl-£i ) , 166.34 ppm 
(2x carbonyl ester-£), 168.19 ppm (2x carbonyl-£ from fumaric acid). 
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Synthesis and in vitro pharmacology of a series of new 1,4-
dihydropyridines . 2. 
Diethyl 4 - [2 - ( co -aminoa lkoxy)pheny l ] -2 ,6 -d imethy l - l , 4 -d i -
hydropyridine-3,5-dicarboxylates and their corresponding 
isothioureas as tools for determining structure-activity 
re lat ionships 1 
1 Introduction 
The introduction of 4-aryl-l ,4-dihydropyridines (DHPs) with highly potent C a 2 + -
channel blocking activity led to a new direction in cardiovascular therapy. The C a 2 + -
channel blockers are now well established in the treatment of angina pectoris, 
hypertension, certain cardiac arrhythmias and peripheral vascular disorders [1-5]. The 
1,4-dihydropyridine Ca 2 + - channe l blockers inhibit the influx of extracellular C a 2 + via 
L- type potent ia l -dependent ca lc ium channels and reduce vascular resis tance. 
Although nifedipine 1 [6] and nicardipine 2 [7] are widely used clinically, their rather 
short duration of action is disadvantageous. For that reason several DHPs have been 
synthesized in which var ia t ions in phenyl subst i tut ion were performed or 
modif ica t ions of ester subs t i tuents on the 3 - and 5-posi t ion on the 1,4-
dihydropyridine ring were carried out. [for reviews see 8-11]. 
H H 
1 nifedipine 2 nicardipine 
Qualitative and quantitative structure-activity investigations have been carried out 
by Loev et a l . (ant ihyper tens ive action in anaesthet ised an imals ) [12] and 
Rodenkirchen et al. (negative inotropic activity 5n isolated, isotonically contracted 
cat papillary muscle) [13]. In both studies the most potent DHPs carry an ortho-
substituent in the 4-phenyl ring. Derivatives with meta or para substituents are less 
active. In the case of 4-aryl-substituted dihydropyridines the biological activity 
depends mainly on steric influences and appears generally to be independent of the 
electronic properties of the substituents. 
EurJ .Med.Chem., 28, 935-941 (1993) 
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For lacidipine 3 and analogues it has been found that increasing steric bulk and 
lipophilicity of the ortho-substituent on the 4-phenyl ring of the 1,4-DHP enhances 
the in vivo calcium channel blocking activity [14]. The lacidipine analogue without a 
cinnamoyl ester is more than 700 times less active then lacidipine. By increasing the 
lipophilicity of the cinnamoyl ester of lacidipine analogues, the in vitro calcium 
channel blocking activity decreases while the duration of action increases [15]. 
Systematic modifications at the 2-position of the DHP ring have been performed to 
increase the rather short duration of action and to improve the bioavailability of the 
classical DHPs , resulting in amlodipine 4 [16] and its derivatives and their thio-
bioisosters such as V U F 9159 5 [17] and tiamdipine 6 [18]. These latter DHPs 
demonstrate that extended 2-substituents bearing a basic functionality are well 
tolerated at the receptor. 
5 tiamdipine 6 VUF 9159 
Calcium channel blocking activity of l ,4 - t )HPs is thought to be achieved by 
interaction with specific receptors present on the L-type voltage dependent calcium 
channels. A major role for contribution to binding to these receptors is played by the 
4-phenyl ring of the 1,4-DHPs. Thus, substituents on the 4-phenyl ring of nifedipine 
analogues significantly influence the affinity to the receptor. Amlodipine and 
tiamdipine analogues possess a basic side chain at the 2-position on the 1,4-DHP ring. 
It has been suggested that this protonated side chain is trapped in the membrane and 
the preferred conformation forces the phenyl ring to move from the position adopted 
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by nifedipine analogues in such a way that the contribution of the 4-phenyl ring 
substituents to binding is reduced [19,20]. This then could explain the rather small 
influence of the substituents on the 4-phenyl ring of amlodipine and tiamdipine 
analogues on their pharmacologic potencies. In the present study we therefore 
established whether substituents of the 0 - ( C H 2 ) m - R type (with m = 5, 6 or 10 and R 
= N H 2 or thiourea or thiouronium bromide) at the ortho-position of the phenyl ring 
are tolerated. The choice of identical ester substitution at the 3- and 5-position on the 
1,4-dihydropyridine ring has been made because of earlier results obtained showing 
that these DHPs were equally active as different ester substituted DHPs [17] and to 
avoid stereochemical complications. 
2 C h e m i s t r y 
The compounds listed in Table I were prepared by a general method illustrated in 
Scheme 1. 
2-(co-substituted-alkoxy)benzaldehydes 9 were available by reaction of 2-hydroxy-
benzaldehyde with N-(co-bromoalkyl)phthalimides. The N-(co-bromoalkyl)phthal-
imides were synthesized according to Soine et al. [21]. Hantzsch type condensation 
of a subs t i tu ted b e n z a l d e h y d e 9 with ethyl ace toaceta te 7 and ethyl 3-
aminocrotonate 8 afforded 4-[2-(o)-phthalimidoalkoxy)phenyl]-l,4-dihydropyridines 
10. Subsequent hydrazinolysis of the phthalimides with hydrazine monohydrate gave 
the 4- [2- ( (D-aminoalkoxy)phenyl ] - l ,4-d ihydropyr id ines 1 1 . The corresponding 
thiourea analogues 13 were obtained via reaction of the amino function of 11 with 
benzoyl isothiocyanate 12 [22] and subsequent basic hydrolysis. Reaction of the 
thioureas analogues 7 with ethyl bromide gave the thiouronium compounds 14. 
3 P h a r m a c o l o g y 
Calcium channel blocking activities were determined in vitro on the rat aorta and 
dihydropyridine receptor binding affinities were determined on isolated rat cortex as 
previously described by Christ iaans et al. [17] . The calcium channel blocking 
activities (expressed as p I C 5 0 ) were assessed as the concentration required to inhibit 
the K + -depolar isat ion induced (50 mM) contractile responses in rat aorta strips by 
50%. Concentration-response curves were utilised to determine PIC50 values. 
The dihydropyridine receptor binding assay was performed on rat cortex microsomes 
which were incubated with [ 3 H]ni t rendipine and various concentrat ions of the 
compounds at 37°C for 60 minutes. The incubations were carried out according to 
Boer et al. [23] in such a way that the final DMSO concentration never exceeded 1% 
(v/v), a concentration which did not affect the binding. The equilibrium dissociation 
constant ( K d ) of the labelled compound and the maximal binding ( B m a x ) were 
determined with the non-linear fitting program LIGAND 4.1 [24] being 0.75 nM and 
270 fmol/mg protein respectively. 
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4 R e s u l t s a n d d i s c u s s i o n 
All compounds described in this paper show in vitro calcium channel blocking 
activity within 5 minutes but do not reach complete equilibrium within 45 minutes. 
This is in accordance with diethyl 2-(5-aminopentyl thiomethyl)-6-methyl-4-(3-
n i t ropheny l ) - l , 4 -d ihydropyr id ine -3 ,5 -d ica rboxy la t e ( V U F 9159) and rela ted 
compounds, described by Christiaans et al. [17]. Complete inhibition of contractile 
responses was obtained for all compounds as was verified by addition of 1 m M 
papaverine. 
In Table I the influence of the variations in the co-aminoalkoxy chain length at the 
ortho position of the 4-phenyl ring on calcium channel blocking activity show a small 
range of potencies . Compounds with co-aminoalkoxy substi tuents at the meta 
position of the 4-phenyl ring are not active at all (data not shown [26]). 
Convert ing the amine function of the co-aminoalkoxy substi tuent into thiourea 
affords species which are not protonated under physiological condit ions. These 
compounds (VUF 4622 and V U F 4671) are as active as the corresponding amines 
(VUF 4599 and V U F 4600). Even, introduction of an isothiouronium bromide, a polar 
group, does not alter the calcium channel blocking activities (VUF 4623 and VUF 
4624). Although, as mentioned by Loev et al. [12] and Rodenkirchen et al. [13], the 
calc ium channel blocking activit ies of 4-aryl -subst i tu ted- l ,4-dihydropyr id ines 
depend mainly on steric influences, no such indications can be found for the 
compounds described in this paper. 
Table I shows that there is a difference between p I C 5 0 values and p K d values. This 
difference can or iginate from the l ipophil ic character of the or tho-phenyl 
substituents. 
Spampinato et al. [27] investigated the role of lipophilicity of lacidipine on its calcium 
channel blocking activities. The potency of lacidipine as a calcium channel blocker 
showed not to be directly related to the amount of drug locked in the cell, indicating 
that lacidipine binds to the lipid bilayer of the cell membrane and then diffuses 
towards a specific binding site. This shows a similarity to the blockade of N a + -
channels by local anaesthetics. The drug receptor for local anaesthetics is situated in 
the sodium channel and l igands reach the receptor via the membrane phase 
(hydrophobic pathway) or via the channel (hydrophilic pathway). The DHP receptor 
is located within the calcium channel in the lipid bilayer near the external end of the 
channel [28,29]. In the three compartment receptor model of Gaviraghi [14] (Figure 
1) the dihydropyridine receptor is seen as a protein compartment surrounded by a 
lipid compartment. Drugs in the aqueous compartment stay in contact with both lipid 
and protein compartments . Increase of the lipophilicity of a dihydropyridine can 
increase the affinity for the lipid compartment from which it is slowly released to the 
protein compartment . Increasing the affinity of dihydropyridines for the receptor 
enhances the potency but does not affect the duration of action [15]. 
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Table I: Calcium blocking activities and radioligand binding affinities of diethyl 
2,6-dimethyl-4-[2-(co-substituted-alkoxy)phenyl]-l,4-dihydro-pyridine-
3,5-dicarboxy lates 
H 
compound R m pICso* rat tissue pKd* 
V U F 4 5 8 7 H 5 6 . 6 1 ± 0 . 0 8 aorta 6 . 8 3 ± 0 . 0 8 
V U F 4 5 9 9 H 6 6.42 ± 0.04 aorta 7.02 ± 0 . 0 5 
V U F 4 6 0 0 H 10 6 . 3 5 ± 0.20 aorta 7.30 ± 0.06 
V U F 4 6 2 2 C(S)NH 2 5 6.44 ± 0 . 1 3 aorta 7.00 ± 0.07 
V U F 4 6 7 1 C(S)NH 2 6 6.39 ± 0.09 aorta 7.09 ± 0.09 
V U F 4 6 2 3 C(NH)SEt HBr 5 6 . 3 1 ± 0 . 1 0 aorta 7.27 ± 0 . 1 5 
V U F 4 6 2 4 C(NH)SEt HBr 6 6.34 ± 0 . 1 1 aorta 7.70 ± 0 . 1 1 
1 nifedipine 8 .77 ± 0 . 0 8 aorta 8 .70 ± 0 . 1 4 
4 amlodipine 8 . 1 A aorta -
5 V U F 9 1 5 9 7.96 + 0.07 aorta 8 . 5 5 ± 0 . 0 3 
pICso Concentration required to produce 50% of its inhibitory effect 
* All values are means ± s.d. for 3 independent observations 
# All values are means ± s.d. for 6-9 independent observations. 
All radioligand binding affinities (pKd) were determined on isolated rat 
cortex membranes 
a A lke re t a l . [25] 
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lipid compartment protein compartment 
proximate lipid receptor 
water 
aqueous compartment 
Figure 1: Three compartment receptor model (from ref. 14) 
By modifying the lipophilicity of dihydropyridines the competition for binding to the 
protein compartment or to the lipid compartment is influenced. Dihydropyridines with 
a slow onset of action and a long duration of effect are thought to compete strongly 
for the lipid compartment in respect to the receptor compartment when delivered by 
the aqueous compartment. 
In accordance with the results obtained on calcium channel blocking activities also a 
narrow potency range is found in affinity for the binding site of the L-type calcium 
channel. All p K d values are slightly higher then the corresponding PIC50 values. The 
phenomenon of differences in p K d values and p I C 5 0 values is also observed by Kwon 
et al. [301. A possible explanation for these differences may be that the calcium 
channel blocking activities and the affinities are determined on different organs. 
5 C o n c l u s i o n s 
The present diethyl 2,6-dimethyl-4-[2-(co-substi tuted-alkoxy)phenyl]-l ,4-dihydro-
pyridine-3,5-dicarboxylates are moderate inhibitors of K + -depolar isa t ion induced 
contractile responses in rat aorta strips. Increasing the co-aminoalkoxy chain length 
from pentoxy to decyloxy does not enhance calcium channel blocking activity. Even 
replacement of the amino function by a thiouronium bromide does not alter the 
calcium channel blocking activity. It is found that calcium channel blocking activity 
is independent on steric influences of the diethyl 2,6-dimethyl-4-[2-(co-substituted-
alkoxy)phenyl]-l,4-dihydropyridine-3,5-dicarboxsylates. 
There seems to be a tendency that with increasing alkyl chain length the differences 
between PIC50 values and p K d values become more substantial. By increasing the 
alkyl chain length, the lipophilicity of the dihydropyridines is increased. According to 
the three compartment receptor model the dihydropyridines with higher lipophilicity 
show a higher affinity for the lipid compartment and therefore in vitro a lower 
potency. This then could explain the more substantial differences between pIC 5Q 
values and p K d values. 
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The narrow activity range does not permit to quantitate the structure-activity 
relationships of these novel 1,4-dihydropyridine derivatives. 
6 E x p e r i m e n t a l p r o t o c o l s 
If indicated, crude reaction products were purified by flash chromatography on 
silicagel (J.T.Baker 70242). Melting points were determined on a Mettler FP 52 with 
microscope. *H-NMR and 1 3 C - N M R spectra were recorded on a Bruker AC 200. The 
chemical shifts are in ppm relative to tetramethylsilane. Mass spectra were determined 
on a Mat 90 (Finnigan Mat) mass spectrometer with Fast Atom Bombardment 
ionisation (matrix: thioglycerol, Ion Tech saddlefield gun, 8 keV Xenon with xenon 
ioncurrent 0.2 mA). Furthermore the purity of the compounds was checked by thin 
layer chromatography (Merck silica gel 60, F254 0.25 mm). Nifedipine was obtained 
from Sigma Chemical Company. [ 3H]nitrendipine (73 Ci/mmol) was purchased from 
Du Pont de Nemours (The Netherlands). 
General synthetic procedure 
2-[co-(phthalimido)alkoxy]benzaldehyde 
50 mmol of the appropriate N-(co-bromoalkyl)phthalimide, 50 mmol salicylaldehyde 
and 50 mmol potassium carbonate were stirred in 50 ml D M F for 5 hours at 110°C 
under nitrogen. After cooling to room temperature, the reaction mixture was filtered. 
The filtrate was evaporated and the residue was crystallized from methanol. 
2-[5-(phthalimido)pentoxy]benzaldehyde 
Yield 100%, melting point 92.1-93.8°C. 
*H-NMR (CDC1 3 ): 1.57 ppm (m, 2H, C-C-CH 2 -C-C), 1.77 and 1.90 ppm (m, 4H, O-C-
CH2-C-CH2-C-N), 3.73 ppm (t, / = 7.0 Hz, 2H, 0 -C-C-C-C-CH 2 -N) , 4.07 ppm (t, J = 
6.3 Hz, 2H, O-CH2-C-C-C-C-N), 6.92-7.04 ppm (m, 2H, 2x phenyl-H), 7.46-7.58 ppm 
(m, 1H, phenyl-H), 7.69-7.88 ppm (m, 5H, 4x phthalimide-H and l x phenyl-H), 10.47 
p p m ( s , l H , - H C = 0 ) . 
2-[6-(phthalimido)hexyloxy]benzaldehyde 
Yield 8 5 % , melting point 85.7-86.6°C. 
*H-NMR (CDCI3): 1.25-2.04 ppm (m, 8H, 0 -C- (CH 2 ) 4 -C-N) , 3.74 ppm (t, J = 7.1 Hz, 
2H, 0 - (C) 5 -CH 2 -N) , 4.07 ppm (t, / = 6.3 Hz, 0 -CH 2 - (C) 5 -N) , 6.92-7.05 ppm (m, 2H, 2x 
phenyl-H), 7.47-7.57 ppm (m, 1H, phenyl-H), 7.71-7.84 ppm (m, 5H, 4x phthalimide-H 
and phenyl-H), 10.50 ppm (s, 1H, -HC=0) . 
2-[10-(phthalimido)decyloxy]benzaldehyde 
Yield 7 5 % , melting point 65.0-67.1°C. 
*H-NMR (CDCI3): 1.10-1.58 ppm (m, 12H, 0-C-C-(CH 2 ) 6 -C-C-N) , 1.58-1.77 ppm (m, 
2H, 0 - (C) 8 -CH 2 -C-N) , 1.77-1.94 ppm (m, 2H, 0 -C-CH 2 - (C) 8 -N) , 3.68 ppm (t, J = 7.0 
Hz, 2H, 0- (C) 9 -CH 2 -N) , 4.05 ppm (t, J = 6.2 Hz, 0 -CH 2 - (C) 9 -N) , 6.93-7.06 ppm (m, 2H, 
2x p h e n y l - H ) , 7.44-7.61 ppm (m, 1H, pheny l -H) , 7.61-7.77 ppm (m, 2H, 2x 
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phthalimide-H), 7.77-7.80 ppm (m, 3H, phenyl-H and 2x phthalimide-H), 10.50 ppm (s, 
1H, -HC=0). 
Diethyl 2,6-dimethyl-4-{2-[co-(phthalimido)alkoxy]phenyl}-1
 f4-dihydro-pyridine-
3,5-dicarboxylate 
1 equivalent of the appropriate 2-[co-(phthalimido)alkoxy]benzaldehyde, 1 equivalent 
ethyl acetoacetate and 0.06 equivalents of glacial acetic acid and benzylamine were 
refluxed in absolute ethanol (2 1/mol) under nitrogen. After 3 hours, 1 equivalent of 
ethyl aminocrotonate was added and refluxing was continued overnight . After 
cooling to room temperature, the solvent was evaporated and the residue was 
crystallized from 2-propanol. 
Diethyl 2t6-dimethyl-4-{2-[5-(phthalimido)pentoxy]phenyl}-l,4-dihydro-pyridine-
3
 f5-dicarboxylate 
Yield 4 3 % , melting point 140:4-141.4°C. 
^ -NMR(CDCI3) : 1 . 1 6 p p m ( t , / = 7.2Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.46-1.58ppm (m,2H, 
C-C-CH 2 -C-C) , 1.70-1.88 ppm (m, 4H, 0 - C - C H 2 - C - C H 2 - C - N ) , 2.28 ppm (s, 6H, 2x 
pyridine-CH 3 ) , 3.66-3.78 ppm (m, 2H, 0-C-C-C-C-CH 2 -N) , 3.88 ppm (t, J = 6.65 Hz, 
2H, 0 -CH 2 -C-C-C-C-N) , 4.00 ppm (q, / = 7.2 Hz, 4H, 2x C H 3 - C H 2 - 0 ) , 5.15 ppm (s, 
1H, pyridine-!^) , 6.13 ppm (s, 1H, pyridine-NH), 6.69-6.82 ppm (m, 2H, 2x phenyl-H), 
7.07 ppm (d, ƒ = 7.5 Hz, 1H, phenyl-H), 7.21 ppm (d, J = 7.5 Hz, 1H, phenyl-H), 7.70-
7.73 ppm (m, 2H, 2x phthalimide-H), 7.81-7.87 ppm (m, 2H, 2x phthalimide-H). 
Diethyl 2f6-dimethyl-4-{2-[6-(phthalimido)hexoxy]phenyl}'14-dihydro-pyridine-
3 ,5-dicarboxylate 
Yield 50%, melting point 131.2-133.3°C. 
^ - N M R (CDC1 3): 1.16 ppm (t,J=7.1Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.44-1.84 ppm (m, 8H, 
0 -C- (CH 2 ) 4 -C-N) , 2.27 ppm (s, 6H, 2x pyridine-CH 3 ) , 3.72 ppm (t, / = 7.1 Hz, 2H, O-
(C) 5 -CH 2 -N) , 3.87 ppm (t, / = 6.8 Hz, 2H, 0 -CH 2 - (C) 5 -N) , 4.01 ppm (q, J = 7.1 Hz, 4H, 
2x C H 3 - C H 2 - 0 ) , 5.16 ppm (s, 1H, p y r i d i n e - ^ ) , 6.12 ppm (bs, 1H, pyridine-NH), 6.70-
6.83 ppm (m, 2H, 2x phenyl-H), 7.01-7.10 ppm (m, 1H, phenyl-H), 7.19-7.27 ppm (m, 
1H, phenyl-H), 7.69-7.74 ppm (m, 2H, 2x phthalimide-H), 7.83-7.87 ppm (m, 2H, 2x 
phthalimide-H). 
Diethyl 2f6-dimethyl-4-{2-[10-(phthalimido)deoxy]phenyl}-l,4-dihydro-pyridine-
3,5-dicarboxylate s 
Yield 60%, melting point 125.5-128.0°C. 
^ - N M R (CDC1 3 ) : 1.17 ppm (t, / = 7.2 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.22-1.88 ppm (m, 
16H, 0 -C- (CH 2 ) 8 -C-N) , 2.29 ppm (s, 6H, 2x pyridine-CH 3 ) , 3.60-3.73 ppm (m, 2H, O-
(C) 9 -CH 2 -N) , 3.90 ppm (t, / = 6.7 Hz, 2H, 0 -CH 2 - (C) 9 -N) , 4.04 ppm (q, / = 7.2 Hz, 4H, 
2x C H 3 - C H 2 - 0 ) , 5.20 ppm (s, 1H, pyridine-E*), 5.65 ppm (s, 1H, pyridine-NH), 6.70-
6.83 ppm (m, 2H, 2x phenyl-H), 7.01-7.10 ppm (m, 1H, phenyl-H), 7.21-7.29 ppm (m, 
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1H, phenyl-H), 7.65-7.78 ppm (m, 2H, 2x phthalimide-H), 7.78-7.90 ppm (m, 2H, 2x 
phthalimide-H). 
Diethyl 4-[2-(Ghaminoalkoxy)phenyl]-2,6-dimethyl-l,4-dihydropyridine-3,5-
dicarboxylate 
45 mmol phthalimide and 3 equivalents hydrazine monohydrate were refluxed in 300 
ml ethanol for 6 hours. After cooling to room temperature the reaction mixture was 
filtered and the solvent evaporated. The residue was dissolved in dichloromethane 
and extracted with 1 M NaOH. The organic layer was evaporated and the residue 
dissolved in ethanol/water (5:1) and acidified with acetic acid. After evaporation of 
the solvent the residue was dissolved in water and washed with diethyl ether (3 x 50 
ml). The water layer was made basic with sodium bicarbonate solution and extracted 
with ethyl acetate. The combined organic layers were dried with M g S 0 4 and the 
solvent evaporated. The free base was obtained as a solid. 
Diethyl 4-[2-(5-aminopentoxy)phenyl]-2,6-dimethyl-l ,4-dihydropyridine-3 >5-
dicarboxylate VUF 4587 
Yield 77%, melting point 146.8-147.1°C, Mass spectrum (FAB + ) 431 [M+H] + , (FAB") 
429 [ M - H ] \ 
*H-NMR (CDC1 3 ): 1.16 ppm (t, / = 7.12 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.58-1.76 ppm (m, 
6H, 0 -C-CH 2 -CH 2 -CH 2 -C-N) , 2.25 ppm (s, 6H, 2x pyridine-CH 3 ), 2.81 ppm (t, J = 5.7 
Hz, 2H, 0 - (C) 4 -CH 2 -N) , 3.85-3.92 ppm (m, 2H, 0 -CH 2 - (C) 4 -N) , 4.01 ppm (q, J = 7.12 
Hz, 4H, 2x C H r C H 2 - 0 ) , 5.14 ppm (s, 1H, pyridine-K*), 6.68-6.79 ppm (m, 2H, 2x 
phenyl-H), 7.01-7.09 ppm (m, 1H, phenyl-H), 7.19-7.26 ppm (m, 1H, phenyl-H), 7.58 
ppm (s, 1H, pyridine-NH). 
Diethyl 4-[2-(6-aminohexoxy)phenyl]-2,6-dimethyl-l ,4-dihydropyridine-3,5-
dicarboxylate VUF 4599 
Yield 7 3 % , melting point 113.9-116.8°C, Mass spectrum (FAB + ) 445 [ M + H ] + , (FAB") 
443 [M-H]-. 
*H-NMR (CDC1 3): 1.15 ppm (t, ƒ = 7.1 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.44-1.81 ppm (m, 8H, 
0 -C- (CH 2 ) 4 -C-N) , 2.27 ppm (s, 6H, 2x pyridine-CH 3 ) , 2.68-2.76 ppm (m, 2H, 0 - ( C ) 5 -
CH 2 -N) , 3.89 ppm (t, / = 6.6 Hz,, 2H, 0 -CH 2 - (C) 5 -N) , 4.02 ppm (q, / = 7.1 Hz, 4H, 2x 
C H 3 - C H 2 - 0 ) , 5.19 ppm (s, 1H, pyridine-HU), 5.85 ppm (bs, 1H, pyridine-NH) 6.72-6.83 
ppm (m, 2H, 2x phenyl-H), 7.01-7.07 ppm (m, 1H, l x phenyl-H), 7.19-7.25 ppm (m, 1H, 
l x phenyl-H). 
Diethyl 4-[2-(10-aminodecoxy)phenyl]~2,6-dimethyl-l,4-dihydropyridine-3,5-
dicarboxylate VUF 4600 
Yield 72%, melting point 117.5-119.2°C, Mass spectrum (FAB + ) 501 [M+H] + , (FAB - ) 
499 [M-H]". 
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^ - N M R (CDCI3): 1.18 ppm (t,J = 7.2 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.22-1.88 ppm (m, 
16H, 0 -C- (CH 2 ) 8 -C-N) , 2.26 ppm (s, 6H, 2x pyridine-CH 3 ) , 3.61-3.72 ppm (m, 2H, O-
(C) 9 -CH 2 -N) , 3.89 ppm (t, J = 6.7 Hz, 2H, 0 -CH 2 - (C) 9 -N) , 4.04 ppm (q, J = 7.2 Hz, 4H, 
2x C H 3 - C H 2 - 0 ) , 5.19 ppm (s, 1H, pyridine-ÊU), 5.82 ppm (s, 1H, pyridine-NH), 6.69-
6.83 ppm (m, 2H, 2x phenyl-H), 7.01-7.08 ppm (m, 1H, phenyl-H), 7.25-7.33 ppm (m, 
1H, phenyl-H). 
N-benzoyl-N'-{(û-[2-(3,5-dicarboethoxy-2,6-dimethyl-l ,4-dihydropyridin-4-yl) 
phenoxy]alkyl}thiourea 
A solution of 30 mmol of a suitable 3,5-dicarboethoxy-2,6-dimethyl-4-[2-(cû-amino-
alkoxy)phenyl]-l ,4-dihydropyridine in 150 ml dichloromethane was added dropwise 
to a solution of an equimolar amount of benzoyl isothiocyanate [22] in 150 ml 
dichloromethane followed by stirring for 4 hours. Then the solvent was evaporated 
and the residue was purified by column chromatography, using dichloromethane/ 
ethyl acetate 9:1 as eluent. 
N-benzoyl-N' -{5-[2-(3,5-dicarboethoxy-2,6-dimethyl-l ,4-dihydropyridin-4-yl) 
phenoxyjpentyl}thiourea 
Yield 5 1 % , melting point 143.2-145.7°C. 
^ - N M R (CDCI3): 1.16 ppm (t, ƒ = 7.15 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.45-1.59 ppm (m, 
2H, 0 -C-C-CH 2 -C-C-N) , 1.77-1.91 ppm (m, 4H, 0 -C-CH 2 -C-CH 2 -C-N) , 2.27 ppm (s, 
6H, 2x pyridine-CH 3), 3.67-3.76 ppm (m, 2H, 0 - (C) 4 -CH 2 -N) , 3.91 ppm (t, J = 6.53 Hz, 
2H, 0 - C H 2 - ( C ) 4 - N ) , 4.00 ppm (q, J = 7.15 Hz, 4H, 2x C H 3 - C H 2 - 0 ) , 5.18 ppm (s, 1H, 
p y r i d i n e - ^ ) , 5.99 ppm (s, 1H, pyridine-NH), 6.74-6.81 ppm (m, 2H, 2x phenyl-H), 
7.01-7.08 ppm (m, 1H, phenyl-H), 7.21-7.29 ppm (m, 1H, phenyl-H), 7.58-7.73 ppm (m, 
3H, 3x benzoyl-H), 7.81-7.92 ppm (m, 2H, 2x benzoyl-H), 9.04 ppm (bs, 1H, -C(S)-NH-
C(O)-), 10.83 ppm (t, J = 4.9 Hz, 1H, C-C-C-NH-C(S)-). 
N-benzoyl-N'-{6-[2-(3,5-dicarboethoxy-2,6-dimethyl-l ,4-dihydropyridin-4-yl) 
phenoxy ]hexyl} thiourea 
Yield 8 5 % , melting point 154.2-157.2°C. 
^ - N M R (CDC1 3): 1.16 ppm (t, / = 7.1 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.44-1.59 ppm (m, 4H, 
0 -C-C-CH 2 -CH 2 -C-C-N) , 1.71-1.90 ppm (m, 4H, 0 -C-CH 2 -C-C-CH 2 -C-N) , 2.28 ppm 
(s, 6H, 2x pyridine-CH 3 ) , 3.68-3.77 ppm (m, 2H, 0 - ( C ) 5 - C H 2 - N ) , 3.91 ppm (t, / = 6.6 
Hz, 2H, 0 -CH 2 - (C) 5 -N) , 4.02 ppm (q, J = 7.1 Hz, 4H, 2x C H 3 - C H 2 - 0 ) , 5.18 ppm (s, 1H, 
pyridine-ILj), 5.83 ppm (bs, 1H, pyridine-NH), 6.70-6.83 ppm (m, 2H, 2x phenyl-H), 
7.02-7.08 ppm (m, 1H, phenyl-H), 7.19-7.25 ppm (m, 1H, phenyl-H), 7.49-7.86 ppm (m, 
5H, 5x benzoyl-H), 9.00 ppm (bs, 1H, -C(S)-NH-C(0)-), 10.78 ppm (t, 1H, C-C-C-NH-
C(S)-NH-C(0)-). 
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N-{co-[2-(3,5-dicarboethoxy-2
 t6-dimethyl~l ,4-dihydropyridin-4-yl)phenoxy]alkyl} 
thiourea 
5 mmol K 2 C O 3 in 20 ml water was added to a solution of 5 mmol of a suitable N-
benzoyl-N'- {co- [2-(3,5-dicarboethoxy-2,6-dimethyl-1,4-dihydropyridin-4yl)phenoxy] 
alkyl}thiourea in 60 ml ethanol. The reaction mixture was refluxed for 4 hours. Then 
50 ml water was added and the ethanol was evaporated. The water layer was 
extracted three times with 50 ml ethyl acetate and the organic layer was dried with 
M g S 0 4 and subsequently evaporated. 
N-{5-[2-(3 £-dicarboethoxy-2,6-dimethyl-l ,4-dihydropyridin-4-yl)phenoxy]pentyl} 
thiourea VUF 4622 
Yield 92%, melting point 65.6-66.0°C, Mass spectrum ( F A B + ) 490 [ M + H ] + , ( F A B ) 
488 [ M - H ] \ 
*H-NMR (CDCI3): 1.18 ppm (t, ƒ = 7.1 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.50-1.75 ppm (m, 6H, 
0 -C- (CH 2 ) 3 -C-N) , 2.24 ppm (s, 6H, 2x pyridine-CH 3 ) , 3.17 and 3.55 ppm (m, 2H, O-
(C) 4 -CH 2 -N) , 3.97-4.21 ppm (m, 6H, 2x C H 3 - C H 2 - 0 and 0 -CH 2 - (C) 4 -N) , 5.18 ppm (s, 
1H, pyridine-]!*), 6.15 ppm (s, 1H, pyridine-NH), 6.52 ppm (bs, 1H, NH), 6.71-6.86 ppm 
(m, 2H, 2x phenyl-H), 7.05-7.30 ppm (m, 3H, 2x phenyl-H and NH). 
N-{6-[2-(3 £-dicarboethoxy-2,6-dimethyl-l ,4-dihydropyridin-4-yl)phenoxy]hexyl} 
thiourea VUF 4671 
Yield 60%, melting point 175.6-175.8°C, Mass spectrum (FAB + ) 504 [M+H] + , (FAB" 
) 502 [M-H]-. 
^ - N M R (DMSO-d 6 ) 1.07 ppm (t, J = 7.0 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.39-1.71 ppm (m, 
8H, 0 -C- (CH 2 ) 4 -C-N) , 2.18 ppm (s, 6H, 2x pyridine-CH 3 ) , 3.03 and 3.33 ppm (m, 2H, 
0 - ( C ) r C H 2 - N ) , 3.86-3.97 ppm (m, 6H, 2x C H 3 - C H 2 - 0 and 0 - C H 2 - ( C ) 5 - N ) , 5.09 ppm 
(s, 1H, pyridine-EO, 6.71-7.09 ppm (m, 5H, 4x phenyl-H and NH) , 7.55 ppm (bs , lH, 
NH), 8.61 ppm (s, 1H, pyridine-NH). 
N-{co-[2-(3f5'dicarboethoxy-2f6-dimethyl-l,4-dihydropyridin-4-yl)phenoxy^ alkylj-
S-ethyl isothiourea hydrobromide 
A suitable N- {co- [2-(3,5-dicarboethoxy-2,6-dimethyl-1,4-dihydropyridin-4-yl)phen-
oxy]alkyl}thiourea was dissolved in 75 ml absolute ethanol; 3 equivalents ethyl 
bromide were added and the reaction mixture was stirred for 8 hours at 60°C under 
nitrogen. Then the solvent was evaporated and the residue was washed with 30 ml 
diethyl ether. x 
N-{5-[2-(3,5-dicarboethoxy-2,6-dimethyl-lt4-dihydropyridin-4-yl)phenoxy] heptyl} 
-S-ethyl isothiourea hydrobromide VUF 4623 
The product was crystallized from ethanol. 
Yield 66%, melting point 155.2-156.4°C, Mass spectrum (FAB + ) 518 [ M + H ] + , (FAB") 
596/598 [ M + B r ] \ 
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*H-NMR (DMSO-d 6 ) : 1.07 ppm (t, / = 7.0 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.26 ppm (t, J = 
7.3 Hz, 3H, CH 3 -CH 2 -S) , 1.37-1.48 ppm (m, 2H, 0-C-C-CH 2 -C-C-N), 1.67-1.80 ppm (m, 
4H, 0 -C-CH 2 -C-CH 2 -C-N) , 2.20 ppm (s, 6H, 2x pyridine-CH 3 ) , 3.22 ppm (q, J = 7.3 
Hz, 2H, CH 3 -CH 2 -S ) , 3.32-3.41 ppm (m, 2H, 0- (C) 4 -CH 2 -N) , 3.84-3.97 ppm (m, 6H, 2x 
C H 3 - C H 2 - 0 and 0 -CH 2 - (C) 4 -N) , 5.09 ppm (s, 1H, pyridine-!^), 6.72-6.86 ppm (m, 2H, 
2x phenyl-H), 7.02-7.09 ppm (m, 2H, 2x phenyl-H), 8.70 ppm (bs, 1H, pyridine-NH), 
9.18 ppm (bs, 2H, -C-N-C(SEt)-NH 2 + .Br) , 9.57 ppm (m, 1H, -C-NH-C(NH)-SEt). 
N-{6-[2-(3,5-dicarboethoxy-2,6-dimethyl-l,4-dihydropyridin-4-yl)phenoxy] hexylj-
S-ethyl isothiourea hydrobromide VUF 4624 
The product was crystallized from ethanol. 
Yield 69%, melting point 154.0-154.3°C, Mass spectrum (FAB + ) 532 [ M + H f , (FAB") 
610/612 [M+Br]-. 
*H-NMR (DMSO-d 6 ) : 1.07 ppm (t, J = 7.1 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.26 ppm (t, / = 
7.3 Hz, 3H, C H 3 - C H 2 - S ) , 1.39-1.48 ppm (m, 4H, 0 -C-C-CH 2 -CH 2 -C-C-N) , 1.55-1.64 
ppm (m, 2H, 0 - (C) 4 -CH 2 -C-N) , 1.70-1.82 ppm (m, 2H, 0 -C-CH 2 - (C) 4 -N) , 2.19 ppm (s, 
6H, 2x pyr idine-CH 3 ) , 3.22 ppm (q, J = 7.3 Hz, 2H, C H 3 - C H 2 - S ) , 3.29-3.37 ppm (m, 
2H, 0 - ( C ) 5 - C H 2 - N ) , 3.79-3.86 ppm (m, 2H, 0 - C H 2 - ( C ) 5 - N ) , 3.91 ppm (q, J = 7.1 Hz, 
4H, 2x C H 3 - C H 2 - 0 ) , 5.10 ppm (s, 1H, pyridine-I^) , 6.71-6.82 ppm (m, 2H, 2x phenyl-
H), 7.01-7.08 ppm (m, 2H, 2x phenyl-H), 8.68 ppm (bs, 1H, pyridine-NH), 9.15 ppm (bs, 
2H, -C-N-C(SEt)-NH 2+*Br), 9.57 ppm (bs, 1H, -C-NH-C(NH)-SEt). 
^ - N M R ( C D 3 O D - d 4 ) : 1.14 ppm (t, / = 7.1 Hz, 6H, 2x C H 3 - C H 2 - 0 ) , 1.36 ppm (t, / = 
7.3 Hz, 3H, C H 3 - C H 2 - S ) , 1.48-1.55 ppm (m, 4H, 0 -C-C-CH 2 -CH 2 -C-C-N) , 1.70-1.79 
ppm (m, 2H, 0 - (C) 4 -CH 2 -C-N) , 1.82-1.91 ppm (m, 2H, 0 -C-CH 2 - (C) 4 -N) , 2.24 ppm (s, 
6H, 2x pyridine-CH 3 ) , 3.19 ppm (q, J = 7.3 Hz, 2H, CH 3 -CH 2 -S ) , 3.39 ppm (t, / = 7.1 
Hz, 2H, 0 - ( C ) 5 - C H 2 - N ) , 3.90-4.04 ppm (m, 6H, 2x C H 3 - C H 2 - 0 and 0 - C H 2 - ( C ) 5 - N ) , 
5.16 ppm (s, 1H, pyridine-H*), 6.75-6.84 ppm (m, 2H, 2x phenyl-H), 7.02-7.17 ppm (m, 
2H, 2x phenyl-H), 8.25 ppm (bs, 1H, pyridine-NH). 
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C h a p t e r 7 
S y n t h e s i s a n d in v i t r o p h a r m a c o l o g y of a s er i e s of h y b r i d 
m o l e c u l e s p o s s e s s i n g 1 , 4 - d i h y d r o p y r i d i n e c a l c i u m c h a n n e l b l o c k i n g 
ac t iv i ty a n d h i s t a m i n e H 2 - a g o n i s t i c p r o p e r t i e s 
1 Introduction 
The 1,4-dihydropyridine-type Ca 2 + - channe l blockers (DHPs) have allowed a new 
direction in therapy of several cardiovascular disorders. Several D H P Ca 2 + - channe l 
blockers are now well established in antianginal and antihypertensive therapy, as 
well as in the treatment of certain cardiac arrhythmias and peripheral vascular 
d i so rders 1 ' 2 ' 3 ' 4 * 5 . DHPs cause vasodilation by inhibiting the influx of extracellular 
C a 2 + into the cell through slow calcium channels , but also decrease ventricular 
contractility by the same mechanism. Although nifedipine 1 and nicardipine 2 are 
widely used clinically, the rather short duration of action of this type of drugs is 
disadvantageous. Examples of the second generation DHPs, such as amlodipine 6 3 
and t iamdipine 7 4 , offer a different pharmacokinetic profile: longer plasma half-life 
and 100% oral availabil i ty. These pharmacokinet ic propert ies apparently are 
responsible for longer durat ion of action and the maintenance of a sustained 
antihypertensive effect by once-a-day administration 8 . 
One of the mechanisms control l ing myocardial contractil i ty proceeds via the 
sympathetic nervous system. In congestive heart failure (CHF) the myocardial 
inot ropic contrac t i l i ty is d is turbed due to increased levels of c i rculat ing 
catecholamines, initiated by the sympathetic nervous system. Prolonged exposure of 
the heart to excessive levels of endogenous catecholamines, in turn, results in a 
decreased number and sensitivity of myocardial (3 r adrenoceptors 9 . 
Al though the heart becomes less sensitive to catecholamine st imulation, other 
mechanisms are able to increase cardiac contractil i ty. One of the mechanisms 
proceeds via histamine H 2 - receptors . Stimulation of the myocardial histamine H 2 -
receptor activates an adenylate cyclase system which, analogous to stimulation of the 
p a d r e n o c e p t o r adenylate cyclase system, results in stimulation of myocardial 
contracti l i ty 1 0 . The histamine H 2 -agonist impromidine 5 is 48 times more potent than 
the natural agonist his tamine 6 on the spontaneously beating guinea pig right 
a t r i um 1 1 . In human papillary muscle impromidine appears to be equally effective as 
the p r a g o n i s t isoproterenol in stimulating the myocardial adenylate cyclase sys tem 1 2 . 
Baumann et a l . 1 3 have demonstrated that in vivo impromidine exhibits a positive 
inotropic effect in humans, resulting in an increased cardiac output. Simultaneously, a 
decrease in both systemic arterial blood pressure and vascular resistance is induced, 
while the heart rate remains constant. Unfortunately, impromidine is a potent 
stimulator of gastric acid secretion and like other cardiac stimulants may cause 
arrhythmias. More recently, new histamine H 2 -agonists have been developed, which 
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seem to have a more beneficial hemodynamic profile and being less arrhythmogenic 
than impromidine 1 4 . 
1 nifedipine 2 nicardipine 
3 amlodipine 4 tiamdipine 
Figure 1: 1,4-Dihydropyridine-type calcium channel blockers 
The imidazolylpropylguanidine structure of impromidine is believed to be responsible 
for the histamine H 2 -agonistic activity, while the methylimidazole group contributes 
affinity. This concept is confirmed by Sterk et al. (VUF 8 4 0 5 1 5 7; V U F 8 4 0 1 1 6 8) and 
Buschaue r 1 7 (arpromidine 9; BU-E-76 10), by replacing the methylimidazole group 
by lipophilic mono or diaryl structural moieties and/or heterocycles , affording 
compounds which are more potent than impromidine and have less stimulatory 
effects on gastric acid secretion. Arpromidine and BU-E-76 are guanidine type 
histamine H 2 -agonists with additional histamine H r an tagon is t i c properties due to the 
pharmacophoric moiety resembling pheniramine-like histamine H r a n t a g o n i s t s . In 
vivo, in guinea pigs, BU-E-76 is more potent in reducing cardiac pre- and afterload 
and enhancing cardiac output and stroke volume, than arpromidine or impromidine. 
Furthermore, BU-E-76 and arpromidine affect the chronotropy and cardiac rhythm 
less than impromidine. Therefore, BU-E-76 might be suitable for the treatment of 
patients suffering from severe heart failure 1 8 . 
Combination of positive inotropic and vasodilator effects into one drug might be 
beneficial in the treatment of congestive heart failure, if the improved cardiac 
performance is achieved independently from the p r adrenerg ic sys tem 1 9 . 
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5 Impromidine 
R2 
9 Arpromidine R 1 = F, R 2 = H 
10 BU-E-76 R t = H, R 2 = F 
Figure 2: Histamine H 2 -agonists 
The goal of our project was to design DHPs which retain calcium channel blocking 
activity and, in addition, possess cardiotonic activity to compensate for negative 
inotropic actions associated with DHP calcium channel blockers. Such dual activities 
in a single molecule might offer some novel and attractive research tools. Our 
objective might be reached by combining in one molecule a 1,4-DHP, which 
possesses a vasodilator property and a negative inotropic action, with a histamine H 2 -
agonist having a positive inotropic activity. Th£ structural modifications carried out 
on impromidine demonstrate than a certain tolerance exists about replacing the 
methylimidazole by lipophilic H 2 -nonspecific structures [for reviews see 14,20,21,22] 
Because of this tolerance, we decided to replace the H 2-nonspecific structural moiety 
by 1,4-dihydropyridines, introducing potential vasodilating properties. 
Based on our previous resul ts regarding the activity of thio-bioisosteres of 
amlodipine (Chapter 5; this thesis), we decided to synthesize several types of hybrid-
molecules (A and B; figure 3) by combining histamine H 2 -agonists and 1,4-dihydro-
pyridine-type calcium channel blockers, following an idea proposed by Schickaneder 
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et a l . 2 3 (type C; figure 3). In type A hybrid-molecules the histamine H 2 -agonistic part 
is coupled via an alkylthiomethyl chain to the 2-position of the DHP. In type B 
hybrid-molecules the histamine H 2 -agonistic part is coupled via an alkoxy chain to 
the 4-phenyl ring of the DHP. In type C hybrid molecules the histamine H 2 -agonistic 
moiety is coupled via an ester to the 1,4-DHP (Schickaneder et a l . 2 3 ) . 
H 
Figure 3: Hybrid molecules combining calcium channel blocking activity and 
histamine H 2 -agonistic activity 
Hybrid molecules of type A seem to be the most promising hybrid molecules as they 
combine a histamine H 2 -agonis t ic activity with calcium channel blockers of the 
second generat ion. Amlodipine 3 and tiamdipine 4 are examples of the second 
generation calcium channel blockers, having a longer-duration of action than first 
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generation calcium channel blockers, such as nifedipine 1. Especially because type A 
hybrid molecules incorporate the tiamdipine structural moiety, these hybrid molecules 
could offer a more beneficial pharmacokinetic profile than type C hybrid molecules. 
2 Chemis t ry 
The general synthetic routes of type A and B hybrid molecules are given in schemes 1 
and 2. The syntheses of the primary amines 1 1 a are carried out as previously 
described (Chapter 5; this thesis). According to scheme 1, the appropriate primary 
amine 11a is treated with diphenyl N-cyanocarbonimidate 12 in diethyl ether or 
methylenechloride to afford the N-cyanoisoureas 13 . Subsequent reaction of the N-
c y a n o i s o u r e a s 1 3 with 3 - ( l H - i m i d a z o l - 4 - y l ) p r o p y l a m i n e 14 gives the N-
cyanoguanidines 15 in only poor yields (10-22%). Acid hydrolysis with 1 M HC1 to 
obtain the guanidines 16 fails because of hydrolysis of the thioether function and/or 
ester functions of the 1,4-dihydropyridines. Therefore, we have developed a new 
synthetic approach to achieve the proposed hybrid molecules. 
Scheme 1 
The synthetic route in scheme 2 appears to be more convenient to obtain the 
guanidines 1 6 . The diethyl 2 , 6 - d i m e t h y l - 4 - [ 2 - ( c o - a m i n o a l k o x y ) p h e n y l ] - l , 4 -
dihydropyr idine-3,5-dicarboxylates l i b used as D H P building blocks in type B 
hybrid-molecules are synthesized according to the previously described procedure 
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(Chapter 6; this thesis). Reaction of the appropriate primary amines 11a or l i b with 
benzoyl i so th iocyana te 17 provides the benzoyl iso th iourea der ivat ives 1 8 . 
Subsequent alkal ine hydrolysis of the benzoyl thiourea der ivat ives and direct 
alkylat ion with ethyl bromide , without isolat ion of 1 9 , give the isothiourea 
hydrobromides 20 . Condensation of 20 with 3-( l / / - imidazol-4-yl)propylamine 14 
gives the guanidines 16. 
Scheme 2 
3 Pha rmaco logy 
3.1 In vitro calcium channel blocking activities and P H P receptor binding assay 
In vitro calcium channel blocking activities and radioligand binding studies were 
carried out as previously described (Chapter 5; this thesis). In this method calcium 
channel blocking activities are determined on t a t aorta strips and are assessed as the 
concentration required to inhibit the K + -depolarization induced (50 mM) contractile 
responses by 50%. 
The DHP receptor affinities are determined on isolated rat cortex by [ 3H]nitrendipine 
displacement s tud ies 2 4 . The equilibrium dissociation constant ( K d = 0.75 nM) of the 
labelled compound and the maximal binding ( B m a x = 270 fmol/mg protein) are 
determined with the non-linear fitting program LIGAND 4 . 1 2 5 . 
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3.2 In vitro histamine Ho-agonistic activities 
Male guinea pigs ( 300-350 g) are killed by a blow on the head. The spontaneously 
beating right atria are removed, attached to a tissue holder (load 0.5g) connected to 
Grass 79D isometric equipment, placed in a 20 ml organ bath with Krebs buffer and 
bubbled with oxygen containing 5 % CO2 at 37 °C. The bath fluid contains 117.5 
m M NaCl, 5.6 m M KC1,1.18 m M M g S 0 4 , 2.5 m M CaCl 2 ,1 .28 m M N a H 2 P 0 4 , 2 . 5 mM 
NaHCC>3 and 5.5 m M glucose, giving a pH of 7.4. The inotropy is measured on the 
isolated guinea pig papillary muscle and is also performed on a Grass 79D isometric 
apparatus (load 0.5 g), using the same Krebs buffer as described for the determination 
of the chronotropic actions. The papillary muscle is electrically stimulated with a 
squarewave stimulator with a frequency of 3 Hz and a duration of 0.5 ms. 
3.3 In vitro histamine H 2 -receptor affinity measured bv radioligand displacement 
Male guinea pigs ( 300-350 g) are killed by a blow on the head. The cerebral cortices 
are isolated and put into 10 ml sodium phosphate buffer (50 mM, pH 7.4). The 
cortices are cooled on ice and homogenized with a polytron (two times during 15 
seconds at 8000 rpm). The homogenate is centrifuged for 1 minute at 260 g. The 
supernatant is removed and centrifugated for 30 minutes at 20,000 g. The pellets are 
resuspended in 3 ml sodium phosphate buffer (50 m M pH 7.4) for each cortex. The 
protein concentration is determined by addition of 20 pi membrane suspension to 1 
ml Merck-Biorad reagens (5 t imes diluted with nanopure water) . Absorption is 
determined at 595 nm. The protein concentration is determined with bovine serum 
albumin as standard. The concentration of the membrane suspension is adjusted to 1 
mg/ml and the suspension is kept at -80°C until usage. 
The incubations are performed in polypropylene tubes during 2 hours at 25°C. 
Incubations are carried out with 100 (ig protein and with a 0.4 nM concentration of 
[ 1 2 5 I ] i o d o a m i n o p o t e n t i d i n e (synthesized according to l i t e r a tu re 2 6 ) with a total 
volume of 400 p i . As incubation medium, a sodium phosphate buffer (50 mM, p H 7.4) 
with 1% bovine gelatine (final concentration) is added in order to prevent absorption 
of [ 1 2 5 I] iodoaminopotentidine. The incubation is stopped by addition of 4 ml ice-cold 
buffer (sodium phosphate buffer 20 mM, containing 0 . 1 % bovine serum albumin to 
prevent filter binding). The membranes are filtered through Whatman GF/B filters, 
which are soaked for 3 hours in a 0 . 3 % polyethyleneimine solution in sodium 
phosphate buffer (50 mM, p H = 7.4), and washed twice with 4 ml ice-cold buffer 
using a Brandel filtration apparatus. The filters are isolated and the radioactivity is 
determined with a LKB Wallace 1282 compugamma S universal gamma counter at an 
efficiency of approximately 60%. 
Non-specific binding is determined in presence of 10 | iM ranitidine. Specific binding 
is obtained by subtracting the non-specific binding from the total binding. The 
equilibrium dissociation constant ( K d = 0.23 nM) of the labelled compound and the 
maximal binding ( B m a x = 83 fmol/mg protein) are determined with the non-linear 
fitting program LIGAND 4 . 1 2 5 . 
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4 Results a n d Discussion 
In vitro calcium channel blocking activities are assessed as the concentration required 
to inhibit the K + -depolarizat ion induced (50 mM) contractile responses in rat aorta 
strips by 5 0 % , and are expressed as p I C 5 0 values. All compounds are tested as 
racemic mixtures and display a complete inhibition of contractile responses as is 
verified by addition of 1 m M papaverine. As reported in chapter 5 (this thesis), the 
onset of calcium channel blocking activity of V U F 9159 (table I) and its analogues 
occurs slowly and does not reach equilibrium within 1 hour. Additional increasing 
doses of the 1,4-DHP derivatives to generate dose-response curves are given every 
45 minutes , so no comple te equi l ibr ium was reached, which could lead to 
underestimated values for the calcium channel blocking activities. 
4.1 Calcium channel blocking activities and affinities of type A hybrid molecules 
In table I, the calcium channel blocking activities and affinities of the tiamdipine 
analogues are shown. The calcium channel blocking activity of t iamdipine is not 
presented in table I because the pharmacological data reported by Kwon et a l . 8 are 
determined on a different tissue (rat tail artery). 
Table I: Calcium blocking activities and affinities of a series of tiamdipine analogues 
H 
compound Z m P I C 5 0 # pKd* 
VUF 9056 H 2 7.27 ± 0.08 8.57 ± 0 . 1 0 
VUF 9158 2,3-diCI 2 7.47 ± 0.03 8.37 ± 0 . 1 0 
VUF 9055 3 - N 0 2 2 7.96 ± 0.07 8.61 ± 0.06 
VUF 9108 3 - N 0 2 3 7.82-± 0.04 8.43 ± 0.05 
VUF 9159 3 - N 0 2 5 7.96 ± 0 . 1 2 8.55 ± 0.08 
VUF 4731 3 - N 0 2 6 7.85 ± 0.02 8.41 ± 0 . 1 5 
1 nifedipine 8.77 ± 0.08 8.70 ± 0 . 1 4 
# All pICso values are means ± s.d. for 3 independent observations, determined on rat aorta 
strips 
$ All affinities (pKd) were determined on isolated rat cortex membranes, and are means ± s.d. 
for 6 to 9 independent observations. 
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As reported previously in chapter 5 (this thesis), 1,4-DHPs with a nitro substituent on 
the 4-phenyl ring are more potent than those compounds possessing a 2,3-dichloro 
substituent (VUF 9158; table I) or no substituent at all (VUF 9056; table I). Increasing 
the length of the 2-(co-aminoalkylthio)methyl side chain on the 2-position on the 1,4-
D H P ring from an ethyl chain to a hexyl chain does not affect calcium channel 
blocking activity. 
Affinities of the t iamdipine analogues ( p K d ) determined by d isplacement of 
[ 3 H]nitrendipine from rat cortex membranes differ from the pICso values possibly 
because of underest imated calcium channel blocking activities. Although tissue 
specificity cannot be ruled out, the established p K d value of nifedipine is in good 
correlation with its p I C 5 0 value. 
In table II, the calcium channel blocking activities and affinities of a series of type A 
hybrid molecules, containing a histamine H 2 -agonist ic structural moiety, are given. 
Within both series of type A hybrid molecules and 2-(co-aminoalkylthio)methyl-l,4-
DHPs, the 1,4-DHP derivatives without a substituent in the phenyl ring (VUF 4752; 
table II and V U F 9056; table I, respectively) are the least active calcium channel 
blockers. The 2-(co-aminoalkylthio)methyl-1,4-DHP derivative with a hexyl chain 
(VUF 4731 ; table I) is equally potent as the DHP derivatives with an ethyl, propyl, 
and pentyl chain (table I), while in the series of type A hybrid molecules V U F 4575 
(table II), with a hexyl chain, is the most potent calcium channel blocker (functional 
studies). The affinity of the original 1,4-DHP derivative VUF 4731 is similar to that of 
the type A hybrid molecule V U F 4575. 
Comparing the activities of the hybrid molecules of table II with the original DHPs of 
table I, it is striking that all hybrid molecules are less potent than the 2-(co-
aminoa lky l th io )me thy l - l , 4 -DHPs . However , the difference in potency varies 
remarkably among the original 1,4-DHPs of table I and the type A hybrid molecules 
(table II). V U F 9055 is a 45 times more potent calcium channel blocker in functional 
studies than V U F 9065, while V U F 9158 is only approximately 4 times more potent 
than VUF 9160, as is demonstrated in table III. This big difference in potency is not 
shared by the affinities established in radioligand binding studies; in these tests VUF 
9056 is 8 times more potent than V U F 4572, while V U F 4731 is equally potent as 
VUF 4575. 
A remarkable phenomenon is observed among the 4-(3-ni t rophenyl)-1 ,4-DHP 
derivatives. Increasing the alkyl chain length from an ethyl chain to a hexyl chain 
results in a decrease of the difference between calcium channel blocking activity of 
the 2-(co-aminoalkylthio)methyl-1,4-DHPs and the hybrid molecules. The differences 
between the affinities nearly remain the same. Obviously, the underestimation of the 
activities differ among the several 1,4-DHPs. 
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histamine H 2 -agonism Ca 2 + -entry blocking activity 
functional binding functional binding 
VUF Z m p E C 5 0 a > i.a. P K d b) P I C 5 0 C ) pK d d> 
4 5 7 2 H 2 nma - 6.19 ± 0 . 2 3 6.26 ± 0.03 7.67 ± 0.05 
9 1 6 0 2,3-diCI 2 nma - 5.51 ± 0.04 6.85 ± 0.07 7.97 ± 0.04 
9 0 6 5 3 - N 0 2 2 nma - 5.82 ± 0.29 6.30 ± 0.07 8.46 ± 0.03 
4 5 7 0 3 - N 0 2 3 nma - 5.77 ± 0.05 6.37 ± 0.02 8 . 1 5 ± 0 . 1 0 
4 5 7 3 3 - N 0 2 5 6.28 ± 0 . 1 3 0.6 5.93 ± 0.09 6.54 ± 0.06 8.07 ± 0.07 
4 5 7 5 3 - N 0 2 6 6.38 ± 0 . 1 4 0.9 6.04 ± 0.02 7.16 ± 0 . 0 5 8.39 ± 0 . 1 0 
histamine 6.06 ± 0 . 1 3 1.0 4.64 ± 0.35 
impromidine 7.63 ± 0.06 1.0 6.97 ± 0 . 0 7 
ranitidine * - - 7.12 ± 0.11 
iodoaminopotentidine * - - 9.52 ± 0.03 
a) All values are means ± s.d. for 3 to 50 independent observations, determined on 
isolated spontaneously beating guinea pig right atrium 
b) All values are means ± s.d. for 3 to 6 independent observations. All affinities (pK d) 
were determined on isolated guinea pig cortex membranes, [ 1 2 5I]iodoaminopotentidine 
was used as hot ligand 
c) All values are means ± s.d. for 3 to 4 independent observations, determined on rat aorta 
strips 
d) All values are means ± s.d. for 5 to 9 independent observations. All affinities (pK^) 
were determined on isolated rat cortex membranes, [3H]nitrendipine was used as hot 
ligand. 
nma No measurable activity due to negative inotropic activity of the DHPs 
i.a Intrinsic activity relative to histamine 
* Histamine H2-antagonist 
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Table III: Relative calcium channel blocking potencies (CCB) and affinities (CC-A) 
of the DHPs from table I compared with the corresponding hybrid 
molecules of table II 
DHP / hybrid CCB rel. act. CC-A rel. aff. 
VUF 9056 / VUF 4572 10 8 
VUF 9158 /VUF 9160 4 2.5 
VUF 9055 / VUF 9065 45 1.4 
VUF 9 1 0 8 / V U F 4570 2 8 1.9 
VUF 9 1 5 9 / V U F 4573 26 3 
VUF 4731 / VUF 4575 4.9 1 
CCB rel. act. Relative calcium channel blocking activity of a 
DHP from table I over the corresponding hybrid molecule 
CC-A rel. aff. Relative affinity of a DHP from table I over the corresponding 
hybrid molecule 
4.2 Histamine H 2 -agonistic activity and H 2 -receptor affinity of type A hybrid 
molecules 
In table II the histamine H 2 -agonis t ic activities and affinities of type A hybrid 
molecu les and some h is tamine H 2 - agon i s t s and H 2 - a n t a g o n i s t s are shown. 
Remarkable in table II is that some hybrid molecules do not display any activity, 
which can be explained as follows. Concentration-response curves (CR-curves) of 
type A hybrid derivatives on isolated spontaneously beating guinea pig right atria 
reveal an abnormal pattern. Normally, histamine H 2 -agonists show a concentration-
dependent increase in heart rate (positive chronotropy) of the isolated guinea pig 
right atria. However, the positive chronotropic activity could not always be detected 
because of an occurring negative inotropic and chronotropic effect, which seem to 
produce a complete standstill of spontaneously beating right atria. The negative 
inotropic and chronotropic effects occurring with CR-curves of the hybrid molecules 
are due to the 1,4-DHP structural moiety. It is known that 1,4-DHPs exert a negative 
inotropic and chronotropic action, as is shown in table IV. The heart rate of some the 
right atria could be partially restored by noradrenaline or histamine stimulation, but 
this was only of a temporary nature. 
Table IV: Nega t ive inot ropic and chronot ropic act ivi t ies of n i fedipine and 
nisoldipine, determined on guinea pig papillary muscle and guinea pig right 
atrium, respectively (calculated from E C 5 0 values from Kazda et a l . 2 7 ) 
nifedipine 1 nisoidipine 
negative inotropy; p E C 5 0 7.35 ± 0.35 7.30 ± 0.21 
negative chronotropy; p E C 5 0 7.66 ± 0.24 7.19 ± 0.43 
Nisoldipine has a sec-butyl ester at the 3-position on the 1,4-DHP ring instead of a 
methyl ester, as in nifedipine 
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By increasing the alkyl chain length of the type A hybrid molecules, carrying a 3-
nitrophenyl substituent on the 4-position on the 1,4-DHP ring, one gets molecules 
which show a chronotropic activity exhibited by the his tamine H 2 - a g o n i s t i c 
structural moiety (table II). Obviously, the his tamine H 2 -agonis t i c effects can 
overcome the effects exerted by the 1,4-DHP calcium channel blockers. Although 
V U F 4573 and V U F 4575 have a higher chronotropic activity than histamine, it 
remains unclear whether the histaminergic effects are increased or that the negative 
inotropic and chronotropic effects of the 1,4-DHP structural moiety are decreased. 
Comparison of the histamine H 2 -agonistic activities of the type A hybrid molecules 
with impromidine shows that V U F 4573 and V U F 4575 are moderate histamine H 2 -
agonists. Although V U F 4573 and VUF 4575 have an intrinsic activity relative to 
histamine of 0.6 and 0.9, respectively, this does not necessarily indicate that these 
two compounds are partial agonists as was verified by addition of 1 0 5 M histamine at 
the end of the CR-curves of V U F 4573 and V U F 4575, which did not lead to the 
initial maximal contractile force produced in control experiments. 
V U F 4573 was also pharmacologically tested on the guinea pig left atrium (used in 
pharmacological studies to demonstrate histamine Hi-activity), but was devoid of any 
effect, demonstrating that V U F 4573 has no histamine H r ac t i v i t y . 
In figure 4 the CR-curves of nifedipine, histamine and of a 1/1 molar mixture of 
nifedipine/histamine are shown. Addition of 10~6 M isoprenaline is unable to restore 
any response at the end of the CR-curve of nifedipine. 
Figure 4: Inotropic activity of histamine (HA), nifedipine (nif), and a 1/1 molar 
mixture of histamine/nifedipine on the electrically stimulated guinea pig 
papillary muscle 
100 i 
50 -
inotropic 
activity (%) 
o -
histamine 
nifedipine 
HA/nif 1/1 
•0. 
•ft 
-50-
-100 
-9 -8 -7 -6 - 5 -4 
log c o n e [M] 
174 
Chapter 7 
Figure 4 nicely demonstrates the idea behind hybrid molecules. Whi le nifedipine 
affects inotropic activity at much lower concentrations than histamine, a 1/1 molar 
mixture of nifedipine/histamine has no overall effect on inotropic activity. Thus 
combination of the two compounds in a 1/1 molar ratio, to mimic the fixed 1/1 molar 
ratio in hybrid molecules, does not simply result in summing up of the two distinct 
CR-curves. 
Inotropic activities of the histamine H 2-agonistic activities of type A hybrid molecules 
are also measured on the electrically stimulated guinea pig papillary muscle. As 
already discussed in the section on chronotropic activity, the negat ive inotropic 
activity of the 1,4-DHP structural moiety hinders the determination of the positive 
inotropic actions exhibited by the histamine H 2 -agonistic structural moiety. 
In table V, the positive inotropic activities of type A hybrid molecules are shown. 
Determination of the positive inotropic activity was only possible for V U F 4573 (VUF 
4575 was not tested). The explanation of the poor intrinsic activity of V U F 4573 
relative to histamine is the same as was discussed for the poor intrinsic activities in the 
section of chronotropic studies. When the CR-curve of V U F 4573 is determined in 
presence of 1 | i M cimetidine (a histamine H 2 -antagonist; p A 2 = 6.1), the CR-curve is 
shifted to the right (higher concentration), confirming that the exhibited effect is a 
histamine H 2-effect. 
By adjusting the experimental procedure, it is possible to avoid the problems 
exhibited by the DHP structural moiety. At the beginning of each CR-curve, 1 | iM 
Bay k 8644 (a DHP-type calcium channel activator) is added. Bay k 8644 has a 
positive inotropic and chronotropic activity, thus the initial contractile force and beat 
frequency is increased. At the same time the effects originating from the DHP 
structural moiety of the hybrid molecules are suppressed by Bay k 8644. So, by 
neutralizing the calcium blocking effect, it is possible to determine the inotropic 
activities of a number of type A hybrid molecules. 
Table V demonstrates that the most active type A hybrid molecules, V U F 4573 and 
V U F 4575, are both full agonists as they have about the same intrinsic activity as 
his tamine and impromidine . The inotropic activities (as pECso) of the hybrid 
molecules are lower than that of histamine or impromidine. V U F 4573 exhibits a 
positive inotropic activity with or without Bay k 8644. It seems that the alkyl chain 
length reaches a point where the overall inotropic activity is positive of nature. VUF 
4573 and V U F 4575 are equally active in the pharmacological assay in which Bay k 
8644 is administered. s 
Although it is tenable to assume that the increased inotropic activity of histamine in 
presence of Bay k 8644 might be explained by an improved availabili ty of 
intracellular calcium for the contractile process, this property is not observed for 
impromidine (table V). 
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Table V: Histamine H 2 -agonistic activités on the electrically stimulated guinea pig 
papillary muscle (inotropic activity) 
VUF Z m P E C 5 0 i.a. 
in presence of 
1 nM Bay k 8644 
p E C 5 0 # i.a.# 
4 5 7 2 H 2 nt 5.73 ± 0.30 1.0 
9 1 6 0 2,3-diCI 2 nt - < 5 
9 0 6 5 3 - N 0 2 2 nma - nma 
4 5 7 0 3 - N 0 2 3 nma - 5.25 1.0 
4 5 7 3 3 - N 0 2 5 5.95 0.3 6.15 + 0.18 1.0 
4 5 7 5 3 - N 0 2 6 NT. - 6 . 1 6 ± 0 . 1 3 1.0 
histamine 6.17 + 0.03 1.0 6.65 + 0.20 1.0 
impromidine 7.24 0.95 7.32 1.0 
PEC50 Concentration required to produce 50% of its maximal effect, all values are means ± 
s.d. for 3 to 20 independent observations 
# Data obtained in presence of lpM Bay k 8644 (a calcium channel activator) in order 
to neutralize the calcium channel blocking activities of the DHP structural moieties 
nt Not tested 
nma No measurable activity at 10~5 M 
i.a. Intrinsic activity relative to histamine 
4.3 Calcium channel blocking activities and affinities of type B hybrid molecules 
In table VI the calcium channel blocking activities and affinities of a number of 
diethyl 2,6-dimethyl-4-[2-(co-subst i tuted-alkoxy)phenyl]- l ,4-dihydropyridine-3,5-
dicarboxylate derivatives are shown. In this series of compounds a remarkable 
tolerance exists upon subst i tut ion pattern wi thout affecting ca lc ium channel 
blocking activity. Only the hybrid molecules V U F 4612 and V U F 4730, having a 
h i s tamine H 2 -agonis t i c structural moiety, are less active than the non hybrid 
molecules (table VI). It is not illogical to assume that the lower calcium channel 
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blocking activities are caused by the histamine H 2 -agonist ic activity. However, this 
assumption is in contrast with the findings of Tenner et a l . 2 8 , who have investigated 
the influence of histamine H 2 -agonists on rabbit aorta strips. In rabbit aortic strips 
contracted by 60 m M KC1, no significant relaxation is produced by histamine or the 
histamine H 2 -agonists impromidine and dimaprit. This is confirmed in our experiments 
in which impromidine did not affect the KCl-induced contractions in rat aorta strips 
(data not shown). The affinities of the hybrid molecules V U F 4612 and V U F 4730 are 
equally potent as the affinities of the non hybrid molecules (table VI), indicating that 
the his tamine H 2 -agonis t ic structural moiety does not affect the conformation 
adopted by the DHP structure to bind to its receptor. W e do not have an explanation 
for the differences in the observed in vitro calcium channel blocking activities 
(functional studies) and the affinities (radioligand binding studies) of V U F 4612 and 
VUF 4730. 
Table VI: Calcium channel blocking activities (pICso) and affinities (pIQ) of a series 
of diethyl 2,6-dimethyl-4-[2-(co-substituted-alkoxy)phenyl]-l,4-dihydro-
pyridine-3,5-dicarboxylates 
H5C2OOC 
H3C 
0-(CH 2) m-R 
COOC2H5 
m = 5 m = 6 
R 
* * 
compound pICso p K / compound pICso* p K / 
NH 2 
NHC(S)NH2 
NHC(NH)SEt 
ipg 
VUF 4587 6.61 +0 .08 6.83 + 0.08 
VUF 4622 6.44 ± 0 . 1 3 7.00 ±0 .07 
VUF 4623 6.31 ± 0 . 1 0 7.27 ±0 .15 
VUF 4612 5.58 ± 0 . 1 6 7.52 ±0 .11 
nifedipine 8.77 ± 0 . 0 8 8.70 ±0 .14 
VUF 4599 6.42 + 0.04 7.02 ±0 .05 
VUF 4671 6.39 ± 0 . 0 9 7.09 ± 0 . 0 9 
VUF 4624 6.34 ±0 .11 7.70 ±0 .11 
VUF 4730 5.39 ±0 .11 7.42 ±0 .17 
* All values are means ± s.d. for 3 independent observations 
# All values are means ± s.d. for 5-9 independent observations. 
All affinities (pKd) were determined on isolated rat cortex membranes 
ipg Imidazolylpropylguanidine structural moiety 
NH 
H H 
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The affinities of the compounds shown in table VI are only marginally affected by the 
nature of the substituents. Compounds with an isothiourea or a guanidino group 
have a little higher affinity than the derivatives with a thiourea or a primary amine 
function. The higher affinity of the derivatives with an isothiourea or a guanidino 
function might be ascribed to additional interaction with the binding site of the L-
type calcium channel due to an ionic interaction between the protonated isothiourea 
or guanidino group and the negatively charged phosphate group of a phospholipid. 
However, this would not explain the lower calcium channel blocking activities (pICso 
values). Although compounds with a primary amine function should obey to the 
same additional interaction described for isothiourea and guanidino functions, the 
affinities of the 1,4-DHPs with a primary amine group are as active as the derivatives 
with a thiourea function (not protonated at physiological pH). 
In table VII the calcium channel blocking activity and affinity of the hybrid molecule 
with a propyl chain (VUF 4588) demonstrates that increasing the alkyl chain length 
of the 2-(co-substituted-alkoxy)phenyl hybrid molecules from propyl to hexyl results 
in a decrease of calcium channel blocking activity, while the affinity slightly 
increases. W e have no explanation for this phenomenon. 
Table W : Histamine H 2 -agonis t ic activity (chronotropic activity), calcium channel 
blocking activities and affinities of a series of type B hybrid structures 
histamine H2-agonism 
functional binding 
Ca 2 + -entry blocking activity 
functional binding 
VUF m p E C 5 0 a> i.a. pKd b> p l C 5 0 c> pKc b) 
4 5 8 8 3 na - 5.76 ± 0 . 1 5 5.88 ± 0 . 1 4 7.03 ± 0 . 1 4 
4 6 1 2 5 na - 5.96 ± 0.22 5.58 ± 0 . 1 6 7.52 ± 0 . 1 1 
4730 6 6.20 ± 0.06 0.75 6.69 ± 0 . 1 5 5.39 ±0 .11 7.42 ± 0 . 1 7 
pECso Concentration required to produce 50% of its maximal contractile effect 
pICso Concentration required to produce 50% of its inhibitory effect 
na Not active 
a) All values are means ± s.d. for 3 to 4 independent observations 
b) All values are means ± s.d. for 5 to 9 independent observations 
c) All values are means ± s.d. for 3 to 4 independent observations 
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4.4 His tamine H r a g o n i s t i c activity and H 2 - receptor affinity of type B hybrid 
molecules 
The only type B hybrid molecule having a positive chronotropic activity is V U F 
4730, possessing a hexyl chain. The hybrid molecules with a propyl or a pentyl chain 
show no activity (table VII). However, all three type B hybrid molecules do have an 
affinity for the histamine H r r e c e p t o r . The inactivity of V U F 4588 and V U F 4612 is 
most likely due to the calcium channel blocking activity of the hybrid molecule. 
Increasing the alkyl chain length, from a propyl to a hexyl chain, decreases calcium 
channel blocking activity, while increasing histamine H 2-agonistic activity. 
V U F 4730 is also the only type B hybrid molecule having a positive inotropic action. 
The inotropic activities of V U F 4588 and VUF 4612 are not determined in absence of 
1 p M Bay k 8644 because they already did not demonstrate any activity in the 
pharmacological system, which contained Bay k 8644 (table VIII). 
Table VIII: His tamine H 2 -agonis t ic activity (inotropic activity) of type B hybrid 
molecules on the electrically stimulated guinea pig papillary muscle 
VUF QD2 i.a. p E C 5 0 * i.a. 
4 5 8 8 not tes ted - not active 
4612 not tes ted - not active 
4 7 3 0 5.63 + 0.23 1.0 5.86 ± 0 . 0 5 1.0 
* In presence of 1 pM Bay k 8644, in order to neutralize the negative inotropic activities of 
the DHP structural moieties, all number of experiments = 2 
There is no statistical difference in inotropic activities of V U F 4730 in absence or 
presence of the calcium channel activator Bay k 8644. 
In the series of t iamdipine analogues it has been shown that increasing the alkyl 
chain length on the 2-position on the 1,4-DHP ring from ethyl to hexyl only 
marginally affects the potent calcium channel blocking activities and affinities. 
In the series of type A hybrid molecules the affinities for the D H P binding site are 
almost equal to the affinities of the tiamdipine analogues. However , the in vitro 
calcium channel blocking activities of type A hybrid molecules are lower than those 
of the tiamdipine analogues. The decrease in calcium channel blocking activity must 
be ascribed to the unfavourable bulky structural moiety and not to any histamine H 2 -
effect. By increasing the alkyl chain length from ethyl to hexyl in type A hybrid 
molecules, the calcium channel blocking activities increases. The increased flexibility 
of the hybrid molecule with an extended alkyl chain makes it possible for the DHP 
structure to adopt a conformation which allows the DHP structural moiety to interact 
with the D H P binding site. At the same time, increasing the alkyl chain length of type 
A hybrid molecules leads to an overall moderate positive chronotropic and inotropic 
activity. 
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The histamine H 2 chronotropic and inotropic activities of type A hybrid molecules 
with an ethyl chain length cannot be determined because of the negative inotropic 
and chronotropic effects exhibited by the DHP structural moiety. This complicated 
attribution on overall inotropic activity makes it impossible to verify the contribution 
of phenyl r ing subs t i tuents , as descr ibed by Rodenki rchen et a l . 2 9 . They 
demonstrated that in a series of nifedipine analogues, the negative inotropic activity 
on cat papillary muscle mainly depends on steric and lipophilic substituent properties 
for aryl derivatives and/or on the steric nature of the ester substituents. Bulky ester 
substituents decrease the negative inotropic activities in cat papillary muscle. In 
general the negat ive inotropic activity of phenyl substituted D H P derivatives 
decrease in the order of ortho > meta > para substitution. These structure-activity 
relationship studies are confirmed by Boyd et a l . 3 0 , who used rabbit papillary muscle. 
The in vitro and in vivo pharmacology of a series of felodipine (ethyl methyl 4-(2,3-
dichlorophenyl)-2,6-dimethyl-l,4-dihydropyridine-3,5-dicarboxylate) analogues with 
different ester groups in 3 - and 5-position on the DHP ring have been evaluated on 
rat papillary muscle and portal vein, leading to the conclusion that the DHP effector 
site in vascular smooth muscle must be structurally different from the DHP effector 
site in cardiac t i ssue 3 1 . 
Type B hybrid molecules have much lower calcium channel blocking activities than 
type A hybrid molecules. The explanation of the lower calcium channel blocking 
activities can be reduced to the discussion on the structure activity relationship of the 
tiamdipine analogues from table I and the 4-(co-substituted-alkoxy)phenyl DHPs from 
table VI. In general, calcium channel blocking activity decreases for 4-(substituted-
phenyl) - l ,4-DHPs in the order of ortho > meta > para substitution, and this effect 
becomes more pronounced when the substituent becomes bulkier. This might explain 
the reduction of calcium channel blocking activity of type B hybrid molecules with 
increasing alkyl substituents on the 4-phenyl ring, although this is not confirmed by 
the radioligand binding studies. 
In a patent concerning a series of type C hybrid molecules, Schickaneder et a l . 2 4 have 
claimed that the compound with a hexyl chain, a methyl ester, and a 3-nitro 
substituent on the 4-phenyl, is a potent histamine H 2 -agonist ( p D 2 = 7.4) and calcium 
channel blocker ( p A 2 = 7.0). Unfortunately, no pharmacological methods are 
described, making it impossible to compare the activities of type C hybrid molecules 
with those of type A and B hybrid molecules. Furthermore, it is not clear whether the 
authors of type C hybrid molecules have encountered the same problems in 
determining the individual actions of the two pliarmacophoric groups. 
5 Conclus ion 
Of the proposed type A and B hybrid molecules combining histamine H 2 -agonis t ic 
properties and calcium channel blocking activities, the type A hybrid molecule VUF 
4575 is the most promissing compound which could provide interesting leads in the 
treatment of myocardial heart failure or some hypertensive disorders, because it 
combines good in vitro Ca 2 + -b lock ing action and an overall positive inotropic and 
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chronotropic activity in one molecule. V U F 4573 has a nearly equivalent histamine 
H2-agonistic potency as V U F 4575, but has a lower calcium channel blocking 
activity. Introduction of an imidazolylpropylguanidine structure on the 4-phenyl ring 
on the D H P structural moiety (type B hybrid molecules) affords V U F 4730 which 
exhibits both overall posi t ive chronotropic and inotropic activity, but is less 
interesting than V U F 4575 or V U F 4573 because it has a lower calcium channel 
blocking activity. 
Experimental protocols 
If indicated crude reaction products were purified by flash chromatography on 
silicagel (J.T.Baker 70242). Melting points were determined on a Mettler FP 52 with 
microscope. !H-NMR and 1 3 C-NMR-spect ra were recorded on a Bruker AC 200. The 
chemical shifts are in ppm relative to tetramethylsilane. 1 3 C - N M R - s p e c t r a were 
verified by CH-cosy NMR experiments. Mass spectra were determined on a Mat 90 
(Finnigan Mat) mass spectrometer with Fast Atom Bombardment ionisation (matrix: 
glycerol + ammonium acetate, thioglycerol or 3-ni trobenzylalcohol , Ion Tech 
saddlefield gun, 8 keV Xenon with xenon ioncurrent 0.2 mA). All compounds gave 
the expec ted (M+H)+ and to a lesser extend ( M - H ) - peaks (negat ive ions) . 
Furthermore the purity of the compounds was checked by thin layer chromatography 
(Merck silica gel 60, F254 0.25 mm). 
General synthetic procedure 
Diethyl 2-[(6-aminohexyl)thiomethyl]-6~methyl-4-(3-nitrophenyl)-l^ 
pyridine-3 yS-dicarboxylate fumarate VUF 4731 
V U F 4731 was synthesized according to VUF 9159 as decribed previously in chapter 
5 (this thesis). 
Yield = 2 4 % (starting from diethyl 2-chloromethyl-6-methyl-4-(3-nitrophenyl)-l ,4-
dihydropyridine-3,5-dicarboxylate); melting point = 98.4-100.1°C. 
Mass spectrum, glycerol + ammonium acetate as matrix (FAB + ) 506 [M+H} + , ( F A B ) 
504 [M-H]". 
^ - N M R (DMSO-d 6 ) : 1.11-1.65 ppm (m, 14H, 2x C / / 3 - C H 2 - 0 and S-C-(C// 2 ) 4 -C-N), 
2.32 ppm (s, 3H, pyridine-C// 3 ) , 2.44-2.56 ppm (m, 2H, C / / 2 ) , 2.73-2.78 ppm (m, 2H, 
C / / 2 ) , 3.70 and 4.09 ppm (AB, = 13.1 Hz, 2H, pyridine-C// 2 -S), 3.98-4.05 ppm (m, 
4H, 2x C H 3 - O / 2 - 0 ) , 5.01 ppm (s, 1H, pyridine-// 4 ), 6.48 ppm (s, 2H, fumaric acid-C//), 
7.52-8.02 ppm (m, 6.5H, 4x phenyl-/ / and N / / 2 ) , 9.36 ppm (bs, 1H, pyridine-N//). 
1 3 C - N M R ( D M S O - d 6 ) : 13.73 and 13.83 ppm (q, 2x C H 3 - C H 2 - 0 ) , 18.00 ppm (q, 
pyr id ine-CH 3 ) , 25.20 and 26.74 and 27.57 and 28.87 and 29.14 and 30.85 ppm (t, S-
( C H 2 ) 6 - N ) , 38.28 ppm (t, pyr id ine-CH 2 -S) , 39.06 ppm (d, pyr id ine-C 4 ) , 59.05 and 
59.33 ppm (t, 2x C H 3 - C H 2 - 0 ) , 100.26 and 101.36 ppm (s, pyridine-C 3 and C 5 ) , 120.99 
and 121.66 and 129.30 and 133.93 ppm (d, 4x phenyl-CH [C 2 , C 4 , C 5 , C 6 ] ) , 134.98 
ppm (d, fumaric acid CH), 146.53 and 147.25 and 147.69 and 149.74 ppm (s, phenyl-
Cx and C 3 and pyr id ine-C 2 and C 6 ) , 165.92 and 166.15 ppm (s, 2x carbonyl-C) , 
167.91 ppm (s, 2x carbonyl-C fumaric acid). 
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N-benzoyl-N'-{cth[3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl~4-(substituted-
phenyl)-pyridin-2~yl]methylthio}alkylthiourea 
Under nitrogen atmosphere at 0°C 20 mmol benzoyl isothiocyanate in 150 ml 
dichloromethane was added dropwise to a solution of 20 mmol diethyl 2-(co-
aminoalkyl)thiomethyl-6-methyl-4-(substituted-phenyl)-1,4-dihydropyridine-3,5-di-
carboxylate in 150 ml dichloromethane. Stirring was continued for 2 hours while the 
temperature was raised until room temperature. The reaction mixture was evaporated 
and the residue was washed four times with 50 ml diethyl ether. 
N-benzoyl-N'-{2-[(3J-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-phenylpyridin-2-
yl)methylthio] ethyl} thiourea 
Yield = 82%; melting point = 52.8-54.1 °C. 
The product was purified by column chromatography, using petroleum ether 60-
80°C/ethyl acetate 3:2 as eluent (R f = 0.5). 
^ - N M R (CDC1 3): 1.15-1.28 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 2.39 ppm (s, 3H, pyridine-
C / / 3 ) , 2.79-2.88 ppm (m, 2H, S-C// 2 -C-N), 3.89-3.96 ppm (m, 2H, S-C-C// 2 -N) , 4.02-
4.18 ppm (m, 6H, pyridine-C// 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.02 ppm (s, 1H, pyridine-/ / 4 ) , 
6.74 ppm (s, 1H, pyridine-N//) , 7.10-7.90 ppm (m, 10H, 5x benzoyl- / / and 5x phenyl-
/ / ) , 9.03 ppm (bs, 1H, -C(S)-N//-C(0)-), 11.01 ppm (bs, 1H, S-C-C-N//-). 
N-benzoyl-N'-{2-{[4-(2J-dichlorophenyl)-3,5-diethoxycarbonyl-l ,4-dihydro-6-
methylpyridin-2-y I] methylthio} ethyl} thiourea 
Yield = 65 %; melting point = 54.5-55.6 °C. 
The product was purified by column chromatography, using petroleum ether 60-
80°C/ethyl acetate 2:1 as eluent (R f = 0.5). 
*H-NMR (CDC1 3): 1.14-1.29 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 2.37 ppm (s, 3H, pyridine-
C/ / 3 ) , 2.88 ppm (t, / = 6.7 Hz, 2H, S-C// 2 -C-N), 3.91-4.15 ppm (m, 8H, S-C-C// 2 -N and 
pyridine-C// 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.51 ppm (s, 1H, pyridine-/ / 4 ) , 6.81 ppm (s, 1H, 
pyridine-N//), 7.06-7.08 ppm (m, 1H, phenyl-//) , 7.22-8.08 ppm (m, 7H, 5x benzoyl-// 
and 2x phenyl-//), 9.06 ppm (bs, 1H, -C(S)-N//-C(0)-), 11.03 ppm (bs, 1H, S-C-C-N//-). 
N-benzoyl-N'-{2-{[3£-diethoxycarbonyl-l ,4-dihydro-6>-methyl-4-(3-nitrophenyl)-
pyridin-2-yl]methylthio}ethyl}thiourea 
Yield = 9 1 % ; melting point = 56.0-57.8 °C. 
The product was purified by column chromatography, using petroleum ether 60-
80°C/ethyl acetate 2:1 as eluent (R f = 0.3; diethyl ether as eluent). 
! H - N M R (CDC1 3): 1.17-1.30 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 2.40 ppm (s, 3H, pyridine-
C/ / 3 ) , 2.87 ppm (t, J = 7.3 Hz, 2H, S-C// 2-C-N), 3.85-4.22 ppm (m, 8H, S-C-C// 2 -N and 
pyridine-C// 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.10 ppm (s, 1H, pyridine-/ / 4 ) , 7.03 ppm (s, 1H, 
pyridine-N//) , 7.28-7.81 ppm (m, 7H, 5x benzoyl-/ / and 2x phenyl-/ /) , 8.00-8.03 ppm 
(m, 1H, phenyl-/ /) , 8.10 ppm (bs, 1H, phenyl-/ / 2 ) , 9.04 ppm (bs, 1H, -C(S)-N//-C(0)-) , 
11.03 ppm (bs, 1H, S-C-C-N//-). 
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N-benzoyl-N'-{3-{[3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-
pyridin-2-yl]methylthio} propyl) thiourea 
Yield = 6 5 % (obtained as an oil). 
The product was purified by co lumn chromatography , using ethyl acetate/ 
dichloromethane 5:1 as eluent (Rf = 0.8). 
iH-NMR (CDC1 3): 1.11-1.25 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.83-1.87 ppm (m, 2H, C-
C/ / 2 -C) , 2.25 ppm (s, 3H, pyridine-C// 3 ) , 2.47-2.54 ppm (m, 2H, S-C// 2 -C-C-N), 3.58-
3.67 ppm (m, 2H, S-C-C-GF/ 2-N), 3.82-4.15 ppm (m, 6H, pyridine-C// 2 -S and 2x CH 3 -
CH2-0\ 5.03 ppm (s, 1H, pyridine-/ / 4 ) , 7.04 ppm (s, 1H, pyridine-N//), 7.23-7.58 ppm 
(m, 5H, 3x benzoyl- / / and 2x phenyl-/ /) , 7.62-7.74 ppm (m, 2H, 2x benzoyl-/ /) , 7.83-
7.86 ppm (m, 1H, phenyl-/ /) , 8.00 ppm (s, 1H, phenyl- / / 2 ) , 9.13 ppm (bs, 0.9H, -C(S)-
N// -C(0)-) , 10.77 ppm (bs, 0.9H, S-C-C-C-N//-). 
N-benzoyl-N'-{5-{[3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)' 
pyridin-2-yl]methylthio}pentyl}thiourea 
Yield = 83 % (obtained as an oil). 
The product was purified by co lumn chromatography , using ethyl acetate/ 
dichloromethane 1:1 as eluent (Rf = 0.9). 
^ - N M R (CDC1 3): 1.22 ppm (t, / = 7.1 Hz, 3H, C / / 3 - C H 2 - 0 ) , 1.23 ppm (t, J = 7.1 Hz, 
3H, C / / 3 - C H 2 - 0 ) , 1.40-1.52 ppm (m, 2H, C-C-C// 2 -C-C), 1.60-1.75 ppm (m, 4H, S-C-
C/ / 2 -C-C/ / 2 -C-N) , 2.41 ppm (s, 3H, pyridine-C// 3 ), 2.51 ppm (t, / = 7.1 Hz, 2H, S-C// 2 -
(C) 4 -N) , 3.65 ppm (t, / = 6.8 Hz, 2H, S-(C) 4 -C/ / 2 -N) , 3.98 and 4.17 ppm (AB, 7 A B = 
14.8 Hz, 2H, pyridine-C// 2 -S), 3.92-4.08 ppm (m, 4H, 2x C H 3 - C / / 2 - 0 ) , 5.14 ppm (s, 1H, 
pyridine-/ / 4 ) , 7.10 ppm (s, 1H, pyridine-N//), 7.35-7.39 ppm (m, 1H, phenyl-/ /) , 7.43-
7.86 ppm (m, 6H, 5x benzoyl- / / and phenyl- / / ) , 8.00-8.03 ppm (m, 1H, phenyl- / / ) , 
8.11-8.16 ppm (m, 1H, phenyl-/ / 2 ) , 9.12 ppm (bs, 1H, -C(S)-N//-C(0)-) , 10.78 ppm (bs, 
1H, S-(C) 5-N//-). 
N-benzoyl-N'-{6-{[3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)~ 
pyridin-2-yl]methylthio}hexyl}thiourea 
Yield = 61 % (obtained as an oil). 
The produc t was purified by co lumn chromatography , using ethyl acetate/ 
dichloromethane 1:1 as eluent (Rf = 0.8). 
^ - N M R (CDC1 3): 1.13-1.58 ppm (m, 14H, 2x C / / 3 - C H 2 - 0 and S-C-(C// 2 ) 4 -C-N), 2.31 
ppm (s, 3H, pyridine-C// 3 ) , 2.44-2.55 ppm (m, 2H, S-C// 2 - (C) 5 -N), 3.63-3.71 ppm (m, 
2H, S-(C) 5 -C/ / 2 -N) , 3.93-4.04 ppm (m, 6H, pyridkie-C// 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.02 
ppm (s, 1H, pyr idine- / / 4 ) , 7.07 ppm (s, 1H, pyridine-N//) , 7.25-7.83 ppm (m, 7H, 5x 
benzoyl - / / and 2x phenyl- / / ) , 8.00-8.04 ppm (m, 1H, phenyl- / / ) , 8.09 ppm (bs, 1H, 
phenyl-// 2 ) , 9.07 ppm (bs, 1H, -C(S)-N//-C(0)-), 10.75 ppm (bs, 0.9H, S-(C) 5-N//-). 
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N-{co-{[3 ^-diethoxycarbonyl-1
 t4-dihydro-6-methyl-4-(substituted-phenyl)-pyridin-
2-yl]methylthio} alky 1}-S-ethylisothiourea HBr 
10 mmol K 2 C 0 3 in 40 ml water was added to a solution of 10 mmol N-benzoyl-N'-{(Q-
{[3,5-diethoxycarbonyl-1,4-dihydro-6-methyl-4-(substituted-phenyl)-pyridin-2-yl] 
methylthio }alkyl} thiourea in 135 ml ethanol. The reaction mixture was refluxed for 
45 minutes. Then the reaction mixture was diluted with 270 ml water and 6 times 
extracted with 50 ml dichloromethane. The organic layer was dried and evaporated. 
The residue was dissolved in 110 ml ethanol and 0.1 mol ethyl bromide was added. 
The reaction mixture was stirred overnight followed by 3 hours refluxing. The 
solvent was evaporated and the residue was washed 5 times with 100 ml hot diethyl 
ether. 
N-{2-[(3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-phenylpyridin-2-yl) 
methylthio]ethyl} -S-ethylisothiourea HBr 
Yield = 5 7 % (obtained as an oil). 
The product was purified by column chromatography, using ethyl acetate/methanol 
4:1 as eluent (Rf = 0.6). 
! H - N M R (DMSO-d 6 ) : 1.13 ppm (t, J = 7.0 Hz, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.26 ppm (t, J = 
7.3 Hz, 3H, S -CH 2 -C / / 3 ) , 2.28 ppm (s, 3H, pyr idine-C/ / 3 ) , 2.69-2.80 ppm (m, 2H, S-
C// 2 -C-N), 3.19 ppm (q, J = 7.3 Hz, 2H, S-C// 2 -CH 3 ) , 3.45-3.54 ppm (m, 2H, S-C-C// 2 -
N) , 3.83-4.06 ppm (m, 6H, pyr id ine-C/ / 2 -S and 2x C H 3 - C / / 2 - 0 ) , 4.89 ppm (s, 1H, 
pyridine-// 4 ) , 7.10-7.26 ppm (m, 5H, 5x phenyl-//), 8.97 ppm (s, 1H, pyridine-N//), 9.26 
ppm (bs, 2H, 2x N/ / ) . 
N-{2-{[3
 t5-diethoxycarbonyl-l f4-dihydro-6-methyl-4-(2,3-dichlorophenyl)-pyridin-
2-y I] methylthio}ethyl}-S-ethylisothiourea HBr 
Yield = 56%; melting point = 84.1-85.3 °C. 
The product was purified by column chromatography, using ethyl acetate/methanol 
1:1 as eluent (R f = 0.7). 
^ - N M R (CDC1 3): 1.15-1.22 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.41 ppm (t,J = 7.4Hz, 3H, 
S - C H 2 - C / / 3 ) , 2.42 ppm (s, 3H, pyr idine-C// 3 ) , 2.80-2.87 ppm (m, 2H, S-C/ / 2 -C-N) , 
3.38-3.57 ppm (m, 4H, S-C-C// 2 -N and S-C/ / 2 -CH 3 ) , 3.97-4.12 ppm (m, 6H, pyridine-
C/ / 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.48 ppm (s, 1H, pyridine-/ / 4 ) , 7.03-7.36 ppm (m, 3H, 3x 
phenyl-//), 7.71-8.15 ppm (bs, 1.4H, N/ / ) , 8.91 ppm (bs, 0.7H, NH), 9.50 ppm (bs, 1H, S-
C-C-N//-). 
N-{2-{[3 £-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-yl] 
methylthio} ethyl}-S-ethylisothiourea HBr VUF 9113 
Yield = 90%; melting point = 73.2-74.1°C. 
! H-NMR (CDCI3): 1.12-1.28 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.39 ppm (t, J = 7.3 Hz, 3H, 
S-CH 2 -C/ / 3 ) , 2.45 ppm (s, 3H, pyridine-C// 3 ), 2.78-2.83 ppm (m, 2H, S-C// 2 -C-N), 3.36 
ppm (q, J = 7.3 Hz, 3H, S-C/ / 2 -CH 3 ) , 3.88-4.33 ppm (m, 8H, S-C-C// 2 -N and pyridine-
CH2-S and 2x C H 3 - C / / 2 - 0 ) , 5.10 ppm (s, 1H, pyr idine- / / 4 ) , 7.39-7.42 ppm (m, 1H, 
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phenyl- / / 5 ) , 7.63-7.67 ppm (m, 1H, phenyl- / / 6 or H4), 7.95 ppm (bs, 1H, pyridine-N//), 
8.00-8.03 ppm (m, 1H, phenyl - / / 4 or H6), 8.30 ppm (bs, 1H, NH), 8.49-8.84 ppm (bs, 
1.4H, N/7), 8.93 ppm (s, 0.9H, NH), 9.51 ppm (bs, 0.6H, S-C-C-N//-). 
N-{3-{[3 ^-diethoxycarbonyl-1
 t4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-yl] 
methylthio}propyl}-S-ethylisothiourea HBr VUF 9110 
Yield = 66%; melting point = 65.6-67.9°C. 
The product was purified by column chromatography, using ethyl acetate/methanol 
7:3 as eluent (R f = 0.6). 
! H - N M R (CDC1 3): 1.00-1.49 ppm (m, 9H, 2x C / / 3 - C H 2 - 0 and S-CH 2 -C/ / 3 ) , 1.77-1.85 
ppm (m, 2H, C-C// 2 -C) , 2.33 ppm (s, 3H, pyridine-C// 3 ), 2.58-2.66 ppm (m, 2H, S-C// 2 -
C-C-N), 3.12-3.57 ppm (m, 4H, S-C-C-C// 2 -N and S-C/ / 2 -CH 3 ) , 3.78-4.17 ppm (m, 6H, 
pyridine-C// 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.00 ppm (s, 1H, pyridine-// 4 ) , 7.38 ppm (bs, 1H, 
phenyl-/ /) , 7.60 ppm (bs, 1H, phenyl-/ /) , 7.90-7.93 ppm (m, 1H, phenyl-/ /) , 8.01-8.03 
ppm (m, 1H, phenyl-//) , 8.27-8.65 ppm (m, 1.9H, pyridine-N// and N / / ) , 9.26 ppm (bs, 
1H, S-(C) 5-N//-). 
N-{5-{[3£-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridm^ 
methylthiojpentyl} -S-ethylisothiourea HBr 
Yield = 7 5 % ; melting point = < 38°C (hygroscopic). 
The product was purified by column chromatography, using petroleum ether 60-
80°C/ethyl acetate 7:3 as eluent (R f = 0.7). 
^ - N M R (CDC1 3): 1.23 ppm (t, / = 7.1 Hz, 3H, C / / 3 - C H 2 - 0 ) , 1.24 ppm (t, / = 7.0 Hz, 
3H, C / / 3 - C H 2 - 0 ) , 1.43-1.62 ppm (m, 9H, C - C / / 2 - C / / 2 - C / / 2 - C and S -CH 2 -C / / 3 ) , 2.44 
ppm (s, 3H, pyridine-C// 3 ) , 2.55 ppm (t, / = 6.7 Hz, 2H, S-C// 2 -(C) 4 -N), 3.30-3.41 ppm 
(m, 4H, S-(C) 4 -C/ / 2 -N and S-C/ / 2 -CH 3 ) , 3.95 and 4.18 ppm (AB, JAB = 75 . / Hz, 2H, 
pyridine-C// 2-S), 4.01-4.12 ppm (m, 4H, 2x C H 3 - C / / 2 - 0 ) , 5.12 ppm (s, 1H, pyridine-// 4), 
7.40 ppm (bs, 1H, phenyl-//), 7.66-7.68 ppm (m, 1H, phenyl-//), 8.00-8.02 ppm (m, 1H, 
phenyl-//), 8.11-8.14 ppm (m, 1H, phenyl-/ / 2 ) , 8.35-8.73 ppm (bs, 2H, pyridine-N// and 
NH), 9.20 ppm (bs, 1H, S-(C) 5-N//-). 
N-{6-{[3
 f5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-yl] 
methylthiojhexyl}-S-ethylisothiourea HBr 
Yield = 6 8 % obtained as an oil (very hygroscopic). 
The product was purified by column chromatography, using petroleum ether 60-
80°C/ethyl acetate 7:3 as eluent. N 
^ - N M R (CDC1 3): 1.13-1.24 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.39-1.76 ppm (m, 11H, S-
C- (C/ / 2 ) 4 -C-N and S -CH 2 -C / / 3 ) , 2.36 ppm (s, 3H, pyridine-C// 3 ) , 2.49-2.55 ppm (m, 
2H, S-C// 2 - (C) 5 -N), 3.27-3.44 ppm (m, 4H, S-(C) 5 -C// 2 -N and S-C/ / 2 -CH 3 ) , 3.88-4.22 
ppm (m, 6H, pyridine-C// 2 -S and 2x C H 3 - C / / 2 - 0 ) , 5.07 ppm (s, 1H, pyridine-/ / 4 ) , 7.40 
ppm (bs, 1H, phenyl-/ /) , 7.63-7.65 ppm (m, 1H, phenyl-//) , 7.98 ppm (bs, 1H, phenyl-
H), 8.05-8.08 ppm (m, 1H, phenyl-/ /) , 8.41-8.81 ppm (m, 2.1H, pyridine-N// and NH), 
9.37 ppm (m, 1H, S-(C) 6-N//-). 
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N-{(D-{[3J-diethoxycarbonyl"l,4-dihydro-6-methyl-4-(su^ 
2-yl]methylthio}alkyl}'N'-[3-(imidazol-4(5)-yl)propyl]guanidine 2HBr 
5 mmol 4(5)-(3-aminopropyl)imidazole and 5 mmol N-{co-{[3,5-diethoxycarbonyl-l,4-
dihydro-6-methyl-4-(substituted-pheny l)-pyridin-2-yl)methylthio]} alkyl} -S-ethyliso-
thiourea were refluxed in 150 ml pyridine during 72 hours. Then the pyridine was 
evaporated and the residue was 3 times coevaporated with ethanol. Then the residue 
was crystallized from ethyl acetate and the precipitate was filtered off. The filtrate 
was purified by column chromatography, using ethyl acetate/ethanol 4:1 as eluent. 
The obtained fractions were crystallized from ethyl acetate/methanol and the 
precipitate was filtered off. The product was obtained as a foam by evaporating the 
solvent. 
N-{[2-(3 yS-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-phenylpyridin-2-yl) 
methylthioJethylJ-N'-p-fimidazol^fSyyOpropylJguanidine 2HBr VUF 4572 
Yield = 17%; melting point = < 30°C; Mass spectrum, thioglycerol as matrix (FAB + ) 
555 [ M + H F , ( F A B ) 5 5 3 [M-H] \ 
*H-NMR (DMSO-d 6 ) : 1.05-1.20 ppm (m, 6H, O / 3 - C H 2 - 0 ) , 1.66-1.78 ppm (m, 5H, N-C-
C// 2 -C-imidazole and O / 3 - C 0 0 ) , 2.30 ppm (s, 3H, pyridine-C// 3 ) , 2.47-2.53 ppm (m, 
2H, N-C-C-C// 2 - imidazole) , 2.69 ppm (t, / = 6.9 Hz, 2H, S - 0 / 2 - C - N ) , 3.12 and 3.44 
ppm (m, 4H, S-C-C// 2 -N and N-C// 2 -C-C-imidazole) , 3.81 and 4.07 ppm (AB, J A B = 
13.8 Hz, 2H, pyridine-C// 2 -S), 3.93-4.04 ppm (m, 4H, 2x C H 3 - C / / 2 - 0 ) , 4.88 ppm (s, 1H, 
pyr idine- / / 4 ) , 6.75 ppm (bs, 1H, imidazole-//) , 7.02-7.28 ppm (m, 5H, 5x phenyl-/ /) , 
7.52 ppm (bs 1H, imidazole-//). 
N-{2-{[3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(2,3-dichlorophenyl)-pyridin-
2-yl]methylthio}ethy\}-W-l3-(imidazolA(5)-y^ 2HBr VUF 9160 
Yield = 24%; melting point = 97.9-101.1°C; Mass spectrum, glycerol+ammonium 
acetate as matrix (FAB+) 625 [M+H] + , ( F A B ) 623 [M-H] \ 
! H - N M R (DMSO-d 6 ) : 1.08 ppm (t, J = 7.1 Hz, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.67-1.77 ppm (m, 
2H, N-C-C// 2 -C-imidazole) , 1.82 ppm (s, 3H, O / 3 - C 0 0 ) , 2.30 ppm (s, 3H, pyridine-
C/ / 3 ) , 2.47-2.53 ppm (m, 2H, N-C-C-C// 2-imidazole), 2.61-2.69 ppm (m, 2H, S-C// 2 -C-
N), 3.10 and 3.30 ppm (m, 4H, S-(C) 4 -C/ / 2 -N and N-C// 2 -C-C-imidazole) , 3.88 and 
4.04 ppm (AB, JAB = 13.3 Hz, 2H, pyridine-C// 2 -S) , 3.91-4.03 ppm (m, 4H, 2x C H 3 -
CH2-0), 5.35 ppm (s, 1H, pyridine-/ / 4 ) , 6.77 ppm (bs, 1H, imidazole-//), 7.21-7.42 ppm 
(m, 3H, 3x phenyl-//) , 7.54 ppm (bs, 1H, imidazole-//), 7.90 ppm (bs, 0.6H, NH), 9.36 
ppm(bs ,0 .6H,N/ / ) . 
N-{2-{[3 £-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-
yl]methylthio}ethyl}-Nf-[3-(imidazol-4(5)-yl)propyl]guanM^ 2HBr VUF 9065 
Yield = 2 1 % ; melting point = 76.5-77.1°C; Mass spectrum, glycerol+ammonium 
acetate as matrix (FAB + ) 600 [M+H] + , ( F A B ) 598 [M-H] \ 678/680 [M+Br] \ 
^ - N M R (DMSO-d 6 ) : 1.00-1.13 ppm (m, 6H, C / / 3 -CH 2 -0 ) , 1.46-1.87 ppm (m, 2H, N-C-
C// 2 -C-imidazole), 2.32 ppm (s, 3H, pyridine-C// 3 ) , 2.45-2.52 ppm (m, 4H, S-C// 2 -C-N 
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and N-C-C-C// 2 - imidazole) , 2.70 and 3.20 ppm (m, 4H, S-C-C// 2 -N and N-C/ / 2 -C-C-
imidazole), 3.92 and 4.18 ppm (AB, / A B = 13.2 Hz, 2H, pyr idine-C/ / 2 -S) , 3.97-4.12 
ppm (m, 4H, 2x C H 3 - C / / 2 - 0 ) , 4.98 ppm (s, 1H, pyr id ine- / / 4 ) , 6.82 ppm (bs, 1H, 
imidazole-/ / ) , 7.40-7.73 ppm (m, 6H, 3x phenyl-/ / and 3x NH), 7.87 ppm (bs, 0.7H, 
pyridine-N//), 8.01-8.06 ppm (m, 2H, imidazole-// and phenyl-//), 9.30 ppm (bs, 0.7H, 
imidazole-N//). 
N-{3-{[3 £-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-yl] 
methylthio}propyl}-N'-[3-(imidazol-4(5 )-yl)propyl] guanidine 2HBr VUF 4570 
Yield = 20 %; melting point = 87.3-88.2°C; Mass spectrum, thioglycerol as matrix 
(FAB + ) 614 [M+H] + , (FAB") 612 [M-H]", 692/694 [M+Br] \ 
J H-NMR (DMSO-d 6 ) : 1.12 ppm (t, J = 7.0 Hz, 3H, C / / 3 - C H 2 - 0 ) , 1.14 ppm (t, J = 7.0 
Hz, 3H, C / / 3 - C H 2 - 0 ) , 1.68-1.83 ppm (m, 4H, S-C-C// 2-C-N and N-C-C// 2-C-imidazole), 
2.32 ppm (s, 3H, pyr id ine-C/ / 3 ) , 2.50-2.63 ppm (m, 4H, S-C/ / 2 -C-C-N and N-C-C-
C// 2 - imidazole) , 3.11-3.24 ppm (m, 4H, S-C-C-C// 2 -N and N-C/ / 2 -C-C- imidazole) , 
3.89 and 4.08 ppm (AB, 7 A B = 13.0 Hz, 2H, pyridine-C// 2 -S) , 3.93-4.06 ppm (m, 4H, 
2x C H 3 - C / / 2 - 0 ) , 5.00 ppm (s, 1H, pyridine-/ / 4 ) , 6.85 ppm (s, 1H, imidazole-//) , 7.52-
7.65 ppm (m, 6.75H, 3x phenyl-/ / and 3.75x NH), 8.02-8.11 ppm (m, 2H, imidazole-// 
and phenyl-//), 9.25 ppm (bs, 1H, NH). 
1 3 C - N M R ( D M S O - d 6 ) : 13.73 and 13.84 ppm (q, 2x C H 3 - C H 2 - 0 ) , 18.03 ppm (q, 
pyr id ine-CH 3 ) , 22.94 and 28.19 ppm (t, S-CH 2 -C-C-N and N-C-C-CH 2 - imidazole) , 
28.54 and 29.43 ppm (t, S-C-CH 2 -C-N and N-C-CH 2 -C- imidazole) , 39.05 ppm (d, 
pyr id ine-C 4 ) , 39.77 and 40.16 (t, S-C-C-CH 2 -N and N-CH 2 -C-C- imidazole) , 55.77 
ppm (t, pyridine-CH 2 -S), 59.08 and 59.40 ppm (t, 2x C H 3 - C H 2 - 0 ) , 100.49 and 101.34 
ppm (s, pyr id ine-C 3 and C 5 ) , 115.55 and 121.68 (d, 2x imidazole-CH), 121.04 and 
129.41 and 133.96 and 134.02 ppm (d, 4x phenyl-CH [C 2 , C 4 , C 5 , C 6 ] ) , 136.04 ppm (s, 
imidazole-C) , 146.40 and 147.21 and 147.67 and 149.71 ppm (s, phenyl-C^ and C 3 
and pyr idine-C 2 and C 6 ) , 155.56 ppm (s, guanidine-C), 165.87 and 166.13 ppm (s, 2x 
carbonyl-C). 
N-{5-{[3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-yl] 
methylthio}pentyl}-N'-[3-(imidazol-4(5)-yl)propyl]guanidine 2HBr VUF 4573 
Yield = 3 3 % ; melting point = < 40°C (hygroscopic); Mass spectrum, thioglycerol as 
matrix (FAB + ) 642 [M+H] + , (FAB") 640 [M-H]", 720/722 [M+Br] \ 
!H-NMR (DMSO-d 6 ) : 1.11 ppm (t, J = 7.1 Hz, 3H, C / / 3 - C H 2 - 0 ) , 1.13 ppm (t, / = 7.1 
Hz, 3H, C / / 3 - C H 2 - 0 ) , 1.20-1.29 ppm (m, 2H, C-C<:/ / 2 -C-C), 1.38-1.49 ppm (m, 4H, C-
C / / 2 - C - C / / 2 - C ) , 1.72-1.78 ppm (m, 2H, N-C-C/ / 2 -C- imidazole) , 2.30 ppm (s, 3H, 
pyridine-C// 3 ) , 2.46-2.61 ppm (m, 4H, S-C// 2 -(C) 4 -N and N-C-C-C// 2 -imidazole), 3.08-
3.19 ppm (m, 4H, S-(C) 4 -C// 2 -N and N-C// 2 -C-C-imidazole), 3.79 and 4.03 ppm (AB, 
/ A B = 13.2 Hz, 2H, pyridine-C// 2 -S), 3.88-4.00 ppm (m, 4H, 2x C H 3 - C / / 2 - 0 ) , 5.00 ppm 
(s, 1H, pyridine-// 4 ), 6.94 ppm (bs, 1H, imidazole-//), 7.41-7.65 ppm (m, 6H, 2x phenyl-
H and 4x NH), 7.85 ppm (d, J = 0.9 Hz, 1H, imidazole-//) , 7.98-8.06 ppm (m, 2H, 2x 
phenyl-//), 9.16 ppm (bs, 1H, S-(C) 5-N//-). 
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1 3 C - N M R ( D M S O - d 6 ) : 13.73 and 13.82 ppm (q, 2x C H 3 - C H r O ) , 18.00 ppm (q, 
pyridine-CH 3 ), 22.59 ppm (t, C-C-CH 2-imidazole), 25.18 ppm (t, C-C-CH 2 -C-C), 27.99 
ppm (t, C-CH 2 -C-imidazole), 28.68 and 29.48 ppm (t, C-CH 2 -C-CH 2 -C) , 30.91 ppm (t, 
S - C H 2 - ( C ) 4 - N ) , 39.04 ppm (d, pyridine-C 4 ) , 40.07 and 40.55 ppm (t, 2x - C H 2 - N ) , 
56.08 ppm (t, pyridine-CH 2 -S) , 59.07 and 59.36 ppm (t, 2x C H 3 - C H 2 - 0 ) , 100.03 and 
101.39 ppm (s, pyridine-C 3 and C 5 ) , 115.49 ppm (d, imidazole-CH), 121.00 ppm (d, 
imidazole-CH), 121.65 and 129.35 and 133.91 and 134.17 ppm (d, 4x phenyl-CH [C 2 , 
C 4 , C 5 , C 6 ] ) , 136.20 ppm (s, imidazole-C), 146.44 and 147.25 and 147.64 and 149.70 
ppm (s, phenyl-Ci and C 3 and pyr id ine-C 2 and C 6 ) , 155.49 ppm (s, guanidine-C), 
165.91 and 166.13 ppm (s, 2x carbonyl-C). 
N-{6-{[3 J-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-(3-nitrophenyl)-pyridin-2-yl] 
methylthio}hexyl}-N^3-(imidazol-4(5)-yl)propyl]guanidine 2HBr VUF 4575 
Yield = 2 7 % ; melting point = < 40°C (hygroscopic); Mass spectrum, 3-nitrobenzyl 
alcohol as matrix (FAB + ) 656 [M+H] + , ( F A B ) 654 [M-H]% 734/736 [M+Br] \ 
iH-NMR (DMSO-d 6 ) : 1.13 ppm (t, / = 7.7 7/z, 3H, C / / 3 - C H 2 - 0 ) , 1.14 ppm (t, / = 7.7 
7/z, 3H, C / / 3 - C H 2 - 0 ) , 1.224.44 ppm (m, 8H, S-C-(C// 2 ) 4 -C-N), 1.46-1.57 ppm (m, 2H, 
N-C-C// 2-C-imidazole), 2.32 ppm (s, 3H, pyridine-C// 3 ), 2.48-2.58 ppm (m, 4H, S-C// 2 -
(C) 5 -N and N-C-C-C// 2 - imidazole), 3.08-3.27 ppm (m, 4H, S-(C) 5 -C// 2 -N and N - C / / 2 -
C-C-imidazole), 3.64 and 4.02 ppm (AB, JAB = 13.2 Hz, 2H, pyr idine-C// 2 -S) , 3.87-
4.00 ppm (m, 4H, 2x C H 3 - C / / 2 - 0 ) , 5.01 ppm (s, 1H, pyridine-/7 4 ), 6.85 ppm (s, 1H, 
imidazole-//), 7.46-7.63 ppm (m, 7H, 3x phenyl-// and 4x N/ / ) , 8.02-8.11 ppm (m, 2H, 
imidazole-// and phenyl-//), 9.20 ppm (bs, 1H, N/ / ) . 
N-{G)-{[2-(3,5-diethoxycarbonyl~2,6-dimethyl-l
 y4-dihydropyr\din-4-yl)phenoxy]}-
alkyl}-N'-[3-(imidazol-4(5)-yl)propyl]guanidine 2HBr 
The N- {co- {[2-(3,5-diethoxycarbonyl-2,6-dimethyl-1,4-dihydropyridin-4-yl)-
phenoxy]}alkyl}-N'-[3-(imidazol-4(5)-yl)propyl]guanidine hydrobromide derivatives 
were synthesized according to the procedure described for the N-fco-{[3,5-diethoxy-
carbonyl-1,4-dihydro-6-methyl-4-(substituted-phenyl)-pyridin-2-yl]methylthio} alkyl} 
- N'-[3-(imidazol-4(5)-yl)propyl]guanidine hydrobromide derivatives, starting from the 
N- {co- {[2-(3,5-diethoxycarbonyl-2,6-dimethyl-1,4-dihydropyridin-4-yl)phenoxy]} -
alkyl}-S-ethylisothiourea hydrobromide derivatives described in chapter 6 (this 
thesis). 
N-{3-{[2-(3 £~diethoxycarbonyl-2 fi-dimethyM ,4-dihydropyridin-4-yl)phenoxy]} 
propyl}-N'-[3-(imidazol-4(5)-yl)propyl]guanidine 2HBr VUF 4588 
Yield = 17%; melting point = 103.0-104.3°C; Mass spectrum, thioglycerol as matrix 
(FAB + ) 553 [M+H] + , (FAB') 551 [M-H]% 631/633 [M+Br] \ 
!H-NMR (DMSO-d 6 ) : 1.01-1.13 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.79-1.97 ppm (m, 4H, 
0 - C - C / / 2 - C - N and N-C-C// 2 -C-imidazole) , 2.22 ppm (s, 6H, 2x pyr idine-C/ / 3 ) , 2.59 
ppm (t, 2H, N-C-C-C// 2 -imidazole), 3.22-3.36 ppm (m, 4H, 0 -C-C-C/ / 2 -N and N - C / / 2 -
C-C-imidazole), 3.92-4.05 ppm (m, 6H, 2x C H 3 - C / / 2 - 0 and 0 -C/ / 2 -C-C-N) , 5.14 ppm 
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(s, 1H, pyridine-/ / 4 ) , 6.74-7.11 ppm (m, 5H, 4x phenyl-/ / and NH), 7.54-7.70 ppm (m, 
5H, imidazole-// [/ = 0.95 Hz] and 4x NH), 8.76 ppm (s, 1H, imidazole-//). 
N-{5-{[2-(3 ^-diethoxycarbonyl-2,6-dimethyl-l ,4-dihydropyridin-4-yl)phenoxy]}-
pentyl}-N'-[3-(imidazol-4(5)-yl)propyl]guanidine 2HBr VUF 4612 
Yield = 2 8 % ; melting point = 91.8-93.3°C; Mass spectrum, 3-nitrobenzyl alcohol as 
matrix (FAB + ) 581 [M+H] + , ( F A B ) 579 [M-H]-, 659/661 [M+Br]-. 
^ - N M R (CD 3 OD): 1.10-.21 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.56-2.00 ppm (m, 8H, O-C-
(C/ / 2 ) 3 -C-N and N-C-C// 2 -C-imidazole), 2.24 ppm (s, 6H, 2x pyridine-C// 3 ) , 2.71 ppm 
(t, J = 7.5 Hz, 2H, N^C-C-C// 2 - imidazole), 3.26 ppm (2 x t, each J = 7.0 Hz, 4H, O-
(C) 4 -C/ / 2 -N and N-C// 2 -C-C-imidazole), 3.90-4.04 ppm (m, 6H, 2x C H 3 - C / / 2 - 0 and O-
C// 2 - (C) 4 -N), 5.16 ppm (s, 1H, pyridine-// 4 ), 6.71-6.84 ppm (m, 2H, 2x phenyl-//), 7.02-
7.16 ppm (m, 3H, 2x phenyl-// and 1 x imidazole-//), 7.99 ppm (s, 1H, imidazole-//). 
N-{6-{[2-(3 ^-diethoxycarbonyl-2,6-dimethyl-l ,4-dihydropyridin-4-yl)phenoxy]}-
hexyl}-Nf-[3-(imidazol-4(5)-yl)propyl]guanidine 2HBr VUF 4730 
Yield = 2 1 % ; melting point = 83.1-85.3°C; Mass spectrum, 3-nitrobenzyl alcohol as 
matrix (FAB + ) 595 [M+H] + , ( F A B ) 593 [M-H]-, 673/675 [M+Br]-. 
!H-NMR (CD 3 OD): 1.10-1.17 ppm (m, 6H, 2x C / / 3 - C H 2 - 0 ) , 1.45-1.97 ppm (m, 10H, O-
C- (C/ / 2 ) 4 -C-N and N-C-C// 2 -C-imidazole) , 2.23 ppm (s, 6H, 2x pyr id ine-C/ / 3 ) , 2.65 
ppm (t, / = 7.3 Hz, 2H, N-C-C-C// 2 - imidazole) , 3.23 ppm (2 x t, each J = 7.0 Hz, 4H, 
0 - ( C ) 5 - C / / 2 - N and N-C// 2 -C-C-imidazole), 3.89-4.04 ppm (m, 6H, 2x C H 3 - C / / 2 - 0 and 
0 -C/ / 2 - (C) 5 -N) , 5.16 ppm (s, 1H, pyridine-// 4 ), 6.71-6.84 ppm (m, 3H, 2x phenyl-// and 
1 x imidazole-/ /) , 7.01-7.17 ppm (m, 2H, 2x phenyl- / / ) , 7.59 ppm (d, J =1.0 Hz,\U, 
imidazole-//). 
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C h a p t e r 8 
A n e w s e r i e s of d i m a p r i t a n a l o g u e s w i t h h i s t a m i n e H 2 - a g o n i s t i c 
a n d H i - a n t a g o n i s t i c a c t i v i t i e s 
1 In t roduct ion 
The clinical use of compounds active on the histamine ^ - r e c e p t o r is mainly restricted 
to histamine ^ - a n t a g o n i s t s , which are useful in the treatment of peptic ulcers. 
However, some efforts have been made with histamine H2-agonists in the treatment of 
patients with catecholamine-insensitive congestive heart failure 1* 2. 
Histamine H2-agonists can be divided in three structural classes: histamine analogues, 
dimaprit, and impromidine 3 and its analogues 4 (reviewed by Van der Goot et a l . 5 ) . 
Histamine 1 and dimaprit 2 (fig. 1) show both moderate histamine H2-agonistic 
activity (pD2 = 6.10 and 5.95, respectively, at guinea pig right atrium). Impromidine 3 
(fig. 1) and its analogues V U F 8532 4b and the racemic arpromidine 5 (fig. 1) are 
potent histamine H2-agonists (pD2 = 7.80, 7.70 and 8.01, respectively, at guinea pig 
right atrium). Furthermore, the hybrid molecules V U F 8532 4b and arpromidine 5 
have also a histamine Hi-antagonist ic activity (pA2 = 6.30 and 7.65 at guinea pig 
ileum, respectively). At the histamine H3-receptor impromidine turned out to be a 
potent antagonist 6 ( p A 2 = 7.2; histamine release, rat cortex) as well. 
Figure 1: Histamine H 2-agonists 
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Dimapri t 3 (fig. 1) is an agonist for the histamine H 2 - r ecep to r 7 ( p D 2 = 5.7 on the 
guinea pig right atrium), while it is an antagonist for the histamine H3-receptor 6 (pA 2 
= 5.5; histamine release rat cortex). Structure-activity relationship studies on dimaprit, 
S-[3-(N,N-dimethylamino)propyl]isothiourea, revealed that the dimethylamino group 
has the same function as the amino group of histamine, while the isothiourea group of 
dimaprit and the imidazole group are regarded bioisosteric for the histamine H 2 -
agonist 8 . 
Two models have been proposed for the mechanism of action of the monocation of 
dimaprit, which is the active species. The first model (the so-called N-fit) implies that 
the amidino group of dimaprit participates in tautomerism or bifunctional acceptor-
donor hydrogen bond ing 8 , analogous to the activation mechanism described for 
histamine at the H 2 - receptor 9 . The second model (the so-called S-fit) suggests that the 
acceptor-donor hydrogen bonding of dimaprit is provided by the sulfur atom and by 
a proton of the amidino g roup 1 0 . Quantum chemical calculations have suggested that 
the S-fit conformation is the most favourable for interaction with the Hr r ecep to r 1 ! » 1 2 . 
Furthermore, similar calculations on 2-amino-5-(2-aminoethyl) thiazole 1 3 6 (fig. 2) 
revealed that this compound can be cons idered as a r ing-c losed dimapri t 
a n a l o g u e 1 4 * 1 5 . Indeed, several substituted 2-aminothiazole derivatives have been 
shown to be active at the histamine H 2 -receptor, of which amthamine 1 6 7 (fig. 2) is 
the most potent H 2 -agonist in this series ( pD 2 = 6.30; guinea pig right atrium). 
H 2N 
Figure 2: Substituted 2-amino-5-(2-aminoethyl)thiazole derivatives 
There are several compounds which show that tautomerism is not involved in 
stimulation of the his tamine H 2 - receptor . Eriks et a l . 1 7 have developed a new 
activation model for the histamine H 2 -receptor, which explains the activities of all 
known tautomeric and nontautomeric H 2 -agonists . In their model, protonation of the 
double-bonded nitrogen atom of heterocyclic rings induces a positive charge, which 
is distributed over the ring. The distribution of the positive charge enables an ionic 
interaction of the heterocyclic ring with a negatively charged receptor site. For the 
mechanism of action of thiazoles, which cannot undergo tautomerism because of the 
inabil i ty to protonate the part ial ly posi t ively charged sulfur a tom, an other 
explanation has been p roposed 1 7 . 
In impromidine, the 3-[4(5)-imidazolyl]propylguanidine moiety is important for 
triggering the histamine H 2 -receptor. Replacement of the 3-[4(5)-imidazolyl]propyl 
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structural moiety of impromidine by a number of substituted 3-(5-thiazolyl)propyl 
moiet ies afforded N' -subst i tu ted-N-[3-(5- th iazolyl ) ]propylguanidines 1 8 as potent 
histamine H2-agonists , such as V U F 8960 8 (fig. 2; p D 2 = 7.30; guinea pig right 
atrium). 
2 A l i t e ra ture survey of s t ruc tu re activity re la t ionship studies on d i m a p r i t 
A number of structural modifications have been carried out on dimapri t 1 9 . Variations 
in the alkylene chain length of dimaprit or alkylation of the amidino group drastically 
reduces the histamine H 2 -agonistic ac t iv i ty 2 0 ' 2 1 . 
Replacement of the dimethylamino fragment of dimaprit by an isothiourea group 
affords a series of alkylenediisothioureas (fig. 3), which are weak H 2 -agonists. 
Figure 3: Alkylenediisothioureas (m = 2 to 8; R = H, CH 3 , N 0 2 , C6H5) 
In the series of unsubstituted alkylenediisothioureas (fig. 3; table 1), the compound 
with an ethylene chain V U F 8332 (fig. 3; R = H, m = 2) is an almost full, but weak 
histamine H 2 -agonist ( p D 2 = 3.8; a = 0.9; guinea pig right atrium) and has a histamine 
H3-antagonistic ac t iv i ty 2 4 ( p A 2 = 6; histamine release, rat cortex). Increasing the 
alkylene chain from ethylene to octylene reduces the weak H 2 -agonist ic activity and 
intrinsic activity. In fact, compounds with an alkylene chain length exceeding 
pentylene turned out to be weak H 2 -antagonis ts . Furthermore, N,N'-disubstituted-
diisothioureas (the substituents are methyl, nitro, or phenyl groups) are devoid of H 2 -
agonistic act ivi ty 2 2 . 
In a series of the co-guanidinoalkylisothioureas (fig. 4; table 1) compounds with m = 2, 
3 or 4 have a weak partial H 2 -agonistic activity at the guinea pig right atrium. Besides 
VUF 8430 (m = 2) is a partial histamine H 3 -agonist ( p D 2 = 5.9, a = 0.5). Elongation of 
the alkylene chain to m = 5 and 6 results in a strong increase in H 2 -agonist ic activity 
with the highest intrinsic activity found for VUF 8 4 3 3 2 3 (table 1). 
R—N N—R 
H 2N NH 2 
HN NH 
H 2N NH 2 
Figure 4: co-Guanidinoalkylisothioureas (m = 2 to 6) 
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Table 1: Histaminergic activities of a series of alkylenediisothioureas and co-
guanidinoalkyl iso th ioureas 2 2 ' 2 3 . 
HN NH 
y - S - ( C H 2 ) m - S — ^ 
H 2N NH 2 
compound m a 
H 2 a 
p D 2 
H 2 b 
pA 2 
H 3 C 
pA 2 
VUF 8332 2 0.9 3.8 < 4 6 
VUF 8333 3 0.5 3.8 < 4 6 
VUF 8334 4 0.4 3.7 < 4 nd 
VUF 8335 5 0.3 3.6 4.4 nd 
VUF 8336 6 0 < 3 . 0 4.8 nd 
VUF 8337 7 0.2 4.5 4.6 nd 
VUF 8338 6 0 < 3 . 0 4.7 nd 
HN NH 
y-S-(CH 2)m-N 
H2N NH2 
VUF 8430 2 0.4 3.8 < 4 p D 2 = 5.9 (a = 0.5) 
VUF 8431 3 0.4 3.8 < 4 nd 
VUF 8432 4 0.4 3.8 nd nd 
VUF 8433 5 0.9 5.0 < 4 nd 
VUF 8434 6 0.5 5.8 5.7 nd 
dimaprit 1 5.7 - 5.5 
histamine 1 6.14 - p D 2 = 7.4 ( a = 1) 
x Histamine H2-agonistic activity at guinea pig right atrium 
b: Histamine ^-antagonistic activity at guinea pig right atrium 
c: Histamine H3-antagonistic activity determined as the inhibition of [3H]histamine release 
from rat cerebral cortex after electrical stimulation2 4 
a: Intrinsic activity relative to histamine 
nd: Not determined 
The postulated bioisosterism of the imidazole group of impromidine and the 
isothiourea group of dimaprit analogues for theNhistamine ^ - r e c e p t o r is verified by a 
series of N,N'-bis(co-isothioureidoalkyl)guanidines 1 9 (fig. 5). 
NH 
HN II NH 
y—S-(CH 2)m N ^ ^ N ( C H 2 ) p - S — ^ 
H 2N H H NH 2 
Figure 5: N,N'-bis((0-isothioureidoalkyl)guanidines (m and p = 3, 4, 5) 
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All compounds except VUF 8422 are full agonists (table 2) and their higher histamine 
H2-agonistic activity compared to the activities of the alkylenediisothioureas (fig. 3) 
or co-guanidinoalkylisothioureas (fig. 4) is explained by postulating an extra binding 
site, analogous to impromidine, on the histamine H 2-receptor. 
Table 2: His tamine H 2 -agonist ic activity at guinea pig right atrium of a series of 
N,N'-bis((0-isothioureidoalkyl)guanidines 1 9 
NH 
HoN 
II ^ 
y~S-(CH2)m N ^ N ( C H 2 ) p - S — ^ 
compound m P p D 2 a 
V U F 8420 3 3 5.7 1 
V U F 8421 3 4 6.5 1 
V U F 8424 3 5 5.0 1 
V U F 8425 4 4 5.8 1 
V U F 8423 4 5 5.7 1 
V U F 8422 5 5 a 0 
dimaprit 5.7 1 
a: V U F 4822 is a weak histamine H 2 -antagonist (pA 2 = 4.6) 
V U F 4821 is the most potent N,N'-bis(isothioureidoalkyl)guanidine derivative in this 
series and it is concluded that the isothiourea group attached to the propylene chain 
in V U F 8421 mimics the methyl imidazole group of impromidine , while the 
butylisothiourea moiety of V U F 8421 mimics the propylimidazole g roup 1 9 . 
The findings that 2-amino-5-(2-aminoethyl)thiazoles can be considered as ring closed 
dimaprit analogues and that substituted 2-amino-5-(3-aminopropyl)thiazoles can 
replace the 3-[4(5)-imidazolyl]propylamine structural moiety, combined with the 
histamine H 2 -agonistic activities of N,N'-bis(isothioureidoalkyl)guanidines, arose the 
question whether the alkylisothiourea structural moiety of dimaprit can replace the 
propylimidazole or propylthiazole structural moieties of impromidine and of 4b (fig. 1) 
/ 8 (fig. 2). 
Based on our literature survey, we decided to synthesize a series of N,N'-substituted 
guanidines with a 2-[(5-methylimidazol-4-yl)methylthio]ethyl 9 or a 3,3-diphenyl-
propyl moiety 10 and a dimaprit structural moiety (fig. 6). 
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Figure 6: Putative histamine H2-agonists incorporating impromidine and dimaprit or 
3,3-diphenylpropylamine and dimaprit structural moieties 
3 Gene ra l synthet ic me thod 
A scheme for the synthesis of compounds 9 and 10 is given in figure 7. The primary 
amines 2-[(5-methylimidazol-4-yl)methylthio]ethylamine a l or 3,3-diphenylpropyl­
amine a 2 are converted into the S-methylisothiourea b by reaction with dimethyl N-
cyanoiminodi th iocarbonate , according to l i t e ra tu re 2 5 . Condensation of b with a 
suitable aminoalcohol affords the cyanoguanidines c . Finally reaction of the 
cyanoguan id ines c with thiourea in hydrobromic acid gives the N-(co-isothio-
ureidoalkyl)guanidines d. 
CH A 
N ^ S-CH2"CH2~ 
NH 
a1 (R) 
R— NH 2 + 
a1 / a 2 
CH2"CH2" 
a 2 (R) 
.CN 
.CN 
N C H 2 C I 2 M 
A " R " N < > S C H 3 
H 3 C S ^ SCH, H b 
NH 
H
 M H NH 2 4 8 % H B r 
d 
H2N-(CH2)m-OH 
N H
 H 2 N < ^ N H 2 | 
R X N X ^ N X ( C H 2 ) M " ° H 
H H C 
Figure 7: General reaction scheme for compounds 9 and 10 (fig. 6) 
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4 Pha rmaco logy 
4.1 Histamine Hb-agonistic activities and affinities 
Histamine H2-agonistic activities are determined as positive chronotropic activities on 
the spontaneously beating guinea pig right atrium; radioligand binding studies were 
performed on guinea pig cerebral cortex membranes , using [ 1 2 5 I ] i o d o a m i n o -
potentidine as the hot ligand, as previously described (chapter 7; this thesis). 
4.2 Histamine Hi-antagonistic activities 
Histamine Hi-antagonist ic activities are determined at the guinea pig ileum with 
histamine as agonist ( p D 2 = 6.95 ± 0.07), as described by Emmett et a l . 2 6 . 
5 Results a n d discussion 
5.1 Attempts to synthesize compounds 9 
The synthesis route to obtain the series of compounds with the general structure 9 
(fig. 6) proceeds via the N-cyano-N'-[co-hydroxyalkyll-N"-[2-[(5-methyl-l//-imidazol-
4-yl)methyl]thio]ethyllguanidine intermediates (c; fig. 7), which are readily prepared 
in high yields from N-cyano-S-methyl-N ,-[2-[(5-methyl-l//-imidazol-4-yl)methyllthiol 
ethyl]isothiourea (b ; fig. 7) and the appropriate co-hydroxyalkylamine. The next step 
concerns the introduction of thiourea and the hydrolysis of the cyano group to 
obtain the isothioureas (d; fig. 7, see also scheme 1; fig 8). The reaction was carried 
out with 2 equivalents of thiourea at 100 °C and at 20°C in 4 8 % HBr. Under both 
react ion condi t ions the thioether is hydrolyzed , resul t ing in a 5-methyl-4-
hydroxymethylimidazole fragment, as was shown by ^ - N M R . These findings forced 
us to look for other synthetic routes as shown in figure 8 (scheme 2). 
In figure 8 (scheme 2), a protective group is introduced at the NH-goup of imidazole 
by trityl choride (step 1). The protected imidazole derivative is purified by column 
chromatography (eluens dichloromethane/ethyl acetate/triethylamine 4/1/0.5 v/v/v). 
The trityl group is partially removed during column chromatography, if triethylamine 
is not added to the eluens. The coupling of aminopropanol to the tritylated imidazole 
moiety and subsequent purification by column chromatography affords the N-cyano-
N'-(3-hydroxypropyl)-N"- {2- [(5-methyl-1 -tritylimidazol-4-yl)methylthio]ethyl} -
guanidine 11 in 50% yield. At this stage of the reaction scheme, we have tried three 
different methods to obtain the isothiourea derivative with the general structure 9 
(fig. 6). 
In step 3 (fig. 8), we tried to tosylate the hydroxyl group of 11; however , tosyl 
chloride rather replaced the trityl group from the imidazole moiety. Therefore this 
method cannot afford compound 9. In step 4 (fig. 8), bromination of the alcohol 11 
with phosphorus tribromide results in the removal of the trityl group. The third route 
(step 5; fig. 8) is performed according to the so-called Mitsunobu reac t ion 2 7 , using 
triphenylphosphine and diisopropyl azodicarboxylate to prepare thioethers starting 
from an alcohol and thiourea. 
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scheme 1 
1-N H 
scheme 2 
C H 3 
NH 
step 3 
TosCI 
(C 2 H 5 ) 3 N 
CH2CI2 
H H 
. N
 N > T 
I 
H2N NH 2 
'(CH 2)m-OH compounds 9 
*CN 
H step 1 
,N ,SCH3 T r C | 
48% HBr 
Y Tr-N ( C 2 H 5 ) 3 N \ = N 
^ C N C H 2 C I 2 
H 
. N ^ . S C H g 
T 
N 
CN 
H H 
step 2 
H 2 N - ( C H 2 ) m - O H 
step 4 
PBr 3 
CH2CI2 
x 
a) thiourea 
b) 1 N HC! 
compounds 9 compounds 9 
step 5 
(C 6 H 5 ) 3 P / thiourea 
iP r0 2 CN=NC0 2 iP r 
in DME 
X 
1 N HCI 
compounds 9 
Figure 8: Al ternat ive synthet ic routes to obtain compounds with the general 
structure 9 
After addition of the reagents in dimethoxyethane (shown in step 5) the yellow 
colour of d i isopropyl azodicarboxylate vanished. Thin layer chromatography 
indicated that triphenylphosphine had disappeared. After working up of the reaction 
mixture, however , ^ - N M R and 1 3 C - N M R have shown that the hydroxyl group 
present in compound 11 is still intact. No signals of thiourea or isothiourea were 
observed in NMR. Also, when n-butanol is used instead of the alcohol 11, no reaction 
with thiourea is observed. Therefore, we have to conclude that the Mitsunobu 
reaction is not of any use for the synthesis of isothioureas, such as compounds 9 
(fig.6). 
5.2 Synthesis of compounds 10 
Because of the difficulties we encountered in the syntheses of the series of 
compounds with the general structure 9, we decided to prove the validity of our idea 
that the imidazolylpropyl structural moiety in impromidine-like histamine F^-agonists 
can be replaced by isothioureidoalkyl structural moieties, by synthesizing analogues 
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of the 3,3-diphenylpropylamine bearing histamine H 2 -agonis ts 4 b (fig. 1) and 8 
(fig.2). These hybrid molecules with general structure 10 (fig. 6) are easily obtained. 
Despite that the 3,3-diphenylpropylamine structural moiety is not optimal for 
histamine Hi-antagonistic activity, the obtained hybrid molecules suit very well as 
model compounds to verify whether the o- i so th ioure idoethyl moiet ies display 
histamine H2-agonistic activity. The synthesis of the compound with an isothio-
ureidoethyl moiety did not succeed. By reaction of N-cyano-N'-(3,3-diphenylpropyl)-
N"-(2-hydroxyethyl)guanidine with thiourea in 4 8 % HBr, we could only isolate the 
hydrobromic salt of 3,3-diphenyl propylamine. 
5.3 Activities of compounds 10 and qualitative structure-activity relationships 
In table 3 the histaminergic activities of a number of dimaprit analogues combining 
3,3-diphenylpropylamine structural moieties (general structure 10; fig. 6) are given. 
Structure-activity relationship studies on histamine and dimaprit analogues reveal 
that the optimal alkylene chain length between the amino group and the group 
responsible for proton-accepting/electrostatic interaction, amounts to two methylene 
groups in histamine and three methylene groups in dimaprit. In impromidine, the 
optimal alkylene chain length between the guanidino group and the imidazole group 
is three methylene groups. The impromidine analogues with an ethylene or butylene 
chain are 25 and 58 times less active histamine H 2 -agonists than impromidine 2 5 . So, in 
impromidine the optimal alkylene chain length is one methylene group longer than in 
histamine. 
S t e r k 1 9 has suggested that in the series of N,N'-bis(co-isothioureidoalkyl)guanidines 
(fig. 5), the isothiourea group of V U F 8421 attached to the butylene chain is mainly 
responsible for the interaction with hydrogen bonding / electrostatic interaction 
regions, while the isothiourea group attached to the propylene chain interacts with 
an extra binding site. However, on closer inspection of the activities of the N,N'-
bis(co-isothioureidoalkyl)guanidines (fig. 5; table 2), it is shown that there are no 
differences in activity between V U F 8420 (with two propylene chains), V U F 8425 
(with two butylene chains) and V U F 8423 (in which the pentylene chain contributes 
to the activity and the propylene chain to the affinity). Elongation of the alkylene 
chain, attached to the isothiourea moiety responsible for the activity, from propylene 
to pentylene (p = 3-5, fig. 5) marginally affects the histamine H 2 -agonistic activity in 
case the other alkylene chain, attached to the isothiourea group responsible for the 
affinity, is varied from propylene to butylene. Apparently with V U F 8422 the 
structural limits for the histamine H 2-agonistic activity on the guinea pig right atrium 
are reached. 
In the series of N-(3,3-diphenylpropyl)-N ,-(co-isothioureidoalkyl)guanidines 10 (fig. 6) 
a similar structure-activity relationship is observed as for the N,N'-bis(co-isothioureido 
alkyl)guanidines. Increasing the alkylene chain length from propylene to hexylene 
decreases the histamine H 2 -agonist ic activity and intrinsic activity. Moreover, VUF 
4642 is a partial agonist with Hi-antagonistic properties. Furthermore, V U F 4643 is a 
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^ - a n t a g o n i s t , which can be explained by the same reasons as described for VUF 
8422. However, in the series of N-(3,3-diphenylpropyl)-N'-((0-isothioureidoalkyl) 
guanidines V U F 4640 with a propylene chain is the most potent H2-agonist, which is 
in disagreement with the findings for the N,N'-bis(co-isothioureido alkyl)guanidines, in 
which V U F 8421 with a butylene chain is the most active compound. 
Table 3: Histamine H 2 -agonist ic/H r antagonist ic activities and H 2 -receptor affinities 
H 2 - activity Hi-antagonism 
compound p D 2 a pKd pA 2 r f ref 
histamine 1 6.14 ± 0 . 0 4 1 4.16 ± 0 . 0 8 3 c 17 
4.64 ± 0.35 b 
dimaprit 2 5.67 + 0.12 1 4.58 ±0 .11 3 17 
impromidine 3 7.80 1 7.89 ± 0 . 1 5 5.47 3 
VUF 8527 4a 5.6 ± 0 . 1 0.9 nt 6.2 ± 0 . 2 
VUF 8532 4 b 7.7 ± 0 . 1 1 nt 6.3 ± 0 . 2 28 
arpromidine 5 8.01 1 nr 7.65 29 
VUF 9149 6 5.53 ± 0 . 1 0 1 4.82 ± 0 . 1 0 3 na 18 
amthamine 7 6.30 ± 0.04 1 5.30 ± 0.08 3 na 18 
VUF 8960 8 7.30 ± 0.04 1 nt nt 18 
VUF 4640 m = 3 6.71 ± 0 . 1 6 1 5.66 ± 0 . 1 4 b 6.69 ± 0 . 1 4 0.82 
VUF 4641 m = 4 6.02 ± 0.25 1 5.41 ± 0.05 b 6.25 ± 0.44 0.52 
VUF 4642 m = 5 6.24 ± 0 . 1 0 0.7 6.42 ± 0.32 b 6.82 ± 0.24 0.81 
5.91 ± 0.08d 0.7 
VUF 4643 m = 6 antagonist e 0 5.98 ±0 .31 b 6.38 ± 0.36 0.81 
x [3H]tiotidine as hot ligand 
b: [1 2 5I]iodoaminopotentidine as hot ligand N 
c: Histamine is an agonist; p D 2 = 6.95 ± 0.07 
d: p D 2 determined on electrically stimulated guinea pig papillary muscle. This compound 
also shows histamine H2-antagonistic activity; p A 2 = 6.56 ± 0.22 (papillary muscle) 
e: Histamine H2-antagonist; p A 2 = 5.75 ± 0.21 on guinea pig right atrium and 
p A 2 = 5.45 ± 0.16 on guinea pig papillary muscle 
f: r = slope of Schild plot 
nt: Not tested 
nr: Not reported 
na: Not active up to 10"4 M 
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Based on the observations that for N-(3,3-diphenylpropyl)-N'-{co-[imidazol-4(5)-
yl]alkyl}guanidines, the compounds with a propylene chain (VUF 8532 4b; fig. 1) is 
more potent than the compound with an ethylene chain (VUF 8527 4a; fig. 1), p D 2 = 
7.7 and 5.6, respectively, and on a similar structure-activity relationship observed for 
impromidine analogues, it is expected that the optimal alkylene chain in the series of 
N-(3,3-diphenylpropyl)-N , -(co-isothioureidoalkyl)guanidines should be a butylene 
chain. 
The his tamine Hi-antagonis t ic activities within the series of presented N-(3 ,3-
diphenylpropyl)-N'-(o)- isothioureidoalkyl)guanidines are all similar. W e cannot 
explain the deviation of unity of the slope in the Schild plot for VUF 4641 . Variations 
in the isothioureidoalkylene chain length does not affect the his tamine H i -
antagonistic activities, which is in agreement with the VUF 8532 4b and V U F 8527 
4a ( p A 2 = 6.3 and 6.2, respectively). 
6 Conclus ion 
The histamine H 2 -agonistic activities within the series of N-(3,3-diphenylpropyl)-N'-
(co-isothioureidoalkyl)guanidines confirm that 2-amino-5-(2-aminoethyl) thiazole 
derivatives can be considered as substituted dimaprit analogues. Replacement of the 
3-(5-thiazolyl)propyl or 3-[4(5)-imidazolyl]propyl moiety in impromidine analogues, 
such as V U F 8960 and V U F 8532, by a co-isothioureidoalkylene moiety, affords 
substituted dimaprit analogues which are more potent histamine H 2 -agonis ts than 
dimapri t . Compared with V U F 8960 and V U F 8532, the presented N- (3 ,3 -
diphenylpropyl)-N'-(co-isothioureidoalkyl)guanidines have a lower H 2 - agon i s t i c 
activity, which is in agreement with the activities of the parent histamine H 2 -agonists 
amthamine, his tamine, and dimaprit , respectively. In the series of the present 
c o m p o u n d s , the H 2 - agon i s t i c activity decreases with e longat ion of the co-
isothioureidoalkylene chain. V U F 4640 (propylene chain) is the most potent H 2 -
agonist in the presented series of N-(3,3-diphenylpropyl)-N ' - ((0- isothioureido-
alkyl)guanidines, while V U F 4643 (hexylene chain) is a weak H 2 - a n t a g o n i s t . 
Obviously, elongation of the co-isothioureidoalkylene chain does not affect the 
histamine H r an tagon i s t i c activities of the present compounds. 
E x p e r i m e n t a l p r o t o c o l s 
If indicated crude reaction products were purified by flash chromatography on 
silicagel (J.T.Baker 70242). Melting points were determined on a Mettler FP 52 with 
microscope. ! H - N M R spectra were recorded on s a Bruker AC 200 and were verified 
by HH-cosy N M R exper iments . The chemical shifts are in p p m relat ive to 
tetramethylsilane. Mass spectra were determined on a Mat 90 (Finnigan Mat) mass 
spectrometer with Fast Atom Bombardment ionisation (matrix: thioglycerol, Ion Tech 
saddlefield gun, 8 keV Xenon with xenon ioncurrent 0.2 mA). All V U F compounds 
gave the expected ( M + H ) + and (M+H+ - HS-C(NH)NH 2 ) + peaks. 
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General synthetic method 
N-cyano-N'-(3,3-diphenylpropyl)-S-methylisothiourea 
A solution of 50 mmol 3,3-diphenylpropylamine in 100 ml dichloromethane was 
added slowly to a stirred solution of 1 equivalent dimethyl N-cyanodithiocarbon 
imidate in 50 ml dichloromethane. After complete addition, the reaction mixture was 
stirred for an additional 30 min. Addition of diethyl ether gave a precipitate, which 
was filtered off, washed with diethyl ether and dried. 
Yield: 94 %, m.p.: 187-189°C. 
iH-NMR (DMSO-d 6 ) : 2.22-2.47 ppm (m, 2H, C-C/ / 2 -C) , 2.52 ppm (s, 3H, S-CH3) 
3.17-3.23 ppm (m , 2H, CH2-N), 4.00 ppm (t, J = 7.8 Hz, 1H, -C/ / -C-C-N), 7.14-7.33 
ppm (m, 10H, lOx phenyl-//), 8.31 ppm (bs, 1H, NH). 
N<yano-N'-(3J-diphenylpropyl)-N"-((D-hydroxyalkyl)guanidine 
One equivalent of N-cyano-N'-(3,3-diphenylpropyl)-S-methylisothiourea and 1.25 
equivalents of the appropriate aminoalcohol were refluxed overnight in absolute 
ethanol under nitrogen atmosphere. Then the solvent was evaporated and the residue 
was dissolved in d ichloromethane and washed three t imes with water . After 
evaporation of the organic solvent, the compounds were obtained as an oil. 
N-cyano-N'-(3,3-diphenylpropyl)-N"-(2-hydroxyethyl)guanidine 
Yield: 71 %, m.p.: oil. 
iH-NMR (CDC1 3 ): 2.21-2.32 ppm (m, 2H, C-C/ / 2 -C-N) , 3.08-3.15 ppm (m , 4H, 2x 
-C/ / 2 -N) , 3.57-3.62 ppm (m, 2H, -C/ / 2 -OH) , 3.93 ppm (t, / = 7.9 Hz, 1H, -C//-C-C-N), 
6.03 ppm (bs, 1H, NH), 6.15 ppm (bs, 1H, NH), 7.09-7.29 ppm (m, 10H, lOx phenyl-//). 
N'Cyano-Nf'(3f3'diphenylpropyl)-N"-(3-hydroxypropyl)guanidine 
Yield: 87 %, m.p.: oil. 
iH-NMR (CDC1 3): 1.58-1.62 ppm (m, 2H, N-C-C/ / 2 -C-OH), 2.22-2.32 ppm (m, 2H, C-
C// 2 -C-N), 3.12-3.16 ppm ( m , 4H, 2x -C/ / 2 -N) , 3.43-3.58 ppm (m, 2H, -C/ / 2 -OH), 3.94 
ppm (t, ƒ = 7.7 Hz, 1H, -C//-C-C-N), 6.01 ppm (bs, 1H, NH), 6.18 ppm (bs, 1H, NH), 
7.07-7.27 ppm (m, 10H, lOx phenyl-//). 
N-cyano-N'-(3f3-diphenylpropyl)-N"-(4-hydroxybutyl)guanidine 
Yield: 95 %, m.p.: oil. 
iH-NMR (CDCI3): 1.41-1.58 ppm (m, 4H, N-C->C// 2 -C// 2 -C-OH), 2.20-2.38 ppm (m, 
2H, C-C/ / 2 -C-N) , 3.00-3.21 ppm (m , 4H, 2x -CH2-N), 3.48-3.55 ppm (m, 2H, -CH2-
OH), 3.91 ppm (t, J = 7.7 Hz, 1H, -C//-C-C-N), 5.96 ppm (bs, 1H, NH), 6.08 ppm (bs, 
1H, NH), 7.09-7.31 ppm (m, 10H, lOx phenyl-//). 
N-cyano-N'-(3,3-diphenylpropyl)-N"-(5-hydroxypentyl)guanidine 
Yield: 100 %, m.p.: oil. 
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iH-NMR (CDCI3) : 1.28-1.50 ppm (m, 6H, N-C-C/ / 2 -C / / 2 -C / / 2 -C-OH) , 2.24-2.35 ppm 
(m, 2H, C-C// 2 -C-N), 2.94-3.05 ppm ( m , 2H, -CH2-N), 3.10-3.23 ppm ( m , 2H, -CH2-N), 
3.51-3.57 ppm (m, 2H, -C/ / 2 -OH) , 3.94 ppm (t, J = 7.8 Hz, 1H, -C//-C-C-N), 5.58 ppm 
(t,J = 5 Hz, 1H, NH), 5.64 ppm (t,J = 5 Hz, 1H, NH), 7.10-7.29 ppm (m, 10H, lOx 
phenyl-/ /) . 
N-cyano-N'-(3,3-diphenylpropyl)-N"-(6-hydroxyhexyl)guanidine 
Yield: 95 %, m.p.: oil. 
iH-NMR (CDCI3): 1.18-1.29 ppm (m, 4H, N-C-C-C/ / 2 -C/ / 2 -C-C-OH) , 1.45-1.51 ppm 
(m, 4H, N-C-C/ / 2 -C-C-C/ / 2 -C-OH) , 2.23-2.34 ppm (m, 2H, C-C/ / 2 -C-N) , 2.95-3.05 
ppm ( m , 2H, -C / / 2 -N) , 3.06-3.19 ppm ( m , 2H, -C / / 2 -N) , 3.48-3.55 ppm (m, 2H, -CH2-
OH), 3.94 ppm (t, J = 7.8 Hz, 1H, -C//-C-C-N), 5.63 ppm (t, J = 5 Hz, 1H, NH), 5.79 
ppm (t, J = 5 Hz, 1H, NH), 7.08-7.28 ppm (m, 10H, lOx phenyl-//). 
N-(3,3-diphenylpropyl)-N'-(co-isothioureidoalkyl)guanidine 
N-cyano-N'-(3,3-diphenylpropyl)-N"-(co-hydroxyalkyl) guanidine and 2 equivalents 
of thiourea were added to 50 ml 4 8 % HBr. The resultant solution was refluxed 
overnight and subsequent ly evaporated . The compounds were obtained as 
dihydrobromic acid salts. The compounds were purified as picrates. The first four 
recrystallizations were carried out in the presence of an excess of picric acid. Final 
recrystallizations were carried out in methanol/water (3 to 6 times). 
N-(3,3-diphenylpropyl)-N'-(2-isothioureidoethyl)guanidine 
The synthesis of this compound did not succeed. 
N-(3,3-diphenylpropyl)-N'-(3-isothioureidopropyl)guanidine hydrobromide 
monopicrate VUF 4640 
Yield: 3 3 % , m.p.: 154-158°C. 
Mass spectrum: (FAB+) 370 (M+H)+, 294 (M+H - HSC(NH)NH 2 ) + . 
iH-NMR (DMSO-d 6 ) : 1.72-1.84 ppm (m, 2H, N-C-C// 2 -C-S), 2.18-2.32 ppm (m, 2H, C-
C/ / 2 -C-N) , 2.90-3.24 ppm (m , 6H, 2x -CH2-N and -CH2-S), 3.99 ppm (t, J = 7.7 Hz, 
1H, -C//-C-C-N), 7.17-7.33 ppm (m, 12H, lOx phenyl-// and 2x NH), 7.59 ppm (bs, 1H, 
NH), 8.61 ppm (s, 2H, 2x -CH- picric acid), 8.92-9.10 (m, 2H, NH2). 
N-(3,3-diphenylpropyl)-N'-(4-isothioureidobutyl)guanidine hydrobromide 
monopicrate VUF 4641 >> 
Yield: 2 1 % , m.p.: 169-177°C. 
Mass spectrum: (FAB+) 384 (M+H)+, 308 (M+H - HSC(NH)NH 2 ) + . 
iH-NMR (DMSO-d 6 ) : 1.85-1.90 ppm (m, 4H, N-C-C/ / 2 -C/ / 2 -C-S) , 2.24-2.36 ppm (m, 
2H, C-C/ / 2 -C-N) , 3.10-3.28ppm (m , 6H, 2x -C/ / 2 -N and -CH2-S), 4.01 ppm (t, / = 7.7 
Hz, 1H, -C/ / -C-C-N), 7.01-7.21 ppm (m, 2H, 2x NH), 7.25-7.36 ppm (m, 10H, lOx 
phenyl-//), 8.62 ppm (s, 2H, 2x -CH- picric acid). 
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N-(3,3-diphenylpropyl)-N'-(5-isothioureidopentyl)guanidine dipicrate VUF 4642 
Yield: 18%, m.p.: 69-72°C. 
Mass spectrum: (FAB+) 398 (M+H) + , 322 (M+H - HSC(NH)NH 2 ) + . 
iH-NMR (acetone-d 6 ) : 1.55-1.84 ppm (m, 6H, N - C - C / / 2 - C / / 2 - C / / 2 - C - S ) , 2.42-2.53 
ppm (m, 2H, C-C// 2 -C-N), 2.95-3.38ppm (m , 6H, 2x -C/ / 2 -N and -C/ / 2 -S) , 4.08 ppm (t, 
J = 8Hz, 1H, -C/ / -C-C-N), 7.12-7.35 ppm (m, 12H, lOx phenyl- / / and 2x N / / ) , 8.63 
ppm (bs, 1H, NH), 8.77 ppm (s, 4H, 4x -CH- dipicrate). 
N-(3,3-diphenylpropyl)-N'-(6-isothioureidohexyl)guanidine hydrobromide 
monopicrate VUF 4643 
Yield: 13%, m.p.: 74-76°C. 
Mass spectrum: (FAB+) 412 (M+H)+, 336 (M+H - HSC(NH)NH 2)+. 
iH-NMR (DMSO-d 6 ) : 1.37-1.92 ppm (m, 8H, N-C-C/ / 2 -C / / 2 -C / / 2 -C / / 2 -C-S) , 2.42-2.49 
ppm (m, 2H, C-C// 2 -C-N), 3.26-3.59ppm (m , 6H, 2x -C/ / 2 -N and -C/ / 2 -S) , 4.09 ppm (t, 
J = 8Hz, 1H, -C/ / -C-C-N), 7.15-7.29 ppm (m, 12H, lOx phenyl- / / and 2x NH), 8.72 
ppm (s, 2H, 2x -CH- picric acid). 
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S u m m a r y 
The investigations described in this thesis were aimed at the development of hybrid 
molecules useful for the treatment of certain cardiovascular diseases. 
In chapter 1 the causes of cardiovascular diseases and their pharmacotherapeutic 
treatment are briefly reviewed. The function of the heart and the circulatory system 
are described, as well as the effects of several cardiovascular drugs , such as 
antiarrhythmics, antianginals, cardiotonics, and antihypertensives. In the last part of 
chapter 1 the prospects for single drug therapy and combination drug therapy are 
evaluated for the treatment of certain cardiovascular disorders. In those cases in 
which treatment with a single drug cannot adequately control the illness or in cases 
in which the use of a therapeutic agent alone is limited by its side effects, combination 
drug therapy is feasible. Combination drug therapy can be achieved by concomitant 
drug administration or by so-called hybrid molecules. 
A classification of hybrid molecules, which combine more than one pharmacological 
property in one single molecule, is given in chapter 2. Although in literature several 
chiral compounds are designated as hybrid molecules, it cannot be ruled out that 
some of the chiral compounds have to be considered as so-called pseudo-hybrids, as 
long as their stereoisomers have not been isolated and pharmacologically evaluated. 
W e have confined the explanation of the principle of hybrid molecules mainly to 
ca rd iovascu la r drugs and some ant i - inf lammatory and ant ia l lergic agents . 
Furthermore, the advantage of hybrid molecules over fixed-ratio combination of 
drugs is considered. 
In chapter 3, hybrid molecules combining the vasodilating properties of nitrate esters 
and the positive inotropic actions of histamine H2-agonists are described. Based on 
known histamine H2-agonists hybrid molecules incorporating a nitrate ester function 
have been proposed. Despite the unsuccessful achievements to obtain the proposed 
hybrid molecules , the original idea still provides interesting thoughts to develop 
cardiotonics with nitrovasodilating properties, as such compounds are of potential 
benefit in treatment of certain cardiovascular disorders. 
Ca l c ium channe l b lockers are used as an t i a r rhy thmic , an t i ang ina l , and 
antihypertensive agents. In chapter 4 the molecular biology, pharmacology, and 
structure of L-type voltage-operated calcium channels, responsible for the regulation 
of the excitat ion-contraction coupling process in the cardiovascular system are 
discussed. There are several distinct classes of calcium channel blockers such as the 
p h e n y l a l k y l a m i n e s , benzo th i azep ines , a n d N 1 ,4-d ihydropyr id ines . The 1,4-
dihydropyr id ine- type ca lc ium channel b lockers , in part icular amlodipine- l ike 
compounds, offer possibilities to introduce a histamine H2-agonistic structural moiety, 
affording so-called hybrid molecules. 
In chapter 5 and 7 some thio-bioisosters of amlodipine derivatives are presented. The 
potent in vitro calcium channel blocking activities and affinities of a series of diethyl 
2-(co-aminoalkylthio)methyl-2,6-dimethyl-4-[(substituted)phenyl]-l,4-dihydropyridi-
ne-3,5-dicarboxylates presented in these two chapters are not affected by increasing 
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the alkyl chain length on the 2-position of the 1,4-dihydropyridine ring from ethyl to 
hexyl of 3-nitrophenyl substituted 1,4-dihydropyridines. 
The same is true for the diethyl 4- [2- (co-aminoalkoxy)phenyl] -2 ,6-dimethyl - l ,4-
dihydropyridine-3,5-dicarboxylates and their corresponding thiourea and isothiourea 
derivatives. Increasing the alkoxy chain length from pentoxy to decoxy does not 
affect the calcium channel blocking activities or affinities. Furthermore, the series of 
1,4-dihydropyridine derivatives shown in chapter 6 are less active calcium channel 
blockers than those presented in chapter 5, indicating that substitution of the phenyl 
ring by large alkyl substituents is unfavourable. 
The 1,4-dihydropyridines discussed in chapters 5 and 6 served as synthons to obtain 
hybrid molecules possessing 1,4-dihydropyridine calcium channel blocking activity 
and histamine H2-agonistic properties, thus combining antihypertensive activity and 
positive inotropic effects. Most calcium channel blockers exert a disadvantageous 
negative inotropic effect. By introduction of a histamine H2-agonistic structural 
moiety the negat ive inotropic effects of the calcium channel blockers can be 
compensated. Based on the two different series of 1,4-dihydropyridines presented in 
chapters 5 and 6, two types of hybrid molecules are synthesized. In general the 
hybrid molecules based on the 1,4-dihydropyridines presented in chapter 5 are more 
active than the hybrid molecules based 1,4-dihydropyridines presented in chapter 6. 
Of the series of describeded N-{co-{3,5-diethoxycarbonyl-l ,4-dihydro-6-methyl-4-
(substituted-phenyl)-pyridin-2-yl]methylthio}alkyl-N'-[3-(imidazol-4(5)-yl]propyl-
guanidines, the hybrid molecule with a hexyl chain is the most promising compound 
which could provide interesting leads in the treatment of myocardial heart failure or 
some hypertensive disorders, because it combines good in vitro C a 2 + - c h a n n e l 
blocking action and an overall positive inotropic and chronotropic activity in one 
molecule. From the series of presented N-{co-{[2-(3,5-diethoxycarbonyl-2,6-methyl-
l,4-dihydropyridin-4-yl)phenoxy]}alkyl}-N ,-[3-(imidazol-4(5)-yl]propyl]guanidines, 
only the hybrid molecule with a hexoxy chain shows some positive inotropic action., 
However, the calcium channel blocking activity of these compounds is low. 
In chapter 8 a series of dimaprit analogues with histamine H2-agonistic and histamine 
Hi -an tagon i s t i c activities reveal that large subst i tuents , such as a diphenyl-
alkylguanidine structural moiety, on the amino function of dimaprit , S-[3-(N,N-
dimethylamino)propyl]isothiourea, are allowed. Furthermore, these hybrid molecules 
confirm that the histamine H2-agonistic 2-amino-5-(2-aminoethyl)thiazole derivatives 
can be considered as ring closed dimaprit analogues. 
In conclusion, a number of hybrid molecules presented in this thesis have shown that 
these type of compounds could give beneficial effects in the treatment certain 
cardiovascular diseases; however, their design and synthesis requires patience and 
t ime, and last but not least a thorough knowledge of their structure-activity 
relationships is needed. 
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S a m e n v a t t i n g 
Het in dit proefschrift beschreven onderzoek was gericht op de ontwikkeling van 
hybride moleculen die gebruikt kunnen worden in de behandeling van bepaalde 
cardiovasculaire aandoeningen. 
In hoofdstuk 1 worden de oorzaken van de cardiovascula i re aandoeningen 
beschreven naast hun pharmacotherapeutische behandeling. De functie van het hart 
en het bloedvatenstelsel worden beschreven, alsmede de effecten van verschillende 
cardiovasculaire geneesmiddelen, zoals antiarrhythmica, antiangineuze middelen, 
cardiotonica en antihypertensiva. In het laatste gedeelte van dit hoofdstuk worden 
de vooruitzichten van mono medicijn therapie en combinatie medicijn therapie voor 
de behandel ing van verschi l lende cardiovascula i re aandoeningen met elkaar 
vergeleken. In die gevallen waarbij behandeling van een ziekte met een enkel 
medicijn niet adekwaat is, of in gevallen waarin het gebruik van een medicijn wordt 
beperkt door bijwerkingen, kan combinatie therapie uitkomst bieden. Combinatie 
therapie kan worden bereikt door gebruik te maken van gelijktijdige toedieningen 
van de afzonderlijke actieve stoffen, al dan niet in een preparaat, of door gebruik te 
maken van zogenaamde hybride verbindingen. 
Een beschrijving van hybride verbindingen wordt gegeven in hoofdstuk 2. Hoewel 
er in de literatuur veel verbindingen worden beschreven die worden beschouwd als 
hybride verbindingen, betreft het in de meeste gevallen chirale verbindingen. Zolang 
de verschillende enantiomeren niet afzonderlijk farmacologisch worden onderzocht, 
kan men niet uitsluiten dat het hierbij eigenlijk om zogenaamde pseudo-hybride 
verbindingen gaat. Het principe van hybride verbindingen wordt uitgelegd aan de 
hand van cardiovascula i re verbindingen en een aantal ant i inf lammatoire en 
anitallergische verbindingen. 
In hoofdstuk 3 worden hybride moleculen beschreven waarin de vaatverwijdende 
activiteiten van nitraat esters en de positief inotrope werking van histamine H2-
agonistische worden gecombineerd in één molecuul. In het eerste gedeelte van het 
hoofdstuk wordt een kort overzicht gegeven van de bestaande nitraat esters en hun 
werking. Tevens wordt het verschijnsel van nitraat ester tolerantie kort toegelicht. 
Aan de hand van bekende his tamine H2-agonistische structuren zijn hybride 
moleculen ontworpen die tevens een nitraat ester functie bevatten. Ondanks de niet 
succesvole pogingen om de gewenste hybride moleculen te verkrijgen, betekent dit 
zeker niet dat het or iginele idee niet kan leiden tot verb indingen die een 
vaatverwijdende activiteit combineren met een positief inotrope werking en daardoor 
geschik t kunnen zijn voor de behande l ing van bepaa lde ca rd iovascu la i re 
aandoeningen. 
Calc ium kanaal blokkers worden gebruikt als ant iarrhythmica, ant iangineuze 
middelen en als antihypertensiva. In hoofstuk 4 wordt een overzicht gegeven van de 
moleculaire biologie, farmacologie en de moleculaire structuur van de calcium 
kanalen. Bovendien wordt er een kort overzicht gegeven van de liganden voor de 
calcium kanalen. Een speciaal type calcium kanalen zijn de zogenaamde L-type 
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potentiaal-gereguleerde calcium kanalen die verantwoordelijk zijn voor het excitatie-
contractie koppelingsproces in het cardiovasculaire systeem. 
Er zijn verschillende typen calcium kanaal blokkers zoals de fenylalkylamines, de 
benzoth iazepines en de 1,4-dihydropyridines. De 1,4-dihydropyridine-achtige 
calcium kanaal blokkers , in het bijzonder amlodipine-acht igen, bieden goede 
aanknopingspunten om histamine H2-agonistische structuureenheden in te voeren, 
zodanig dat hybride moleculen worden verkregen. 
In de hoofdstukken 5 en 7 worden een aantal thio-bioisosteren van amlodipine 
derivaten beschreven. De hoge in vitro calcium kanaal blokkerende activiteiten en 
affiniteiten in de serie van diethyl 2- (co-aminoalkyl th io)methyl -2 ,6-d imethyl -4-
[ (gesubs t i t uee rd ) f eny l ] -1 ,4 -d ihydropyr id ine -3 ,5 -d i ca rboxy la t en worden niet 
beïnvloed door verlenging van de alkyl keten op de 2-plaats van de 1,4-dihydro-
pyridine ring van ethyl naar hexyl in 3-nitrofenyl gesubsti tueerde 1,4-dihydro-
pyridine derivaten. 
Het zelfde fenomeen bij keten verlenging wordt ook waargenomen voor een serie 
van diethyl 4 - [2 - (co-aminoa lkoxy) feny l l -2 ,6 -d imethy l - l ,4 -d ihydropyr id ine -3 ,5 -
dicarboxylaten en de overeenkomst ige th ioureum en i so th ioureum derivaten. 
Verlenging van de alkoxy keten van pentoxy naar decoxy beinvloedt de calcium 
kanaal blokkerende activiteiten en affiniteiten niet. Verder zijn dit type verbindingen 
minder actief dan die beschreven in hoofdstuk 5. Hieruit blijkt dat substitutie van de 
fenyl ring door grote substituenten niet bijdraagt tot verhoging van de activiteiten. 
De 1,4-dihydropyridines beschreven in de hoofdstukken 5 en 6 dienden als synthons 
voor de synthese van hybr ide moleculen die calc ium kanaal b lokkerende en 
h is tamine H2-agonist ische e igenschappen bezi t ten; aldus worden bloeddruk 
verlagende en positief inotrope effecten gecombineerd in één molecuul. Door het 
invoeren van een histamine H2-agonistische structuur worden de negatief inotrope 
effecten van de calcium kanaal blokkers gecompenseerd. Gebaseerd op de twee 
typen calcium kanaal blokkers beschreven in de hoofdstukken 5 en 6 werden twee 
verschil lende soorten hybride moleculen gepresenteerd. In het algemeen zijn de 
hybride verbindingen gebaseerd op de 1,4-dihydropyridines uit hoofdstuk 5 actiever 
dan die welke gebaseerd zijn op de 1,4-dihydropyridines uit hoofdstuk 6. Uit de serie 
van de N-{co-[3,5-diethoxycarbonyl-1,4-dihydro-6-methyl-4-(gesubstitueerd-fenyl)-
pyr id in -2-y l ]methy l th io}a lky l -N ' - [3 - ( imidazo l -4(5) -y l ]p ropylguan id ines is het 
hybride molecuul met een hexyl keten de meest veel belovende verbinding om een 
bijdrage te leveren aan de therapie van een insufficiënt hart en sommige vormen van 
hypertensie, daar deze verbinding in één molecuul een hoge in vitro calcium kanaal 
b lokkerende werking combineer t met een posi t ieve inotrope en chronotrope 
werking. Uit de serie van N - { c o - { [ 2 - ( 3 , 5 - d i e t h o x y c a r b o n y l - 2 , 6 - m e t h y l - l , 4 -
dihydropyridin-4-yl)fenoxy]}-alkyl}-N ,-[3-(imidazol-4(5)-yl]propyl]guanidines 
vertoont alleen het hybride molecuul met een hexoxy keten een positieve inotrope 
werking. De calcium kanaal blokkerende werking is echter vrij laag. 
In hoofdstuk 8 wordt een serie dimaprit analoga met een histamine H2-agonistische 
en his tamine Hi-antagonis t i sche werking beschreven; er is gevonden dat grote 
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substituenten, zoals een difenylalkylguanidine eenheid, aan de amino groep van 
dimaprit, S-[3-(N,N-dimethylamino)propyl]isothioureum, zijn toegestaan. Bovendien 
bevestigen deze hybride moleculen dat de histamine H2-agonistische 2-amino-5-(2-
aminoethyl)thiazolen kunnen worden beschouwd als ring gesloten dimaprit analoga. 
Kort samengevat worden er in dit proefschrift een aantal hybride verbindingen 
gepresenteerd waarmee wordt aangetoond dat dit type verbindingen een aantal 
voorde len kan b ieden in de behande l ing van bepaa lde ca rd iovascu la i r e 
aandoeningen ten opzichte van mono of combinatie therapie. Het ontwerp en de 
synthese van hybride verbindingen vergt echter veel geduld en niet in de laatste 
plaats een gedegen kennis van de structuur-activiteit relaties van de verbindingen. 
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